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What does man gain from all his labour 
at which he toils under the sun? 
Generations come and generations go, 
but the earth remains for ever. 
The sun rises and the sun sets, 
and hurries back to where it rises. 
The wind blows to the south 
and turns to the north; 
round and round it goes, 
ever returning on its course. 
All streams flow into the sea, 
yet the sea is never full. 
To the place the streams come from, 
there they return again. 
All things are wearisome, 
more than one can say. 
The eye never has enough of seeing, 
nor the ear its fill of hearing. 
What has been will be again, 
what has been done will be done again; 
there is nothing new under the sun. 
Is there anything of which one can say, 
"Look! This is something new"? 
It was here already, long ago; 
it was here before our time. 
There is no remembrance of men of old, 
and even those who are yet to come 
will not be remembered 
by those who follow. 
Ecclesiastes 1 Vs 3-11 
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Abstract 
Nitrile oxide-isoxazoline methodology has been employed in a novel 
convergent approach towards 2-ulosonic acid analogues, in particular those of 3-
deoxy-D-arabino-2-heptulosonic acid (DAH) and 3 -deoxy-D-manno-octulosonic acid 
(KDO). It involves regio- and diastereoselective [3+2] cycloaddition of a nitrile 
oxide to carbohydrate alk- 1 -enes containing four, five or six carbons, yielding 2-
isoxazolines. Subsequent deprotection followed by reductive hydrolytic cleavage 
affords the 2-ulosonic acid analogues. 
The four carbon alkene 1,2-dideoxy-3,4-0-cyclohexylidene-D-glycero-1-
enitol was chosen as a model alkene on which to establish the methodology which 
could then be applied directly to the two target classes of compounds. Cycloadditions 
were performed using four nitrile oxides: ethoxycarbonylformonitrile oxide, 
benzonitrile oxide, acetonitrile oxide and (diethoxyphosphoryl)acetonitrile oxide. 
These proceeded in 40-88% yield with moderate it-facial selectivity (54-64% d.e.) in 
favour of erythro adducts, with the major product in each case possessing S-
configuration at the new asymmetric centre, C-5. This selectivity can be rationalised 
in terms of the 'inside alkoxy effect' proposed by Houk et a!, and the 'homoallylic' 
modification offered by De Micheli et al. 
In an attempt to control selectivity in the nitrile oxide cycloaddition reactions, 
a dispiroketal protecting group was utilised. However, the increase in steric bulk and 
presence of a six-membered ring as the protecting group incorporating the diol, rather 
than the five-membered ring, does not appear to influence it-facial selectivity. 
Cycloadditions were also performed using the five carbon alkenes 1,2-
dideoxy-3 ,5-0-ethylidene-D-erythro-pent- 1 -enitol and 1 ,2-dideoxy-3 ,5-O-benzyl- 
VII' 
idene-L-threo-pent-1-enitol. With the former alkene these proceeded in 40-80% yield 
but with minimal it-facial selectivity (4-6% d.e.). However, changing the homoallylic 
substituent from equatorial to axial in the latter alkene significantly increased the 
selectivity (to 62-64% d.e.). In both instances the major product was shown by X-ray 
crystallography to possess S-configuration at the new chiral centre (C-5) 
corresponding to an erythro relationship about the C-5/C-6 bond. The analogous 
acetate derivatives also yielded erythro adducts preferentially. 
Using the six carbon alkene 1,2-dideoxy-3,4:5,6-di-0-isopropylidene-D-
arabino-hex-l-enitol the cycloadditions (30-88% yield) showed poor it-facial 
selectivity (25-34% d.e.). Although the isoxazolines were chromatographically 
inseparable, X-ray crystal analysis of the major isomer established that the new chiral 
centre at C-5 had R-configuration, corresponding to an erythro relationship about the 
C-5/C-6 bond. An alternative approach to the same target compound involved 
addition to methyl 5 ,6-dideoxy-2,3 -O-isopropylidene-a-D-lyxo-hex-5 -enofuranoside. 
This proved to be more selective (62-76% d.e.) and yielded separable products. The 
selectivities in both cases were rationalised in terms of the 'inside alkoxy effect'. 
Deprotection of the 2-isoxazolines to provide the precursors for the final 
reductive hydrolytic cleavage occurred with good yields. For the hexulose series a 2-
ulosonic acid analogue has been isolated, and its structure established by mass 
spectrometry and NMR spectroscopy which shows that it exists predominantly in its 
keto form. A KDO analogue has also been prepared and is mainly in the ring closed 
hemiketal form. Reductive hydrolytic cleavage of the 2-isoxazolines using Raney-
Nickel catalysed hydrogenolysis also provided the desired J3-hydroxyketones, along 
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The subject of this thesis is the application of nitrile oxide-isoxazoline 
methodology to accomplish the key synthetic steps in the synthesis of 2-ulosonic acid 
analogues. In the introduction three topics are discussed. First a section describing the 
importance of 3-deoxy-2-ulosonic acids; then an outline of nitrile oxide-isoxazoline 
chemistry and rationalising its choice for the present work; and finally reviews of 3-
deoxy-D-arabino-2-heptulosonic acid (DAH) (1) and 3-deoxy-D-manno-2-octulosonic 
acid (KDO) (2), including their mode of action, analogues previously synthesised, 
and recent approaches to their construction. 
1.2 	3-Deoxy-2-ulosonic Acids 
Higher 3-deoxy-2-ulosonic acids containing seven, eight and nine carbons 
are widely diffuse natural carbohydrates which participate in various important 
biological processes. For example the 7-phosphate of the seven-carbon compound 3-
deoxy-D-arabino-2-heptulosonic acid (DAH) (1) is a key intermediate in the 
biosynthesis via the shikimate pathway of aromatic amino acids from glucose in 
plants and bacteria but not in mammals; 1 the eight-carbon analogue 3-deoxy-D-
manno-2-octulosonic acid (2-keto-3-deoxy-D-manno-octonic acid) (KDO) (2) occurs 
in the lipopolysaccharide region of the cell surface of all Gram-negative bacteria and 
is an essential component for their replication; 2,3  and the nine-carbon compound N-
acetyl-5-amino-3 ,5-dideoxy-D-glycero-D-galacto-2-nonulosonic acid (N-acetyl-
neuraminic acid, Neu5Ac or NANA) (3) is a sialic acid (aminononulosonic acid) 
1 
which is found at the terminal positions of glycolipids, glycoproteins, and 
oligosaccharides, often in nerve tissues and cellular membranes of various living 
organisms. 4 These sialyl conjugates play an important role in biological molecular 
recognition processes such as differentiation phenomena and cell adhesion.' The 5-
deamino compound 3 -deoxy-D-glycero-D-galacto-2-nonulosonic acid (KDN) (4) also 
occurs naturally, but is less common; it was isolated in 1986 from rainbow trout egg 
polysialoglycoprotein and is believed to play a role in activation by protecting against 
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3-Deoxy-2-ulosonic acids exist in both open chain and cyclic hemiketal 
forms in the same way as the simple sugar D-fructose. The pyranose form results from 
intramolecular nucleophilic addition of the hydroxyl group at C-6 to the C-2 ketone 
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The biosynthesis of sialic and ulosonic acids and particularly DAH, KDO, 
Neu5Ac and KDN, is thought to involve the stereoselective aldol condensation of 
2 
aldoses with phosphoenol pyruvate catalysed by the appropriate aldolase enzyme. 2,4 
For example, Scheme 2 shows the biosynthesis of KDO from D-arabinose. 
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Much effort has been devoted to the isolation, characterisation and 
preparation of these unusual carbohydrates and to investigating their biological 
functions. As these compounds are potential herbicidal and antibacterial agents, many 
synthetic studies are being carried out throughout the world, with particular interest 
directed towards the development of short and efficient syntheses of DAH and KDO 
analogues as specific enzyme inhibitors. Most approaches to 3-deoxy-2-ulosonic 
acids have made use of readily accessible carbohydrate precursors  such as D-glucose 
(DAH),8 D-arabinose (KDO), 9 D-glyceraldehyde (KDO),' ° D-mannose (KDO)" and 
D- or L-mannose (KDN) . 7 Our retrosynthetic strategy to 3-deoxy-2-ulosonic acids is 
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1.3 	Nitrile Oxide/Isoxazoline Methodology 
The principal aim of the work is to develop a general route from readily 
available precursors which is appropriate for the whole series of 2-ulosonic acids and 
which is sufficiently flexible to provide access to a wide range of analogues with 
control of stereochemistry. Nitrile oxide cycloaddition methodology is considered to 
be well suited for the construction of 2-ulosonic acids, in particular DAH and KDO. 
1.3.1 	Nitrile Oxide Cycloaddition Chemistry 
1.3.1.1 Introduction 
The concept of 1,3-dipolar cycloadditions for the construction of five-
membered ring heterocycles was developed by Huisgen' 2" 3 in the 1960's, and since 
then much work has been performed in this area. Due to the immensity of this field, 
1,3-dipolar cycloaddition chemistry will not be reviewed extensively. Instead a brief 
overview of the properties of nitrile oxides and their reactions will be presented. 
Further details can be obtained from Padwa's comprehensive monograph '1,3-Dipolar 
Cycloaddition Chemistry', 13  Grundmann and Grunanger's text 'The Nitrile Oxides'. 
14 
Torssell's more recent book 'Nitrile Oxides, Nitrones and Nitronates in Organic 
Synthesis" 5 and a recent review article entitled 'Recent Advances in Synthetic 
Applications on Nitrile Oxide Cycloadditions" 6 by Kanemasa and Tsuge. 
Nitrile oxides are members of the nitnlium betaine family of 1,3-dipoles and 
exist as a three atom four it-electron system. The most common representation of a 
nitrile oxide is that of a zwitterionic octet structure of the linear propargyl-allenyl type 
(5) which contains an orthogonal it-bond. They can be represented as a resonance 
4 
hybrid of the structures (5)-(10) shown in Scheme 4. The main contributions in the 
ground state are the octet structures (5) and (6). 
RCN — O 4 	RCNO 4 	RCN — O 
(5) 	 (6) 	 (7) 
RC=N-0 4 	RC —N0 4 	RCN — O 
(10) 	 (9) 	 (8) 
Scheme 4 
The most significant synthetic reaction of nitrile oxides is their [3+2] 
cycloaddition to dipolarophiles to form five-membered heterocyclic rings (Scheme 5). 
A range of multiple bonds (X=Y, X=—Y) have been utilised including C=C, CEC, 
C=N, CN and C=O. 
(v 
RCN—O 	 ,N, 





There has been much controversy regarding the mechanism of nitrile oxide 
cycloadditions. The most widely accepted mechanism involves a concerted,' 
9,20  but 
not necessarily synchronous, one-step process proposed by Huisgen.' 2" 7" 8 1,3-
Dipolar cycloaddition reactions to asymmetric dipolarophiles are stereospecific with 
formation of four possible stereoisomers, two stereoisomers for each regioisomer 
(Scheme 6). Stereoelectronic factors normally control the regioselectivity with the 
5 
least hindered side of the dipolarophile being favoured by the approaching dipole. 
Hence, often only two stereoisomers are observed. Retention of dipolarophile 
stereochemistry is maintained in the hererocyclic adduct. 
Rico 	Ri RI—C=—N-0 	 co 
+ _ R2 	R3 	R 
Scheme 6 
The observed reactivities and regioselectivities have been rationalised by 
Sustmann21 '22 using Frontier Molecular Orbital (FMO) theory, in which the 
interactions of the dipole and dipolarophile are classified into three cases depending 
on whether the reaction is under dipole HOMO or dipole LUMO control (Sustmann 
Type I or III respectively) or a combination of both (Type II). Nitrile oxide FMO 
interactions are normally dipole LUMO controlled (Type III). The regioselectivity of 
nitrile oxide cycloadditions can be predicted by FMO theory with the major 
regioisomer being formed from maximum overlap of like orbitals. 23  Steric factors can 
also influence the relative abundance of each stereoisomer. 
1.3.1.2 Generation of Nitrile Oxides 
Nitrile oxides are reactive species and have a tendency to dimerise [Section 
1.3.1.3], and so they are usually generated slowly in situ at low concentration in the 
presence of excess dipolarophile, thus minimising the competing formation of 
furoxans (furazan N-oxides). The routes normally employed for their preparation are 
summarised in Scheme 7. 
RCXNOH RCH2NO2 











One of the most common methods is that developed by Huisgen et a124 
which involves triethylamine-mediated, and recently potassium fluoride 
 25  or 
thermally-induced,  26,27  dehydrohalogenation of hydroximoyl halides (11). These are 
readily accessible from the reaction of aldoximes (12) with halogens  28  or nitrosyl 
chloride,  29  or by milder in situ treatment with N-bromosuccinimide (NB S) 3° or N-
chiorosuccinimide (NCS). 3 ' One-pot generation of nitrile oxides via their 
hydroximoyl halides has also been accomplished using alkaline sodium 
hypochlorite, 32 hypobromite33 and chloramine-T. 34 Lead tetraacetate has been used 
for direct dehydrogenation of syn aldoximes 35 (12). 
An equally important and useful alternative for the generation of nitrile 
oxides is the Mukaiyama36 method involving dehydration of a primary nitro 
compound (13) using a catalytic amount of triethylamine and an isocyanate as a 
dehydrating agent. Access to nitrile oxides is also provided by the thermal 
cycloreversion3739 of furoxan dimers (1 ,2,5-oxadiazole-2-oxides) (14). 
7 
1.3.1.3 Dimerisation and Rearrangement Reactions (Scheme 8) 
In the absence of a dipolarophile, nitrile oxides usually dimerise to yield 
furazan N-oxides (14).4041 These dimers are often also formed as by-products in 
cycloaddition reactions. The rate of dimerisation is variable and depends on the 
electronic nature and steric bulk of the R substituent. Electron deficient analogues are 
prone to rapid dimerisation; eg. at room temperature the half-life varies from seconds 
to minutes for a neat sample of an aliphatic nitrile oxide, whereas many sterically 
hindered nitrile oxides can be isolated and stored indefinitely. 
14  Dimers such as 1,2,4-
oxadiazole-4-oxide (15) and 1 ,4,2,5-dioxadiazine (16) are also sometimes formed. 
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Scheme 8 
Other reactions competing with cycloaddition include thermal and 
photochemical rearrangements to isocyanates' 4 (17) and 1,3-addition using 
nucleophiles (18). 
1.3.1.4 Cycloaddition to Alkenes and Alkynes (Scheme 8) 
Nitrile oxides are sufficiently reactive to undergo cycloaddition to a wide 
range of dipolarophiles affording five membered heterocycles containing the C=N-O 
unit, (19) and (20). Of direct relevance to the work being discussed is the 
cycloaddition to an alkene yielding 2-isoxazolines (4,5-dihydroisoxazoles) (21). The 
corresponding reaction with alkynes affords isoxazoles (22). 
Cycloaddition to most monosubstituted and 1,1 -disubstituted alkenes occurs 
regiospecifically yielding the 5-substituted- (23) (Scheme 9) and 5,5-disubstituted-2- 
isoxazolines respectively. The reaction is regiospecific when the dipolarophile 
contains electron donating or conjugating substituents, eg. hex-1-ene or styrene. 
However, the presence of a strong electron-withdrawing group results in a mixture of 
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Scheme 9 
1 ,2-disubstituted alkenes undergo cycloaddition with complete retention of 
dipolarophile stereochemistry to produce a mixture of regioisomers. More highly 
substituted alkenes show decreased reactivity. Sustmann Type III [LUMO (dipole)] 
01 
controlled reactions become more Sustmann Type II [HOMO + LUMO (dipole)] for 
dipolarophiles containing electron withdrawing substituents or dipoles with electron 
donating groups and this explains the differences in reactivity observed. 
1.3.2 	Synthetic Utility of Nitrile Oxide-Isoxazoline Chemistry 
For many years the 1,3-dipolar cycloaddition reactions of nitrile oxides have 
been used for the synthesis of 5-membered heterocycles incorporating the C=N-O 
unit, but it is only in the last decade that their potential for natural product synthesis 
has been realised. 
15,16,43-45  Their utility stems from their ease of generation under mild 
conditions from readily accessible precursors and the regio- and stereo-chemical 
control of their cycloaddition reactions with alkenes. The well established chemistry 
of the resulting 2-isoxazoline cycloadducts 435 permits rapid accumulation of 
polyfunctionality in a small molecular framework, and this methodology has been 
used successfully for the preparation of a variety of natural products including 
prostaglandins, 46 terpenoids,47 and various alkaloids 
43  and carbohydrates. 45  The use of 
nitrile oxides in synthesis has been reviewed by Jager, 44 Kozikowski,43 Curran45 and 
Torssell.' 5 
Three basic steps are involved in the nitrile-oxide/isoxazoline route to natural 
products and analogues. The first is the 1,3-dipolar cycloaddition with predictable 
regio- and stereochemistry of a nitrile oxide to an alkene. The resulting 2-isoxazoline 
can be modified if required. Isoxazolines are stable ring structures, and this allows a 
range of transformations to be performed on the ring and/or side chains by 
appropriate reagents without disruption of the heterocycle. The final stage involves 
ring cleavage of the isoxazoline at the N-O bond to reveal the target functionalities. 43 
10 
Modification of a 3,5-substituted isoxazoline ring at the 4-position can be 
effected by a method developed by Jager 48 ' 49 which involves deprotonation using 
lithium di-isopropylamidc (LDA) or butyllithiurn at -78°C, and reaction of the 
resulting carbanion with an electrophile to produce stereoselectively the 4-substituted 
isoxa.zoline. 
Cleavage of the isoxazoline N-O bond has been reported by Curran, 45 Jdger44  
and Kozikowski 43 and can lead to a number of acyclic products, depending on the 
reaction conditions (Scheme 10). Reductive hydrolytic cleavage 45  releases the latent 
3-hydroxyketone functionality and is an alternative to the classical aldol 
condensation. It also avoids the problems normally encountered with aldol reactions: 
reversibility, cross and self-aldol side reactions, lack of stereocontrol and selective 
enolate formation. The two approaches produce different, but complementary C-C 
bonds (Figure 1). 




The most widely used procedure for ring cleavage of isoxazolines is catalytic 
hydrogenation 45  with a palladium-on-charcoal or Raney-nickel catalyst under aqueous 
methanolic conditions. Alternative reagents include titanium trichloride, 5° 
molybdenum hexacarbonyl 5 ' and ozone. 52  The -hydroxyketone can then provide 
access to 1,3-diols by reduction, or a-enones by dehydration. 
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Scheme 10 
A y-aminoalcohol is another functionality that can be unmasked from 
isoxazolines. This is accomplished using lithium aluminium hydride (LAH) 43 
reduction or non-aqueous catalytic hydrogenation. 53  The reaction is stereoselective, 
although the extent of this diastereoselectivivty is dependent on the substituents on 
the isoxazoline ring. LAH reduction is more stereoselective due to complexation with 
the nitrogen of the isoxazoline ring. 
Other functionalities can also be unmasked. Oxidation of 2-isoxazolines to 
isoxazoles, 54 and subsequent ring opening provides access to 1,3-diketones and 3-
keto nitriles. The presence of base releases 3-hydroxynitriles from 3-unsubstituted 
isoxazolines, 55 as does thermal decarboxylation 56 of isoxazoline 3-carboxylic acids. 
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1.4 DAH/DAIIP Inhibitors 
1.4.1 Shikimate Pathway 
The shikimate pathway (Scheme 11) is a major biosynthetic pathway in 
plants and microorganisms 1,57,58  and is responsible for the production of a range of 
important primary and secondary metabolites, including the three aromatic amino 
acids L-phenylalanine (L-Phe), L-tyrosine (L-Tyr) and L-tryptophan (L-Trp). These 
aromatic compounds are essential for the growth of these hosts, but cannot be 
synthesised de novo by animals. 
In prokaryotes and plants, 3 -deoxy-D-arabino-heptulosonate 7-phosphate 
(DAHP), a seven-carbon acid, is produced from phosphoenol pyruvate (PEP) and 
erythrose 4-phosphate, the condensation of which is mediated by DAHP synthase. 59 
DAT-IP is present at the beginning of the enzyme-catalysed cascade that starts with 
this seven-carbon carbohydrate and ends with the amino acids. It is an important 
intermediate, standing at the crossover point from the sugar phosphates to the 
cyclitols that eventually are transformed into the aromatic amino acids. 
The conversion of the keto-acid DAHP to the six-membered cyclic 
intermediate (DHQ), the first carbocyclic metabolite in the pathway is catalysed by 
DHQ synthase. The chemical mechanism for this process is one of the more 
fascinating steps in the shikimate pathway, 60-62  and will be discussed briefly later. 
Subsequently shikimic acid is obtained in two steps from DHQ. This then reacts 
further with PEP to eventually produce the desired aromatic acids. 
The rational design of herbicidal chemicals has been influenced by 
recognition that plant death can result from chemical disruption of the aromatic 
amino acid biosynthesis. For years, the synthesis of large numbers of chemical 
13 
compounds followed by screening led the way for the discovery of new herbicides. 
Thus the development of specific inhibitors for the shikimate pathway (not found in 
animals) offers a non-toxic approach to potential herbicides as well as antimicrobial 
agents. A convenient synthetic route to DAHP could provide access to structural 
analogues of DAHP and strategies for achieving potent inhibition of DHQ synthase 
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1.4.2 Mechanism for the Conversion of DAHP to DHQ 
The proposed pathway for catalytic conversion of DAHP (25) to DHQ (26) is 
shown in Scheme 12. In this sequence, which is mechanistically diverse for a single 
enzyme, the DHQ synthase6° is involved in five transformations: (i) NAD mediated 
oxidation of the secondary alcohol at C-5; (ii) n-elimination of inorganic phosphate 
across C-6 and C-7; (iii) reduction of the resulting enone at C-5; (iv) ring opening of 
the enol pyranose; (v) and the final intramolecular aldol-like reaction which proceeds 
via a chairlike transition state to produce DHQ. Recently it has also been proposed 63 
that kinetic parameters influence these transformations. The key features of DHQ 
synthase and its role in this catalytic conversion are summarised below. 
DHQ synthase is a homogeneous monomeric metalloenzyme (MW = 39000) that 
contains a precisely stoichiomeric amount of tightly bound Co(II) (1 mol) and also 
1 mol of NAD, the presence of which are essential for both catalytic activity and 
stability of the enzyme. 60-62 
The metal ion has a central role in the catalytic mechanism, since it not only 
influences the catalytic activity of the enzyme but also affects the rate of NAD 
dissociation from the active site during turnover. 
NAD is employed catalytically to effect a transient oxidation at C-5 of the 
substrate, and the redox cofactor need never dissociate from the active site. 
It is suggested by Bartlett 64 that DHQ synthase catalyses the reaction up to the 
reduction of ketone 27 and that 28 is the actual product of the enzymatic reaction. 
f3-Elimination of inorganic phosphate is syn. 
The aldol transition state is chair-like. 
15 
7. The C-7 side chain has to have a gauche conformation, to allowproton abstraction 
from C-6. This positions the C-6 proton close to one of the peripheral oxygens of 
the phosphate group. 
In summary the enzyme DHQ synthase possesses remarkable properties for 
the catalytic conversion of DAHP to DHQ. 
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1.4.3 Inhibitors of Dehydroquinate (DHQ) Synthase 
There have been numerous strategies directed towards the synthesis of 
substrate analogues of DAHP as potential inhibitors of DHQ synthase, 5871 and in 
vitro inhibition studies on these compounds have been performed. Representative 
examples of such analogues are shown in Appendix 1. From the results the following 
conclusions can be drawn about the structural features known to be essential for 
inhibition of this enzyme. 
Micromolar competitive inhibition of the enzyme was first achieved with a 
organophosphonate analogue (29) of substrate DAHP. 65 The discovery of the 
reversible slow-binding, carbocyclic analogue 
(39)6166  resulted in inhibition being 
lowered to nanomolar levels. Ketocarbaphosphonate (31)67  constituted the next step 
in inhibitory potency; it was the first reported irreversible inhibitor of the enzyme, 
and is ideal for maintaining in vivo enzyme inhibition. It is a lead compound for a 
large class of reaction-intermediate analogues of considerable agricultural and 
pharmacological importance. 
Enhanced binding to DHQ synthase has been achieved by incorporation of 
features into an inhibitor that favour oxidation at C-5 eg. analogue 32. Also the 
importance of the phosphate monoester in substrate binding to DHQ synthase has 
been demonstrated by the inability of DAH itself to serve as a substrate of DHQ 
synthase. 58 
Numerous phosphonate and homophosphonate analogues have been 
synthesised, with the phosphonomethyl moiety becoming an influential feature of 
many inhibitors of DHQ synthase. 68 A major advance was the discovery of a new 
class of inhibitory substrate analogues where the pyranosyl ring oxygen was replaced 
17 
with a methylene group. 61  These carbocyclic analogues bind 25-100 times more 
tightly than the corresponding oxacyclic compounds (33 cf 34)61  This has been 
attributed to a change in conformation of the enzyme. Other carbocyclic analogues 
eg. 35 have been prepared in an attempt to generate a Michael acceptor at the enzyme 
active site which is capable of suicide inactivation of DHQ synthase. 69 
The conformation of the alkenyl side chain also appears to be important for 
inhibitory activity, 61  and the preferred binding mode has the side chain bound in a 
gauche conformation for increased activity (36). Analogues that are more nearly 
isosteric with the substrate bind less tightly to the enzyme than those containing a 
shortened side chain; for example (29) is a competitive inhibitor of the enzyme 
whereas (33) is inactive. 58 
Substrate analogues (30) and (37) have been synthesised 63,66  where one or 
both of the secondary hydroxyl groups have been removed from a carbaphosphonate 
inhibitor. Removal of a single hydroxyl group from the carbocyclic backbone of 
carbaphosphonate (eg. 30 cf 34) appears to decrease the inhibitor potency by a factor 
of 100. Tight interactions between active site residues and the C-4 carbanophosphate 
(34) are responsible for its nanomolar-level inhibition. 66  However, it does not seem 
to matter which hydroxyl group, (at C-4 or C-5) is removed for the observed decrease 
in inhibition. Carbaphosphonate (34) is thus a lead compound for the design and 
synthesis of future in vivo inhibitors of DHQ synthase. 
The enzyme does not tolerate the acyclic substrate (38)62  which does not 
bind to the active site. Also replacement of the carboxyl group by an isopolar and 
isosteric tetrazole unit 70 (eg. 39) results in no significant inhibition even at sub 
millimolar concentrations. Finally in vitro inhibition 68  of DHQ synthase has been 
18 
previously shown not to be very selective in the nature of the products afforded, 71 
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1.4.5 Syntheses of DAH and Analogues 
The potential herbicidal and antimicrobial benefits of DAHIDAHP inhibitors 
of the shikimate pathway have been the focus of much interest in recent years, as has 
the development of short, efficient and stereoselective routes to such compounds and 
their analogues. Indeed, more potent and specific inhibitors are still sought. 
There have been many reported routes for the chemical syntheses of 
DAH/DAI-IP and their analogues. 59,74-82  However, to date no reference has used nitrile 
oxide/isoxazoline chemistry. Most approaches have employed 2-deoxy-D-glucose (a 
relatively costly carbohydrate) as the starting material, and require a one-carbon chain 
extension of the aldose followed by specific phosphorylation at the primary hydroxyl 
group at C-7, and oxidation at C-2. The most efficient 59  gives 6% overall yield after 
eight steps [Section 1.4.5.1.1]. Since the first preparation of DAH in 1963, there 
have been numerous successful syntheses. Several of these methods are detailed in 
Haslam' s comprehensive monograph 'Shikimic Acids'. 1 
The following account presents some of the recent procedures used for the 
formation of DAHIDAHP and analogues. The first section deals with their preparation 
via the modification of carbohydrates, while the second covers non-carbohydrate 
based approaches. Chemoenzymatic and whole cell syntheses follow and finally a 
miscellaneous section covering work not categorised elsewhere is presented. 
1.4.5.1 Syntheses from Carbohydrates 
1.4.5.1.1 From 2-Deoxy-D-glucose 
This route 59  enables the production of substrate analogues of both DAH and 
DAHP (Scheme 13). Conversion of 2-deoxy-D-glucose (59) to the propylene 
20 
dithioacetal (60) is achieved using acid catalysis and subsequent reaction with acetone 
containing a trace of sulphuric acid leads to the 3,4:5,6-di-0-isopropylidene derivative 
(61). Metallation of (61) with butyllithium was followed by methoxycarbonylation 
with methyl chiorofonnate. NBS in aqueous acetone was then used to remove the 
dithioacetal protection. The resulting methyl 3-deoxy-heptulosonate (62) was 
converted to methyl glycoside (63) by heating in refluxing acidic methanol. 
Phosphorylation of this cyclic heptulosonate (63) with diphenyl phosphochioridate 
gave (64). Exhaustive hydrogenation removed the phenyl ester groups and was 
followed by basic hydrolysis of the methyl ester. Finally, heating with Dowex 50 (H 
form) hydrolysed the methyl pyranoside (65) to yield DAHP (25). 
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Scheme 13 
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1.4.5.1.2 Via 5-Ylidene-1 ,3-dioxalan-4-one Intermediates 83,84 
The advantage of this approach results from the nature of the dioxalanone 
ring system which is relatively stable to acidic cleavage, but which can produce salts 
of the a-keto carboxylic acid when hydrolysed by alkali under very mild conditions. 
The synthesis of DAI-1 has two key stages; the first involves the preparation in three 
steps from D-arabinose (66) of protected aldehyde (67) containing the desired 
stereochemistry at each carbon atom. In the second, crucial step the protected 
aldehyde (67) is reacted with the Wittig reagent (68) thus introducing the masked a-
keto acid function. The ulosonic acid is then released by hydrolysis as shown in 
Scheme 14. 
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(a) CASH, conc. HCI, 0°C; (b) acetone, conc. H2SO4;  (c) HgO/HgC12, 2 hr, 30°C, 1 hr 50°C, 2 
hrreflux; (d) 60°C under N 2, 10 mm, then r.t. 30 mm; (e) CF3 COOHIFI20(3:2), 80°C, 14 hr; (0 0.5 
M eq Ba(OH)2 in aq. MeOH 
Scheme 14 
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1.4.5.2 Synthesis from Non-Carbohydrates 
1.4.5.2.1 Wittig Olefination-Michael Addition Route 
Dondoni et a185 have developed a strategy which involves the stereoselective 
carbon-carbon bond formation via Wittig olefination of an aldose (70) with a thiazole-
armed acyl ylide (71), followed by carbon-oxygen bond formation by conjugate 
Michael-type addition of a benzyloxy anion to the resultant trans-a-enone (72) 
(Scheme 15). 
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(a) BnONa, 80%; (b) HCIi'MeOH, 90%; (c) BnBr-NaH, 100%; (d) TfOMe, then NaBH 4 , then 
CuCl2-CuO-H20, 76%; (e) A920,96%; (f) H2-Pd/C, 100%; (g) AcOH-H 20, 70% 
Scheme 15 
A Felkin-Anh transition-state model, 85  predicts the stereochemical outcome for 
the carbonyl and alkene addition, with the large a-substituent being orientated 
antiperiplanar to the forming new bond and the medium-size substituent in the inside 
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position. The thiazole ring serves as a masked formyl group and is important in the 
success of this approach, being stable to a wide variety of conditions and yet 
undergoing efficient conversion to the aldehyde under neutral conditions. This formyl 
unmasking involves a one-pot sequence using methyl triflate for N-methylation to a 
thiazolium salt, sodium borohydride reduction, and CuC1 2 and CuO for the metal 
assisted hydrolysis of the resulting thiazolidine. In this way aldehyde (70), formed by 
one-carbon homologation of D-glyceraldehyde acetonide, is converted into DAH. 
1.4.5.3 Chemoenzymatic Approaches 
In this section two different routes will be described. The first very recent 
approach involves a filly stereocontrolled total synthesis of the parent DAH by a 
strategy which uses a simple, cyclic hydrocarbon cycloheptatriene as a non-
carbohydrate, achiral starting material. 86  Monoacetate (75) (and its derivatives) are 
readily prepared form cycloheptatriene via an enzymatic asymmetrisation 87 ' 88 of the 
meso-diol (74) with Pseudomonas cepacia lipase in isopropenyl acetate (Scheme 16). 
The monoacetate was then converted into the a,3-unsaturated ketone (76)89  which 
yielded the cx-bromo enone (77) on treatment with bromine and triethylaniine. A 
mixture of epimeric alcohols was afforded by Luche reduction 90  of (77) and 
ozonolysis of this mixture followed by chemoselective reduction of the intermediate 
aldehyde with sodium borohydride gave ester (78) as a mixture of alcohols epimeric at 
C-2. Conversion of the terminal hydroxy group of (78) to the tert-butyldiphenylsilyl 
ether followed by PDC oxidation 91  of the secondary alcohol yielded protected 
heptulosonic acid (79) possessing the required arabino stereochemistry. Cyclised 
24 
DAIFI derivative (80) was obtained by treatment of (79) with methanol containing an 
acid catalyst. DAH was formed by cleavage of the silyl ethers and characterised as its 
tetraacetate derivative (81). 
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(a)i HBF4, Ph3 COH; ii Na2CO3 , CH3CN; iii NaBH, MeOH; iv TBDMSCI, imidazole, DMF; v 1 02 , 
CH2Cl2IMeOH; vi ZnIHOAC, CH 2C12; (b) Pseudomonas cepacia lipase (Ammo PS-30), isopropenyl 
acetate; (c)i TBDPSC1, imidazole, DMF; ii 0s0, NMO, acetone, H 20 iii dimethoxypropane, p-
TsOH; iv KOH, MeOH; v MsCI, Et3N, CH2Cl2; vi p-TsOH, MeOH; vii (Cod) 2, DMSO, Et3N; (d) 
Br,, Et3N, CH2C12; (e)i NaBH4 , CeCI 3 , MeOH, -78°C; ii 03 , DMS, MeOH; iii NaBH; (Oi  TPSC1, 
Et3N, CHCl2 ; ii PDC/4A sieves, CH 2C12; (g) TsOH, MeOH, 59%; (h)i TBAF, THF ii Ac20/Py/ 
DMAP. 
Scheme 16 
An earlier report by Whitesides et a!92 described an alternative approach to the 
synthesis of DAHP using a rabbit muscle aldolase to catalyse the formation of the C- 
25 
4/C-5 bond. (Scheme 17). Two chiral centres are generated diastereospecifically in 
this aldol condensation. Quantitative production of methyl ester was obtained by 
treatment of N-acetyl-D/L-allylglycine with diazomethane. Ozonolysis, followed by 
reductive workup with dimethyl sulphide afforded the aldehyde (82). In the presence 
of aldolase reaction of aldehyde (82) with dihydroxyacetone phosphate (83) gave 40% 
maximum conversion, and the product (84) as a mixture of diastereomers epimeric at 
C-2 (2R:2S = 1.5:1.0) was obtained in 37% yield after ion-exchange chromatography. 
Hydrolysis of the methyl ester also occurs. The sodium salt of (84) was reduced using 
tetramethylammonium triacetoxyborohydride to give the desired anti configuration as 
the dominant isomer. Hydrolysis of (85) gave a diastereomeric mixture of amino acids 
(86). The final transformation of (86) to ketoacid (1) was accomplished by a 
transamination reaction with sodium glyoxylate. 
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Scheme 17 
This route to DAI-IP has four attractive features. First, there are few protection 
and deprotection steps, and the reactions are all carried out in aqueous media. Second, 
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formation of the carbon-carbon bond is accomplished simultaneously with the 
introduction of the phosphate group. In other syntheses this step often occurs with low 
yields. Third, use of an appropriately labelled aldehyde (82) or dihydroxyacetone 
phosphate (83) can allow for the preparation of isotopically labelled DAHP. Finally, 
this route provides a potentially useful method for synthesising analogues of DAHP 
due to the high tolerance of rabbit muscle aldolase for the aldehyde component, and 
also the possibility of structural modification at centres other than C-4 and C-5 (those 
formed in the aldolase-catalysed reaction). 
1.4.5.4 Whole Cell Syntheses 
One of the difficulties of exploiting whole cells for the production of 
intermediary metabolites results from the accumulation in the growth medium of 
contaminants produced in normal cellular processes. Manipulation of large volumes of 
crude product is required during purification of such metabolites as well as isolation of 
the target molecules free from contaminants of closely similar structure and charge 
type. Frost and Knowles 59  have successfully synthesised DAHP using mutants of 
E. coli that contain no dehydroquinate synthase. Two different E. coli were used and 
shown to secrete considerable quantities of the dephospho material DAH (in addition 
to DAHP). The DAHP was purified by anion-exchange chromatography on DEAE-
cellulose. These refinements allowed the ready preparation in a few days of 100 mg 
quantities of pure DAHP. The advantage of the microbial route is that the process is 
shorter and less skill is required. However, the concomitant production of substrate 
analogues is prohibited. 
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1.4.5.5 Miscellaneous Approaches 
1.4.5.5.1 1,4-Cyclic Sulphate Approach 
Nucleophilic opening of a sugar cyclic sulphate  93  gives easy access to 
interesting precursors of DAHP analogues. The key intermediate required for the 
preparation of such analogues is 2,3,5-tri-O-benzyl-D-arabinitol 1,4-cyclic sulphate 
(87) (Scheme 18). 
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0°C, 5 mm 
Scheme 18 
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The cyclic sulphate (87) was prepared from 2,3,5-tri-O-benzyl-D-arabinitol 
using thionyl chloride, followed by ruthenium chloride oxidation. Removal of the 
sulphate group in for example intermediate (88) by mild acidic hydrolysis was 
effected in situ to give (89), and final unmasking with NBS of the dithioketal function 
in (89) yielded anomerically pure (a form) (90). 
This methodology has also been applied to the successful synthesis of KDO 
and its corresponding derivatives, 94  and is also applicable to a 1 ,4-diol system present 
in an open-chain sugar configuration. It allows for exclusive formation of the required 
D-arabino or D-manno configuration, respectively, and not the concomitant formation 
of the unwanted D-gluco configuration as observed in most routes to KDO via an aldol 
or Wittig-type elongation. 
1.4.5.5.2 Plasmid-Based Biocatalysis 
Plasmid-based biocatalysis 95 is useful for the synthesis of small molecules 
which are normally difficult to obtain, and for their production in quantities suitable 
for use in chemical synthesis. The synthesis is accomplished without the need for 
adenosine triphosphate regeneration, co-factor, co-substrate, enzyme immobilisation 
and enzyme purification required by enzymatic synthesis. 
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1.5 KDO Inhibitors 
1.5.1 Introduction 
The eight carbon carbohydrate 3-deoxy-D-manno-octulosonic acid (KDO) (2) 
is an essential and unique constituent of the outer membrane lipopolysaccharide 
(LPS) of all Gram-negative bacteria, 2,96  and has been identified in several acidic 
capsular exopolysaccharides (K-antigens). 2 '97 '98 It has also been found in the primary 
cell wall of higher plants,99100  the protozoan Trypanosona cruzi 101 , 102  andgreen alga 
Tetraselmis striata, 103 but has never been detected in Gram-positive bacteria. iO4 
Since its discovery in 1959, KDO has steadily grown in importance as a natural 
product of bacterial origin. While Gram-positive bacteria are susceptible to many 
antibacterial agents, Gram-negative bacteria are more difficult to target effectively. 05 
O HO 	H 
HO 
0 
HO 	 CO2H 
OH 
(2) 
A continuing problem in chemotherapy is the development of resistance by 
bacteria to existing antibacterial agents. There is thus an increasing need to discover 
novel classes of compounds 106-111  which could be used in conjunction with those 
presently employed in the treatment of bacterial infections. Recent efforts have 
therefore been directed toward identifying new biochemical pathways that are 
essential to bacterial survival, but are unique to prokaryotes. Specific compounds are 
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then designed with the hope that they will possess antibacterial activity without being 
toxic to eukaryotic cells. 
The vital rate-limiting step in LPS biosynthesis involves incorporation of 
KDO which is required for the growth and proliferation of Gram-negative bacteria. 
Therefore, since mutants unable to produce KDO are 103,112  KDO is an 
attractive target in the rational design of novel antibacterial agents and 
chemotherapy. 113 In addition, as KDO is not present in mammalian cells, 
99  agents 
directed against KDO metabolism ought to have a high degree of selective toxicity. 
There is thus a great interest in the immunochemistry, biochemistry and synthetic 
carbohydrate chemistry involving KDO and in particular the synthesis of KDO 
analogues as specific enzyme inhibitors of the KDO pathway. 2,7,100,106-108,113,114 
1.5.2 Structure of KDO 
The initial structural determination on the KDO molecule was carried out by 
Levin and Racker, 3 who observed the enzyme-catalysed formation of KDO 8-
phosphate from enolpyruvate phosphate and D-arabinose-5-phosphate. They assigned 
the configuration of C-5 to C-7 as arabino and this was verified by Heath and 
Ghalambor" 5"6 who also tentatively assigned the D-manno configuration to KDO 
derived from LPS. This was subsequently confirmed by a Wittig synthesis of 
KDO" 7 NMR analysis' 8"9 and X-ray crystallography' 
20  of the a-D-ketosidic KDO 
derivative (91). 
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1.5.3 Structure of LPS 
The outer membrane of Gram-negative bacteria is composed of a bilayer with 
endotoxic LPS outside and an inner phospholipid region. The most important 
component is LPS which serves as an effective barrier towards the penetration of a 
wide variety of lipophilic compounds including xenobiotics of molecular weight 
>600 which would be harmful to the organism. 
LPS' 2 ' consists of three regions. The hydrophobic portion, a 2-amino-2-
deoxy-D-glucosyi disaccharide substituted with the unique fatty acid Lipid A L 
 ,6)-D-glucosamine], possesses the lipid anchor required for 
membrane binding, and determines the endotoxic, antigenic specificity, 
adhesiveness, invasiveness, penetrability and immunostimulatory properties of LPS. 
The hydrophilic polysaccharide domain is composed of two regions. The first is a 
complex oligosaccharide that projects from the cell surface into solution. The other is 
an inner carbohydrate core region comprising a non-repetitive sequence of residues. 
The last constituent of the core, always KDO, 2 is situated at the reducing ends of the 
polysaccharide domains linking them through a a-(2-6') ketosidic bond to the 0-6' of 
the D-glucosamine disaccharide backbone, Lipid A. This structural unit appears to be 
a prerequisite for the growth and survival of the bacterial cell. One or more KDO 
units may be present (normally three) and very often one of these is substituted by L-
glycero-D-manno-heptopyranose to form the sequence : heptose-( 1 ,5)-KDO-(KDO)- 
(2,6)-glucosamine. Figure 2 shows the structure of the lipid A-KDO region of LPS. 96  
Evidence suggests that one of the final stages involved in constructing LPS 96 
is the incorporation of KDO, allowing nascent LPS molecules to move from the inner 
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1.5.4 Biosynthesis of KDO and Incorporation into Lipid A 
In lipopolysaccharide biosynthesis the incorporation of KD096 consists of 
two steps: the formation of cytidine 5'-monophospho-3-deoxy-D-manno-2-
octulosonic acid (CMP-KDO) by CMP-KDO synthetase' 22 and the subsequent 
coupling with Lipid A precursor. Since the rate limiting step is the activation of the 
KD0 moiety,  122  inhibitors of CMP-KDO synthetase are potentially useful as 
bacterial agents. Kohibrenner and Fesik' 23 elucidated the stereochemistry of this 
reaction which provides the basis for a rational design of enzyme inhibitors. 
The biosynthetic pathway of KDO is well understood  96  and is shown in 
Scheme 19. 
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Five enzymes are required for the biosynthesis and incorporation of KDO into 
LPS. Each has a specific role. D-Arabinose-5-phosphate isomerase is involved in 
isomerisation of D-ribulose-5-phosphate (92) to D-arabinose-5 -phosphate (93). KDO-
8-phosphate synthetase catalyses the condensation of (93) with phosphoenol pyruvate 
(PEP) to afford KDO-8-phosphate (94). KDO-8-phosphate phosphatase hydrolyses 
the phosphate ester to provide KDO. The fourth enzyme, CMP-KDO synthetase, is 
involved in activation of the anomeric hydroxyl group; KDO reacts with CTP to 
produce labile CMP-KDO (95). The final stage requires glycosylation for 
incorporation of KDO into LPS. 
The key enzyme is CMP-KDO synthetase, which determines the rate of 
reaction, and hence this enzyme has attracted most interest as a target for inhibition 
of the biosynthetic pathway. The design of inhibitors for this enzyme is the focus of 
part of this thesis. 
A number of conclusions about the enzyme CMIP-KDO synthetase can be 
made. 123,124 
It is specific for the 3-pyranose form of KDO (a minor form in solution) and this 
anomeric configuration is retained in the CMP-KDO product. KDO is assumed to 
be in the 5 C2 ring conformation. 
CMP-KDO formation is via a nucleophilic displacement mechanism' 24 (Figure 4) 
and is in agreement with the transition-state model 
125  shown in Figure 3. 
The biosynthesis of CMP-KDO appears to occur in a manner completely 
analogous to the biosynthesis of CMP-N-acylneuraminic acids. 
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4. Transfer of KDO in the 3-configuration from CMP-KDO to LPS is thought 2 to 
occur with inversion of configuration at the anomeric centre, C-2, resulting in 
KDO a-linked in LPS. 
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Figure 3: Transition-state Model 
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Figure 4: Nucleophilic Displacement Mechanism for CMP-KDO Formation 
The metabolism of KDO in Gram-negative bacteria still has many interesting 
questions which need to be answered, not only in the role KDO plays in the 
functioning of the outer membrane macromolecular structures, but also in the reaction 
mechanisms involved. Of particular interest are the mechanism for transfer of KDO 
into LPS, the rates of interconversion of KDO forms in the cell, and the role KDO 
performs in maintaining the outer membrane barrier of Gram-negative bacteria. 
Wi 
1.5.5 Inhibitors of CMP-KDO Synthetase 
A large number of analogues of KDO have been synthesised via different 
strategies 2,102,106-111,113,125- . 138 as potential inhibitors of the enzyme CMP-KDO 
synthetase, and in vitro inhibition studies performed. Representative examples of 
such analogues are presented in Appendix 2. The following conclusions can be 
drawn about the requirements for an enzyme inhibitor. 
Inhibitors possessing high affinity are likely to be those which are able to 
form many strong interactions with the enzymes active site. When the active site is 
fully occupied these requirements can be satisfied. A ternary complex between 
enzyme, inhibitor and CTP is the probable mode of binding of an inhibitor, eg. 
(96),' 13  in the active site of CMP-KDO synthetase. 
2-Deoxy-3-KDO (96)" was found to be a potent inhibitor of CMP-KDO 
synthetase, whereas 2-deoxy-a-KDO (97) was inactive. 111,132  This finding led to the 
synthesis of many analogues of 2-deoxy-3-KDO in an attempt at retaining, or even 
enhancing, the inhibitory activity.' 31  Modification of the anomeric centre is desirable 
since this is the reacting centre during incorporation of KDO into the developing LPS 
of the outer membrane. Carbocyclic analogues of -KDO,' 30"32 eg. (98) the cyclic 
analogue of 2-deoxy-3-KDO (99), 109  analogues of 2-deoxy--KDO modified at the 
carboxylic group' 02  such as (100), and an isosteric phosphonate analogue °7 of CMP-
KDO (101) have all been shown to be inferior to 2-deoxy-[3-KDO as inhibitors of 
CMP-KDO synthetase. 
A potential advantage of carbocyclic analogues 134  of 2-deoxy-3-KDO is that 
they are likely to be more stable than 2-deoxy-KDO as well as being more lipophilic, 
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thus allowing easier access across the bacterial cell membrane. However, this was not 
found to be the case, and analogues possessing the required a-orientation for the 
carboxyl group (98) lack substrate or inhibitory activity. 110,112  Retention of the ring 
oxygen of KDO appears to be required for activity, 129  with this oxygen being involved 
in a critical hydrogen bond to the enzyme. 136  The mandatory a-stereochemistry of the 
anomeric centre is maintained in the azacyclic analogue of 2-deoxy--KDO' 09 (102) 
and can donate a strong hydrogen bond 21  to the enzyme. Despite this, the azacyclic 
derivative (102) has poor binding capability compared to the oxacyclic analogue (96) 
which is an excellent inhibitor. This can be attributed to replacement of the ring 
oxygen with nitrogen rather than to removal of the C-2 hydroxyl group. 
Compounds such as (103) resulting from replacement of H-2 with small 
substituents of varying polarity were found to display low activity (<15% inhibition). 
The potent enzyme inhibitor 2-deoxy--KDO (96) has a close fit in the enzyme active 
site, whereas there is almost complete loss of inhibitory activity 131  for the 
corresponding methyl compound (104). This great difference in inhibitory activity 
between the 2-methyl-2-deoxy-KDO (104) and 2-deoxy-3-KDO (96) has been 
explained through a hypothesis proposed by Claesson et al, 113  which suggests that 
KDO binds to the active site together with CTP. However, when other substituents 
are introduced an unfavourable thermodynamic equilibrium develops thus resulting in 
loss of activity. 
Conformational factors appear to be irrelevant, 131  since alteration of the 2-
substituent does not affect the conformation of the pyranose ring. It is observed that 
the compound with CH 20H replacing the anomeric H (103), which is closely related 
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the compound with CH 20H replacing the anomeric H (103), which is closely related 
to KDO, exhibits low activity. The 8-substituted derivatives" of 2-deoxy-3-KDO 
eg. (105) are all potent inhibitors of CMP-KDO synthetase with the exception of the 
azido derivative (99). Compounds (105), (106) and (107) containing the substituents 
F, CH3 and NI-12  respectively at the 8-position are all inhibitors, indicating that the 
electronic properties of the substituent do not influence activity. However, steric 
factors are suggested to be important from the observation that the derivative (108) 
containing the larger thiol group is noticeably less active than 2-deoxy--KDO and 
that with the linear azido group (99) is even less active. 
In general, the enzyme binds isosteric phosphonate analogues several times 
more weakly than the naturally occurring phosphate 107  [(101) cf (109)]. This effect 
has been attributed to small differences in bonding geometries, deletion of a 
hydrogen bond to the phosphonate oxygen and steric interactions with the methylene 
hydrogen. 
One of the main difficulties encountered with analogues synthesised to date is 
that, although they may exhibit potent in vitro inhibition of the isolated enzyme eg. 
(96), their inability to penetrate the bacterial cell membrane results in limited, if any, 
antibacterial activity. However, by linking the 8-amino group or carboxyl substituent 
at C-2 to a dipeptide, eg. (110) and (111), it is possible to obtain derivatives with 
good antibacterial activity. 96,111,133  This involves the transport of inhibitor across the 
cytoplasmic membrane by the ubiquitous bacterial peptide permeases, with 
subsequent hydrolysis to give the active inhibitor. 
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1.5.6 Syntheses of KDO and Analogues 
There is an increasing interest 139  in short and efficient syntheses of KDO due 
to the continuing difficulty of its isolation from biological material as well as the 
requirement for the biological function of such complex glycoconjugates to be studied. 
The synthesis of KDO analogues is also important for the development of an entirely 
new class of Gram-negative antibacterials targeting the KDO biosynthetic pathway. 132 
Most of the approaches in the literature assemble the eight carbon skeleton of 
KDO by extending a five or six carbon chiral 
143141 140, 	
synthon, either D-arabinose or D- 
mannose, with a two 83, or three 142, carbon unit respectively via aldol or Wittig 
reactions. The methods required for the construction of the D-manno structure involve 
many steps for the completion of the structure of KDO and also separation of KDO 
and its isomers is often required. To date no reference has been found which makes 
use of nitrile oxide/isoxazolines for the formation of 2-ulosonic acids. 
Many enzymatic (based on sialic acid aldolase' 44 or KDO-8 phosphate 
synthase' 45) and chemical 2,140-169  syntheses have been developed, however the 
Cornforth method' 70,171  is considered to be the most practical involving chemical aldol 
condensation of D-arabinose with the four-carbon unit oxalacetic acid. Despite this, 
although several improved procedures have been reported, 159,164  eg. one pot reaction 
using Ni2 catalysed decarboxylation of the aldol adduct, the yield, stereoselectivity, 
and reproducibility of the reaction are not satisfactory. KDO and epi-KDO (epimeric 
at C-4) are both produced in a ratio >10:1 respectively. Oxalacetic acid, the starting 
material, is also rather expensive. The enzymatic aldol reaction 165  of D-arabinose and 
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pyruvate and reactions under nearly neutral and mild conditions catalysed by KDO 
aldolase may thus be useful for the synthesis of KDO and analogues. 
Kuhn 2,118  applied a different approach utilising the formation of lactone esters 
which could be hydrolysed to the corresponding enol lactone, then to the KDO salt. 
There have been many syntheses using the Wittig reaction, in particular those 
by Kochetkov,' 42 Hellwig" 7 and Collins. 140  Kochetkov uses protected D-arabinose 
and condenses this with a phosphonium salt (ylide) to yield a betaine, which is 
unstable and decomposes to form an alkene. In most of these procedures several 
additional steps are required to liberate the latent 2-keto group. 
Paquet and Sinay' 66 suggested the use of a phosphonate of a functionalised 
acceptor sugar, followed by mercuration/demercuration, thus providing directly a 
KDO-containing disaccharide in good yield but with low a/13  selectivity. Shiba et all 
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reported the preparation of KDO by nucleophilic substitution of a triflate group at C-i 
of a D-mannitol derivative with the anion of methyl glyoxylate dithioacetal. An 
interesting variation of this approach, using the 1,4-cyclic sulphate of D-mannitol, was 
reported by van Boom et al .94  Branchaud et al152 have described the use of 
cobaloxime-mediated radical alkyl-alkenyl cross coupling to construct the C-C bond. 
The total synthesis of KDO has many advantages, allowing analogues to be 
produced as potential inhibitors of the key rate determining enzyme. The following 
account will present some of the recent procedures used for the formation of KDO and 
its analogues. The first section deals with their preparation via the modification of 
carbohydrates, the second covers non-carbohydrate based approaches, and finally the 
enzymatic syntheses will be presented. 
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1.5.6.1 Syntheses from Carbohydrates 
1.5.6.1.1 Wittig Approach 
Schmidt et al 139  have reported the chain elongation of 4-0-benzyl-2,3:5,6-
di-0-isopropylidene-D-mannose (151) by a Wittig reaction with [(benzyloxy)(benzyl-
oxycarbonyl)methyl]triphenylphosphonium bromide (152) (Scheme 20). This Wittig 
salt is obtained via a one pot reaction from glyoxylic acid. Hydrogenolytic removal of 
the benzyl groups yielded the 4,5 :7,8-di-O-isopropylidene protected KDO (153) and 
subsequent deprotection afforded KDO. 
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(a) NaBH4; (b) PivCl, Py; (c) Nail, BzlBr; (d) NaOMe, 60°C; (e) DMSO, Ac70; 
(t) NaOBzl; (g) NaOMe, MeOH; (h) Pd/C, H 2 
Scheme 20 
KDO has also been synthesised via the Horner-Wittig adduct 
172  (Scheme 
21). The synthesis starts with protected D-mannose (154) which then reacts with 
methyl 2-benzyloxycarbonylamino-2-(diethoxyphosphoryl)acetate in the presence of 
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sodium hydride to give the Homer-Wittig adduct (155). The methyl a-oxoalkanoate 
derivative (156) was obtained by selective debenzyloxycarbonylation of (155). 
Subsequent debenzylation yielded the required derivative (157). 
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Scheme 21 
1.5.6.1.2 Radical Carbon-Carbon Bond Formation 
Giese et all  62  have reported the formation of a chain elongated product 
1 73  via the reaction of arabinosyl cobaloxime (158) with the pyruvate ester (159) 
in a radical C-C bond forming reaction. An intermediate in this reaction is assumed to 
be the acyclic derivative (160) of KDO, which eliminates acetic acid. Subsequent 
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Scheme 22 
Another approach via radical C-C bond formation was reported by Giese !61 
in the same year (Scheme 23). The ammonium salt of KDO is synthesised from D-
lyxose (162). 5-Bromo compound (163) reacts with alkene (164) via radical C-C bond 
formation and results in the production of a diastereoisomeric mixture of (165) and 
(166). After deprotection and reduction of (165), ozonolysis of 2,3-dideoxy-2-






No AcO 6—r 
(163) 	OAc 
OAc OAc 







(163) 	 (164) 
t.BuO2C 














OH OH 	 HO 
jOAcO 
AcO 	
d, e HO cO2H f, g, h 
HO COfNH4 
AcO OH OH 
(165) 	OAc 	 (167) 	
OH 
(a) Ac2OfPy, 68%; (b) NBS/CCI 4, reflux, 1 hr, ho, 35%; (c) AIBN/benzene, 80°C, 1.5 hr; 
(d) NaOHIH 20, r.t., 30 mm; (e) NaBH4/H20, r.t., 30 mm; (0 03/THF-H20 (9:1), 0°C, 10 mm; 
(g) Me2S, r.t., 10 hr; (h) NI-1 40H 
Scheme 23 
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1.5.6.1.3 -Oxy-a-diazo Carbonyl Compounds 
Both KDO and DAH are readily prepared by this method. 163  Reasonably 
high yields of both 3-deoxy-2-keto aldonic acids are produced under very mild 
conditions. For synthesising KDO, the 3-hydroxy-a-diazo carbonyl derivatives (169) 
and (170) are formed by aldol-like condensation of aldehyde 174 with ethyl 
diazoacetate. The Z:E enol acetates (171) are afforded after acetylation and rhodium 
catalysed decomposition. These acetates are then converted through to the ammonium 
salt of KDO (Scheme 24). 
J-0 	O_.I 
0 	 0 
TBSO 	CHO 
(168) 










O HO 	H 
HO 







— O 	 /—o r\ 
_L. 	O 	e, f 0 )-• 1 1 0 
.4- 
 OH	L.0O2Et 	TBSO 	LCO2Et 
N2 
(a) HCN2CO,Et, 74%; (b) Ac 20fPy; (c) Rh 2(AcO)4; (d) NH2NH2IMeOH, 88%; 
(e) Mn02fHCC13 ; (f) TBAF/THF; (g) m-CPBAIHCC1 3 ; (h) AcOH, 90°C, 15 mm; (j)  NH40H 
Scheme 24 
1.5.6.1.4 Dihalogeno Ester Carbanions 
This approach 11  involves the direct introduction of an a-keto ester moiety 
onto a carbonyl containing substrate via an alkyldichioro or dibromoacetate anion 
(Scheme 25). Starting from the protected D-mannose (172), the methodology allows 
for the installation of a pyruvic acid unit onto a glucidic aldehyde. This has two 
advantages; firstly the commercial availability of the alkyl dihalogenacetate, and 
secondly the desired ketosidic carboxylic acid is also readily accessible. Since the 
overall yield of the (+)-KDO ammonium salt from protected D-mannitol (172) is 63%, 
this is far better than any previously reported chemical syntheses of KDO, the best 
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15 mm, then K2C031H20, 60°C, 15 mm 
Scheme 25 
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1.5.6.1.5 Indium Mediated Allylation in Aqueous Media 
Whitesides et al have demonstrated  176  the use of metal mediated allylation 
for the construction of KDO. Addition of indium metal to 2,3:4,5-di-0-
isopropylidene-D-arabinose (173) and ethyl 2-(bromoethyl)acrylate afforded a mixture 
of diastereomers (174) (Scheme 26). The stereochemistry of this reaction is based on 
similar work performed by Schmidt  177  using acetonide-protected aldoses. After 
separation of the isomers, ozonolysis produces the cx-keto ester (175), which is 
converted through to the ammonium salt of KDO. 
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(a) In ethyl a-(bromomethyl)acrylate, 10% formic acid, aq. CH 3CN; (b)i 03 , MeOH, -78°C; 
ii Me2S, MeOH, 78°C to r.t.; (c) aq. TFA; NH 40H 
Scheme 26 
1.5.6.2 Syntheses from Non-Carbohydrates 
A number of syntheses using non-carbohydrate based starting materials have 
been utilised for the synthesis of KDO. The use of thiazoles as the synthetic equivalent 
of a formyl group has also been demonstrated in the synthesis of carbohydrates,  178  as 
already mentioned for the synthesis of DAH. The octulosonic acid KDO has been 
produced in 6.8% by chain elongation of D-arabinose diacetonide.' 78 
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1.5.6.2.1 Furan Route 
This route 10,179  provides a concise and efficient strategy for the asymmetric 
synthesis of (+)-KDO in twelve steps from furan and isopropylidene-D-glyceraldehyde 
(Scheme 27). The methodology can be extended to the de novo syntheses of other 
higher monosaccharides. The approach to KDO involves the oxidative conversion of a 
suitably functionalised furfuryl carbinol (176) into the desired dihydro-3-pyranone 
(177). The dihydropyranone then provides an excellent template for efficient, 
stereoselective introduction of new functional groups and substituents onto the 
hydropyran ring. 



























(a)i n-BuLl, THF, -78°C; ii ZnBr,, isopropylidene-D-glyceraldehyde, THF, 0°C: iii t-TBDMS, THF, 
r.t.; (b)i t-BuLi, THF, -78°C; ii BnOCH,Cl, n-Bu 4NF, r.t., 10 hr; (c) VO(acac) 2 , t-BuOOH, CH 2C12 , 
r.t., 3 hi; (d) Mel, A920, r.t., 12 hi; (e) K-Selectride, TI-IF, -78°C; (f) trichioroacetyl isocyanate, 
CH2Cl2 ; (g) I(Collodone) 2C104 , CH3CN, 24 hi; (h) HSn(n-Bu) 3 , AIBN, toluene, reflux, 3 hi; 
(j) Ra-NiIH2, 48 hi; (k) Oxalyl chloride; (1) A9 20, aq. NaOH, aq. EtOH, r.t., 24 hi; (m)i DOWEX 
50W(H), H 20, 80°C, 1 hr (pH<2); ii 5% NH40H, 0°C, 24 hi (pH 10); iii DOWEX 50W(H) (pH 7); 
iv sequential chromatography on cellulose and Sephadex G-10. 
Scheme 27 
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1.5.6.2.2 Using Functionally Substituted Vinyl Carbanions 
This synthesis 151  uses a C-lithiated, functionally substituted acrylic acid (2-
benzyloxy-3-(phenylthio)acrylic acid N-methylamide) (178) as a pyruvic acid-
equivalent three carbon building block and 2,3 :4,5-di-O-isopropylidene-D-arabinose 
(179) as a five carbon unit (Scheme 28). Steric and stereoelectronic influences favour 
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(a) LDA, THF, HMPT; (b) AcOEtJ petroleum ether, reflux, 6 hr; (c) Bu 3SnH, benzene, AIBN, 
reflux, 8 hr; (d) Py, HBr, reflux, 24 hr; (e) Pd/C, H 2; (0 CF3COOH; (g) NH3 
Scheme 28 
1.5.6.2.3 Aqueous Hetero Diels-Alder Reaction 
This route 105  involves synthesis of 2-deoxy-KDO as a synthetic 
intermediate, which can then be used as a precursor of glycosyl donors of KDO, 
leading to a large range of compounds (Scheme 29). 
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The strategy is based upon three key steps leading to an activated form of 
KDO. The first step which has never been used before for the construction of 
carbohydrates is via a hetero-Diels Alder reaction involving the formation of the C-
2/C-3 and C-6-0 bonds in (180). Cis dthydroxylation via osmylation of the newly 
created double bond, followed by oxidation (his inversion) of a 2-deoxy-ulosonic acid 
provided access to KDO. The heterocycloaddition, both in water or in neat conditions, 
exhibits only modest facial stereoselectivity (74:26), however the next two steps are 
totally stereospecific. The advantage of this method is that it uses the cheap 
commercial aqueous solution of glyoxylic acid. 
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min, then H2, Pd/C, then dimethoxypropane, acetone, p-TsOH; (h) LDA, TFA; (j) PhSSPh; (k) 
NBS-H20; (1) Dowex 50 (H'), NaOH, Dowex 50 (NH) 
Scheme 29 
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1.5.6.3 Enzymatic Approaches 
Enzyme catalysis has a major advantage synthetically in that the 
stereoselectivity of the resulting products can be predicted. 80  However, different 
solvents, 181  substrate structures,' 82  or temperatures 183  can occasionally change the 
stereoselectivity. The diastereofacial selectivity of the aldehyde component in 
enzymatic aldol reactions is often consistent and completely controlled by the 
65 enzyme. 
Sialic acid aldolase-catalysed condensation of pyruvate with D-arabinose 
(181) (Scheme 30) results in a lack of stereoselectivity of the aldolase with equimolar 
amounts of KDO and epi-KDO being observed both in their pyranose and furanose 
forms. 144,168,184,185 
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R=H, R'=OH(KDO) 	R=H, R=OH 
R= OH, R'=H(epi-KDO) R= OH, R=H 
(a) sialyl aldolase, pyruvate 
Scheme 30 
However, a practical preparation of KDO can be obtained by this method 
using a high concentration of the acceptor D-arabinose, and this leads to an increase in 
percentage of KDO up to 83%. The inverted stereoselectivity originates from the 'C 4 
major D-arabinose conformer. Complete inversion of stereoselectivity has been 
noticed recently ' 68" 69 for this aldolase with various sugars such as 6-deoxy-L-mannose 
and L-mannose which are known to adopt the preferred 'C 4 conformation. In each of 
these cases facial attack was exclusively re resulting in generation of a single product 
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in 80% yield with R configuration at the new stereogenic centre. Synthesis of KDO 
was achieved with a 25-fold excess of D-arabinose in an enzyme membrane reactor 
allowing a continuously operating process. Anion-exchange chromatography 185  was 
used to successfully separate the diastereoisomers and isolate pure KDO. 
Enzymic synthesis of KDO has been reported using KDO-8-phosphate 
synthetase 	to 	catalyse the 	reaction of D-arabinose-5-phosphate 	with 
phosphoenolpyruvate.' 45 The enzymatic synthesis using KDO aldolase 7 on a multi-
mmol scale can also be achieved using D-arabinose (182) and a 10 molar excess of 
pyruvate (183) to give 67% yield of ammonium KDO (Scheme 31). 
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(a) KDO aldolase 
Scheme 31 
The re face of the carbonyl group of the acceptor substrate is attacked by the 
pyruvate. This is complementary to the majority of sialic acid aldolase reactions which 
are under si face attack. The yield of enzymatic reaction is comparable to the highest 
one obtained by the modified Cornforth synthesis (66%).164  So KDO aldolase-
catalysed condensation is effective for the synthesis of KDO and analogues. The 
reactions are stereospecific with formation of a new R stereocentre at C-3 from D-
arabinose and related substructures. 
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2 	RESULTS AND DISCUSSION 
2.1 	Introduction 
There is considerable interest in the role of ulosonic acids in various 
biological systems and in their potential pharmaceutical and agrochemical 
applications. Although much effort  2,4,68,96,1 44  has been devoted to the isolation, 
characterisation and preparation of the ulosonic acids themselves, and to investigating 
their biological fttnctions, there is a need for novel synthetic routes designed to 
produce a variety of analogues. A number of methods, including iterative procedures, 
convergent and non-convergent syntheses have been used (see Sections 1.4.5 and 
1.5.7 for surveys). The approach adopted in the present work has been to construct 
ulosonic acid analogues via an intermediate isoxazoline formed by the cycloaddition 
of a nitrile oxide to a sugar alkene. In comparison to the complexity of the routes 
outlined in the above mentioned surveys, our approach is short and offers access to a 
wide range of analogues. Nitrile oxide/isoxa.zoline methodology, which is widely 
used in natural product synthesis,  186  involves three basic steps (Scheme 32). 
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This chemistry is considered to be particularly well suited for the 
construction of the ulosonic acid framework. The overall synthetic strategy (Scheme 
33) involves regiospecific and diastereoselective cycloaddition of the nitrile oxide to 
the appropriate sugar alk-1-ene. Deprotection and reductive hydrolytic ring cleavage 
of the resulting isoxa.zoline should then afford the target compound, initially in its 
open chain form. Analogues can be produced by varying the alkene and nitrile oxide 
components and by modification of substituents at the isoxazoline stage (Scheme 32). 
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A model system (Scheme 34) involving hexulosonic acid analogues was first 
investigated in order to establish the methodology which could then be applied to the 
synthesis of higher 2-ulosonic acid derivatives of biological significance. 











2.2 Synthesis of Nitrile Oxide Precursors 
Two methods were used for the generation of the nitrile oxides: 
dehydrochiorination of the parent hydroximoyl chloride with triethylamine and 
dehydration of nitroethane with isocyanate and tnethylamine (Scheme 35). In each 
case the nitrile oxide was formed in situ to minimise the formation of unwanted side 
products. 
-HC 	 + 	-H20 
RCCINOH 	0, RC=—N-0 4 	RCH2NO2 
R=CO2Et 
R = Ph 
Scheme 35 
Ethyl chloro-oximinoacetate (Et0 2CCCI=N0H) (184) was prepared 187  in 48% 
yield by nitrosation of glycine ester hydrochloride using hydrochloric acid and sodium 
nitrite. Synthesis of benzohydroximoyl chloride (PhCCI=NOH) (185) 188  involved 
conversion of benzaldehyde to the corresponding oxime with subsequent chlorination 
using chlorine gas to the desired compound in 80% yield. 
(Diethoxyphosphoryl)acetohydroximoyl chloride (189) was prepared by the 
method of Tsuge' 89 from bromoacetaldehyde diethyl acetal (Scheme 36). After 
heating with triethyl phosphite fractional distillation yielded the phosphonate 
derivative (186) which was converted to aldehyde (187) by treatment with aqueous 
hydrochloric acid. Reaction of the aldehyde (187) with hydroxylamine hydrochloride 
provided the oxime (188) in 61% yield which was shown to be present as an 
approximately 7:4 mixture of the antilsyn isomers. The hydroximoyl chloride (189) 
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was produced by addition of chlorine gas to oxime (188) and then in situ 
dehydrochiorination afforded the desired nitrile oxide. 
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(d) C12 , - 10°C 
Scheme 36 
Acetonitrile oxide (191) was generated by a modification of the Mukaiyama 
method. 36  This involved in situ dehydration of nitroethane (190) using tolylene-2,4-
diisocyanate (TDI) in conjunction with a catalytic amount of triethylamine (Scheme 
37). 




(190) 	 (191) 
Scheme 37 
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2.3 3-Deoxy-hexulosonic Acid Analogues 
The approach selected for the synthesis of hexulosonic acid analogues is via 
the four carbon alkene (195) and involves three stages; cycloaddition of the alkene to 
an appropriate nitrile oxide followed by, either deprotection and subsequent reductive 
hydrolytic ring opening of the isoxazoline or vice versa (Scheme 34). Previous 
observations' 90 have shown that isopropylidene-protected D-glyceraldehyde (192) is 
difficult to handle with a tendency to polymerise, as well as being unstable in the 
presence of acids. To minimise these difficulties cyclohexylidene protection' 9° which 
affords a more stable aldehyde was chosen as the source of our model alkene (195). 
2.3.1 Synthesis of 1,2-Dideoxy-3,4-0-cyclohexylidene-D-glycero-but-1 -enitol 
(195) 
1 ,2-Dideoxy-3 ,4-O-cyclohexylidene-D-glycero-but- 1 -enitol 	(195) 	has 
previously been prepared from but-3-ene- 1,2-diol and cyclohexanone/2,2-
dimethoxypropane/p-TsOH(catalyst) in benzene by transketalisation.' 91 ' 92 However 
the starting material is not readily accessible. In the present work, the route selected 
involved Wittig olefination of the easily prepared D-glyceraldehyde derivative (194) 
(Scheme 38), 10 and the title compound was thus available in three steps from D-
mannitol with an overall yield of 45%. Selective protection' 9° of the free C-i, C-2 and 
C-5, C-6 vicinal hydroxyls using cyclohexanone, triethyl orthoformate and boron 
trifluoride etherate as a catalyst yielded the dicyclohexylidene adduct (193). The 
reaction is suggested' 90 to proceed in two steps: formation initially of cyclohexanone 
diethyl acetal, followed by acetal exchange with mannitol. Subsequent treatment with 
sodium periodate and tetrabutylammonium bromide as phase transfer catalyst afforded 
the aldehyde (194). Since (194) polymerises on standing, its purification by 
distillation/sublimation using a cold-finger distillation apparatus was performed 
immediately prior to the Wittig reaction using methyl triphenylphosphorane for the 




















(a) Cyclohexanone, HC(OE0 3 , BF3 .Et20, DMSO; (b) Na1 4, Bu4NBr; 
(c) Ph 3PCH3I, (CH3 )3 COK, TI-IF 
Scheme 38 
2.3.2 Investigation of it-Facial Selectivity in Nitrile Oxide Cycloadditions to 
1,2-Dideoxy-3,4-0-cyclohexylidene-D-glycero-but-1-enitol (195) 
2.3.2.1 Nitrile Oxide Cycloadditions to Alkene (195) 
Four nitrile oxides were examined: ethoxycarbonylformonitrile oxide 
[Et02CCNtO], benzonitrile oxide [PhCNtO], (diethoxyphosphoryl)acetonitnle 
oxide [(Et0) 2P(0)CH2CN-0] and acetonitrile oxide [CH 3 CN-O]. The first three 
were generated in situ by slow addition, via a motorised syringe pump, of 
triethylamine (1.1 M eq) in diethyl ether to a chilled solution of the hydroximoyl 
chloride and a slight excess of the appropriate alkene (1:1.5) in diethyl ether at 0°C. 
These conditions were chosen to generate a low concentration of the nitrile oxide in 
the presence of excess dipolarophile in order to minimise the competing dimerisation 
of the nitrile oxide to unwanted furazan N-oxide (furoxan) by-products. The 
diastereoisomeric cycloadducts were separated from the excess alkene and dimers by 
chromatography. A small quantity of the adduct mixture was retained for isomer ratio 
determination, while the remainder was separated by flash chromatography to afford 
the pure isoxazolines. The diastereoisomeric ratios were determined by comparison of 
corresponding integrals in the 'H NMR spectra of the cycloadduct mixtures. The 
recovered alkene was sufficiently pure for reuse. The individual adducts were 
characterised by 'H and ' 3C NMR spectroscopy, FAB mass spectroscopy and optical 
rotation. Chemical formulae were verified by high resolution FAB mass spectroscopy 
and/or combustion analysis. The assignment of configuration for the newly created 
chiral centre at C-5 is based on correlation of NMR and optical rotation data with a 
previously reported X-ray analysis' 9 ' for benzonitrile oxide adduct (196). 
M. 
Cycloaddition of alkene (195) to benzonitrile oxide (Scheme 39) was carried 
out as outlined above. A mixture of diastereoisomeric isoxazolines (196) and (197) in 
combined yield of 88% and ratio of 79:21 was obtained after chromatography to 
remove 3,4-diphenylfurazan N-oxide (the nitrile oxide dimer) (5%). The isomer ratio 
was determined by comparison of the integrals for the epimeric 5-H signals in the 'H 
NMR spectrum of the mixture. The assignment of 5S-configuration for the major 
isomer (196) corresponding to an erythro relationship about the C-5/C-6 bond was 
made by correlation of ' 3C NMR shift differences with those reported by Jager' 9 ' for 
addition of benzonitrile oxide to the same alkene (195), and also on optical rotation 
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(196) R=Ph 
(198) R=CO2Et 
(200) R = CH2P(0)(OEt) 2 
(202) R =Me 
(204) R = CH20H 
Scheme 39 
(197) R = Ph 
(199) R=CO2Et 
(201) R = CH2P(0)(OEt) 2 
(203) R = Me 
(205) R = CH20H 
Similarly, the corresponding cycloaddition of ethoxycarbonylformonitrile 
oxide to the same alkene (195) afforded the adducts (198) and (199) in combined 
yield of 68% and ratio 77:23 together with the nitnle oxide dimer 3,4- 
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diethoxycarbonylfurazan N-oxide (17%). The ratio was again determined by 
comparison of the integrals of the 5-H signals in the 'H NMR of the mixture. 
Although crystalline solids were obtained for both adducts, X-ray analysis was not 
necessary since the configuration at C-5 for the main product could be confidently 
assigned by correlation of ' 3C NMR shift differences, 19 ' optical rotation data and TLC 
properties. The major adduct (198) was thereby assigned S-configuration at C-5, 
corresponding to an erythro relationship about the C-5/C-6 bond. 
Cycloaddition of (diethoxyphosphoryl)acetonitrile oxide to the title alkene 
(195) produced a 40% combined yield of the diastereoisomeric 2-isoxazolines (200) 
and (201) in a ratio of 81:19 (Scheme 39). Again the ratio was determined by 
comparison of the integrals for the 5-H signals in the 'H NMR. Although the 
isoxazolines were chromatographically inseparable the isoxazoline ring protons for 
each isomer could be assigned in the 'H NMR of the mixture due to differences in 
signal intensities. The major isomer was identified as the erythro adduct (200) based 
on comparison of its spectral parameters with those of similar adducts, as above. 
Finally, the cycloaddition of acetonitrile oxide to alkene (195) was 
accomplished using the Mukaiyama procedure. In situ dehydration of nitroethane 
(190) using tolylene-2,4-diisocyanate (TDI) in conjunction with a catalytic amount of 
triethylamine generated the desired acetonitrile oxide and the diastereoisomeric 2-
isoxazolines (202) and (203) were formed in a ratio 82:18 and a combined yield of 
65% (Scheme 39). The ratio was determined from the epimeric 5-H proton signals 
which were well resolved. Again the major isomer was assigned as having erythro 
stereochemistry based on comparison of spectral and TLC properties. 
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The nitrile oxide cycloadditions to alkene (195) all proceed with moderate it-
facial selectivity in favour of eiythro adducts with d.e. values ranging from 54% for 
ethoxycarbonylformonitrile oxide to 64% for acetonitrile oxide. The erythro:threo 
ratios for the four case are presented in Table 1. 






Table 1 : Isomer Ratios for Cycloaddition of Nitrile Oxides to Alkene (195) 
2.3.2.2 Characterisation of Isoxazoline Cycloadducts 
It has been reported by Jager et al'91 that correlation of 'H and ' 3C NMR data 
and optical rotation is a reliable method for predicting the stereochemistry at the new 
chiral centre at C-5 of the isoxazoline. A similar approach has been adopted for 
assigning structures to the individual major and minor adducts in the present work. 
These characteristic properties are therefore summarised below, along with those for 
(204) and (205) obtained after borohydride reduction (Section 2.3.7). 
TLC 
The major erythro adduct in each case has a larger R f value on silica than the 
corresponding minor threo adduct [0.23 cf 0.14 for (196)1(197), 0.15 cf 0.09 for 
Me 
(198)/(199) (30% ether/hexane); 0.28 cf 0.21 for (202)/(203), 0.57 cf 0.52 for 
(204)/(205) (100% ether)]. 
'H NMR 
The 'H NMR spectra show major differences between the isomers for protons 
4a-H, 4b-H, 5-H and 6-H. The isoxazoline ring protons 4a-H and 4b-H give rise to a 
characteristic ABX system with 5-H, which is adjacent to the ring oxygen at highest 
chemical shift. The 3J values of 6-11 Hz for 4ab-H/5-H and the geminal coupling of 
ca 18 Hz for 4a-H14b-H are also typical of 3,5-disubstituted isoxazolines.' 93 ' 95 It is 
observed that for the major erythro adduct the 5-H signal absorbs at significantly 
lower frequency than for the corresponding minor threo product 1A6 H -0.17 ppm for 
(196)/(197), -0.13 ppm for (198)/(199), -0.08 ppm for (200)/(201), -0.18 ppm for 
(202)/(203), -0.14 ppm for (204)/(205)]. The signals for the methylene protons of the 
isoxazoline ring, 4a-H and 4b-H, are closer together in the major erythro adducts. 
This is particularly noticeable when comparing isomers (198) and (199). In the case 
of major erythro adduct (198) they are coincident, while in the minor threo 
diastereoisomer (199) they are separated by 0.10 ppm. It is noteworthy that the 
coupling between 5-H and 6-H in the erythro isomer is significantly greater than that 
in the minor threo product [7.6 cf 4.4 Hz for (196)1(197), 7.0 cf 4.2 Hz for 
(198)/(199), 7.8 cf 4.6 Hz for (202)/(203), 7.1 cf 4.4 Hz for (204)1(205)]. This 
suggests that the two compounds adopt different conformations in solution. The 
chemical shifts and coupling constants are summarised in Tables 2 and 3. 
Q Q 










4a-H 4b-H 5-H 6-H 
Ph Erythro (196) 3.37 3.47 4.64 4.05 
Threo (197) 3.88 3.26 4.81 4.33 
CO2Et Erythro (198) 3.26 3.26 4.70 4.08 
Threo (199) 3.14 3.24 4.83 4.25 
CH2P(0)(OEt) 2 Erythro (200) 3.12 3.20 4.54 nd 
Threo (201) 3.25 3.17 4.62 nd 
Me Erythro (202) 2.91 3.01 4.41 3.95 
Threo (203) 2.94 2.81 4.59 4.20 
CH20H Eiythro (204) 3.06 3.14 4.53 4.02 
Threo (205) 2.97 3.10 4.67 4.23 




4a,4b 4a,5 4b,5 5,6 
Ph Erythro (196) 17.0 7.3 9.3 7.6 
Threo (197) 17.1 10.7 8.3 4.4 
CO2Et Erythro (198) - 8.9 8.9 7.0 
Threo (199) 17.8 11.4 8.5 4.2 
CH2P(0)(OEt) 2 Erythro (200) nd 6.5 10.6 6.5 
Threo (201) nd 11.1 8.0 5.2 
Me Erythro (202) 17.3 6.4 10.1 7.8 
Threo (203) 17.2 10.9 7.9 4.6 
CH20H Erythro (204) 17.5 6.9 10.1 7.1 
Threo (205) 17.5 11.0 7.9 4.4 
Table 3: Selected 'H NMR data for cycloadducts 
' 3C NMR 
The ' 3 C NMR spectra for the pairs of isomers show significant differences for 
C-4 to C-7. In each case the major erythro adduct has a higher 6-value for C-4 [A6 
+1.2 ppm for (196)1(197), +0.7 ppm for (198)/(199), +0.7 ppm for (202)/(203), +1.0 
ppm for (204)/(205)] as does C-5 (6c +1.0 ppm for each of the pairs of isomers). 
There is also a marked difference shown for C-7 [M +2.0 ppm for (196)1(197), +1.8 
ppm for (198)/(199), +2.1 ppm for (202)/(203), +1.9 ppm for (204)/(205)]. These 





C-4 C-5 C-6 C-7 
Ph Erythro (196) 37.7 81.3 75.5 66.8 
Threo (197) 36.5 80.3 75.8 64.8 
CO2Et Erythro (198) 36.3 83.5 75.1 66.4 
Threo (199) 35.6 82.5 75.6 64.6 
Me Erythro (202) 36.4 80.3 75.6 66.8 
Threo (203) 35.7 79.3 75.8 64.7 
CH20H Erythro (204) 37.6 81.0 75.5 66.7 
Threo (205) 36.6 80.0 75.5 64.8 
Table 4: Selected ' 3 C NMR data for cycloadducts 
Optical Rotation 
The major erythro isomer in each case was found to have a more positive [am 
value. These values were measured at similar concentrations in chloroform. This 
result is important for correlation with known adducts' 9 ' and for thus assigning 

















It is observed that the minor threo isomer always has a slightly higher m.p. 




Ph 61-63' s ' 96-98 
CO2Et 40.8-41.9 47-49 
CH20H 80-82 83.5-85.5 
Table 6 
2.3.2.3 Rationale for Stereoselectivity of Nitrile Oxide Cycloadditions 
The degree of it-facial selectivity observed for cycloadditions to alkene (195) 
in favour of erythro adducts can be rationalised in terms of the so-called "inside 
alkoxy effect" hypothesis proposed by Houk et al' 96  to account for nitrile oxide 
cycloadditions to chiral allyl ethers. 
Control of selectivity in nitnle oxide cycloaddition reactions is a key target in 
the development of the nitrile oxide-isoxazoline synthetic route to natural products 
and analogues, and has been the subject of intensive investigation. 15,16,43-45,193  Whereas 
the reaction with monosubstituted alkenes is either regiospecific or highly 
regioselective (>90:10) in favour of 5-substituted 2-isoxazoline cycloadducts,' 3 the 
extent of it-facial discrimination in additions to alkenes bearing an allylic stereocentre 
is more variable. ' 9699 The ratio of products is dependent on the steric and electronic 
nature of both the allylic and homoallylic substituents, and appears to be subject to 
7011.1 
subtle variations in geometry. Chiral allyl ethers (206) yield predominantly erythro 
adducts' 97  resulting from anti addition (Scheme 40, R' # H), this preference being 
attributed to the so-called "inside alkoxy effect" proposed by Houk et al. 196- 198  There 
is negligible effect on the selectivity by varying the alkoxy substituent R'. 
R, 














However, for the special case of allyl alcohols (R' = H), the selectivity can be 
markedly different, with a slight preference for the threo product sometimes being 
observed. 197  Changing the bulkiness of the R group results in an increase in erythro 
selectivity. In contrast, for S-but-3-ene- 1,2-diol (207) and its diacetate derivative 
(208) the reported 196  diastereoselectivity is low with d.e. values of 22% and 6% 
respectively for the formation of isoxazolines (210)/(211) and (212)/(213) on reaction 
with benzonitrile oxide (Scheme 41). Somewhat higher levels of selectivity (50-60% 
d.e.) were found for the corresponding addition to 2-vinyl-1,3-dioxolane (209), the 
cyclic analogue in which the 1,2-diol is protected as its isopropylidene derivative. 196,198 
This level of selectivity is similar to that observed in our present work involving 
cyclohexylidene protection. 
we 





Erythro 	 Threo 
(207)R=R'=H 	(210)R=R'=H 	(211)R=R'=H 
R = R'= Ac (212) R = R'= Ac (213) R = R' = Ac 
RR' = CMe2 
Scheme 41 
As already mentioned Houk's 'inside alkoxy effect' hypothesis can account for 
the observed it-facial selectivity. Six possible staggered transition state structures can 
be drawn for the cycloaddition of a nitrile oxide to a chiral allyl ether (Figure 5). 
Theoretical calculations by Houk et al' 96  of the relative energies of these transition 
states places them in ascending order of energy : A<A'czB<B'<C'<C. The major 







The preferred lowest energy transition state based on a Felkin 200-Ahn20 ' model 
has the largest substituent (R) anti, the smallest (H) "outside", and the alkoxy (OR') 
in the "inside" position (Figure 6). 
	
- 	a: anti 
i 	•' o 	i : inside 
0 : outsid 
Figure 6 
This results in formation of the major isomer with erythro stereochemistry. 
The minor threo isomer is produced from the second lowest energy transition state A'. 
Increase in size of the R group causes an increase in the C=CCR dihedral angle e, and 
hence increased 7t-facial selectivity. The reverse is true for A'. A is stabilised relative 
to A', since the unfavourable lone pair interactions between the allylic oxygen and 
nitrile oxide oxygens are reduced due to the two oxygens being forced further apart. 
Secondary orbital interactions were proposed by Houk 
196  to explain the 
preference of the inside position for the alkoxy group over the anti position. 
Unfavourable oxygen lone pair interactions between the oxygen of the nitrile oxide 
and the allylic alkoxide make the outside position less favourable. Nitrile oxide 
cycloadditions are mildly electrophilic; hence electron donating substituents on the 
dipolarophile will stabilise the resulting transition state. With the alkoxy (OR') group 
anti there is maximum overlap of the aK  and ir-orbitals, resulting in destabilisation 
of the transition state. In comparison, with the OR' group inside this unfavourable 
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overlap is minimised. Electron donating orbitals CYCH and CYCR further stabilise this 
transition state by overlap with the ic-orbital. 
The low selectivities observed for addition to chiral allyl alcohols may be 
explained in terms of a hydrogen bond interaction between the oxygen of the nitrile 
oxide and the allyl hydroxyl, resulting in A' being the slightly preferred transition 
state; hence a reduction in erythro selectivity. The isomer ratios predicted correlate 
well with experimentally determined values. 
An alternative, non-theoretically based model has been proposed by 
Kozikowski.' 99 It predicts that the major isomer is formed by antiperiplanar addition 
of the incoming nitrile oxide to the alkoxy group (equivalent to transition state B in 
Houk's analysis, Figure 5). He argues that the transition state minimises secondary 
antibonding orbital interactions, a direct contradiction of Houk's proposal. The more 
widely accepted explanation is that proposed by Houk. 
The hypothesis that the stereochemistry of the cycloadditions is determined by 
electrostatic interactions between the nitrile oxide oxygen and allylic oxygen has been 
reinforced recently by improved calculations. 202  These have also shown that the exact 
diastereoselectivity is dependent on the charge distribution in the nitrile oxide. 203 
As will become apparent in later discussions (Section 2.4.2) the presence of 
homoallylic substituents also has a marked influence on selectivity. This effect has 
been studied by De Micheli et a1204 and Paton et a1205 for nitrile oxide cycloadditions 











X Alkene Nitrile 
Oxide 
erythro : threo 
Expt. Caic. 
H (214) HCNO 73.5 : 26.5b 65 : 35 
OMe (214) HCNO 96.5 : 15b 67: 37 
OBn (214) Et02CCNO 86: 14' 







 MesCNOa 74: 26b 
OBn  Et02CCNO 51: 49C - 
(215) PhCNO 42: 58' - 
a  2,4,6-Trimethylbenzonitrile oxide 	b  Ref. 204 	C  Ref. 205 
Table 7: Isomer ratios for addition of nitrile oxides to alkenes (214) and (215) 
It was observed that for the xylo-alkenes (214) homoallylic alkoxy substituents 
at C-3 resulted in significantly higher e,ythro selectivity than would be predicted by 
Houk's 'inside alkoxy effect' model. For the deoxy analogue (X = H), the 
experimental and calculated values are much more comparable. From these results De 
Micheli et a1204concluded that the lone pair on the homoallylic oxygen (3-0R) must be 
exerting a stereoelectronic effect. They proposed that in the lowest transition states A 
and A' there is an unfavourable and destabilising interaction of the homoallylic oxygen 
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lone pair with the double bond. However, in B the next lowest transition state, this 
interaction (lone pair/ic-bond) cannot occur and hence the relative importance of B 
increases and there is an increase in erythro selectivity (Figure 7). In marked contrast 
the D-ribo alkene (215) exhibits low selectivities 205 indicating the the 'inside alkoxy 
effect' exerted by the furanose ring oxygen (0-4) is not the only factor governing 
selectivity, and that the effect of the allylic group may be either reinforced or 
counteracted by homoallylic groups. 
fit 
H 
C:R'fO— H R'Ot 





2.3.3 Synthetic Utility of (Diethoxyphosphoryl)acetonitrile Oxide (216) 
There are many advantages of using (diethoxyphosphoryl)acetonitrile oxide 
(216) as an a-functionalised dipole, not least its synthetic versatility 16,189  (Scheme 42). 
It should afford C-glycosides eg.(217) which might prove to be inhibitors for the 
glycosyl transferases. 206  As already mentioned in Section 1.4.3, the presence of a 
phosphorus containing substituent (as a phosphonate) in DAH analogues enhances the 
inhibitory activity. This therefore makes the introduction of phosphorus substituents 
an important area of study. 
74 
OH 
HO 0 O 





It may also allow in vivo inhibition by facilitating transport of these 
phosphonate compounds across the protein cell membrane. Often analogues are able 
to act in vitro, but penetration of the membrane is the stumbling block preventing 
antibacterial action. Furthermore, the resulting 2-isoxazolines (218) could be altered 16 
by replacement of the phosphorus moiety with an alkene substituent to give (219). 
Other possible modifications include reductive ring cleavage of the isoxazoline (220) 
using Raney-Ni affording phosphorus-functionalised -hydroxyketones (221), and 
displacement of the phosphorus group by aldehydes or alkyl halides to yield (222). 













R2 	 R 
(219) 
Scheme 42 
T k(2 2 2) R 
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Hence, the use of (diethoxyphosphoryl)acetonitrile oxide (216) has great 
potential for the synthesis of inhibitors of DAH and KDO. However, its application 
still needs to be investigated in more detail, since the 2-isoxazoline mixtures have so 
far proved to be inseparable. 
2.3.4 Stereoselective Cycloadditions of Nitrile Oxides to a Dispiroketal-
Protected S-But-3-ene-1,2-dio! (226) 
In an attempt to control selectivity in nitrile oxide cycloaddition reactions to 
but-3-ene- 1,2-diols, a dispiroketal protecting group has been utilised. This is a new 
protecting group developed by Ley et a1207 for vicinal diols and incorporates the diol 
into a six membered 1 ,4-dioxane ring as a spiroketal. Prompted by a report 208 that the 
addition of various organometallic reagents to the carbonyl group of a dispiroketal-
protected D-glyceraldehyde (223) is highly selective, an effect attributed to the rigidly-
defined geometry of the dioxane ring and the large steric bulk of the dispiroketal 
moiety, the corresponding 2-vinyl-1 ,4-dioxane spiroketal alkene (226) has been 
prepared, and its cycloaddition reactions with nitrile oxides examined. 
2.3.4.1 Synthesis of (6R,7R,14S)- 14-Ethenyl-1,8,13,1 6-tetraoxadispiro[5.O.5.4] 
hexadecane (226) 
The required 2-vinyl-1 ,4-dioxane spiroketal dipolarophile (226) was prepared 
in two steps from 3-hydroxyethy1 compound (224) according to Scheme 43, with an 
overall yield of 35%. (224) was converted to the tosyl derivative (225), as previously 
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described, 208 followed by elimination of toluenesuiphonic acid using potassium ten'
butoxide to give the desired vinyl compound (226) which was purified by dry flash 
chromatography. 









(a) TsCI, Py, r.t., 3 hr; (b) t-BuOK, DMSO, r.t., 2 hr 
Scheme 43 
2.3.4.2 Nitrile Oxide Cycloadditions to Alkene (226) 
The cycloaddition of ethoxycarbonylformonitrile oxide to alkene (226) 
(Scheme 44) was carried out as outlined in Section 2.3.1. After chromatography to 
remove 3,4-diethoxycarbonylfurazan N-oxide (6%), a mixture of diastereoisomeric 








(227) R = CO2Et 




(228) R = CO2Et 
(230) R = Ph 
The isomer ratio was measured from the 'H NMR spectrum of the product 
mixture by comparison of the 5-H signals, which were well separated. HPLC analysis 
gave a similar value (71:29). In order to identify the individual isomers, and assign the 
relationship between the newly created chiral centre (C-5) and the adjacent 
asymmetric centre (C-14') of the 1,3-dioxane unit, the major isomer was deprotected 
and the product compared with authentic samples generated from cyclohexylidene-
protected adducts. These correlation experiments will be discussed in Section 2.3.8.6. 
The major isomer (227) was therefore assigned S-configuration at C-5, corresponding 
to an erythro relationship between C-5 and C-14'. This predominance of erythro 
adduct can be rationalised in terms of the 'inside alkoxy effect' proposed by Houk et 
al' 96  to account for nitrile oxide cycloadditions to chiral allyl ethers. 
Similarly the corresponding cycloaddition of benzonitrile oxide to the same 
alkene (Scheme 44) afforded the adducts (229) and (230) in a ratio 75:25 and a 
combined yield of 40%, together with 3,4-diphenylfurazan N-oxide (8%). The ratio 
was again determined by comparison of the 5-H signals in the 1 11 NMR spectrum of 
the mixture. The structures of the individual isomers were assigned by comparison of 
W. 
their physical and spectroscopic properties with those of the ethoxycarbonyl 
analogues (227) and (228). Further confirmation of the erythro configuration for the 
major isomer was obtained from X-ray crystallography of isomer (229). 
The nitrile oxide cycloadditions to alkene (226) both proceeded with moderate 
it-facial selectivity in favour of the erythro adducts with d.e. values of 44% for 
ethoxycarbonylformonitnie oxide and 50% for benzonitrile oxide. 
2.3.4.3 X-Ray Crystal Structure of Adduct (229) 
The major adduct (229) obtained from addition of benzonitrile oxide to alkene 
(226) was isolated as a crystalline solid suitable for X-ray analysis. The crystal 
structure (Figure 8) provided further confirmation that the new asymmetric centre at 
C-5 possessed S-configuration, thus establishing the ervthro relationship between C-5 
and C- 14'. This assignment is consistent with that predicted by the 'inside alkoxy 
effect.' 
Using the Haasnoot parameterisation 209 of the Karplus equation the proton-
proton coupling constants were calculated from the H-C-C-H torsion angles obtained, 
and compared to those observed in solution (Table 8). Consideration of the data 
indicates satisfactory correlation between the observed and calculated J-values for the 
isoxazoline ring protons, as well as between J4,5a  and J4,5e.  However, there is a 
significant deviation associated with the coupling between 3-H/4-H at the ring 









HX ,HY 1 
2a,3 3b,3 3,4 4,5a 4,5e 
°Obs -150.5 -27.0 178.2 174.7 56.0 
SObs 8.8 8.8 7.7 9.3 4.7 
CaIc 8.2 6.6 10.3 10.2 3.2 
3.J 1  = 7.76Cos8 - 1.1Cos9 + 1.4 
Table 8: Calculated and observed coupling constants for (229) 
2.3.4.4 Characteristics of Isoxazoline Cycloadducts 
Comparison of the physical and spectroscopic properties of the major and 
minor cycloadducts obtained, together with those previously reported for 
cycloadditions to the cyclohexylidene-protected alkene (195), indicated a number of 
distinctive features upon which the prediction of the stereochemistry at the new chiral 
centre could be made. These characteristic properties are summarised below. 
TLC 
The major erythro adduct in each case has a larger R f value on silica (60% 
ether/hexane) than the corresponding minor adduct [0.33 cf 0.23 for (227)/(228), 0.37 
cf0.26 for (229)/(230)]. 
'Labelling of protons in X-ray picture is different from that used in characterisation of products 
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1H NMR 
The 'H NMR spectra show major differences between the isomers for protons 
4a-H, 4b-H and 5-H. The isoxazoline ring protons 4a-H and 4b-H give rise to a 
characteristic ABX system with 5-H, which is adjacent to the ring oxygen, at highest 
chemical shift. It is observed that for the major erythro adducts the 5-H signal absorbs 
at significantly lower frequency [töH -0.12 ppm for (227)/(228), -0.10 ppm for 
(229)/(230)] and 4b-H at higher frequency [LIöH +0.07 ppm for (227)/(228), +0.09 
ppm for (229)/(230)] than the corresponding peaks for the minor threo product. 
Again the 3J values of 8-11 Hz for 4ab-H15-H and the geminal coupling of ca 18 Hz 
for 4a-H/4b-H are observed for the isoxazolines. 193 ' 95 It is noteworthy that the 
coupling between protons 5-H and 14'-H in the major erythro isomer is significantly 
greater than that for the minor threo product [7.0 cf 4.8 Hz for (227)/(228), 7.7 cf 5.3 
Hz for (229)1(230)]. This suggests that in each case the two compounds adopt 
different conformations in solution. Tables 9 and 10 give selected chemical shifts and 
coupling constants for the isomers. 
13C NMR 
The ' 3C NMR for the pairs of isomers are very similar. The major difference is 
associated with the signal for C-4. In each case the major eryrhro adduct has a higher 
8-value than the minor [c  +0.9 ppm for (227)1(228), +1.3 ppm for (229)1(230)]. 






4a 4b 5 
CO2Et Erythro (227) 3.18 3.25 4.64 
Threo (228) 3.18 3.18 4.76 
Ph Erythro (229) 3.40 3.40 4.63 
Threo (230) 3.31 3.31 4.73 
Table 9: Selected 'H NMR data for cycloadducts 
R Coupling 
f/Hz 
4a,5 0 95 5,14' 
CO2Et Erythro (227) 10.9 8.1 7.0 
Threo (228) 10.2 10.2 4.8 
Ph Erythro (229) 8.8 8.8 7.7 
Threo (230) 9.8 9.8 5.3 





Erythro (227) Threo (228) Erythro (229) Threo (230) 
C-4 35.4 34.5 37.2 35.9 
Table 11 : Selected ' 3C NMR data for cycloadducts 
Optical Rotation 
The major erythro isomer in each case was found to have a more positive/less 
negative [aID  value (Table 12). 
Erythro (227) Threo (228) Erythro (229) Threo (230) 
+14.9 -200.5 -3.5 -175.7 
Table 12 
2.3.5 Selectivity of Nitrile Oxide Cycloadditions to Alkene (226) 
The it-facial selectivities resulting from cycloadditions of ethoxycarbonyl-
formonitrile oxide and benzonitrile oxide to dispiroketal-protected but-3-ene- 1,2-diol 
(226) are compared in Table 13 with those found for cycloadditions to 2-vinyl-1,3-
dioxo1anes and acyclic analogues. '9' .197,199 
01 
ROOR 
R I 	R' Nitrile Oxide Erythro Threo Reference 
dispiroketal Et02CCNO 75 25 210 
PhCNO 72 28 210 
H H PhCNO 61 39 197 
H CPh3 PhCNO 54 46 197 
Ac Ac PhCNO 53 47 197 
SiMe3 SiMe3 PhCNO 75 25 197 














-CO- PhCNO 82 18 197 
-COCO- PhCNO 66 34 197 
PhCO PhCO PhCNO 54 46 197 
Me H PhCNO 40 69 197 
Table 13 
ENI 
The predominance of erythro adducts in each case can be rationalised in terms 
of the "inside alkoxy effect "proposed by Houk et al. 111- 198  For 2-vinyl-1,3-dioxanes 
and 2-vinyl-1,3-dioxolanes the anti substituent is linked via the five membered ring to 
the inside alkoxy as illustrated in Figure 9. The increased selectivity observed in these 
systems may be associated with a through-space interaction of the alkene it bond and 
a lone pair of the homoallylic oxygen. 204 
Rc o 
0—C—H 
n=1,2 	 I H 
Figure 9 
In contrast to nucleophilic additions to the carbonyl group of the dispiroketal-
protected D-glyceraldehyde (223), which are reported 208  to be highly selective, the 
preference for erythro adducts for nitrile oxide cycloadditions to alkene (236) is only 
moderate and similar to that found for the same nitrile oxides with cyclohexylidene 
(Section 2.3.2) and isopropylidene protected alkenes. It is therefore concluded that 
the large steric bulk of the dispiroketal moiety and changing from a five to six-
membered ring system appears to have negligible effect on diastereoselectivity. 
M. 
2.3.6 Attempted Cycloadditions of Nitrile Oxides to trans-3,4-Didehydro-3,4-
dideoxy-1 ,2 :5,6-di-O-cyclohexylidene-D-threo-hexitol (232) 
In order to investigate the influence of bulky substituents on reactivity and 
hence selectivity, alkene (232) was synthesised and its reaction with nitrile oxides 
examined. As both faces of the alkene are sterically hindered by the cyclohexylidene 
groups it was anticipated that this would have a significant effect on the reaction. 
2.3.6.1 Synthesis of trans-3,4-Didehydro-3,4-dideoxy-1 , 2 :5,6-di-O-
cyclohexylidene-D-threo-hexitol (232) 
Alkene (232) was prepared in three steps from D-mannitol according to 
Scheme 45, with an overall yield of 26%. Selective protection of D-mannitol as 
referred to in Section 2.3.1 yielded the dicyclohexylidene adduct (193). This 3,4-diol 
was then refluxed with 1,1 '-thiocarbonyldiimidazole in toluene to afford the cyclic 
thionocarbonate derivative (231) in good yield. Conversion to the symmetrically 
substituted alkene (232) was via an elimination reaction (desuiphurisation-
decarboxylation) using triethyl phosphite, which is acting as both solvent and 
reactant. Addition of alkali to the reaction mixture hydrolysed excess phosphoesters, 
and the alkene was purified by dry flash chromatography. 
Specific cis-elimination 211  is observed for conversion of (231) to the 

















(a) Cyclohexanone, HC(OE0 3 , BF3 .Et20, DMSO; (b) 1,1 '-thiocarbonyldiimidazole, 
toluene, reflux; (c) (EtO) 3 P, reflux 
Scheme 45 
2.3.6.2 Attempted Cycloadditions to trans-3,4-Didehydro-3,4-dideoxy-1 ,2 : 5,6-di-
O-cyclohexylidene-D-threo-hexitol (232) 
Ethoxycarbonylformonitrile oxide was generated in the presence of alkene 
(232) (Scheme 46). However, there was no evidence by TLC or 'H NMR analysis of 
the reaction mixture that cycloadducts (233) or (234) had been produced. Similarly 
attempted cycloaddition of benzonitrile oxide to alkene (232) did not yield adducts 
(235) and (236). 
The failure to form cycloadducts suggests that the presence of the bulky 
substituents is preventing the incoming nitrile oxide from getting close enough to the 








;H 	 Hill- 	H 
06  06  + 06  06  
(233) R = CO 2Et 	 (234) R = CO2Et 
(235) R = Ph (236) R = Ph 
Scheme 46 
2.3.7 Reduction of 3-Ethoxycarbonyl Substituent to Hydroxymethyl 
In order to convert the 3-ethoxycarbonyl isoxazolines (198) and (199) to 
hexulosonic acid analogues, reduction of the ester group to provide a hydroxymethyl 
substituted isoxazoline is required. This modification is a prerequisite for the reductive 
hydrolytic cleavage of the 2-isoxazoline to the -hydroxyketone, since isoxazolines 
containing an ester substituent at the 3-position are known to be resistant to ring 
opening. 53 
Adducts (198) and (199) were therefore reduced with sodium borohydride in 
ethanol at room temperature to provide the corresponding alcohols (204) and (205) in 











The presence of the hydroxymethyl group should also allow access to a wide 
range of derivatives including mesylate and tosylate. These will be discussed in 
Section 2.3.9. The characteristic properties of the isomers (204) and (205) are 
compared with those of the parent major erythro and minor threo cycloadducts (198) 
and (199) in Section 2.3.2.2. 
2.3.8 Conversion of 2-Isoxazolines to 2-Hexulosonic Acid Analogues 
Two approaches for the conversion of the 2-isoxazolines to the desired 2-
ulosonic acid analogues have been investigated: either initial reductive hydrolytic 
cleavage of the N-O bond of the isoxazoline to the 3-hydroxyketone, followed by 
removal of the cyclohexylidene protection (Route A), or vice versa (Route B) 
(Scheme 48). In the final step it was envisaged that pyranose ring structures would be 
formed by ring closure of the resulting 6-hydroxyketone. 
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Each of these approaches will be considered in turn, starting with ring 
opening followed by deprotection ie. Route A, and their relative merits discussed. 
However, before either route is considered a brief overview of the conditions 
required to bring about ring cleavage will be presented. 
2.3.8.1 Reductive Hydrolytic Cleavage of 2-Isoxazolines to 3-Hydroxyketones 
While a number of reductive procedures have been devised to release the 3-
hydroxyketone from the isoxazoline, the choice of precise reaction conditions does 
depend on the type of functionality present within the substrate and on the necessity 
of preserving chirality at C-5. The most widely used method 
 212  involves catalytic 
hydrogenation in the presence of palladium-on-charcoal or Raney-nickel and boric 
acid, using aqueous methanol as the solvent. These optimised conditions specifically 
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incorporating boric acid have been shown by Curran 45  to be particularly effective at 
minimising epimerisation, and are critical to the overall success of the process. 
In this ring opening, for which the mechanism is now well understood, the N-
0 bond of the isoxazoline (237) is cleaved by addition of hydrogen to form initially a 
-hydroxyimine intermediate (238). Subsequent hydrolysis of (238) produces a 
hydroxyketone (239) (Scheme 49). This hydrolysis competes with further reduction 
to the y-amino alcohols (240). 
Curran 45 has rationalised the key role of the acid as follows: Firstly, it 
promotes imine hydrolysis by protonation of the imine nitrogen; it can also neutralise 
the ammonia produced during the hydrolysis and finally, when Raney-nickel is used, 
it neutralises excess hydroxide present on the catalyst. 
92 	 92 
R, 	 R3 	
. R, 	 R3 
N-0 	 NH OH 
(237) 	 (238) 
Scheme 49 
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A number of other acidic additives have previously been employed including 
acetic acid, 213  aluminium  52  and boron trichlorides, 214 concentrated HCI, 52 trimethyl 
borate 212  and acetate or phosphate buffers. 
212  However, boric acid has proved to be 
the best available, and remains the most commonly used reagent. 
OX 
The reaction uses mildly acidic conditions (pH 5.5-6.0) resulting in the - 
hydroxyimine undergoing rapid hydrolysis45 and hence it is not normally detectable. 
However, some 3-hydroxyimines, eg. (241)2 15 and (242), have been isolated on 
hydrolysis of the corresponding isoxazolines; their increased stability is attributed to 
steric hindrance by the bulky neighbouring groups slowing down the rate of 
hydrolysis. 
Strong evidence for the proposed mechanism is given by subsequent 
conversion of these irnines to 3-hydroxyketones when resubjected to hydrolysis 
conditions. 
Me Me Me 
Me 







The use of acetate or phosphate buffers minimises the formation of -y-amino 
alcohols but other unwanted products, sometimes as the major constituent, are often 
obtained. These include products resulting from epimerisation at the a-position 
which leads to diastereoisomeric mixtures of ketones (239) and (243), and also from 
retro-aldol reactions. Curran 45  has proposed that the epimerisation is due to imine-
enamine tautomerisation of the intermediate 3-hydroxyimine (Scheme 50). 
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Using boric acid as the acid additive minimises the formation of the above 
unwanted products (retro-aldol compounds and diastereoisomeric ketones), and in 
most cases eliminates their formation altogether. This additive is believed 43  to form a 
cyclic borate ester (Figure 10), that is capable of increasing the rate of imine 




2.3.8.2 Reductive Hydrolytic Cleavage of Isoxazolines Followed by Deprotection 
(Route A) 
The first stage in this route to the desired 3-deoxy-hexulosonic acid analogues 
involved reductive hydrolytic cleavage of the isoxazoline. It was therefore important 
to establish optimum conditions for this ring opening process. Hydrogenolysis of 
isoxazolines (196) and (204) using both palladium-on-charcoal (Pd/C) and Raney-
nickel (Ra-Ni) catalysts has been investigated in order to determine whether changing 
the reaction conditions alters the yields of -hydroxyketone produced. Pd/C was 
initially employed for the proposed N-O bond cleavage of the isoxazolines. 
Palladium-on-Charcoal Catalysed Hydrogenolysis of 2-Isoxazolines 
The procedure selected for reductive hydrolytic cleavage of 2-isoxazolines 
uses 10% (Pd/C) as the catalyst using conditions optimised by Curran .45 The reaction 
involved vigorous stirring of the isoxazoline (1 M eq), boric acid (6 M eq) and 
catalyst under an atmosphere of hydrogen for 18 hours in a 5:1 mixture of 
methanol/water (Scheme 51). 
Q 	QQ
No. 
5S. 	 5S 	
5S 
O 	,- R 	 HO 	R 	
HO 	R 
N 0 
(196) R = Ph 	 (244) R = Ph 	 (245) R = Ph 
(204) R = CH20H 	 (246) R = CH20H 	(247) R = CH 20H 
Scheme 51 
Initial experiments were performed using 3-phenyl-isoxazoline (196). TLC 
analysis of the reaction mixture indicated when all the starting material had been 
consumed. Two products were identified and separated by preparative TLC; the less 
polar component gave a positive stain with Brady's reagent and was assumed 
therefore to be the desired -hydroxyketone (244) (64%). The more polar (baseline) 
component was proven to be an inseparable mixture of diastereoisomeric y-amino 
alcohols (245) (28%). Similarly, ring cleavage of hydroxymethyl-isoxazoline (204) 
resulted in the formation of -hydroxyketone (246) (60%) and a mixture of y-
aminoalcohols (247) (25%). 
The 3-hydroxyketones were identified by 'H and ' 3 C NMR spectroscopy and 
FAB mass spectrometry and verification of the chemical formulae made by high 
resolution FAB mass spectrometry. Complicated 'H NMR spectra were produced for 
the mixtures of y-amino alcohols. However, characteristic signals 216 within the region 
- 53-57 ppm were observed in the ' 3C NMR spectra for the CI-1N1 2  (C-3) 
resonance. Further evidence for these compounds is given by a positive ninhydrin 
stain on TLC, together with high resolution FAB mass spectrometry analysis. Due to 
their instability the structures were not verified further. These y-amino alcohols are 
formed by reduction of the intermediate 3-hydroxyimine implying that this reduction 
competes with the hydrolysis to the 3-hydroxyketone. 
Raney-Nickel Induced Hydrogenolysis of 2-Isoxazolines 
In an attempt to increase the yields of -hydroxyketones (244) and (246) and 
minimise the competing formation of y-amino alcohols (245) and (247), the 
alternative Ra-Ni catalysed process was pursued. Standard conditions as detailed 
above were employed, with Ra-Ni substituted for the PcIJC catalyst. The starting 
material in each case was consumed in 4 hours. Isoxazoline (196) was initially 
employed and after preparative TLC, the reaction provided the desired 3-
hydroxyketone (244) (80%), identical to that obtained from the previous Pd/C 
process, together with an inseparable mixture of -y-amino alcohols (245) (10%). 
Isoxazoline (204) was treated in the same manner. Again, after preparative 
TLC the more polar and unwanted inseparable mixture of y-amino alcohols (247) 
(8%) was obtained along with f3-hydroxyketone (246) (78%). 
The consistency of the yields obtained is influenced by the quality of the Ra-
Ni used. Curran 45  has reported that best results are obtained using Ra-Ni washed with 
water (- x20) and stored in a freezer under methanol for 3-4 weeks prior to use, and 
which was used within 6 weeks of initial storage. Our findings are in agreement with 
this. 
Comparison of the yields obtained from the two methods is shown in Table 
14. These results indicate that yields of the desired -hydroxyketones relative to the y-
amino alcohols are improved by using Ra-Ni rather than Pd/C as the catalyst for 
reductive hydrolytic cleavage of the isoxazoline N-O bond. All subsequent 
hydrogenations were therefore performed using these optimised conditions. 
Isoxazoline Catalyst 
% Yield 
-hydroxyketone 7-amino alcohol 
(196) Pd/C 64 28 
Ra-Ni 80 10 
(204) Pd/C 60 25 
Ra-Ni 78 8 
Table 14 Palladium-on-charcoal versus Raney-Nickel Induced Hydrogenolysis 
2.3.8.3 Characteristics of -Hydroxyketones 
TLC 
The parent 2-isoxazoline has a larger R f value on silica (100% ether) than the 
corresponding 3-hydroxyketone [eg. 0.58 cf 0.23 for (196)1(244)1. Brady's Reagent 
also stains the 3-hydroxyketone thus aiding in its identification. 
'H NMR 
The 'H NMR data for protons 4-H to 6-H reflect major differences between 
the 2-isoxazolines and 3-hydroxyketones. Tables 15 and 16 compare the chemical 
shifts and coupling constants for the D-mannitol derived isoxazolines (196) and (204) 
with those of the 3-hydroxyketones (244) and (246). It is observed that the 5-H signal 
absorbs at significantly higher frequency for the isoxazoline than for the 
corresponding 3-hydroxyketone [M H +0.61 ppm for (196)/(244), +0.50 ppm for 
(204)1(246)]. Comparison of the large coupling constant for J4a,5 (8.7 Hz) and the 




consistent with a hydrogen-bonded half-chair conformation for the 3-hydroxyketone 
(Figure 11) with 5-H and 4a-H occupying pseudo axial positions and 4b-H an 
equatorial position. The bulky cyclohexylidene substituent R 1 occupies the sterically 
least demanding quasi-equatorial position in this conformation. Similar observations 




0 	 R2 = CH20H or Ph 
Figure 11 
' 3C NMR 
Major differences for C-4 to C-6 are observed in the spectra for the 3-
hydroxyketones compared to those of the respective isoxazolines. These differences 
are shown in Table 17 . In both cases, C-4 resonates at a higher frequency for the 3-
hydroxyketone [toc +3.3 ppm for (196)/(244), +4.1 ppm for (204)/(246)1. In 
comparison C-5 resonates at a higher frequency for the isoxa.zolines [bo c +4.6 ppm 
for (196)/(244), +3.7 ppm for (204)/(246)1, as does C-6 [zS.ö c +6.7 ppm for 
(196)/(244), +6.6 ppm for (204)/(246)]. 
Q 	0 0 




4a-H 4b-H 5-H 6-H 
Ph Isoxazoline (196) 3.37 3.47 4.64 4.05 
-Hydroxyketone (244) 3.12 3.42 4.03 4.12 
CH20H Isoxazoline (204) 3.06 3.14 4.53 4.02 
-Hydroxyketone (246) 2.58 2.74 4.03 4.05 
Table 15: Selected 'H NMR data 
R Coupling 
JIll2 
4a,5 4b,5 5,6 7a,7b 
Ph Isoxazoline (196) 7.3 9.3 7.6 7.7 
-Hydroxyketone (244) 8.7 2.5 4.9 14.1 
CH20H Isoxazoline (204) 6.9 10.1 7.1 8.4 
3-Hydroxyketone (246) 8.7 3.1 5.7 12.0 









C-3 	1 C-4 C-s C-6 
Ph Isoxazoline (196) 156.5 37.7 81.3 75.5 
3-Hydroxyketone (244) 200.0 41.0 76.7 68.8 
CH20H Isoxazoline (204) 158.5 37.6 81.0 75.5 
-Hydroxyketone (246) 209.6 41.7 77.3 68.9 
Table 17: Selected ' 3C NMR data 
Optical Rotation 
The 3-hydroxyketone in each case was found to have a more negative [a] 0 









+23.4 -22.6 +59.5 -11.5 
Table 18 
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2.3.8.4 Attempted Removal of Cyclohexylidene Protection from 
-Hydroxyketone (244) 
Deprotection of 3-hydroxyketone (244) was attempted by stirring with a 
mixture of water/glacial acetic acid (1:4) at 80°C for 23 hr (Scheme 52). Although 
TLC analysis indicated that reaction had occurred (all starting material being 
consumed) analysis by 'H NMR and FAB MS showed no evidence for the desired 
product (248). This may be due to the 3-hydroxyketone being unstable under the 
conditions required to remove the cyclohexylidene protecting group, and also to the 
possibility of side reactions producing for example a-enones. 
OQO  X 











It was therefore decided that access to the desired analogues would be more 
likely to be achieved via deprotection followed by ring opening, ie. Route B. This 
approach was thus adopted and is considered next. 
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2.3.8.5 Deprotection of Isoxazolines Followed by Reductive Hydrolytic Cleavage 
(Route B) 
The alternative approach to the desired hexulose analogues involves removal 
of the cyclohexylidene protection of the 2-isoxazoline prior to reductive ring opening 
of the isoxazoline. 
The procedure for the first stage involved stirring the isoxazoline with a 
mixture of water/glacial acetic acid (1:4) at 80°C (Scheme 53). TLC of the mixture 
indicated when reaction was complete (2-10 hours). Deprotection of each pair of 
cycloadducts resulted in yields ranging from 70% for (249) to 80% for (253). 
HO 	OH 
Q a 
N 0  
N 
5S (196) R= Ph SS (249) R= Ph 
(198) R = CO,Et (250) R = CO-,Et 
(204) R = CH20H (251) R = CH20H 
5R (197) R= Ph SR (252) R=Ph 
(199) R = CO2Et (253) R = CO2 Et 
(205) R = CH20H (254) R = CH20H 
(a) Water/glacial acetic acid (1:4), 80°C 
Scheme 53 
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2.3.8.6 Characteristics of Isoxazolines 
Removal of the cyclohexylidene or dispiroketal protecting groups provided 
the corresponding diols in moderate yields (70-80%). The characteristic properties of 
these adducts compared to the starting isoxazolines are summarised below. 
TLC 
The parent 2-isoxazoline has a larger R f value on silica (100% ethyl acetate) 
than the corresponding diol. It is also observed that the major diol occurs at larger R f 
value than the minor isomer. 
'HNMR 
Considering initially the deprotected diastereoisomeric adducts. The 'H NMR 
spectra reflect a major difference between the 5-H signal for the major erythro and 
minor threo isomers. As before the isoxazoline ring protons 4a-H and 4b-H give rise 
to a characteristic ABX system with 5-H at highest chemical shift. It is observed that 
for the minor threo adduct the 5-H signal absorbs at significantly higher frequency 
than for the corresponding major erythro product [ASH +0.07 ppm for (249)/(252), 
+0.05 ppm for (250)/(253), +0.08 ppm for (251)1(254)]. Compared to the protected 
adducts (see Section 2.3.2.2) 5-H has shifted to slightly higher frequency. Available 
data also indicates that 6-H, 7a-H and 7b-H shift to lower frequency in the 
deprotected adducts. The coupling between 5-H and 6-H is smaller for both the major 
erythro and minor threo isomers compared to the protected products [eg. 7.0 cf 4.5 Hz 
for (198)1(250), and 4.2 cf 3.1 Hz for (199)1(253)]. It is also noticeable that LöH 
104 
between the major erythro and minor threo isomers is significantly less when they are 
deprotected. J56 changes much more markedly for the major erythro isomers than the 
minor threo isomers (Aö H 1.5-2.5 Hz cf 0.5-1.1 Hz). There is a marked increase in the 
coupling between 7a-H and 7b-H on going to the deprotected adducts [7.7 cf 11.1 Hz 
for (196)1(249), 8.4 cf 10.8 Hz for (204)/(251). The chemical shifts and coupling 
constants for the deprotected adducts are summarised in Tables 19 and 20. 
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4a-H 4b-H 5-H 
Ph Erythro (249) 3.48 3.37 4.75 
Threo (252) 3.47 3.40 4.82 
CO2Et Erythro (250)a  3.30 3.18 4.88 
Erythro (250)7  3.29 3.17 4.86 
Threo (253) 3.28 3.20 4.91 
CH20H Erythro(251) 3.14 3.04 4.53 
Threo (254) 3.17 3.05 4.61 
Table 19: Selected 'H NMR data 
Product from dispiroketal-protected isomer (227) 




4a,4b 4a,5 4b,5 5,6 
Ph Erythro (249) 16.9 8.1 10.8 5.4 
Threo (252) 16.8 10.7 8.9 3.5 
CO2Et Erythro (250)a 17.6 8.2 11.3 nd 
Erythro (250)0 17.6 8.5 11.4 4.5 
Threo (253) 17.4 11.3 9.0 3.1 
CH20H Erythro (251) 17.3 8.0 10.7 5.6 
Threo (254) 17.2 10.5 8.8 3.9 
Table 20: Selected 'H NMR data 
a  Product from dispiroketal-protected isomer (227) 
b  Product from cyclohexylidene-protected isomer (198) 
' 3C NMR 
The ' 3 C NMR spectra for the deprotected isomers show significant differences 
for C-4 and C-6. In each case the minor threo adduct has a higher 5-value for C-4 
[Mc 0.9 ppm for (249)/(252), 1.5 ppm for (250)/(253), 0.7 ppm for (251)1(254)]. This 
is the reverse of that seen for the protected isomers where C-4 for the major erythro 
isomer appears at higher chemical shift (see Section 2.3.2.2). The major erythro 
deprotected isomers have shifted to lower frequency by -2 ppm compared to the 
protected adducts, whereas the minor threo isomers have remained at the same 
chemical shift in the protected and deprotected isomers. There is also a marked 
difference shown for C-6 in the deprotected adducts [M c +1.0 ppm for (249)/(252), 
+1.3 ppm for (250)/(253), +0.9 ppm for (25 1)/(254)]. C-6 appears at a lower chemical 
shift relative to the protected adducts. It is noteworthy that in the protected isomers 
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there is no difference in C-6. Considering C-7 for the deprotected isomers one can see 
no difference in the values, whereas the corresponding protected isomers show a 
noticeable difference [eg..A8c 1.8 ppm for (198)/(199)]. However, the 6-values for the 
deprotected adducts do occur at lower frequency than for the corresponding isomers. 






C-4 C-S C-6 C-7 
Ph Erythro (249) 35.5 81.8 72.3 63.5 
Threo (252) 36.4 81.6 73.3 63.3 
CO2Et Erythro(250)a 34.1 84.1 71.8 63.0 
Erythro(250)D 33.8 84.2 71.8 63.1 
Threo (253) 35.3 83.8 73.1 63.0 
CH20H Erythro (251) 36.0 80.8 72.3 63.5 
Threo (254) 36.7 80.8 73.2 63.3 
Table 21: Selected ' 3 C NMR data 
a Product from dispiroketal-protected isomer (227) 
b Product from cyclohexylidene-protected isomer (198) 
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Optical Rotation 









+83.1 -158.9 +110.0 -124.9 
Table 22 
2.3.8.7 Deduction of Stereochemistry at C-5 in Dispiroketal-protected 
Isoxazoline (227) 
Access to the deprotected isomers (250) and (253) allowed the identity of the 
adducts from the dispiroketal-protected S-but-3-ene- 1,2-diol (226) experiments 
(discussed earlier in Section 2.3.4) to be identified by correlation. The major adduct 
(227) was deprotected by treatment with aqueous trifluoroacetic acid (TFA) at room 
temperature, to afford the corresponding 1 ,2-dihydroxyethyl-isoxazoline (Scheme 
54) and the product compared with authentic samples of compounds (250) and (253). 












The product resulting from deprotection of the major dispiroketal adduct (227) 
proved to be identical by 'H and especially ' 3 C NMR, and also Rf value to product 
(250) obtained from deprotection of isomer (196). Therefore, the adduct (227) is 
assigned as having S-configuration at the new chiral centre C-5 corresponding to an 
erythro relationship between this carbon and the adjacent asymmetric centre (C-14'). 
The minor isomer (228) therefore has a threo structure. 
2.3.8.8 Reductive Hydrolytic Cleavage of 2-Isoxazoline (249) 
The reductive hydrolytic cleavage of deprotected isoxazoline (249) constitutes 
the final stage in our approach to 2-ulosonic acid analogues. The procedure selected 
was based on the model studies discussed earlier (Section 2.3.8.3) and involves 
vigorous stirring of the isoxazoline (1 M eq), boric acid (6 M eq) and Raney-Nickel 
catalyst in a 5:1 mixture of methanol/water under an atmosphere of hydrogen 
(Scheme 55). TLC analysis of the reaction mixture indicated when reaction was 
complete (4 hours). 
HO 	OH 
OH 
a 	 HO-.-0 
HO 	 Ph 	 Ph 
OH 0 	 HO 	OH 
N 
(249) 	 (255) 	 (256) 
(a) Raney-Ni, MeOHIH 20 (5:1), H3B03 (6 M eq) 
Scheme 55 
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The product, which has a smaller TLC Rf value on silica (100% ethyl acetate) 
than the parent 2-isoxa.zoline (0.27 cf 0.10), was isolated by removal of solvent in 
vacuo with subsequent addition and evaporation of methanol to remove boric acid. 
The resulting pale yellow oil (37%) was not purified further. It was characterised by 
mass spectrometry and from its NMR spectra. 
The FAB mass spectrum showed a characteristic peak at 212 for M+2H. 
Accurate mass analysis (212.10483) of this peak gave the elemental composition as 
C, ,H, 404, consistent with compounds (255) or (256). 
It was anticipated that the product could exist in open-chain and cyclic 
hemiacetal forms. Three structures were thus considered: a pyranose-like chair 
conformation (256), a furanose envelope conformation (257) with the 5-hydroxyl and 


















H7b H7a OH 	0 
(255) 
To identify which of the above structures was most likely for the product, 'H 
NMR data was initially considered. The product was tentatively assigned as the 
pyranose-chair with 'C 4 conformation (256). Examination of the 'H NMR spectrum 
(Figure 12) allowed a number of deductions to be made. The two protons at lowest 
chemical shift are assigned to 4a-H and 4b-H, which have no oxygen attached. The 
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pattern shown is a key feature of an ABX system. There is a large geminal coupling 
of 16.5 Hz between 4a-H and 4b-H, and both are coupled to 5-H which appears as a 
multiplet at 4.22 ppm. 5-H has a large coupling of 8.7 Hz to 4a-H (larger than would 
normally be expected for axial-equatorial coupling) and a smaller coupling of 3.1 Hz 
to 4b-H. The smaller geminal coupling for 7a-H/7b-H of 10.6 Hz is consistent with 
this methylene group being next to an oxygen. Protons 7a-H and 7b-H also appear at 
higher chemical shift than those at C-4 as expected. However, the couplings for 5-
H/6-H (6.7 Hz) and 6-H to both 7a-I-I and 7b-H (5.5, 4.1 Hz) are not consistent with 
this structure. Therefore an alternative furanose envelope conformation (257) was 
considered. The large geminal coupling between 4a-H/4b-H is still appropriate, as are 
the couplings 4a-H/5-H and 4b-H, but now the couplings between 5-H/6-H, 6-H/7a-H 
and 6-H/7b-H are more consistent with this structure. 
However, when the ' 3 C NMR was examined a peak was detected at 8 C 200.7 
ppm attributed to a carbonyl group. This observation is consistent only with the open 
chain form (255). All the 'H-'H couplings observed also fit with this structure. 
The data obtained for the open chain product (255) are compared with those 
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(249) (255) (249) (255) 
4a-H 3.48 3.17 4a,4b 16.9 16.5 
4b-H 3.37 3.39 4a,5 8.1 8.7 
5-H 4.75 4.22 4b,5 10.8 3.1 
6-H 3.90 3.61 5,6 5.4 6.7 
7a-H 3.61 3.77 6,7a 6.0 5.5 
7b-H 3.68 3.68 6,7b 4.5 4.1 
7a,7b 11.1 10.6 
Table 23: 1 H NMR data 
öc/Ppm 
Compound C-3 C-4 C-S C-6 C-7 
(249) 156.6 35.5 81.8 72.3 63.5 
(255) 200.7 41.9 74.4 68.7 62.9 
Table 24: ' 3C NMR data 
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To provide further evidence for the proposed structure, compound (255) was 
converted to its triacetate derivative (257) using acetic anhydride and pyridine. 
Accurate mass measurement of 337.12873 (M+H) gave an elemental formulae of 
C 17H2007 in accord with compound (255). 
OAc 
AcO 	 Ph 
OAcO  
(257) 
It is therefore proposed that the product formed from reductive hydrolytic 
cleavage of isoxazpline (249) exists predominantly in its open-chain form, rather 
than the pyranose ring structure. This may be a consequence of conjugation of the 
C=O to the phenyl substituent. It is predicted that replacement of Ph with non-
conjugating groups such as CH20H would be more likely to allow ring closure to 
occur, although this experiment has not yet been performed. 
2.3.9 Mesylation and Tosylation of 3-Hydroxymethyl-Substituted Isoxazoline 
(204) 
One of the objectives of our work is to synthesise a range of 3-deoxy-
hexulosonic acid analogues. Hence, conversion of the 3-hydroxymethyl group of 
(204) to the corresponding mesylate (258) or tosylate (259) should allow for 
alternative functionalisation of the isoxazoline by providing a suitably positioned 
leaving group for manipulation at later stages if required. 
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Alcohol (204) was treated with methanesuiphonyl chloride in dry 
dichioromethane using triethylamine as base, affording the desired mesylate (258) in 
96% yield (Scheme 56). The corresponding tosyl derivative (259) (40%) was 
prepared in a similar way. Both derivatives were yellow oils which were purified by 






	 0 	CH2OX 
(204) 
	
(258) X = S02Me 
(259) X = S02C6H4Me-p 
Scheme 56 
Comparison of the 'H NMR data of the mesylate and tosylate with those of 
the parent alcohol indicates that changing from OH to OMs or OTs has little effect on 
the chemical shift values apart from that due to CH20R, which moves to much higher 
frequency for OMs as expected (ö H +0.53 ppm). There is a smaller change for OTs 
(AH -0.12 ppm). 5-H also shifts to slightly lower frequency {'H  -0.07 ppm for (258), 
-0.09 for (259)]. However, there is a marked change in coupling between 5-H and 6-H 
[7.1 cf 3.8 Hz for (258)] indicating that the presence of OMs influences the 
conformation adopted in solution. This difference in coupling is not observed in the 
tosylate (259). In the ' 3 C NMR for (258) there is a noticeable increase in the chemical 
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shift for CH20R on changing from OH to OMs (M c +5.0 ppm) and also in the 
adjacent quaternary carbon (M c -5.3 ppm). 
2.3.10 Conclusions 
A synthetic route to hexulosonic acid analogues using nitrile oxide-
isoxazoline chemistry has been established using alkene (195) as the starting material. 
Cycloaddition of nitrile oxides to cyclohexylidene-protected alkene (195) and also the 
dispiroketal-protected alkene (226) have afforded adducts in good yields (40-88%) 
and moderate ic-facial selectivity (72:28 to 79:21) with preference for erythro adducts 
in each case. The large steric bulk of the dispiroketal moiety and changing from a five 
to six membered ring system appears to have negligible effect on diastereoselectivity. 
Two approaches for the conversion of the 2-isoxazoline to the desired 2-
ulosonic acid analogues were investigated; either initial reductive hydrolytic cleavage 
of the N-O bond of the isoxazoline to the -hydroxyketone followed by removal of 
the cyclohexylidene protection or vice versa. It was found that the desired analogues 
could best be formed via deprotection followed by Raney-nickel catalysed 
hydrogenolysis. One such analogue has been synthesised and proposed to exist 
predominantly in its open-chain form (255). 
In summary, this work may provide access to a wide range of hexulosonic 
acid analogues via nitrile oxide-isoxazoline chemistry. Future work could involve the 
synthesis of the CH20H analogue to determine whether this also exists in an open-
chain form or as predicted in the pyranose-ring structure. 
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2.4 3-Deoxy-D-arabino-heptulosonic Acid (DAlI) Analogues 
The approach selected for the synthesis of heptulosonic acid (DAH) 
analogues is via the five carbon sugar alkene (260) which incorporates the correct 
stereochemistry for C-6 and C-7 of the DAH framework. The choice of ethylidene 
protection for D-glucose was made based on literature precedent  218  which suggests 
that synthesis via the alternative 4,6-0-benzylidene-D-glucose would be unreliable 
and difficult. 
By analogy with the route described earlier for the six-carbon analogues 
(Section 2.3.2) cycloaddition of the alkene to an appropriate nitrile oxide, followed 
by deprotection and subsequent reductive hydrolytic ring opening of the isoxazoline, 
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2.4.1 Synthesis of 1 ,2-Dideoxy-3,5-O-ethylidene-D-erythro-pent-l-enitol ( 260) 
Alkene (260) was prepared in three steps from D-glucose as outlined in 
Scheme 58, with an overall yield of 32%. Treatment of D-glucose with freshly 
distilled paraldehyde (1.01 M eq) containing concentrated sulphuric acid afforded the 
desired 4,6-0-ethylidene-D-glucose (261)219  as a mixture of a and 13  anomers (a:13 
79:21 shown by 'H NMR). It is interesting to note that on addition of d 6-acetic acid, 
the ratio of a to 13 changes to 37:63, with the 13  form becoming predominant. This 
mixture of anomers was used for later stages without any attempt at separation, since 
the anomeric carbon is lost in the following steps. Subsequent metaperiodate 
cleavage afforded aldehyde (262) as a white glass. The aldehyde is reported 220  to 
exist in more than one form; as a dimer m.p. 149-150°C, and also in a different 
crystalline form with m.p. 110-1 11°C indicating the presence of water of hydration. 
The conversion of aldehyde (262) to alkene (260) using a Wittig reaction was then 
performed and the product purified by dry flash chromatography to afford a pale 


















(a) (CH 3 CHO)3, conc. H2SO4; (b) Na1 4; (c) Ph3PCH3 F, (CH3) 3COK, TI-IF 
Scheme 58 
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2.4.2 Investigation of 7t-Facial Selectivity in Nitrile Oxide Cycloadditions to 
1,2-Dideoxy-3,5-0-ethylidene-D-erythro-pent-1-enitol (260) 
2.4.2.1 Nitrile Oxide Cycloadditions to Alkene (260) 
Three nitrile oxides were examined: ethoxycarbonylformonitrile oxide, 
benzonitrile oxide and (diethoxyphosphoryl)acetonitrile oxide. Cycloaddition of 
alkene (260) to ethoxycarbonylformonitrile oxide (Scheme 59) was carried out as 
outlined in Section 2.3.2. A mixture of diastereoisomeric isoxazolines (263) and 
(264) in combined yield of 77% and ratio 53:47 was obtained after chromatography 






R— C = N —0 
CH3 	o 




(263) R = CO 2Et 
(265) R=Ph 
(267) R = CH2P(0)(OEt) 2 
(269) R = CH20H 
Scheme 59 
CH3 
+ 	0 -----.::_- OH 
o" 	R 
N 
(264) R = CO 2Et 
(266) R=Ph 
(268) R = CH 2P(0)(OEt)2 
(270) R = CH 20H 
The isomer ratio was determined by comparison of the integrals of the 
epimeric 5-H signals in the 'H NMR spectrum of the mixture. The assignment of 5S-
configuration for the major isomer (263) corresponding to a erythro relationship 
about the C-5/C-6 bond was deduced unambiguously by X-ray analysis (Section 
2.4.6). 
The overall stereochemistry for the isomers can be assigned as D-ribo for the 
5S isomer and D-arabino for the 5R isomer. However, in the following discussion the 
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terms erythro and threo will be used, referring to the relationship about the newly 
created chiral centre at C-5 and the adjacent centre C-6. 
Similarly the corresponding cycloaddition of benzonitrile oxide to the same 
alkene (260) afforded the adducts (265) and (266) in a combined yield of 75% and 
ratio of 52:48, together with the nitrile oxide dimer 3,4-diphenylfurazan N-oxide 
(1%). The ratio was again determined by comparison of the integrals of the 5-H 
signals in the 'H NMR of the mixture. The assignment of configuration for the major 
isomer as erythro was made by correlation of NMR shift differences, optical rotation 
data and TLC properties with those of the ethoxycarbonylformonitrile adducts. 
Cycloaddition of (diethoxyphosphoryl)acetonitrile oxide to the title alkene 
(260) produced a 38% combined yield of the inseparable diastereoisomeric 2-
isoxazolines (267) and (268) in a ratio of 50:50 in favour of the erythro adduct. 
Again the ratio was determined by comparison of the integrals for the 5-H signals in 
the 'H NMR. Although the isoxazolines were chromatographically inseparable, the 
isoxazoline ring protons for each isomer could be assigned in the 'H NMR of the 
mixture due to differences in signal intensities. The major isomer was identified as 
the erythro adduct (267) based on comparison of its spectral parameters with those of 
similar adducts, as above. 
The nitrile oxide cycloadditions to alkene (260) all proceed with little it-facial 
selectivity with d.e. values ranging from 0% for (diethoxyphosphoryl)acetonitrile 
oxide to 6% for ethoxycarbonylformonitrile oxide. The erythro:threo ratios for the 
three cases are presented in Table 25. 
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Nitrile Oxide erythro : lhreo 
Et02CCNO 53 :47 
PhCNO 52 : 48 
(EtO)2P(0)CH2CNO 50 : 50 
Table 25 : Isomer Ratios for Cycloaddition of Nitrile Oxides to Alkene (260) 
2.4.2.2 Characterisation of Isoxazoline Cycloadducts 
The stereochemistry at the new chiral centre C-5 of the isoxazoline can be 
predicted by correlation of 'H and ' 3C NMR and optical rotation data. These 
characteristic properties of the major and minor isomers are therefore summarised 
below, along with those for (269) and (270) obtained after borohydride reduction of 
the ethoxycarbonyl compounds (263) and (264) (Section 2.4.8). 
TLC 
The erythro adduct has a larger R f value on silica (100% ether) than the 
corresponding threo isomer [0.25 cf 0.21 for (263)1(264), 0.28 cf 0.24 for 
(265)1(266)]. 
'HNMR 
The 'H NMR spectra reflect major differences between the isomers for 
protons 4-H to 7-H. The isoxazoline ring protons 4a-H and 4b-H give rise to a 
characteristic ABX system with 5-H, which is adjacent to the ring oxygen, at highest 
chemical shift, and the 3J values observed are typical of 3,5-disubstituted 
isoxazo1ines.' 93195 It is observed that for the threo adduct the 5-H signal absorbs at 
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significantly higher frequency than for the corresponding erythro product [AS H +0.14 
ppm for (263)/(264), +0.18 ppm for (265)/(266), +0.12 ppm for (267)/(268)]. The 
exception is that for the pair of isomers (269) and (270) where 5-H resonates at the 
same frequency for each isomer. The signals for the methylene protons of the 
isoxazoline ring, 4a-H and 4b-H, are closer together in the erythro adducts. It is 
noteworthy that the coupling between 5-H and 6-H in the erythro isomer is 
significantly greater than in the threo product [4.8 cf 2.9 Hz for (263)1(264), 5.3 cf 
3.2 for (265)1(266), 6.2 cf 3.4 for (267)1(268)]. This may be due to the two 
compounds adopting different conformations in solution. There is also an appreciable 
difference in the proton 7-H signal, which resonates at a higher frequency for the 
threo isomer compared to the erythro isomer [.öH +0.3 5 ppm for (263)1(264), +0.17 
ppm for (265)1(266), +0.28 ppm for (269)1(270)]. Evidence for the chair 
conformation of the 1 ,3-dioxane ring is shown by the large diaxial coupling between 
7-H and 8a-H (Ca 10 Hz) and the smaller axial-equatorial coupling between 7-H and 
8e-H. Selected data for the chemical shifts and coupling constants are summarised in 
Tables 26 and 27. 
' 3c NMR 
The ' 3 C NMR spectra for the pairs of isomers show significant differences for 
C-4 to C-7. In the adducts (263) to (266) the erythro adduct has a higher5-value for 
C-4 [Aoc +1.1 ppm for (263)1(264), +1.9 ppm for (265)/(266)] as does C-S [oc +2.9 
ppm for (263)/(264), +1.7 ppm for (265)1(266)]. There is also a marked difference 
shown for C-7 [i..öc -2.9 ppm for (263)/(264), -3.2 ppm for (265)1(266)]. These 
findings are shown in Table 28. 
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H7  HO HO 
H5  A 	•"lH4a JH '4a 
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4a-H 4b-H 5-H 6-H 7-H 8a-H 
CO2Et Erythro (263) 3.34 3.23 5.01 3.53 3.63 3.36 
Threo (264) 3.21 3.38 5.15 3.45 3.98 3.38 
Ph Erythro (265) 3.44 3.45 4.89 3.45 3.77 3.38 
Threo (266) 3.34 3.45 5.07 3.53 3.94 3.46 
CH2P(0)(OEt)2 Erythro (267) 3.20-2.85 4.83 3.42 3.86 nd 
Threo (268) 3.20-2.85 4.95 3.48 3.73 nd 
CH20H Erythro (269) 3.19 3.07 4.85 3.58 3.48 3.35 
Threo (270) 3.10 3.13 4.85 3.36 3.76 3.33 
Table 26: Selected 'H NMR data for cycloadducts 
R Coupling 
f/Hz 
4a,4b 4a,5 4b,5 5,6 7,8a 
CO2Et Erythro (263) 17.8 7.7 11.4 4.8 10.0 
Threo (264) 17.6 11.7 8.8 2.9 10.6 
Ph Erythro (265) 17.5 7.1 11.5 5.3 10.2 
Threo (266) 16.7 11.5 8.6 3.2 9.9 
CH2P(0)(OEt)2 Erythro (267) nd 6.2 11.4 6.2 9.3 
Threo (268) nd 11.5 8.2 3.4 9.8 
CH20H Erythro (269) 16.9 8.3 11.2 2.6 10.0 
Threo (270) - 10.7 9.3 2.8 10.4 







C-4 C-S C-6 C-7 
CO2Et Erythro (263) 35.1 83.8 79.8 63.6 
Threo (264) 34.0 80.9 80.5 60.7 
Ph Eiythro (265) 37.5 82.1 79.8 64.6 
Threo (266) 35.6 80.4 78.8 61.4 
CH20H Erythro (269) 35.1 81.1 80.0 62.8 
Threo (270) 35.6 81.7 77.7 61.5 
Table 28: Selected ' 3 C NMR data for cycloadducts 
Optical Rotation 
For the pair of ethoxycarbonyl adducts (263, 264) and their reduced 
analogues (269, 270) the erythro isomer was found to have a more positive [aID 
value. This result is important for correlation and for thus assigning the configuration 
at the new chiral centre C-S. Table 29 summarises this information. 
Erythro (263) Threo (264) Erythro (269) Threo (270) 




These results indicate that there is negligible it-facial selectivity for nitrile 
oxide cycloaddition reactions to alkene (260). This lack of selectivity is possibly due 
to the presence of the homoallylic hydroxyl at C-7. It has previously been 
observed 204,205  (Section 2.3.2.3) that homoallylic alkoxy substituents have a 
significant effect on selectivities. For example, with the ribo-alkene (215) the 
selectivity is 42:58 (erythro:threo) compared to 90:10 (erythro:threo) for the lyxo-
alkene (214). Hydrogen-bonding interactions between an alcohol group on the 
dipolarophile and the oxygen of the nitrile oxide may also influence the isomer 
ratio. 196  In order to investigate the influence of the homoallylic substituent on it-facial 
selectivity the alkene (260) was therefore acetylated and subsequent cycloaddition 
reactions performed. Removal of the ethylidene protecting group of alkene (260) 
followed by cycloaddition reactions to this deprotected alkene have also been carried 
out in order to investigate the effect on selectivity. It has been reported 
196  that 
cycloaddition to (207) gives an erythro:threo ratio of 61:39. This represents a marked 
decrease in selectivity compared to cycloadditions to alkenes containing 
cyclohexylidene or isopropylidene protecting groups (see Table 13, Section 2.3.5). 
HO 	OH 	
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2.4.4 Synthesis of 1,2-Dideoxy-4-0-acetal-3,5-0-ethylidene-D-erythro-pent-1 - 
enitol (271) 
Alkene (271) was prepared as a pale yellow oil in 62% yield by acetylation of 





(260) 	 (271) 
(a) (CH3CO)20, Pyridine 
Scheme 60 
2.4.5 Investigation of it-Facial Selectivity in Nitrile Oxide Cycloadditions to 
1 ,2-Dideoxy-4-O-acetal-3,5-O-ethylidene-D-erythro-pent-1-enitol (271) 
2.4.5.1 Nitrile Oxide Cycloadditions to Alkene (271) 
Two nitrile oxides were examined: ethoxycarbonylformonitrile oxide and 
benzonitrile oxide. Cycloaddition of alkene (271) to benzonitrile oxide (Scheme 61) 
was carried out as outlined in Section 2.3.2 and a mixture of diastereoisomeric 
isoxazolines (272) and (273) in combined yield of 74% and ratio 63:37 was obtained 





10 	 5S 
(271) 	
o 
+ + N - 
RC=N-0 	
(272) R=Ph 
(274) R = CO 2Et 
Scheme 61 
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(273) R=Ph 
(275) R = CO2Et 
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The isomer ratio was determined by comparison of the integrals of the 6-H 
signals in the 'H NMR spectrum of the mixture. X-ray crystal structures for both the 
phenyl adducts (272) and (273) were obtained to assign unambiguously the 
configuration of the new asymmetric centre C-5. These are discussed in Section 
2.5.6. The results show that the major isomers (272) and (274) have S-configuration 
at C-5, corresponding to an erythro relationship about the C-5/C-6 bond. 
Similarly the corresponding cycloaddition of ethoxycarbonylformonitrile 
oxide to alkene (271) afforded the adducts (274) and (275) in a combined yield of 
46% and ratio of 59:41, together with the nitrile oxide dimer 3,4-diethoxycarbonyl 
furazan N-oxide (12%). The ratio was again determined by comparison of the 
integrals for the 6-H signals in the 'H NMR of the mixture. The assignment of 
configuration for the major isomer as erythro was made by correlation of NMR shift 
differences, optical rotation data and TLC properties with the benzonitrile adducts 
(272) and (273). 
The stereoselectivity of the nitrile oxide cycloadditions to alkene (271) both 
proceed with moderate it-facial selectivity with d.e. values ranging from 18% for 
ethoxycarbonylformonitrile oxide to 26% for benzonitrile oxide. Table 30 gives, a 
comparison of the selectivities observed using alkenes (260) and (271). 
Alkene Nitrile Oxide eryt/iro : threo 
(260) Et02CCNO 52 : 48 
PhCNO 53 : 47 
(271) Et02CCNO 59 : 41 
PhCNO 63 : 37 
Table 30 : Isomer Ratios for Cycloaddition of Nitrile Oxides to 
Alkenes (260) and (271) 
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The results obtained indicate that, although there is enhanced selectivity in 
favour of the erythro isomer, the extent of this increase is small. 
The small increase in selectivity (d.e. 4% cf 26%) may be attributed to the 
presence of the acetyl group which may be preventing the hydrogen bonding 
interactions which are possible for the free hydroxy compound. Six possible transition 
states (Figure 13) can be drawn for the cycloaddition of alkene (260) to a nitrile oxide. 
The erythro adduct results from A, B and C, and the threo adduct from A', B', and C'. 
The influence of an equatorial hydroxy at the homoallylie position effects the 
transition states B and C' (Figure 14), with these two states being favoured by 
hydrogen bonding. Figure 14 represents the hydrogen bonding interactions that exist 
in these two states. 
OH 
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The selectivity for the 1 ,3-dioxan is also low compared to 1 ,3-dioxolanes 
('-60:40 cf 80:20). Replacing acetate with a more bulky substituent eg. benzoate 
might be expected to increase the selectivity further. However, additional 
investigations need to be performed to determine the precise influence of this 
equatorial homoallylic substituent. 
2.4.5.2 Characterisation of Isoxazoline Cycloadducts 
Correlation of 'H and ' 3C NMR and optical rotation data allow prediction of 
the stereochemistry at the new chiral centre C-5. Comparison of results with those 
from cycloadditions to alkene (260), which contains a hydroxyl substituent at the 
homoallylic position, can also be made. These characteristic properties of the major 
and minor isomers are therefore summarised below. 
TLC 
The erythro adduct has a larger Rf value on silica (100% ether) than the 
corresponding threo isomer [0.50 cf 0.41 for (272)1(273), 0.47 cf 0.39 for 
(274)1(275)]. This is in agreement with results obtained from cycloadditions to 
alkene (260) (Section 2.4.2.2). 
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'H NMR 
The 'H NMR spectra reflect major differences between the isomers for 
protons 4-H to 7-H. As observed in previous systems, the isoxazoline ring protons 
4a-H and 4b-H give rise to a characteristic ABX system. It is observed that for the 
threo adduct the proton 5-H signal absorbs at significantly higher frequency than for 
the corresponding erythro product (M H +0.11 ppm for each of the pairs of isomers). 
This difference is essentially the same as for the previously mentioned cycloadditions 
to alkene (260). However, changing from 7-OH to 7-OCOCH 3 , has resulted in proton 
5-H shifting to lower frequency [eg. 4.79 cf 5.01 ppm for (274)/(263)]. The signals 
for the methylene protons of the isoxazoline ring, 4a-H and 4b-H, are closer together 
in the threo adducts, which is a reversal to that obtained in the hydroxyl compounds, 
and may be a consequence of conformational change. Again it is noteworthy that 
proton 7-H resonates at a higher frequency for the threo isomer compared to the 
erythro isomer [MH +0.22 ppm for (272)1(273), +0.27 ppm for (274)1(275)]. This 
proton also occurs at -1.0 ppm higher frequency in these acetylated adducts than the 
corresponding hydroxyl compounds [4.69 cf 3.63 ppm for (274)1(263), 4.96 cf 3.98 
ppm for (275)1(264), 4.82 cf 3.77 ppm for (272)1(265), 5.04 cf 3.94 ppm for 
(273)1(266)]. There is also a noticeable difference for 6-H. In this case it absorbs at a 
significantly higher frequency than for the corresponding 7-OH compounds [Aö 
+0.27 ppm for (274)/(263), +0.16 ppm for (275)1(264), +0.39 ppm for (272)1(265), 
+0.18 ppm for (273)1(266)]. The difference is much more pronounced for the erythro 
isomers. The coupling between 5-H and 6-H for both isomers is essentially the same. 
This is in comparison to the values obtained for the 7-OH compounds, and may be 
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due to an altered conformation of the erythro isomer in solution on changing the 
homoallylic substituent. The chemical shifts and coupling constants are summarised 
in Tables 3l and 32. 
H8a 
















4a-H 4b-H 5-H 6-H 7-H 8a-H 
Ph Erythro (272) 3.51 3.32 4.77 3.84 4.82 3.46 
Threo (273) 3.32 3.41 4.88 3.71 5.04 3.37 
CO2  Erythro (274) 3.38 3.15 4.79 3.80 4.69 3.44 
Threo (275) 3.16 3.24 4.90 3.61 4.96 3.32 
Table 31 : Selected 'H NMR data for cycloadducts 
R Coupling 
JIll2 
4a,4b 4a,5 4b,5 5,6 7,8a 
Ph Erythro (272) 16.6 7.9 11.2 3.2 10.2 
Threo (273) 16.4 11.2 8.4 2.9 10.0 
CO2Et Erythro (274) 17.7 8.3 11.7 3.2 10.1 
Threo (275) 17.5 11.4 8.6 2.6 9.9 
Table 32: Selected 'H NMR data for cycloadducts 
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'3C NMR 
The ' 3 C NMR spectra for the pairs of isomers show significant differences for 
C-4 to C-6. In each case the threo adduct has a higher 6-value for C-4 (& +0.5 ppm 
for each of the pairs of isomers) as does C-6 [c  +0.3 ppm for (272)/(273), +0.6 
ppm for (274)/(275)]. However, the erythro isomer has a higher frequency for C-5 
than the corresponding threo isomer +2.0 ppm for (272)/(273), +2.4 ppm for 







C-4 C-5 C-6 
Ph Erythro (272) 35.1 80.2 77.9 
Threo (273) 35.6 78.2 78.2 
CO2Et Erythro (274) 33.6 82.5 77.5 
Threo (275) 34.1 80.1 78.1 
Table 33: Selected ' 3 C NMR data for cycloadducts 
Optical Rotation 
The erythro isomer was found in each case to have a more positive [ct] 0 value 
(Table 34). This result is again important for correlation and assignment of 
configuration at C-S. 
Erythro (272) Threo (273) Erythro (274) Threo (275) 
+41.8 -200.0 +68.6 -224.0 
Table 34 
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2.4.6 X-Ray Crystallography to Determine Configuration at New Asymmetric 
Centre C-5 for Compounds (263), (272) and (273) 
The major adduct. (263) (first isomer recovered by chromatography) obtained 
from addition of ethoxycarbonylformonitrile oxide to alkene (260), was isolated as a 
crystalline solid suitable for X-ray analysis. Examination of the crystal structure 
(Figure 15) established S-configuration at the new asymmetric centre C-5 representing 
an erythro relationship between C-5 and C-6. The assignment of S-configuration for 
the acetate analogue (272) confirmed this erythro relationship. Each asymmetric unit 
of (263) was shown by the X-ray data to be composed of two molecular shapes within 
the crystal. The other two X-ray structures for (272) and (273) were single shapes 
(Figures 16 and 17). 
The H-C-C-H torsion angles obtained for each X-ray structure were used to 
calculate the proton-proton coupling constants by applying the Haasnoot 
parameterisation 209 of the Karplus equation. These values are compared to those 
observed in solution in Tables 35, 36 and 37. Consideration of the data indicates 
satisfactory correlation for some of the data, eg. J45
, J5,6a 
 and 5,6e  however significant 
deviations are noticed elsewhere. The relationship between the calculated and 
observed J-values for the isoxazoline ring protons is poor; this has previously been 
observed for other isoxazolines. 221 ' 222 A noteworthy feature of the crystal structure for 
(263) is the -72.0/-75.5 torsion angle for H(3)-C(3)-C(4)-H(4) involving the protons 
attached to the carbon atoms linking the six membered 1 ,3-dioxane ring and newly 





















much greater than the calculated value (1.8/1.6 Hz). This suggests that the preferred 
conformation in solution differs markedly from that found in the crystal. In contrast, 
the data for (272) and (273) shows good correlation between the two values, which 
suggests that the presence of the equatorial 7-OAc locks the molecule in a 







2a,3 2b,3 3,4 4,5 5,6e 5,6a 
OObSa -123.3 -1.2 -72.0 175.4 -55.6 -174.2 
SObs 7.7 11.4 4.8 9.3 5.3 10.0 
jcalca 5.3 8.1 1.8 10.2 3.3 10.2 
O ? ObSa -122.5 -0.4 -75.5 174.4 -54.9 -173.4 
SObs 7.7 11.4 4.8 9.3 5.3 10.0 
7CaIc 4.2 8.1 1.6 10.2 3.3 10.2 
a : 8 and jCIIC  represent the torsion angles and coupling constants respectively for 
one crystal type , 8' and JCaIc  are the corresponding values for the alternative. 
3J7.76Cos20- 1.1 CosO+ 1.4 
Table 35 : Calculated and observed coupling constants for the two crystal 
types of adduct (263) 




































2a,3 2b,3 3,4 4,5 5,6e 5,6a 
0Obs -134.5 -12.0 -68.3 172.0 -51.5 -170.3 
SObs 7.9 11.2 3.2 9.8 5.4 10.2 
CaIc 6.0 7.7 2.1 10.1 3.7 10.0 






2a,3 2b,3 3,4 4,5 5,6e 5,6a 
0ObS 118.5 -59.6 175.5 -54.3 -174.1 
SObs 11.2 8.4 2.9 9.7 5.4 10.0 
CaIc 8.0 3.7 2.8 10.2 3.4 10.2 
Table 37: Calculated and observed coupling constants for adduct (273) 
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2.4.7 Synthesis of 1,2-Dideoxy-D-erythro-pent-1-enitol ( 276) 
The deprotected alkene (276) was afforded as a colourless oil (41%) by 
stirring of alkene (260) with a mixture of water/glacial acetic acid (1:4) at 80°C for 7 
hours (Scheme 62) and the product purified by preparative TLC. The parent alkene 
has a larger Rf value on silica (50% ether/ethyl acetate) than the corresponding triol 
as expected (0.59 cf0.09). 
CH3 	0 
	 a 	HO 




(a) Glacial acetic acid/water (4:1), 80°C 
Scheme 62 
2.4.7.1 Nitrile Oxide Cycloadditions to Alkene (276) 
Cycloaddition of ethoxycarbonylformonitrile oxide to alkene (276) (see 
Scheme 63) was carried out as outlined in Section 2.3.2. The reaction mixture was 
analysed by 'H NMR and from this a ratio of 55:45 for the isoxazolines (277) and 
(278) obtained. The ratio of products was determined from the crude reaction 
mixture. Unreacted alkene:furoxan:isoxazolines was estimated to be in a ratio of 
1.0:0.7:1.0. 
Similarly the corresponding cycloaddition of benzonitrile oxide to the same 
alkene (276) afforded the adducts (279) and (280) in a combined yield of 25% and 
ratio of 62:38. The ratio was again determined by comparison of the integrals in the 
crude reaction mixture. 
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The products were identified by comparison with authentic samples prepared 
by removal of the ethylidene group (Scheme 63) from (263) and (264) or (272) and 
(273). The major adducts (277) and (279) were thereby assigned S-configuration at 
















(263) R = CO2Et, R' = H 







(278) R = CO,Et 
(280) R = Ph 
deprotectioni 
CH3 
(264) R = CO,Et, R' = H 
(273) R = Ph, R' = Ac 
The nitrile oxide cycloadditions to alkene (276) both proceed with low it-
facial selectivity with d.e. values of 10% for ethoxycarbonylformonitrile oxide and 
24% for benzonitrile oxide. The ratios obtained (Table 38) indicate there is little 
change in it-facial selectivity for cycloadditions to the triitol alkene (276) compared 
with those to the ethylidene protected alkene (260). 
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Alkene Nitrile Oxide erythro: threo 
(260) Et02CCNO 53 : 47 
PhCNO 52 : 48 
(276) Et02CCNO 55 : 45 
PhCNO 62:38 
Table 38 : Isomer Ratios for Cycloaddition of Nitrile Oxides to 
Alkenes (260) and (276) 
2.4.8 Reduction of 3-Ethoxycarbonyl Substituent to Hydroxymethyl 
Conversion of the 3-ethoxycarbonyl isoxazolines (263) and (264) to 
heptulosonic acid analogues requires reduction of the ester group to provide the 
hydroxymethyl substituted isoxazoline. This transformation should also provide 
access to a range of analogues in addition to facilitating the hydrolytic ring cleavage 
of the 2-isoxazoline to the 3-hydroxyketone. 
Isoxazolines (263) and (264) were therefore reduced with sodium 
borohydride in ethanol at room temperature to afford alcohols (269) and (270) 
respectively (Scheme 64). Each adduct was obtained in good yield (77% and 84% 
respectively). The characteristic properties of the isomers (269) and (270) are 
compared with those of the parent major and minor cycloadducts (263) and (264) in 
Section 2.4.2.2. 
OH 	NaBH4 	 OH 
CH3 -0 	 CH3 
CO 2 Et 	 0, 	CH,OH 
'p 
N 	 N 
5S 	 (269) 5S 
5R (270) 5R 
Scheme 64 
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2.4.9 Deprotection of 2-Isoxazolines 
It has been established from model studies carried out for the hexulosonic 
acid series that initial deprotection followed by reductive hydrolytic ring cleavage 
(Section 2.3.8.5) is the better approach to the required analogues. Thus the route 
selected to DAH analogues first involved removal of the ethylidene protecting group 
from the 3-substituent of the 2-isoxazoline. Subsequent ring opening of the 
isoxazoline would then be expected to afford the product in hemiketal form. 
The procedure involved stirring of the isoxazoline with a mixture of 
water/glacial acetic acid (1:4) at 80°C (Scheme 65) and TLC of the mixture indicated 
when reaction was complete (4-10 hours). Deprotection of each pair of cycloadducts 
resulted in yields ranging from 48% for (278) to 87% for (277) 
CH3 	0 
OH 
5S (263) R = CO2Et 
(265) R=Ph 
(269) R = CH20H 
5R (264) R = CO2Et 
(266) R=Ph 
(270) R = CH20H 
5RJS (267)/(268) R = CH7P(0)(OE02 
HO 
a 	HO 	 OH 
1W 	
5 
O)-  R 
N 
5S (277) R = CO2Et 
(279) R = Ph 
(281) R=CH2OH 
5R (278) R = CO2Et 
(280) R=Ph 
(282) R = CH,OH 
5R/S (283) R = CH2P(0)(OEt) 2  
(a) Glacial acetic acid/water (4:1), 80°C 
Scheme 65 
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2.4.9.1 Characteristics of Triols 
The characteristic properties of the triols resulting from removal of the 
ethylidene protecting group are compared with those for the starting isoxazolines 
below. 
TLC 
The parent 2-isoxazoline has a larger R f value on silica (100% ethyl acetate) 
than the corresponding trio! [eg. 0.49 cf 0.09 for (265)1(279)]. Tne erythro trio! also 
occurs at larger R f value than the threo isomer. 
'HNMR 
The deprotected diastereoisomeric adducts will be considered initially, and 
then these results compared with the parent isoxazolines. The 'H NMR spectra reflect 
a major difference between the 5-H signal for the erythro and threo isomers. It is 
observed that for the threo adduct the 5-H signal absorbs at significantly higher 
frequency than for the corresponding erythro product [Aö H +0.04 ppm for 
(277)/(278), +0.05 ppm for (279)/(280), +0.04 ppm for (282)/(283)]. Compared to 
the protected adducts (see Section 2.4.2.2) 5-H has also shifted to higher frequency 
for the erythro adduct whereas the value for the threo isomer remains unchanged. It 
is noteworthy that the coupling between 5-H and 6-H is smaller for both the erythro 
and threo isomers compared to the protected products [eg. 4.8 cf 2.6 Hz for 
(263)1(277), 2.9 cf 2.4 Hz for (264)/(278)]. The A6H for J56 between the erythro and 
threo isomers is also significantly less when they are deprotected with J5,6  changing 
much more markedly for the erythro isomers than the threo isomers (MH -2 Hz cf 
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0.5 Hz). The coupling J67 (ca 7 Hz) and 7,8a  (Ca 5.5 Hz ) indicates that once 
ethylidene protection has been removed the isomers no longer have diaxial couplings 
between these protons and adopt a different conformation in solution, perhaps due to 
loss of rigidity imposed by the 1 ,3-dioxane ring. A torsion angle of 1310  is predicted 
from the 5.5 Hz coupling. The chemical shifts and coupling constants for the 
deprotected adducts are summarised in Tables 39 and 40. 
' 3c NMR 
The 13C NMR spectra for the deprotected isomers show significant 
differences for C-4 to C-6. In each case the threo adduct has a higher5-value for C-4 
[A5c +2.7 ppm for (277)/(278), ±1.4 ppm for (279)1(280)]. This the reverse of that 
seen for the protected isomers where C-4 for the erythro isomer appears at higher 
chemical shift (see Section 2.4.2.2). The peaks for the erythro deprotected isomers 
have shifted to lower frequency by '-3 ppm compared to the protected adducts. There 
is also a marked difference shown for C-5 in the deprotected adducts [A6 c +1.7 ppm 
for (277)1(278), +2.7 ppm for (279)1(280)]. This was also observed in the protected 
adducts. It is noteworthy that C-6 in the deprotected adducts occur at much lower 
frequency than in the corresponding protected isomers [E.6 c -7.4 ppm for (277)1(263), 
-7.3 ppm for (264)1(278)]. This is a consequence of C-6 now being adjacent to a 
hydroxyl group. There is no difference between the isomers for C-7 in the 
deprotected compounds whereas the corresponding protected isomers show a 
noticeable variance [eg. A& 2.9 ppm for (263)1(264)]. However, the signals for the 
deprotected adducts occur at much lower frequency than for the corresponding 
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protected isomers (Ca 8 Hz for the erythro adduct and 10 Hz for the threo isomer). 




















4a-H 4b-H 5-H 6-H 8a-H 
CO2Et Erythro (277) 3.30 3.14 5.10 3.92 3.65 
Threo (278) 3.29 3.20 5.14 3.73 3.67 
Ph Erythro (279) 3.51 3.34 5.01 3.98 3.69 
Threo (280) 3.47 3.44 5.06 3.58 nd 
CH20H Erythro(281) 3.16 3.00 4.79 nd nd 
Threo (282) 3.11 3.10 4.83 nd nd 
Table 39: Selected 'H NMR data 
R Coupling 
Jill1 
4a,4b 4a,5 4b,5 5,6 6,7 7,8a 
CO2Et Erythro(277) 17.4 9.1 11.6 2.6 7.9 5.6 
Threo (278) 17.5 11.5 9.0 2.4 nd 5.1 
Ph Erythro (279) 16.7 8.9 11.1 3.3 7.0 5.8 
Threo (280) - 10.7 9.1 2.6 4.7 5.4 
CH20H Erythro (281) 17.1 9.0 10.9 3.6 nd nd 
Threo (282) - 10.5 9.4 3.0 nd nd 





C-4 C-5 C-6 C-7 
CO2Et Erythro (277) 32.6 85.1 72.4 71.4 
Threo (278) 35.3 83.4 73.2 71.5 
Ph Erythro (279) 34.1 82.6 72.8 71.9 
Threo (280) 35.5 79.9 72.5 70.8 
Table 41: Selected ' 3 C NMR data 
2.4.9.2 Deprotection of 2-Isoxazolines Containing an Acetoxy Homoallylic 
Substituent 
The ethylidene protecting group for each of the isoxazolines (272) and (273) 
was removed by stirring with a mixture of water/glacial acetic acid (1:4) at 80°C for 
5 hours (Scheme 66) and the products purified by preparative TLC. 
The reaction was initially performed using isoxazoline (272). TLC analysis of 
the reaction mixture indicated the presence of two products which could be separated 
by preparative TLC. By comparison of R f values with an authentic sample of (279), 
the deprotected isomer obtained from (265), the more polar component was predicted 
to be the fully deprotected compound in which the acetate ester has also been 
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hydrolysed. This was confirmed by its 'H and ' 3C NMR spectra which were identical 
to those of (279). The conditions used have also been successful at partial removal of 
the acetyl group to provide (284). The analogous reaction was performed using 
isoxazoline (273). However, in terms of ease of reaction, although the acetylated 
cycloadducts (272) and (273) are easier to separate by nature of their Rf values, the 
subsequent deprotection is achieved much more readily for the 7-OH adduct (265) 
and much higher yields are obtained (82% cf 12%). The less polar components were 
characterised by 'H and ' 3C NMR data and identified as the deprotected isomers 
(284) and (285) containing an intact homoallylic acetyl group at C-7. 
CH3 	0 
OAc 









(272) 5S 	 (279) 5S R'=H 
(284) 5S R'=Ac 
(273) 5R 	 (280) SR R'=H 
(285) SR R'=Ac 
(a) Glacial acetic acid/water (4:1), 80°C 
Scheme 66 
2.4.9.3 Characteristics of Triols (279), (280), (284) and (285) 
: si I 1 
The deprotected diastereo isomeric adducts will first be compared. The 'H 
NMR spectra reflect a major difference between proton 5-H for the erythro and threo 
isomers. It is observed that for the threo adduct the 5-H signal absorbs at 
significantly higher frequency than for the corresponding erythro product (MM +0.05 
S1 
ppm for each of the pairs of isomers). Compared to the protected adducts (see 
Section 2.4.5.2) 5-H has also shifted to significantly higher frequency [MH +0.24 
ppm for (272)/(279), +0.18 ppm for (273)/(280)]. It is worth noting that changing 
from 7-OH to 7-OCOCH 3 has a marked influence on the chemical shift. This has 
previously been remarked upon for the protected isomers (272) to (275) in Section 
2.4.5.2. Proton 7-H resonates at higher frequency for the threo isomer compared to 
the erythro isomer [z.6H +0.02 ppm for (279)/(280), +0.61 ppm for (284)/(285)]. This 
difference is much more pronounced for the acetylated adducts (284) and (285) and 
may be due to the conformation adopted in solution. Again the coupling constant 
is very much smaller in the deprotected adducts compared to the parent isoxazolines 
[eg. 5.8 Hz in (279) cf 10.2 Hz in (272), 6.5 Hz in (284) cf 10.2 Hz in (272)] 
suggesting that there is no longer diaxial coupling between 7-H and 8a-H. The J 78 
value is also smaller for the deprotected adducts [eg. 3.7 Hz in (279) cf 5.4 Hz in 
(272), 3.0 Hz in (284) cf 5.4 Hz in (273)]. The chemical shifts and coupling constants 
for the deprotected adducts are summarised in Tables 42 and 43. 
13C NMR 
The 13C NMR spectra for the deprotected isomers show significant 
differences for C-4 to C-7. The threo adduct has a higher8-value for C-4 [z\öc  +1.4 
ppm for (279)1(280)]. There is a marked difference shown for C-S in the deprotected 
adducts [Aöc 2.7 ppm for (279)/(280)]. This was also observed for the protected 
adducts. It is noteworthy that the signals for C-6 in the deprotected adducts occur at 
much lower frequency than in the corresponding protected compounds [oc -5.1 ppm 
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for (272)/(279), -5.7 ppm for (273)1(280)]. This is a consequence of C-6 now being 
adjacent to a hydroxyl group. Once again the C-75-values for the protected adducts 
occur at much higher frequency than for the corresponding protected isomers (8 Hz 
for both the erythro and threo isomers). The differences for the deprotected adducts 













4a-H 4b-H 5-H 6-H 7-H 
Ph H Erythro (279) 3.51 3.34 5.01 3.98 3.93 
H Threo (280) 3.47 3.44 5.06 3.58 3.95 
Ac Erythro (284) 3.51 3.36 5.03 3.91 3.37 
Ac Threo (285) 3.51 3.43 5.08 3.58 17T:1  
Table 42 : Selected 'H NMR data 
R R' 
f/Hz 
5,6 6,7 7,8a 7,8e 
Ph H Erythro (279) 3.3 7.0 5.8 3.7 
H Threo (280) 2.6 7.7 5.4 3.7 
Ac Erythro (284) 3.4 4.7 6.5 3.0 
Ac Threo (285) 2.5 8.9 6.3 2.6 






C-4 C-5 C-6 C-7 C-8 
Ph H Erythro (279) 34.1 82.6 72.8 71.9 64.0 
H Threo (280) 3 5. 55 79.9 72.5 70.8 63.2 
Ac Threo (285) 36.6 80.6 73.0 70.0 66.7 
Table 44: Selected ' 3 C NMR data 
2.4.10 Conclusion 
Cycloaddition of nitrile oxides to D-erythro-alkenes (260), (271) and (276) 
afforded adducts in variable yields (38-77%) and with poor ir-facial selectivity (50% 
erythro : 50% threo to 63% erythro : 37% threo) with slight preference for erythro 
adducts. In order to investigate further the influence of homoallylic substituents at C-
7 on selectivity an alternative five-carbon alkene containing an axial hydroxyl at C-7 
was synthesised. 
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2.4.11 Synthesis of 1 ,2-Dideoxy-3,5-O-Benzylidene-L-threo-pent-l-enitol (286) 
The five-carbon sugar alkene (286) which contains an axial hydroxyl at C-7 
was prepared in three steps from D-arabinitol (equivalent to L-arabinitol) according to 
Scheme 67, with an overall yield of 22%. The route involves protection of the 1- and 
3- positions as the benzylidene derivative, periodate cleavage of the vicinal 5,6-diol, 
and finally Wittig olefination of the resulting aldehyde. 
HO 	OH 
Ph 	0 
a 	 \ 	\ 
HO 	 OH 	
0 
f\OH 
OH 	 HO OH 
(287) 
4, b 
Ph C 	Ph 
OH 	 OH 
(286) 	 (288) 
(a) PhCHO, dry HC1(g); (b) Na10 4; (c) Ph 3PCH3 1 -, (CH3)3COK, T}{F 
Scheme 67 
A series of experiments was performed using various solvents, catalysts and 
temperature conditions to try and optimise conditions for the first step. The technique 
selected involved passage of a rapid stream of dry hydrochloric acid gas into a 
suspension of D-arabinitol in benzaldehyde to afford the 1 ,3-O-benzylidene-L-
arabinitol (287).223224  This reaction, however, proved to be very unpredictable 
yielding mixtures of isomers. In order to assign the structure of (287) unambiguously 
NOE experiments were carried out. Irradiation of 6-H resulted in the expected 
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enhancement of the 3-H and 5a-H signals (Figure 18) thus confirming that the phenyl 
substituent occupies the equatorial position. There was no observed enhancement of 
5e-H or 4-H. These results are consistent with the structure shown since, if the 
phenyl were axial and 6-H equatorial there would be no enhancement of 5a-H or 3-H 










Subsequent metaperiodate cleavage of (287) at pH 4 followed by rapid 
hydrolysis at pH 6.5 afforded aldehyde (288) as white crystals (70%). This was 
converted via a Wittig reaction with methyltriphenylphosphorane to the desired 
alkene (286) in 49% yield. 
2.4.12 Investigation of it-Facial Selectivity in Nitrile Oxide Cycloadditions to 
1 ,2-Dideoxy-3,5-O-benzylidene-L-threo-pent-1 -enitol (286) 
2.4.12.1 Nitrile Oxide Cycloadditions to Alkene (286) 
Two nitrile oxides were examined: ethoxycarbonylformonitrile oxide and 
benzonitrile oxide. Cycloaddition of benzonitrile oxide to alkene (286) (Scheme 68) 
was carried out as outlined in Section 2.3.2 and a mixture of diastereoisomeric 
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isoxazolines (289) and (290) in combined yield of 64% and ratio 81:19 obtained after 
chromatography to remove 3,4-diphenylfurazan N-oxide. 
	








5S'\__ 	 R\___. 
+ 
+ - 
R—CN—O 	 N 	 N  
(289) R = Ph 	 (290) R = Ph 
(291' ) R = CO2Et (292) R = CO 2Et 
Scheme 68 
The product ratio could not be determined from the 'H NMR spectrum of the 
mixture. Instead it was measured by reverse phase HPLC. An X-ray structure of 
(289) was obtained to assign unambiguously the configuration at the new asymmetric 
centre C-5 and this will be discussed in Section 2.4.13. The major isomer (289) was 
thus assigned S-configuration at C-5, corresponding to an erythro relationship about 
the C-5/C-6 bond. The overall stereochemistry for the isomers can be assigned as L-
lyxo for the 5S isomer and L-xylo for the 5R isomer. 
The corresponding cycloaddition of ethoxycarbonylformonitrile oxide to 
alkene (286) afforded the adducts (291) and (292) in a combined yield of 69% and 
ratio 83:17, together with the nitrite oxide dimer 3,4-diethoxycarbonylfurazan N-
oxide. The ratio was determined by comparison of the integrals for the 6-H signals in 
the 'H NMR, as well as by reverse phase HPLC (ratio 82:18). The assignment of 
configuration for the major isomer as erythro was made by comparison of its spectral 
parameters with those of the benzonitrile oxide adducts (289) and (290). 
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The nitrite oxide cycloadditions to alkene (286) proceed selectively with d.e. 
values of —64%. The erythro:threo ratios for the reactions studied are presented in 
Table 45. 
Alkene Nitrile Oxide erythro:threo 
(286) Et02CCNO 83: 17 
PhCNO 81: 19 
Table 45 : Isomer Ratios for Cycloaddition of Nitrite Oxides to Alkene (286) 
2.4.12.2 Characterisation of Isoxazoline Cycloadducts 
The characteristic properties of the cycloadducts obtained from 
cycloadditions to alkene (286) are summarised below. 
TLC 
The eryrhro adduct has a larger Rf value on silica (100% ether) than the 
corresponding threo isomer [eg. 0.23 cf 0.14 for (289)/(290)]. 
'H NMR 
The Ill  NMR reflect major differences between the isomers for protons 4-H 
to 7-H. It is observed that for the etythro adduct the 5-H signal absorbs at a slightly 
higher frequency than for the corresponding threo product [Aö H +0.03 ppm for 
(289)/(290), +0.01 ppm for (291)/(292)]. The signals for the methylene protons of the 
isoxazotine ring, 4a-H and 4b-H, are closer together in the erythro adducts. It is also 
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worth noting that proton 7-H resonates at a higher frequency for the erythro isomer 
compared to the threo isomer [L6H  +0.19 ppm for (289)/(290), +0.15 ppm for 
(291)/(292)]. There is also a noticeable difference for proton 6-H which absorbs at a 
higher chemical shift for the threo isomer than the erythro isomer 16H  +0.17 ppm 
for (289)/(290), +0.10 ppm for (291)/(292)]. In comparison to the results obtained for 
cycloadditions to alkenes (260) and (271) (Sections 2.4.2 and 2.4.5 respectively), 
opposing trends are observed here for 6-H and 7-11. This can be rationalised in terms 
of changing from an equatorial homoallylic substituent OR' in alkenes (260) and 
(271) to an axial substituent in alkene (286). In this system containing the axial 7-OH 
there is no observable difference in the coupling between 5-H and 6-H for either of 








Ph 	2tIr_.. H7 
\ OH HO 
H5' )' 'H4a 
O • —R 
N 
Threo 
R 4a-H 4b-H 5-H 6-H 7-H 
Ph Erythro (289) 3.46 3.45 5.06 3.86 3.90 
Threo (290) 3.49 3.26 5.03 4.03 3.71 
CO2Et Erythro (291) 3.35 3.26 5.07 3.88 3.78 
Threo (292) 1 3.33 3.13 5.06 3.98 3.63 




4a,4b 4a,5 4b,5 5,6 
Ph Erythro (289) 17.1 7.7 9.2 8.4 
Threo (290) 16.7 10.8 8.4 7.4 
CO2Et Erythro (291) 18.2 7.3 10.9 7.5 
Threo (292) 17.7 11.4 8.9 7.5 
Table 47: Selected 'H NMR data for cycloadducts 
2.4.13 X-Ray Crystal Structure of Adduct (289) 
The major adduct (289) obtained from cycloaddition of benzonitrile oxide to 
alkene (286) was isolated as a crystalline solid suitable for X-ray analysis. 
Examination of the crystal structure (Figure 19) established the S-configuration at the 
new asymmetric centre at C-5 representing an erythro relationship between C-6 and 
C-S. This assignment is consistent with those obtained for the adducts (263), (272) 
and (273), which were also determined by X-ray crystallography (Section 2.4.6). 
The torsion angles obtained for the X-ray crystal structure were used to 
calculate the proton-proton coupling constants by applying the Haasnoot 
parameterisation 209 of the Karplus equation and these then compared to those 
observed in solution (Table 48). In this case the relationship between the observed 
and calculated f-values for the isoxazoline ring protons is satisfactory. There is also 
reasonable correlation for .14,5, 5,6a and J5,6e.  However, there is a significant deviation 
associated with the coupling between the hydrogens at the ring junction 3-H/4-H, 
indicating a difference of preferred conformation in solution and in the crystal. 4 








2a,3 2b,3 3,4 4,5 5,6a 5,6e 
0 -147.9 -25.1 -68.7 54.2 67.0 -51.7 
SObs 9.2 7.7 8.4 1.1 1.2 1.9 
CaIc 7.9 6.8 2.0 3.4 2.2 3.7 
3Jcaic =7.76C0S20 1.1 CosO+ 1.4 
Table 48: Calculated and observed coupling constants for adduct (289) 
2.4.14 Conclusions 
The approach selected for the synthesis of heptulosonic acid (DAH) 
analogues is via nitrile oxide-isoxazoline chemistry using the five-carbon alkene 
(260) as the starting material. Cycloaddition of nitrile oxides to D-erythro-alkene 
(260) afforded adducts in variable yields (38-77%) and with negligible it-facial 
selectivity (0-6% d.e.). The low selectivity is possibly due to the presence of the 
homoallylic hydroxyl at C-7. 
In order to investigate the influence of the homoallylic substituent on it-facial 
selectivity cycloadditions to alkene (271) containing an equatorial acetoxy 
homoallylic substituent at C-7 were performed. These afforded adducts in variable 
yields (46-74%) with moderate it-facial selectivity (18-26% d.e.) and again with 
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preference for erythro products. Cycloadditions to alkene (276), resulting from 
removal of the ethylidene protection of (260), also proceed with low selectivities (10-
24% d.e.). 
In contrast, the corresponding cycloaddition to the isomeric L-threo-alkene 
(286), which has an axial hydroxyl at C-7, proceeded with high erythro selectivity 
(60-62% d.e.) 
These results illustrate the influence that can be imparted on selectivity 
merely by changing from an equatorial to axial homoallylic substituent at C-7 (Table 
49). This change may be attributed to subtle changes in the relative energies of the 
transition states proposed by Houk et al 196  (Figure 13, Section 2.4.5.1). 
Alkene Nitrile Oxide erythro:threo 
Equatorial Homoallylic 
Substituent 
(260) Et02CCNO 53:47 
PhCNO 52:48 
(271) Et02CCNO 59:41 
PhCNO 63:37 




(286) Et02CCNO 83:17 
PhCNO 81:19 
Table 49 : Isomer Ratios for Cycloaddition of Nitrile Oxides to 
Alkenes (260), (271), (276) and (286) 
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Removal of the ethylidene protecting group from the 5-substituent of the 2-
isoxazolines derived from alkene (260) has also been accomplished to yield 
precursors required for the final ring opening of the 2-isoxazoline. 
This final stage has yet to be investigated. Reductive hydrolytic cleavage of 
the isoxazoline would be expected to afford the hemiketal form for the 
hydroxymethyl analogues. In contrast the phenyl compounds may be expected to 
exist in the open-chain keto form as previously observed in the six-carbon model 
system (Section 0 O\  
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2.5 3-Deoxy-D-manno-octulosonic Acid (KDO) Analogues 
The approach selected for the synthesis of octulosonic acid (KDO) analogues 
initially focussed on preparation of the D-arabinose-derived six-carbon alkene (293), 
which has the required configuration for C-6, C-7 and C-8 of the KDO framework. 
Cycloaddition of this alkene to an appropriate nitrile oxide, followed by deprotection 
and subsequent reductive hydrolytic cleavage of the isoxazoline, should therefore 








RC:-` N - 0 
Scheme 69 
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2.5.1 Synthesis of 1 ,2-Dideoxy-3,4 :5,6-di-O-isopropylidene-D-arabino-hex-1-
enitol (293) 
The title compound was prepared in four steps using two different synthetic 
pathways. 
0 From D-arabrnose (Scheme 70) by the method of Zrn 
225  i ner 	n 29/0 overall yield. 
From D-mannitol (Scheme 71) by the method of Wiggins 
226  in 14% overall yield. 
The method of Zinner was first considered. The aldehyde function of D-
arabinose was initially protected as a thioacetal (294) by reaction with ethanethiol. 225 
This thioacetal (294) was then treated with acetone containing 1.5% sulphuric acid, 
followed by anhydrous copper sulphate in acetone, to afford the 2,3:4,5-di-0-
isopropylidene derivative (295).225  Treatment with mercury(II)oxide and 
mercury(II)chloride unmasked 225 the aldehyde function (Scheme 70). Since (296) 
was found to degrade on standing, purification by distillation/sublimation using a 
cold-finger distillation apparatus was performed immediately prior to the Wittig 
olefination for the conversion to alkene (293). This Wittig reaction was performed in 
the same way using methyltriphenyl-phosphonium iodide as for the lower 
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(a) CASH, HCI; (b) Acetone, H2SO4;  (c) HgO, HgC12; (d) PhPCH3 1-, (CH3)3 COK, THF 
Scheme 70 
The alternative Wiggins preparation of aldehyde (296) (Scheme 71) starts 
from D-manmtol and avoids the use of ethanethiol. 1,2:3,4:5,6-Tri-0-isopropylidene-
D-mannitol (297), prepared by reaction of D-mannitol with acetone using a catalytic 
amount of concentrated sulphuric acid,  226  was hydrolysed selectively at the more 
reactive terminal ketal using 70% ethanol containing concentrated hydrochloric acid. 
The desired 1,2:3,4-di-0-isopropylidene-D-mannitol (298) (35%) was separated from 
the mono- and tri-ketal derivatives by column chromatography. Subsequent treatment 
with sodium periodate afforded aldehyde (296) which was purified by distillation, 
and then converted via a Wittig reaction to alkene (293). 
The overall yield (14%) of alkene (293) prepared by this method is slightly 
less than that for the preceding method (29%), mainly due to losses during 
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chromatography. However, this is a more environmentally friendly route to the 
desired aldehyde (296) and thence alkene (293). 
OH OH 
HO 	












OO 	 O><O 
(293) 	 (296) 
(a) Acetone, H 2SO4; (b) 70% EtOH, HCI, 40-45°C; (c) Na10 4 , 0°C; 
(d) Ph 3PCH3 1-, (CH3 )3COK, THF 
Scheme 71 
2.5.2 Investigation of 7t-Facial Selectivity in Nitrile Oxide Cycloadditions to 
1 ,2-Dideoxy-3,4 : 5,6-di-O-isopropylidene-D-arabino-hex-1 -enitol (293) 
2.5.2.1 Nitrile Oxide Cycloadditions to Alkene (293) 
Three nitrile oxides were examined: ethoxycarbonylformonitrile oxide, 
benzonitrile oxide and (diethoxyphosphoryl)acetonitrile oxide. Cycloaddition of 
benzonitrile oxide to the title alkene (293) (Scheme 72) was carried out as outlined in 
Section 2.3.2. After chromatography to remove 3,4-diphenylfurazan N-oxide (26%), 
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a mixture of isoxazolines (299) and (300) in a ratio of 67:33 and a combined yield of 












(299) R =Ph 
(301) R = CO2Et 
(303) R = CH2P(0)(OEt)2 
(305) R = CH20H 
Scheme 72  
(300) R =Ph 
(302) R = CO2Et 
(304) R = CH2P(0)(OEt) 2 
(306) R = CH20H 
The isomer ratio was determined by comparison of the integral of the 
epimeric 5-H signals at 4.98 and 4.87 ppm in the 'H NMR spectrum of the mixture. 
Although the isoxazolines were chromatographically inseparable, the 1 H NMR of the 
mixture was readily interpreted on the basis of the differing signal intensities. 
Repeated recrystallisation from ether provided a small quantity of the pure major 
isomer. Subsequent X-ray analysis of this sample showed that the new chiral centre 
at C-5 possessed R-configuration, corresponding to an erythro relationship about the 
C-5/C-6 bond. Thus, the major isomer was identified as (299) and the minor isomer 
as the threo adduct (300). 
The overall stereochemistry for the isomers can be assigned as D-manno for 
the major isomer and D-gluco for the minor isomer. However in the subsequent 
discussion the terms erythro and threo will be used, referring to the relationship 
about the newly created chiral centre at C-5 and the adjacent centre C-6. 
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The corresponding cycloaddition of alkene (293) to ethoxycarbonylformo-
nitrile oxide afforded an inseparable mixture of diastereoisomeric isoxazolines (301) 
and (302) in combined yield of 88% together with the nitrile oxide dimer 3,4-
diethoxycarbonylfurazan N-oxide (24%). The isomer ratio was determined as 
62.5:37.5 in favour of erythro adduct (301) by comparison of the integrals of the 5-H 
signals at 5.06 and 4.92 ppm in the 'H NMR of the mixture. Again, although the 
isoxazolines were chromatographically inseparable the 'H NMR of the mixture was 
readily interpreted on the basis of the differing signal intensities. The assignment of 
configuration for the major isomer (301) was made by correlation of its NMR shift 
differences with those of the benzonitrile oxide adducts. 
Cycloaddition of (diethoxyphosphoryl)acetonitrile oxide to alkene (293) 
(Scheme 72) furnished a 30% combined yield of the inseparable diastereoisomeric 2-
isoxazolines (303) and (304) in a ratio of 63:37 in favour of the erythro adduct. 
Again the ratio was determined by comparison of the integrals for the 5-H signals in 
the 'H NMR. Although the isoxazolines were chromatographically inseparable, the 
'H NMR of the mixture was readily interpreted for the isoxazoline ring protons. The 
major isomer was assigned as the erythro adduct (303) based on comparison of its 
spectral parameters with those of similar adducts, as above. 
The nitrile oxide cycloadditions to alkene (293) all proceed with low 7E-facial 
selectivity with d.e. values ranging from 25% for ethoxycarbonylformonitrile oxide 
to 34% for benzonitrile oxide. The erythro:threo ratios for the three cases are 
presented in Table 50. 
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Table 50: Isomer Ratios for Cycloaddition of Nitrile Oxides to Alkene (293) 
2.5.2.2 Characterisation of Isoxazoline Cycloadducts 
The stereochemistry at the new chiral centre C-S of the isoxazoline can be 
predicted by correlation of 1 H and ' 3C NMR and optical rotation data. The 
characteristic properties of the major and minor isomers are summarised below, 
along with those for (305) and (306) obtained after borohydride reduction (Section 
2.5.4). 
TLC 
The major erythro adduct has a slightly larger R f value on silica (50% 
ether/hexane) than the corresponding minor threo adduct [0.26 cf 0.24 for 
(299)1(300), 0.26 cf 0.22 for (301)1(302)]. However, this difference was not sufficient 
to be able to resolve the isomers by dry flash chromatography. 
'H NMR 
Since the cycloadducts were unable to be separated, the 'H NMR spectra 
obtained show the signals for both isomers. However, major differences between the 
isoxazoline ring protons 4a-H, 4b-H and 5-H could still be identified. As seen in 
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previous systems the isoxazoline ring protons 4a-H and 4b-H give rise to a 
characteristic ABX system. It is observed that for the major erythro adducts the 
proton 5-H signal absorbs at significantly higher frequency than for the 
corresponding minor threo product 15H  +0.11 ppm for (299)/(300), +0.14 ppm for 
(301)/(302), +0.10 ppm for (303)1(304), +0.11 ppm for (305)/(306)]. The isoxazoline 
methylene proton signals (4a-H and 4b-H) are coincident in the minor threo adducts 
(302) and (306), while in the major erythro adducts (301) and (305) they are 
separated by 0.17 ppm and 0.10 ppm respectively. This pattern has previously been 
observed for other cycloadducts, involving different alkenes. 217 The couplings 
between 5-H and 6-H [eg. 3.9 cf 3.8 Hz for (299)1(300), 3.0 cf 2.2 Hz for (301)/(302)] 
are similar for the two isomers, indicating that they adopt similar conformations in 
solution. The chemical shifts and coupling constants are summarised in Tables 51 
and 52. 
' 3c NMR 
The ' 3C NMR spectra were assigned for each isomer in the mixture. The 
major differences between the adducts are associated with the signals for the 
epimeric center at C-5 and also that for C-4. In each case the major erythro adduct 
has a lower 6-value for C-4 ['.6c  -1.5 ppm for (299)1(300), -0.8 ppm for (301)/(302), 
-2.1 ppm for (305)1(306)], and for C-5 [A6c -1.2 ppm for (299)/(300), -1.8 ppm for 
(305)1(306)]. These differences are shown in Table 53. 
167 








4a-H 4b-H 5-H 
Ph Erythro (299) 3.34 3.45 4.98 
Threo (300) 3.47 3.38 4.87 
CO2Et Erythro (301) 3.15 3.32 5.06 
Threo (302) 3.27 3.27 4.92 
CH2P(0)(OEt)2 Erythro (303) 3.03* 2.94k 4.85 
Threo (304) 2.88k 2.99* 475 
CH20H Erythro (305) 3.02 3.12 4.87 
Threo (306) 3.11 3.11 4.76 
Table 51 : Selected 'H NMR data for cycloadducts 
* , 	Alternative assignments 
R Coupling 
JJHz 
4a,4b 4a,5 4b,5 5,6 
Ph Erythro (299) 16.5 11.2 7.8 3.9 
Threo (300) 16.5 7.9 10.8 3.8 
CO2Et Erythro (301) 17.5 11.7 8.4 3.0 
Threo (302) - 8.6 11.0 2.2 
CH2P(0)(OEt)2 Erythro (303) 15.0 10.6 8.4 3.8 
Threo (304) 15.0 8.4 10.8 2.4 
CH20H Erythro (305) 17.0 11.1 7.8 3.5 
Threo (306) - 8.8 1 	10.0 1 	2.5 







Ph Erythro (299) 35.6 80.7 
Threo (300) 37.1 81.9 
CO2Et Erythro (301) 35.1 nd 
Threo (302) 35.9 nd 
CH20H Erythro (303) 35.1 80.2 
Threo (304) 37.2 82.0 
Table 53: Selected ' 3 C NMR data for cycloadducts 
2.5.3 X-Ray Crystal Structure of Adduct (299) 
A small amount of major isomer (299) obtained from addition of benzonitrile 
oxide to alkene (293) was isolated as a crystalline solid suitable for X-ray analysis. 
The crystal structure (Figure 19) showed that the new asymmetric centre at C-S 
possessed R-configuration, thus indicating an erythro relationship between C-6 and 
C-5. This assignment is consistent with that predicted by the 'inside alkoxy effect'. 
Table 54 shows the proton-proton coupling constants calculated for the 
crystal from the torsion angles using the Haasnoot parameterisation 209 of the Karplus 
equation, compared to those observed in solution. From the data available, there is 
satisfactory correlation for J45 . However, the relationship between the observed and 
calculated J-values for the isoxazoline ring protons is poor. Also there is a significant 
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deviation associated with the coupling between the hydrogens at the ring junction 3-
H/4-H, indicating a difference of preferred conformation in solution and in the 
crystal. 5 
OO R 
2a,3 	I 2b,3 3,4 4,5 5,6 6,7a 6,7b 
9 8.7 131.8 79.3 -142.7 175.1 91.4 -30.2 
JO b, 11.2 7.8 3.9 8.2 nd nd nd 
CaIc 6.5 5.6 1.5 7.2 10.2 1.4 6.2 
3 Jcdc = 7.76 Cos 2O - 1.1 Cos9 + 1.4 




Labelling of protons in X-ray picture is different from that used in characterisation of products 
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2.5.4 Reduction of 3-Ethoxycarbonyl Substituent to Hydroxymethyl 
In order to convert the 3-ethoxycarbonyl isoxazolines (301) and (302) to 
octulosonic acid analogues, reduction of the ester group to provide a hydroxymethyl 
substituted isoxazoline is required. A wide range of derivatives should also become 
available by this modification including, for example, the mesylate. 
The mixture of adducts (301) and (302) was therefore reduced by sodium 
borohydride in ethanol to provide the corresponding diastereoisomeric mixture of 
alcohols (305' ) and (306) in excellent yield (88%) (Scheme 73). As for the parent 
compounds these were found to be chromatographically inseparable. The isomer 
ratio (60 : 40), which was measured by integration of the 5-H signals at 4.87 and 4.76 
ppm in the 'H NMR, is similar to the value obtained for the ester mixture from which 
the alcohols were derived. The characteristic properties of the isomers (305) and 
(306) are compared with those of the parent major erythro and minor threo 
cycloadducts (301) and (302) in Section 2.5.2.2. 
0 0 	 0 0 
NV2 NaBH4 0007cH20H 
(301)/(302) 	 (305)/(306) 
Scheme 73 
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2.5.5 Deprotection of 2-Isoxazolines (305)/(306) 
Based on the model studies carried out for the hexulosonic acid series where 
initial deprotection was followed by reductive hydrolytic ring opening (Section 
2.3.8.5) the route selected to the KDO analogues therefore first involved removal of 
the isopropylidene protection of the 2-isoxazolines (Scheme 74). Subsequent ring 
opening of the isoxazoline would then be envisaged to provide the desired pyranose 
ring structure. 
A series of pilot experiments were carried out in order to establish conditions 
for deprotection. The results are summarised in Table 55. 
HO 	OH 
0, 	0 0, 	CH2OH a 
	
HOOH;7CH2OH 
(305)/(306) 	 (307)/(308) 





MeOH containing 4% HBr Reflux, 24 hr No 
CH3 CO2I-I/I-120 (3:2) 40°C, 16 hr Yes 
90% CH3CO2H 90°C, 2 hr 
r.t,_l8hr  
No 
TFA containing 5% H20 r.t, 1 hr No 
Table 55 
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Examination of the 'H NMR spectra gave no evidence of deprotection having 
occurred using any of these methods apart from under conditions 2, where partial 
deprotection had occurred. The product obtained was analysed by 'H NMR and 
proved to be a mixture of the inseparable isomers (309)/(310) in a ratio erythro:threo 
5:3, and combined yield of 66%. This product results from hydrolysis at the more 
reactive terminal positions. The chemical formulae were verified by high resolution 









Since conditions had been established for partial deprotection, it was 
envisaged that increasing the temperature of the reaction, without altering any other 
factors, would facilitate the complete removal of the isopropylidene protecting 
groups. Two different experiments were performed, the first at 60°C and the second 
at 80°C. At 60°C, monitoring the reaction by TLC, it was evident that deprotection 
was occurring, however there were still two products present: that due to the partially 
deprotected product (309)1(310), and also a more polar component assumed to be the 
desired product (307)/(308). Increasing the temperature to 80°C, resulted in only one 
detectable product being observed by TLC after 2.5 hours. This product (307)1(308) 
was recrystallised from ethanol in 66% yield. The identity of both the partially and 
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fully deprotected products is discussed below. Each of these products is present as a 
mixture of inseparable isomers. 
2.5.5.1 Characteristics of Deprotected Adducts (307)/(308) and (309)/(310) 
Removal of either one or both of the isopropylidene protecting groups 
resulted in the formation of the partially and fully deprotected products respectively. 
The characteristic properties of these adducts compared to the starting isoxazoline are 
summarised below. 
'H NMR 
When the partially and fully deprotected isoxazolines are compared with the 
parent isoxazolines major differences are observed. The 'H NMR spectra reflect a 
major variation between the 5-H signal for the major erythro and minor threo 
isomers in all cases. It is observed that for the minor threo isomer this proton absorbs 
at significantly lower frequency than the corresponding major erythro adduct 11.5H - 
0.11 ppm for (305)1(306), -0.11 ppm for (309)1(310)]. For the deprotected 
compounds the methylene protons of the isoxazoline ring, 4a-H and 4b-H are closer 
together in the major erythro adducts and in the fully deprotected major erythro 
adduct they are coincident. It is worth noting that the coupling between 5-H and 6-H 
changes dramatically on going from (305)1(306) to (307)/(308) [3.5 cf 6.8 Hz for 
(305)/(307), 2.5 cf 6.9 Hz for (306)/(308)]. A significant change is also observed for 
the coupling between 6-H and 7-H, but in the opposite direction, ie. a decrease in 
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coupling [A6H -5.8 ppm for (305)/(307), -6.5 ppm for (306)1(308). Selected chemical 


















4a-H 4b-H 5-H 6-H 
(305) 3.02 3.12 4.87 4.16 
(306) 3.11 3.11 4.76 4.12 
 3.29 3.22 4.97 3.95 
 3.05 3.36 4.86 3.90 
(307) 3.21 3.21 4.80* 3.91 
(308) 2.96 3.24 4.86* 3.86 
Table 56 : Selected 'H NMR data for cycloadducts 
* Data obtained from deprotection of (327) and (328) (Section 2.5.13). 
Isoxazolines 
J/Hz  
4a,4b 4a,5 4b,5 5,6 6,7 
(305) 17.0 11.1 7.8 3.5 7.3 
(306) - 8.8 10.0 2.5 8.5 
 17.1 10.9 7.4 3.6 6.9 
 17.4 8.3 11.0 3.3 6.7 
(307) - 99* 7.0* 6.8 1.5 
(308) 17.6 8.3 1 	10.7 6.9 2.0 
Table 57 : Selected 1 H NMR data for cycloadducts 
* Approximate values. 
175 
'3c im 
The ' 3C NMR spectra for the partially and fully deprotected isomers show 
significant differences for C-4 and C-5. In each case the major erythro adduct has a 
lower chemical shift for C-4 [Mc -2.1 ppm for (305)/(306), -1.5 ppm for (309)1(310), 
-0.3 ppm for (307)/(308)]. It is also interesting to note that as the isopropylidene 
groups are removed there is a marked decrease in A8 c for C-4. There is also an 
observable increase for C-5 [Mc +1.8 ppm for (305)1(306), +1.5 ppm for 







C-3 C-4 C-S 
(305) 158.3 35.1 80.2 
(306) 158.1 37.2 82.0 
 160.8 35.2 - 
 160.6 36.7 - 
(307) 161.2 36.6 80.3 
(308) 160.9 36.9 81.8 
Table 58: Selected ' 3 C NMR data for cycloadducts 
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2.5.6 Reductive Hydrolytic Cleavage of 2-Isoxazolines (305)/(306) 
In order to synthesise the desired 3-deoxy-octulosonic acid analogues, 
reductive hydrolytic cleavage of the isoxazoline has to be accomplished. Although it 
has previously been shown that it is best to remove the protecting group first, 
followed by Raney-nickel catalysed hydrogenolysis (Sections 2.3.8.7 and 2.3.8.8), it 
was decided to perform the ring opening to allow characterisation of the resulting 3-
hydroxyketones in the hope that the products would be separable. 
The reductive hydrolytic cleavage of isoxazolines (305)/(306) was carried out 
using Raney-nickel in the same manner as for (196) and (204) (Section 2.3.8.2). 
After preparative TLC the desired 3-hydroxyketones (311)/(312) (65%) (a mixture of 
inseparable isomers) together with a complex mixture of diastereoisomeric 7-amino 
alcohols (313)1(314) (10%) were isolated (Scheme 75). 
The 3-hydroxyketones were characterised by 'H and ' 3 C NMR spectroscopy 
and FAB mass spectrometry, and the chemical formulae verified by high resolution 
FAB mass spectometry. Brady's reagent also stains the 3-hydroxyketone aiding in its 
identification. The y-amino alcohols were identified by a positive ninhydrin stain on 
TLC, together with high resolution FAB mass spectrometry analysis. 
0




0 HO 	, -CH2OH 
0 
(311)/(312) 









2.5.6.1 Characteristics of -Hydroxyketones 
'H NMR 
The 1 H NMR data for protons 4-H to 6-H reflect major differences between 
the 2-isoxazolines and f-hydroxyketones. Tables 59 and 60 compare the chemical 
shifts and coupling constants for the isoxazolines (305)/(306) with those of the - 
hydroxyketones (311)1(312). It is observed that the 5-H signal absorbs at 
significantly higher frequency for the isoxazoline than for the corresponding f3-
hydroxyketone [.öH ±0.91ppm for (305)1(311), +0.72ppm for (306)1(312)]. This 
trend has previously been observed in the six-carbon series (Section 2.3.8.3). 
Although there is a change in conformation of the -hydroxyketone in solution 
relative to the isoxazoline, as seen by the marked reduction in J67 [H  -4.7 ppm for 
(305)/(311), -5.9 ppm for (306)/(312)], the -hydroxyketone does not appear to be 
adopting a hydrogen bonded half-chair conformation as in previous examples. This 
may be due to steric interactions of the bulky isopropylidene side chain preventing 
such a structure being assumed. It is also noticeable that the methylene protons (4a-H 
and 4b-H) occur at higher 5-value (-P0.4 ppm) in the isoxazoline than in the 
corresonding -hydroxyketone. Proton 6-H has also moved to much lower frequency 
in the 3-hydroxyketones (H  0.45 ppm). 
'3C NMR 
Major differences for C-3 and C-4 are observed in the spectra for the - 
hydroxyketones compared to those of the respective isoxazolines (Table 61). As seen 
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in previous examples (Section 2.3.8.3) C-4 resonates at a higher frequency for the 3-
hydroxyketone [M c + 7.5 ppm for (305)/(311), + 5.7 ppm for (306)1(312)]. 
0 	0 
H 
H N" CH2OH 
0 	o 
HO  
/ 	H5 	\ 
HO 1_CH2OH 
Proton 4a-H 4b-H 5-H 6-H 
Isoxazoline (305) 3.02 3.12 4.87 4.16 
Isoxazoline (306) 3.11 3.11 4.76 4.12 
f3-Hydroxyketone (311) 2.63 2.76 3.96 3.70 
-Hydroxyketone (312) 2.76 2.76 4.04 3.70 
Table 59: Selected 'El NMR data 
Coupling 
JIHz 
4a,5 4b,5 5,6 6,7 
Isoxazoline (305) 11.1 7.8 3.5 7.3 
Isoxazoline (306) 8.8 10.0 2.5 8.5 
3-Hydroxyketone (311) 11.5 8.3 3.8 2.6 
3-Hydroxyketone (312) 8.9 11.1 4.0 2.6 








Isoxazoline (305) 158.3 35.1 
Isoxazoline (306) 158.1 37.2 
3-Hydroxyketone (311) 209.0 42.6 
-Hydroxyketone (312) 209.0 42.9 
Table 61 : Selected ' 3 C NMR data 
2.5.7 Mesylation of 3-Hydroxymethyl-Substituted Isoxazoline (305)/(306) 
One of the objectives of our work is to synthesise a range of 3-deoxy-
octulosonic acid analogues. Hence, conversion of the 3-hydroxymethyl group of 
(305)/(306) to the corresponding mesylates (315)/(316) should allow for the 
alternative functionalisation of the isoxazoline, and provide a suitably positioned 
leaving group for manipulation at later stages if required. 
The mixture of alcohols (305) and (306) was treated with methanesuiphonyl 
chloride in dry dichioromethane using triethlyamine as base, to afford a mixture of 
mesylates (315) and (316) in 80% yield (Scheme 76). As for the parent compounds 
these mesylates were found to be chromatographically inseparable. The isomer ratio, 
measured by integration of the 5-H signals at 4.17 ppm [6-H (erythro)] and 4.82 ppm 
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[5-H (threo)] in the 'H NMR was found to be 59:41, consistent with the value 
obtained for the alcohol mixture. The chemical formula was verified by high 
resolution FAB mass spectrometry. Comparison of 'H NMR of the mesylates with 
the parent alcohols indicates that changing from OH to OMs has little effect on the 
chemical shift values apart from that due to the CH20R, which moves to much 
higher frequency as expected (AS H -0.55 ppm for both isomers). In the ' 3 C NMR 
there is a noticeable increase in the chemical shift for CH 20R on changing from OH 
to OMs (L\6H -5.2 ppm) and also in the adjacent quaternary carbon (M c -5.4 ppm). 













Cycloaddition of nitrile oxides to the D-arabino-alkene (293) afforded 
adducts in variable yields (30-88%) and moderate t-facia1 selectivity (63:37 to 
67:33) with preference for erythro adducts in each case. Unfortunately, it has proved 
impossible to separate these isomers by dry flash chromatography to afford sufficient 
quantities of pure isomer for subsequent reactions. Therefore an alternative strategy 
was required for the synthesis of KDO analogues. 
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2.5.9 Alternative Approach to KDO Analogues 
This approach involves cycloaddition of nitrile oxides to the D-mannose 
derived alkene (317) in which the alkene moiety is at the non-reducing end of the 
sugar dipolarophile. A known literature procedure 227  is used to synthesise alkene 
(317) which incorporates the correct configuration for C-6, C-7 and C-8 of the KDO 
framework. This alkene has been shown previously 
217,221  to cycloadd to nitrile oxides 
with a high degree of selectivity, and to also yield isomers separable by 
chromatography. Subsequent deprotection, reduction of the aldehyde, followed by 
reductive hydrolytic ring opening of the isoxazoline should provide access to 
octulosonic acid analogues (Scheme 77). 
HO OH HO OH 
HO - 















2.5.10 Synthesis of Methyl 5,6-Dideoxy-2,3-0-isopropylidene-a-D-lyxo-hex-5-
enofuranoside (317) 
Alkene (317) was prepared from D-mannose in four steps (Scheme 78) using 
the literature procedure, 




OH ' H a xO- 
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(318) 	 (319) 4,c 
MsO 





(317) 	 (320) 
(a) Acetone, MeOH, conc HCI, reflux; (b) conc HCI, H 20, 23°C; (c) MsC1, pyridine; 
(d) ZnlCu couple, Na!, 133°C 
Scheme 78 
Acid catalysed reaction of D-mannose with acetone and methanol 
227  yielded 
the fully protected glycoside (318). Selective hydrolysis of the 5,6-isopropylidene 
group and subsequent treatment of the diol (319) with methanesulphonyl chloride 
and pyridine afforded the dimesylate (320)227  as a white crystalline solid, without the 
need for purification of the intermediate compounds (318) and (319). The dimesylate 
is a stable compound with a good shelf-life, whereas the resulting alkene (317) is 
found to decompose on prolonged storage. Therefore, conversion to lyw-alkene 
183 
(317) by the zinc/copper couple mediated reduction of the dimesylate, in a 
modification  228  of the Tipson-Cohen 229 reaction, was carried out as required. 
2.5.10.1 Cycloaddition of Nitrile Oxides to Methyl 5,6-dideoxy-2,3-0- 
isopropylidene-a-D-/yxo-hex-5-enofuranoside (317) 
Cycloaddition of benzonitrile oxide to the title alkene (317) (Scheme 79) was 
carried out as outlined in Section 2.3.2. Removal of excess alkene and 3,4-
diphenylfurazan N-oxide (14%) afforded a mixture of known 217 cycloadducts (321) 
and (322) in a ratio of 81:19 and a combined yield of 83%. 








(323) R = CO2Et 
(325) R = CH2P(0)(OEt) 2 




(322) R = Ph 
(324) R = CO2Et 
(326) R = CH2P(0)(OEt) 
(328) R = CH20H 
The isomer ratio was determined by comparison of the integrals for the 
glycosidic methyl proton signals which are well separated. In this case the individual 
adducts were readily separated by chromatography. This cycloaddition had 
previously been performed by K. McGhie, 217 so there was no need to characterise the 
adducts. 
The major isomer was assigned by comparison of its TLC data and melting 
point to an authentic sample. It had already been established unambiguously by X- 
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ray analysis 195  that the new chiral centre C-5 had R-configuration, indicating the 
preferential formation of the erythro adduct. The overall stereochemistry for the 
isomers can be assigned as D-manno for the major isomer and D-gluco for the minor 
isomer. 
The corresponding cycloaddition of ethoxycarbonylformonitrile oxide to 
alkene (317) (Scheme 79) afforded the adducts (323) and (324) in ratio 82:18 and a 
combined yield of 80%, together with the nitrile oxide dimer 3,4-diphenylfurazan N-
oxide (20%). This cycloaddition had previously been carried out by K. Penman 
195,221 
and G. Kirkpatrick, 191,230  and the major isomer was assigned as being the erythro 
adduct by comparison of its TLC data and melting point with an authentic sample. 
Cycloaddition of (diethoxyphosphoryl)acetonitrile oxide to alkene (317) 
(Scheme 79) afforded a 30% combined yield of the inseparable diastereoisomeric 2-
isoxazolines (325) and (326) in a ratio of 88:12. The ratio was determined by 
comparison of the integrals for the methoxy signals in the 'H NMR and the major 
isomer was assigned as the erythro adduct (325) based on comparison of its spectral 
parameters with those of similar adducts. 
2.5.10.2 Characterisation of Isoxazoline Cycloadducts 
The new chiral centre C-5 of the isoxazolines (325) to (328) was assigned by 
correlation of 'H and ' 3C NMR and optical rotation data, to cycloadducts previously 
characterised by K. McGhie 217 and K. Penman. 
221  The stereochemistry for the major 
isomer (321) had also previously been determined' 95 by X-ray crystallography. These 
characteristic properties of the major and minor isomers are summarised below along 
with those for (327) and (328) obtained after borohydride reduction (Section 2.5.11). 
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'H NMR 
The 'H NMR spectra reflect major differences between the isomers for the 
isoxazoline ring protons 44-11, 4b-H and 5-H. It is observed that for the major erythro 
adduct the 5-H signal absorbs at significantly higher frequency than for the 
corresponding minor threo product [MH +0.11 ppm for (321)/(322), +0.06 ppm for 
(323)/(324), +0.10 ppm for (327)/(328)]. The signals for the methylene protons of the 
isoxazoline ring, 4a-H and 4b-H, are closer together in the major erythro adducts. 
Indeed, in the case of the major erythro adduct (321) they are coincident, while in the 
minor threo diastereoisomer (322) they are separated by 0.45 ppm. It is worth 
mentioning that the coupling between 5-H and 6-H in the minor threo isomer, is 
significantly greater than that in the major erythro product [8.6 cf 6.3 Hz for 
(322)1(321), 8.5 cf 5.3 Hz for (324)/(323) and 8.5 cf 6.0 Hz for (328)/(327)]. This 
suggests that the two compounds adopt different conformations in solution. Also 
observed are larger chemical shift values for the OMe signal of the minor threo 
isomers. The chemical shifts and coupling constants are summarised in Tables 62 
and 63. 
' 3c NMR 
The ' 3 C NMR spectra for the pairs of isomers are very similar. The major 
difference is associated with the signal for the epimeric center at C-5. In each case 
the major erythro adduct has a lower 8-value than the minor threo adduct [c  -1.5 
ppm for (321)/(322), -0.6 ppm for (323)/(324), -1.8 ppm for (327)1(328)]. These 










4a-H 4b-H 5-H OMe 
Ph 
(Ref 217) 
Erythro (321) 3.45 3.45 5.05 3.30 
Threo(322) 3.57 3.12 4.94 3.34 
CO2Et 
(Ref. 195) 
Erythro (323) 3.32 3.20 5.03 3.26 
Threo (324) 3.40 2.99 4.97 3.32 
CH2P(0)(OEt)2 Erythro (325) 3.19 3.18 4.91 3.98 
Threo (326) 3.20 3.18 4.91 3.98 
CH20H Erythro (327) 3.13 3.12 4.90 3.29 
Threo (328) 3.24 2.85 4.80 3.32 
Table 62: Selected 'H NMR data for cycloadducts 
R Coupling 
f/Hz 
4a,4b 4a,5 4b,5 5,6 
Ph 
(Ref 217) 
Erythro (321) - 8.6 9.7 6.3 
Threo (322) 16.9 10.7 8.7 8.6 
CO2Et 
(Ref. 195) 
Erythro (323) 18.1 8.3 11.2 5.3 
Threo (324) 18.0 11.2 9.1 8.5 
CH2P(0)(OEt)2 Erythro (325) - 8.5 9.6 6.4 
Threo (326) - 10.5 8.8 6.4 
CH20H Erythro (327) - 8.5 10.0 6.0 
Threo (328) 17.5 10.6 8.8 8.5 
Table 63: Selected 'H NMR data for cycloadducts 
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R = Ph R = CO2Et R = CH20H 
C-5 Erythro (32 1) 78.1 Erythro (323) 78.8 Erythro (327) 80.2 
Threo (322) 79.6 Threo (324) 79.4 Threo (328) 82.0 
Table 64: Selected ' 3C NMR data for cycloadducts 
Optical Rotation 
The major isomer was found to have a more negative [aID  value. This 













-35.2 +84.8 -43.8 +90.1 -5.6 +77.9 
Table 65 
2.5.11 Reduction of 3-Ethoxycarbonyl Substituent to Hydroxymethyl 
In order to convert the 3-ethoxycarbonyl isoxazolines (323) and (324) to 
octulosonic acid analogues, reduction of the ester group to provide a hydroxymethyl 
substituted isoxazoline is required. This should also allow access to a wide range of 
derivatives as well as facilitating the hydrolytic ring cleavage of the 2-isoxazoline to 
the -hydroxyketone. 
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Isoxazolines (323) and (324) were therefore reduced by sodium borohydride 
in ethanol at room temperature to provide the corresponding alcohols (327) and (328) 
in excellent yields, 99% and 98% respectively (Scheme 80). The characteristic 
properties of the isomers (327) and (328) are compared with those of the parent 
major erythro and minor threo cycloadducts (323) and (324) in Section 2.5.10.2. 




5R 	 (327) 5R 
5S (328) 5S 
Scheme 80 
2.5.12 Deprotection of 2-Isoxazolines 
The next step en route to KDO analogues involves the removal of the 
isopropylidene protecting group 231,232  and hydrolysis of the methyl glycoside of the 
2-isoxazolines (Scheme 81). Subsequent ring opening of the furanose followed by 
reduction and hydrogenolysis of the isoxazoline would be envisaged to provide the 
desired pyranose ring structure. 
Removal of the isopropylidene protecting group and hydrolysis of the methyl 
glycoside was accomplished for hydroxymethyl compounds (327) and (328) after a 
number of pilot experiments had been performed using (327) (Table 66). Monitoring 
189 
the reactions by TLC, it was evident that much more polar components were being 







CF3CO2HIH20 (9:1) r.t., 20 min Yes No 
40°C, 3 hr Yes Yes 
60°C, 2 hr Yes Yes 
H2SO4 0 M) 100°C, 5 hr No evidence of 
required product 
No evidence of 
required product 
Table 66 
Analysis of these experiments indicated that total deprotection could be 
acccomplished at 40°C or 60°C. From these results it was decided to perform all 
subsequent deprotections at a temperature intermediate to these, i.e. at 50°C to 
ensure total deprotection occurred. The partially and fully deprotected products (329) 
and (331) were obtained as oils in 70% and 60% yields respectively. Each was 
identified and characterised by 'H and ' 3 C NMR and FAB mass spectrometry. (331) 
was shown to be present as a mixture of anomers. The chemical formulae were 
verified by high resolution FAB mass spectrometry. 
Pilot experiments for the phenyl analogue (321) under similar conditions 
show partial deprotection to intermediate (330). To take this compound through to 





5R (329) R = CH20H 
5R (330) R=Ph 
/ 






SR (327) R = CH20H 
	
SR (331) R = CH20H 
5S (328) R = CH20H 5S (332) R = CH20H 
SR (321) R=Ph 
	
5R (333) R = Ph 
(a) CF 3CO2HIH20 (9:1), 50°C, 3 hr 
Scheme 81 
2.5.12.1 Characterisation of Deprotected Compounds (329) to (331) 
The characteristic properties of the partially and fully deprotected isoxazoline 
derivatives resulting from removal of the isopropylidene protecting group and 
hydrolysis of the methyl glycoside are compared below with those of the starting 
isoxazolines. 
'HNMR 
When the partially and filly deprotected isoxazolines are compared with the 
parent isoxazolines major differences are observed. On removal of the isopropylidene 
protecting group the signal due to 6-H absorbs at significantly higher frequency [H 
+0.27 ppm for (327)1(329), +0.36 ppm for (321)/(330)]. In comparison protons 7-H 
191 
and 8-H both shift to lower frequency [eg. 4.74 cf 4.34 for (327)/(329)]. However, 
there is no observable change in5-value for 7-H and 8-H on removal of the methoxy 
substituent. It is noticeable that as deprotection is accomplished 9-H gives rise to 
higher chemical shifts [4.88 cf 4.99 cf 5.33 for (327)/(329)/(331)]. The main 
difference in coupling values is that due to J89 which increases dramatically on 
deprotection [eg. 0.0 cf 4.1 cf 5.1 Hz for (327)/(329)/(331)1. These differences are 
shown in Tables 67 and 68. 
' 3c NMR 
The ' 3C NMR spectra for the deprotected isomers show significant 
differences for C-4 and C-9 (Table 69). On removal of the isopropylidene group C-4 
shifts to a much lower frequency [oc -2.7 ppm for (327)/(329), -2.6 ppm for 
(321)/(330)]. However, once the methoxy substituent has been removed to yield the 
free OH C-4 moves to a higher chemical shift than in the original protected isomers 





5R 0 	OH 
7 z 
HO OH 
5R (327) R = CH20H 
	
5R (329) R = CH20H 
	
5R (331) R = CH20H 
5R (32 1) R=Ph 
	
5R (330) R = Ph 
Isoxazoline 
6H/PPM 
6-H 7-H 8-H 	
1 9-H OMe 
 4.01 4.74 4.54 4.88 3.29 
 4.28 4.34 4.14 4.99 3.44 
(331) 4.23 4.40 4.35 
4.14  
5.33 - 
(321) 4.08 4.81 4.58 4.91 3.30 
(330) 4.44 4.39 4.21 5.04 3.49 
Table 67: Selected 'H NMR data 
Isoxazoline 
f/Hz 
5,6 6,7 7,8 8,9 
 6.0 3.7 5.9 0.0 
 5.9 3.8 4.7 4.1 
(331) 5.4 3.7 5.9 
6.3  
5.1 
(321) 6.3 3.6 5.9 <1 
(330) 5.7 3.9 4.6 j 	4.0 






R = CH20H 
R=Ph 
R r' 5R 
40 
HO OH 
(33 1) R=CH2OH (327) R = CH 20H 
(32 1) R=Ph 
Isoxazoline 
sc/ppm 
C-4 C-5 C-6 C-7 C-8 C-9 OCH3 
(327) 37.4 78.0 84.7 793* 79.1* 1 	107.1 54.6 
 34.7 77.6 76.1 73.6 68.4 106.2 53.9 
 39.3 81.9, 81.0, 79.2, 73.3 103.6 - 
(321) 37.3 78.1 84.8, 79.4, 79.1 107.1 54.6 
 34.7 77.8 76.7 73.6 	1 68.5 1 	106.2 53.9 
Table 69: ' 3 C NMR data 
* Alternative assignments 
2.5.13 Ring Opening of Furanose 
The route to KDO analogues requires reduction of the aldehyde afforded on 
the removal of the isopropylidene protecting group and hydrolysis of the methyl 
glycoside. Therefore sequential hydrolysis and reduction was examined. In practice 
the fully deprotected adduct (331) was not isolated and reduction was performed on 
this product as soon as deprotection had occurred. 
Reduction at 0°C by sodium borohydride 23 ' in water (after successful 
deprotection) was initially accomplished for hydroxymethyl-isoxazoline (327) 
(Scheme 82). Removal of sodium ions with Amberlite IR-120 (H) followed by 
194 
addition and evaporation of methanol to remove boric acid afforded alcohol (307) as 
a white solid (74%). Isoxazoline (328) was treated in the same manner yielding (308) 
as a white solid (80%). 
HOCH2 	 HOCH2 







5S (328) 5S (308) 
(a) CF3 CO2HIH20 (9:1), 50°C, 3 hr; (b) NaBH 4, 0°C, 3 hr 
Scheme 82 
The products isolated [(307) and (308)] are identical to those obtained by 
deprotection of the mixture of hydroxymethyl isoxazolines (305)1(306) (Section 
2.5.5). However this route is much better since it provides access to each compound 
as a pure isomer. This is a significant advantage for the subsequent reductive 
hydrolytic ring cleavage of the isoxazoline. The NMR data for (307) and (308) are 
shown in Tables 56 and 57 (Section 2.5.5.1). As deprotection and ring cleavage of 
the furanose occur it is observed that the coupling between 8-H and 9-H increases 
dramatically [0.0 cf 6.2/2.7 for (327)/(307), 0.0 cf 6.0/2.8 for (328)/(308)] suggesting 
that the products (307) and (308) adopt different conformations in solution to the 
starting isoxazolines (327) and (328). 
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2.5.14 Reductive Hydrolytic Cleavage of 2-Isoxazolines 
It has been established in the six-carbon series (Section 2.3.8) that 
deprotection of the isoxazoline adducts followed by ring opening of the isoxazoline 
is the better route to adopt for conversion to ulosonic acid analogues. However, in 
order to characterise 3-hydroxyketones (6-deoxy-7-octosuloses) the ring opening of 
the protected compounds (327) and (321) was first examined. This was performed by 
catalytic hydrogenolysis using Raney-nickel as outlined in Section 2.3.8.2. After 
preparative TLC the desired -hydroxyketones (334) (5 1%) and (336) (47%) were 
afforded, together with inseparable mixtures of the diastereoisomeric 'y-amino 
alcohols (335) (9%) and (337) (16%) (Scheme 83). 
OMe 	
a 
	RO)__y.. IOMe + 
	
HOd 
	 1 OMe 
10 
(327) R = CH20H 
	
(334) R = CH20H 
	
(335) R = CH,OH 
(32 1) R=Ph 
	
(33 6) R=Ph 
	
(337) R=Ph 
(a) Ra-Ni, MeOHIH 20 (5:1) 
Scheme 83 
The -hydroxyketones were characterised by 'H and 13 C NMR spectroscopy 
and FAB mass spectrometry, and their chemical formulae verified by high resolution 
FAB mass spectrometry. The y-amino alcohols were identified by a positive 
ninhydrin stain on TLC, together with high resolution FAB mass spectrometry. 
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2.5.14.1 Characteristics of -Hydroxyketones 
The 'H NMR data for protons 4-H to 6-H reflect major differences between 
the parent 2-isoxazolines and -hydroxyketones. Tables 70 and 71 compare the 
chemical shifts and coupling constants for the D-manno isoxazolines (327) and (321) 
with those of the 3-hydroxyketones (334) and (336). It is observed that in both series 
the 5-H signal absorbs at significantly higher frequency for the isoxazoline than for 
the corresponding 3-hydroxyketone [MH +0.52 ppm for (327)1(334), + 0.47 ppm for 
(321)1(336)]. The large coupling constant for J4,5a  (8.9 Hz and 8.6 Hz respectively) 
and the smaller value for J4b,5  (3.3 Hz and 2.9 Hz respectively) for (334) and (336) 
are consistent with the -hydroxyketone adopting a hydrogen-bonded half-chair 
conformation (Figure 21). A similar obervation was noted in Section 2.3.8.3 for the 
six-carbon analogues. 
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R 1 = 
R 1 
R2 















4a-H 4b-H 5-H 6-H 
CH20H Isoxazoline (327) 3.13 3.12 4.90 4.01 
-Hydroxyketone (334) 2.67 2.80 4.38 3.77 
Ph Isoxazoline (321) 3.32 3.20 5.03 4.06 
-Hydroxyketone (336) 3.22 3.43 4.56 3.91 
Table 70: Selected 'H NMR data 
R Coupling 
JIHz 
4a,4b 4a,5 4b,5 5,6 
CH20H Isoxazoline (327) 17.5 8.5 10.0 6.0 
f3-Hydroxyketone (334) 16.1 8.9 3.3 8.3 
Ph Isoxazoline (321) 18.1 8.3 11.2 5.3 
3-Hydroxyketone (336) 17.3 8.6 2.9 8.3 
Table 71: Selected 1 H NMR data 
' 3CNMR 
Major differences for C-3 to C-S are observed in the spectra for the 13-
hydroxyketones compared to those of the respective isoxazolines (Table 72). As for 
the six-carbon analogues (Section 2.3.8.3), C-4 resonates at a higher frequency for 
198 
the -hydroxyketone [Ab c +5.3 ppm for (327)1(334), + 6.0 ppm for (321)/(336)] and 







C-3 C-4 C-5 
CH20H Isoxazoline (327) 159.0 37.4 78.0 
-Hydroxyketone (334) 209.0 42.7 66.1 
Ph Isoxazoline (321) 159.4 36.0 78.8 
3-Hydroxyketone (336) 200.5 42.0 66.1 
Table 72: Selected ' 3 C NMR data 
Optical Rotation 
The -hydroxyketone in each case was found to have a more positive [()CID 









-5.6 +37.5 -43.8 +1.3 
Table 73 
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2.5.15 Reductive Hydrolytic Cleavage of 2-Isoxazoline (307) 
The final stage in the route to 3-deoxy-D-manno-octulosonic acid analogues 
involved the reductive hydrolytic cleavage of deprotected isoxazoline (307). This 
was performed by stirring the isoxazoline (1 M eq), boric acid (6 M eq) and Raney -
nickel catalyst in a 5:1 mixture of methanol/water under an atmosphere of hydrogen 
(Scheme 84). The reaction was judged to be complete (2 hours) by TLC analysis. 
1.0cli, 	 OH OH 
OH OH 	 OH 
OH a HO.)y(CH2OH 	
- HO r_CH2OH 
HO OH 	 OH 
(307) 	 (338) 	 (339) 
(a) Raney-Ni, MeOH/1-1 20 (5:1), H 3B04 (6 M eq) 
Scheme 84 
The parent 2-isoxazoline has a greater TLC R f value on silica (50% 
methanol/ethyl acetate) than the product (0.20 cf 0.05). The product which was not 
purified further was isolated as a pale yellow oil (43 %) by removal of solvent in 
vacuo with subsequent addition and evaporation of methanol to remove boric acid. It 
was characterised by mass spectrometry and from its NMR spectra. There was a 
characteristic peak at 222 for M +-2H in the FAB mass spectrum, and accurate mass 
analysis (222.07424) of this peak gave the elemental composition as C 8H 1607 
consistent with compounds (338) or (339). 
Three structures were considered for the product: a pyranose-like chair 
conformation (339), a furanose envelope conformation (340) with the 5-hydroxyl 
occupying an axial position, and the open-chain structure (338). 
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OHH8 OHH5  H bH4a 










HZ4b Iq R' CH2OH 
H48 
R' = CHCH(OH)CH20H 
(340) 
13C NMR data were initially considered to identify which of the above 
structures was most likely. When the spectrum was examined three distinct CH 2 
peaks and four CH peaks were observed, but no peak was detected at & —200 ppm, 
indicating the absence of a carbonyl group and thus eliminating structure (338). In 
order to distinguish between the hemiacetal forms (339) and (340) the 8 c values were 
compared to literature data 185  for 3-deoxy-D-manno-octulosoriic acid in its pyranose 
(341) and furanose (342) forms (Table 74). The corresponding data for the parent 

























C-3 C-4 C-5 C-6 C-7 C-8 C-9 
(307) 159.1 34.6 78.3 68.6 67.8 76.2 60.9 
(339) or (340) 80.4 36.7 73.3, 70.8, 70.0, 69.4 63.0 
 96.5 33.7 66.7 66.2 71.2 69.5 62.9 
 103.1 44.7 72.4 85.2 70.6 71.7 60.5 
Table 74: ' 3C NMR data 
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The 8c  values for C-4 to C-9 are much closer to those for the pyranose 
structure (341) than the furanose structure (342), and the product is therefore 
tentatively assigned the 'C 4 structure (339). As expected the hemiketal carbon C-3 
resonates at lower chemical shift (80.4 ppm cf 96.5 ppm) in ketose (339) due to the 
adjacent carboxyl group in KDO itself. 
A number of deductions can be made by examination of the 'H NMR 
spectrum. The two protons at lowest chemical shift are assigned to 4a-H and 4b-H 
which have no oxygen attached. These protons occur at low frequency (1.78 and 1.83 
ppm respectively) in accord with the hemiketal form. If they had been next to a 
carbonyl group as in (338) they would have been expected to occur at a higher - 
value of -3.00 ppm. There is a large geminal coupling of 13.0 Hz between 4a-H and 
4b-H (smaller than would normally be expected), and both are coupled to 5-H which 
appears as a multiplet at 4.09 ppm. 5-H has a large coupling of 9.0 Hz to 4a-H and 
smaller couplings of 6.0 Hz to 4b-H and 3.0 Hz to 6-H. These couplings indicate that 
the pyranose-ring may be slightly distorted. Comparison of this data to literature 
values for KDO in its pyranose and furanose forms' 85  further confirms that the 
product is existing predominantly in the pyranose form (Table 75). The methylene 
group at C-9 has a geminal coupling of 11.8 Hz consistent with being adjacent to an 
oxygen. Each of these protons 9a-H and 9b-H also appear at higher chemical shift 
than 4-H as expected. The couplings between 8-H/9a-H and 8-H/9b-H (2.6, 5.5 Hz) 
are also consistent with the proposed structure. The data obtained for product (339) 
are compared for reference with the isoxazoline precursor (307) in Table 76. 
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OH 
H,, 90H 	1119b 
HO 	 R 
(339) R = CH 20H 
(341) R=CO 2H 
HO 









(339) (341) (342) (339) (341) 
4a-H 1.78 1.92 2.53 4a,4b 13.0 12.5 
4b-H 1.83 1.83 2.02 4a,5 9.0 12.5 
4b,5 6.0 5.5 
Table 75: Selected 1 H NMR data 
OH 






H7 	 H8 	
HO.._--.A..CH2OH 
H7 H4e I 






(307) (339) Coupling (307) (339) 
4a-H 3.25 1.78 4a,4b - 13.0 
4b-H 3.25 1.83 4a,5 8.4 9.0 
5-H 4.80 4.09 4b,5 10.6 6.0 
6-H 3.95 3.87-3.80 5,6 6.7 3.0 
7-H 3.69 3.87-3.60 6,7 1.4 nd 
8-H 3.78 3.87-3.80 7,8 8.7 nd 
9a-H 3.88 4.02 8,9a 2.7 2.6 
9b-H 3.69 3.63 8,9b 6.2 5.5 
CH20H 4.43 3.87-3.60 9a,9b 11.7 11.8 
Table 76 
6  NMR data measured in D,O. 
It is therefore proposed that the product resulting from reductive hydrolytic 
cleavage of isoxazoline (307) exists predominantly in the pyranose-ring form (339) 
although the presence of small amounts of furanose cannot be discounted. 233  This is 
as predicted with the non-conjugating CH 20H group facilitating ring closure. 
Confirmation for this structure could be obtained by more detailed NMR experiments 
and by the preparation of derivatives. 
2.5.16 Mesylation of 3-Hydroxymethyl-Substituted Isoxazoline (327) 
One of the aims of our current work is to be able to synthesise a range of 3-
deoxy-octulosonic acid analogues. Thus conversion of the 3-hydroxymethyl group of 
(327) to the corresponding mesylate (343) allows for alternative functionalisation of 
the isoxazoline. Alcohol (327) was reacted with methanesuiphonyl chloride in dry 
dichioromethane using triethylamine as base, affording the desired mesylate (343) in 
81% yield (Scheme 85). This mesylate was purified by preparative thin layer 
chromatography. 
HOCH2 	 MsOCH2 
OMe 
	 L. i OMe 
MsCIIEt3N 
go 
(327) 	 (343) 
Scheme 85 
Comparison of' H NMR of the mesy late with the parent alcohol indicates that 
changing from OH to OMs has little effect on the chemical shift values apart from 
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that due to CH20R, which moves to much higher frequency as expected (AS H +0.59 
ppm). 5-H shifts to slightly lower frequency 06H - 0.07 ppm). There is no significant 
change in coupling between 5-H and 6-H (6.0 cf 5.3 Hz) indicating that the presence 
of OMs is not influencing the conformation adopted in solution. In the ' 3C NMR 
there is a noticeable increase in the chemical shift for CH 20R on changing from OH 
to OMs (Eöc +5.4 ppm) and a decrease in the adjacent quaternary carbon (6c  5.4 
ppm). 
2.5.17 Modification of Side Chain at C-3 of 2-Isoxazoline 
2.5.17.1 Reduction of 3-Ethoxycarbonyl Substituent to Aldehyde 
Conversion of the ester substituent at C-3 to an aldehyde was carried out to 
allow further manipulations of the side chain and to provide easy access to a wide 
variety of isoxazoline derivatives containing different functional groups. These 
aldehydes are potential precursors for KDO analogues differing only in the 
substituent at the ariomeric centre, thus providing a whole series of derivatives for 
screening for antibacterial action. The presence of an aldehyde at C-3 would permit 
the introduction of side chains containing -(CH 2)R via Wittig reactions and 
subsequent hydrogenolysis/reduction, and allow the effect of separation of the CO 2H 
from the pyranose ring on activity to be examined. The procedure for the direct 
conversion of ester (323) to aldehyde (344) involves DIBAL reduction (Scheme 86). 
This approach was developed for 3-formylisoxazolines by Wade and 
coworkers. 234  The aldehyde (344) was purified by preparative TLC and isolated as a 
colourless oil in 68% yield. It was difficult to get the reaction to go to completion, 
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and increasing the amount of DIBAL caused overreduction of the aldehyde to 
alcohol. It has been reported  234  that at -78°C a small amount (<5% by TLC and 
NMR) of alcohol is produced, probably due to the high reactivity of the carbonyl 
group attached to a carbon-nitrogen double bond. Also in this case, aldehyde and 
ester run at the same R f value on TLC, independent of the solvent conditions tried, 
making it difficult to monitor completion of the reaction. Although pure aldehyde 
was obtained, an alternative approach was investigated. 
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Scheme 86 
2.5.17.2 Oxidation of Alcohols (327) and (328) to Aldehydes (344) and (345) 
This second and less direct approach to aldehyde (344) involved reduction of 
ester to alcohol followed by partial reoxidation using pyridinium chlorochromate 
(PCC)235 (Scheme 87). 
Et02C 	 HOCH2 
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The oxidation proceeded to completion with no TLC evidence of any 
unconsumed starting material. There was no need for purification of the aldehyde 
which was obtained in . 70% yield. Spectral comparisons indicated that it was 
identical to that obtained by reduction of ester (323). 
Having used both methods, and compared the ease of isolation of the 
resulting aldehydes, it was decided to adopt the latter approach (ie. PCC oxidation of 
the alcohol) for the preparation of aldehyde (345) (Scheme 87). This was prepared as 
a white solid in 54% yield. The direct reduction (-0O 2Et -+ -CHO) method is 
quicker, but the two step approach (-0O 2Et -+ -CH20H -). -CHO) requires less 
stringent control of conditions, and isolation of pure aldehyde is easier. 
2.5.18 Synthesis of Aldehyde Derivatives 
Once a method had been established for the successful synthesis of pure 
aldehyde (344), a number of manipulations of this group were performed. The 
aldehyde was converted via Wittig reactions to two different alkenes (346) and (347) 
and also to the corresponding oxime (348). 
Conversion of aldehyde (344) to alkene (347) was achieved using the 
Wadsworth-Emmons modification of the Wittig reaction which utilises a resonance-
stabilised phosphonate anion 336  (Scheme 88). Alkene (347) was purified by 
preparative thin layer chromatography and afforded as a colourless oil in 75% yield. 
As expected, in this case the E-alkene was formed exclusively. This was deduced 
from the characteristic 'H NMR spectrum which had well separated doublets for the 
olefinic protons (MH = 1.47 ppm and J = 16.1 Hz) which indicates trans geometry. 
207 
The 3-vinyl analogue (346) was prepared as a colourless oil in 80% from 

















(a) Ph3PCH3 1-, (CH3)3COK, THF; (b) (CH 3 CH20)2P(0)CH,C0 7C2H4, (CH3)3 COK, ethylene glycol 
dimethyl ether; (c) NH 20H.HC1, NaOH 
Scheme 88 
Hydrogenation of the unsaturated alkene double bonds of (346) and (347) 
may provide access to active analogues of KDO with an alkane side chain, and ester 
substituent separated by two methylenes removed from the isoxazoline ring [eg. 
(349) and (350) respectively]. 






Preparation of oxime (348) involved use of a two phase system and addition 
of hydroxylamine hydrochloride to an aqueous solution of sodium hydroxide, 
followed by addition of an ethereal solution of the aldehyde (344) (Scheme 88). The 
oxime (348), a colourless oil (75%), was present as a 2 : 3 mixture of syn and anti 
isomers as determined by the 'H NMR spectrum. The methylene protons (4a-H and 
4b-H) are well separated making identification and ratio determination 
straightforward. 
2.5.19 Conclusions 
Two approaches using nitrile oxide-isoxazoline chemistry have been 
employed for the synthesis of octulosonic acid (KDO) analogues. In the first route 
cycloaddition of nitrile oxides to D-arabino-alkene (293) occurred in variable yields 
(30-88%) and with moderate t-facial selectivity (63:37 to 67:33) and afforded 
adducts which proved to be chromatographically inseparable. Preference for erythro 
adducts was observed in each case. All subsequent manipulations to substituents at 
C-3 on the isoxazoline ring also gave inseparable isomers, so an alternative strategy 
was sought. 
Using the D-mannose derived alkene (317), a synthetic route to KDO 
analogues via nitrile oxide-isoxazoline chemistry has been established yielding 
separable cycloadducts. Cycloadditions of nitrile oxides to alkene (317) yielded 
adducts in variable yields (30-83%) and good it-facial selectivity (81:19 to 88:12), 
again with preference for erythro adducts. Sequential hydrolysis of the 
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isopropylidene protecting group and methyl glycoside and reduction of the aldehyde 
resulting from deprotection has been successfully accomplished for the 
hydroxymethyl compounds (327) and (328). Subsequent conversion of the resulting 
2-isoxazoline (307) to the KDO analogue has been performed in one case by Raney-
nickel catalysed hydrogenolysis, and the product tentatively assigned the pyranose 
ring structure (339) on the basis of its NMR data. 
Modification of the side chain at C-3 of the isoxazoline has also been 
investigated. The hydroxymethyl and 3-ethoxycarbonyl substituents have been 
converted to an aldehyde function suitable for subsequent manipulation. In the 
present work, Wittig olefinations have resulted in the synthesis of isoxazolines 
containing alkene side chains at C-3. 
In summary, this approach may provide access via nitrile oxide-isoxazoline 
chemistry to a wide range of octulosonic acid analogues. 
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2.6 Conclusions and Future Work 
The general approach adopted for the construction of ulosonic acid analogues 
which is suitable for all members of the homologous series has been via an 
intermediate isoxazoline formed by the cycloaddition of a nitrile oxide to a sugar 
alkene. 
The strategy proposed for assembling the hexulosonic acid analogues in our 
model system was via the four-carbon D-mannitol-derived alkene (195) which gave 
moderate it-facial selectivity in the nitrile oxide cycloadditons. In an attempt to 
control selectivity to but-3-ene-1 ,2-diols, a dispiroketal protecting group was utilised 
[alkene (226)]. However the large steric bulk of the dispiroketal moiety and changing 
from a five to six-membered ring system appears to have negligible effect on 
diastereoselectivity. 
The seven-carbon DAH skeleton has been created by combination of a five-
carbon alkene dipolarophile such as the D-glucose-derived alkene (260) with the 
appropriate nitrile oxide, and the eight-carbon (KDO) in a similar way from the six-
carbon alkene (317) prepared from D-mannitol. 
The it-facial selectivity for the key cycloaddition step in which the carbon 
frameworks are assembled was found to vary, with d.e. values ranging from 0% to 
76% (Appendix 3). 
Deprotection of the 2-isoxazolines to provide the precursors for the final 
reductive cleavage of the N-O bond has occurred with variable yields (48% to 87%). 
It has been established in the six-carbon series that deprotection of the isoxazoline 
adducts followed by ring opening of the isoxazoline is the better route to adopt for 
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the conversion to ulosonic acid analogues. For the hexulose series a 2-ulosonic acid 
analogue containing a 3-phenyl substituent has been isolated, and its structure 
established by mass spectrometry and NMR spectroscopy which shows that it exists 
predominantly in its open-chain keto form. Preliminary experiments for the eight-
carbon KDO system indicate that an analogue containing a non-conjugating CH 20H 
attached to the anomeric centre exists mainly in the pyranose-ring form. Further work 
is required to optimise the ring cleavage conditions and establish techniques for 
puri'ing the products in order to prepare a whole series of seven and eight carbon 
analogues of DAH and KDO. The final reductive cleavage of the isoxazoline has still 
to be performed for the DAH analogues; however it is anticipated to proceed in the 
same way as for those already mentioned. 
Having established the methodology for the key synthetic steps, a series of 
analogues could be prepared to demonstrate the scope of this route. Either the nitrile 
oxide component can be altered, or modifications performed at the isoxazoline stage. 
In the KDO series, the 3-ethoxycarbonyl substituent has been converted to an 
aldehyde, which provides access to a wide range of analogues. 
The route is ideally suited, not only for replacement of the carboxylate 
function at the anomeric centre, but also for the synthesis of analogues with different 
configurations at the various ring positions. For DAH analogues for example, the 6-
epimer (351), and (352) and (353) could be formed by a different choice of starting 
alkene component or by manipulation of the isoxazoline. It should also be possible to 
introduce functionality at the 4-position of the isoxazoline by treatment with base 
























The methodology described above for DAB and KDO compounds can be 
applied equally well to the synthesis of higher homologues, eg. the nine carbon KDN 
analogues (355). The approach envisaged for the assembly of nonulosonic acid 
analogues is shown in Scheme 89. The dipolarophile component (356) has D-manno 
stereochemistry and it is proposed that it could be prepared by chain elongation at the 
reducing end of D-mannose. Reductive hydrolytic ring opening of isoxazoline (357), 
followed by deprotection and ring closure should afford KDN compounds. 
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Elemental analyses were performed by Mrs. L. Eades using a Perkin Elmer 
2400 elemental analyser. 
Infrared spectra were recorded as films or nujol mulls on a Perkin Elmer 781 
spectrometer and on a Bio-Rad FTS-7 spectrometer. 
FAB mass spectra and exact mass measurements were recorded by Mr. A. 
Taylor and Miss. E. Stevenson on a Kratos MS50TC instrument using either glycerol 
or thioglycerol as a matrix. 
Melting points were measured on a Gallenkamp capillary tube apparatus and 
are uncorrected. 
'H NMR spectra were recorded on Bruker WP200SY, AX250 and WH360 
instruments by Miss H. Grant, Mr. J. R. A. Millar and Dr. D. Reed. ' 3C NMR spectra 
were recorded on the WP200SY, AX250 and WH360 instruments. Chemical shifts 
(ö) in all spectra are measured in parts per million using tetramethylsilane (8 = 0.0) 
as the reference signal. 
Optical rotations were measured on a Perkin Elmer 141 polarimeter using 
1.8 ml of filtered solution. 
X-ray diffraction analyses were performed on a Stoë STADI-4 four circle 
diffractometer by Dr. A. J. Blake and Dr. R. 0. Gould. 
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3.1.2 Chromatography 
Preparative thin layer chromatography was carried out on glass plates (20 x 
20 cm) coated with a layer of Kieselgel GF 254 (0.5 mm) which contains 13% calcium 
sulphate and a fluorescent indicator. Analytical thin layer chromatography was 
carried out on Merck aluminium-backed plates coated with Kieselgel GF 254 (0.2 
Dry flash chromatography was carried out with a variety of sintered funnels 
filled with Kieseigei (IF 254 and eluted under water pump vacuum. 
3.1.3 	Solvents and Reagents 
All reagents and solvents were standard laboratory grade and were used as 
supplied unless otherwise stated. 
Dry ether and toluene were Analar grade dried over sodium wire. 
Dry acetone was Analar grade stored over 4A molecular sieve. 
Pyridine was dried by distillation from and stored over KOH. 
Dry THF was freshly distilled from sodium and benzophenone. 
Dry methanol was obtained by distillation from calcium hydride. 
Dry chloroform was obtained by distillation from phosphorous pentoxide 
and stored over molecular sieve. 
Dry DMSO was obtained by allowing the solvent to stand over activated 
calcium sulphate for 24 hr, filtering and distilling from calcium hydride under water 
pump vacuum. The distilled solvent was stored over molecular sieve. 
Acetic anhydride was purified by fractional distillation and stored over 4A 
molecular sieve. 
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3.2 	Synthesis of Nitrile Oxide Precursors 
The nitrile oxides were generated in situ by dehydrochiorination of the 
parent hydroximoyl chloride with triethylamine. 
3.2.1 	Ethyl Chloro-oximinoacetate (184) 
This was prepared utilising the method of Skinner. 187  Glycine ethyl ester 
hydrochloride (29.30 g, 0.21 mol) in water (90 ml) was cooled to -35°C and 
hydrochloric acid (36% w/w, 18 ml, 0.21 mol) added followed by dropwise addition 
of sodium nitrite (14.45 g, 0.21 mol) in water (25 ml). The additions were then 
repeated, and the cooled solution left stirring for 1 hr. The white precipitate which 
formed was filtered, washed with petroleum ether (b.p. 40-60°C, 5 ml) and dried to 
afford a white crystalline solid (15.69 g, 48%), m.p. 76-78°C (lit. 
187  79-80°C). 
3.2.2 Benzohydroximoyl Chloride (185) 
This was prepared according to the method of Chiang. 188 
To a stirred solution of sodium hydroxide (23.10 g, 0.58 mol) in water (66 
ml) and freshly distilled benzaldehyde (33 ml, 0.33 mol) was added hydroxylamine 
hydrochloride (24.75 g, 0.36 mol) in small portions. The benzaldehyde eventually 
disappeared, and upon cooling at -5°C, a crystalline mass of the sodium derivative of 
the oxime formed. Sufficient water was added to form a clear solution, and carbon 
dioxide added until the solution was saturated. A colourless emulsion of the a-
aldoxime separated out, which was extracted with ether, dried (MgSO 4), and 
evaporated in vacuo. Distillation under reduced pressure yielded the pure a- 
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benzaldoxime as a liquid which solidified on cooling to a white solid (31.94g, 80%). 
Chlorine gas was passed through a cooled solution (-20°C) of the a-benzaldoxime 
(10.27 g, 85.00 mmol). in chloroform (300 ml) until the solution had gone 
yellow/green (via an intermediate blue colour), when chlorination was judged to be 
complete. Nitrogen was then bubbled through the solution for 40 min to remove 
dissolved chlorine gas, the solution going very pale yellow. The solvent was 
evaporated in vacuo, and afforded a colourless oil. Trituration with petroleum ether 
(b.p. 80-100°C) (5 ml) and chloroform (4 ml) followed by cooling to 0°C, afforded 
white crystals (5.56 g, 42%), m.p. 48-50°C (lit. 188  50-51°C). 
3.2.3 	(Diethoxyphosphoryl)acetohydroximoyl Chloride (189) 
This was prepared from bromoacetaldehyde diethyl acetal in four steps 
according to Scheme 36. 
3.2.3.1 Diethyl 2,2-diethoxyethylphosphonate (186) 189 
Bromoacetaldehyde diethyl acetal (21.8 ml, 0.15 mol) was heated with 
triethylphosphite (26.47 g, 0.16 mol) at reflux for 5 hr. After this period the low 
boiling material (below 100°C) was distilled under reduced pressure (-20 mmHg) 
and the residual oil fractionated under reduced pressure to yield diethyl 2,2-
diethoxyethyl phosphonate (186) (16.57 g, 45%) as a colourless oil, b.p. 52°C, 2 
mmHg (lit."' 146-149°C, 14 mmHg; 101-103°C, 8 mmHg); 8H  (360 MHz, CDCI 3) 
4.75 (1H, dt, JCH2CH 5.6 Hz, JCH.P = 5.5 Hz, CH2CI]), 3.96 [2H, qd, JcH3cm = 7.1 
Hz, JCH2,p = 7.5 Hz, (CH3 CH20)2P0], 3.46 [2H, 2 x qd, Jcnc = 7.1 Hz, JCR2,P = 
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8.2 Hz, CH(OCH2CH3)21, 2.05 (2H, dd, JCH2CH = 5.6 Hz, 	18.8 Hz, CH2CH), 
1.18, 1.06 [12H, 2 x t, Jch,3cq2 = 7.1 Hz, (CH3CH20)2CH, (CH3 CH20)2P0); E, (90 
MHz, CDC13) 98.1 (CH2CH), 61.4 (OCH2CH3 , d, Jp = 8.7 Hz), 31.5 (CH2CH, d, Jp 
= 139.9 Hz), 16.1 (OCH2CH3)
1 
 14.9 [P(0)(OCH 2CH3) d, Jp = 6.3 Hz]; p (90 MHz, 
CDC13) 26.65 (P=O); mlz (FAB) 255.13610 (M+H), C 10H2405P requires 255.13612; 
umax/cm (film) 2976.9, 2930.9, 2904.9 (CH), 1609.9, 1479.6 (P=O), 1391.9, 1254.8. 
3.2.3.2 (Diethoxyphosphoryl)acetaldehyde (187) 189  
Diethyl 2,2-diethoxyethylphosphonate (186) (5.28g, 20.80 mmol) was 
heated at reflux with aqueous hydrochloric acid (2% w/w, 33.8 ml) for 20 mm. To 
the cooled mixture was added sodium chloride to saturation and the mixture 
extracted with CH 2C12 . The combined organic extracts were dried (MgSO 4), filtered 
and evacuated in vacuo to yield (diethoxyphosphoryl)acetaldehyde (187) (3.67 g, 
98%) as a colourless oil; 6H  (360 MHz, CDC1 3 ) 9.56 (1H, m. CHOC!J = 3.2 Hz, 
CHO), 4.13-4.00 (4H, 2 x q, JCH3cm = 7.1 Hz, CH3 CH20), 3.01 (2H, dd, JCHO.CH2 
3.2 Hz, JCH2,p = 22.0 Hz, CH2); E (90 MHz, CDC1 3) 192.6 (CHO, d, Jp = 5.6 Hz), 
62.4 (C2, d, Jp = 5.7 Hz), 42.6 (OCH2CH3 , d, Jp = 128.4 Hz), 15.9 (OCH2CH3 , d, 
Jc = 5.3 Hz); mlz (FAB) 18 1.06297 (M+H), C 6H 1404P requires 181.06296; 
l)maxkm ' (film) 2980.8, 2907.4 (CH), 1723.8 (CO), 1393.2, 1254.9, 1029.3, 966.0. 
3.2.3.3 (Diethoxyphosphoryl)acetaidehyde oxime (188) 189 
To a solution of (diethoxyphosphoryl)acetaldehyde (187) (4.30 g, 24.00 
mmol) in water (10 ml) was added aqueous hydroxylamine hydrochloride (2.78 g, 
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40.00 mmol) in water (20 ml) and the mixture stirred for 17.5 hr at room 
temperature. After this period the mixture was poured into water (40 ml) and 
extracted with CH 2C12 (3 x 50 ml). NaCl was added to aid extraction into the organic 
layer. The combined organic extracts were dried (MgSO 4), filtered and evaporated in 
vacuo to yield (diethoxyphosphoryl)acetaldehyde oxime (188) (3.02 g, 65%) as a 
very pale yellow oil; 5H  (360 MHz, CDC1 3) 9.06 (1H, b, OH), 7.30 [0.36 x 1H, dt, 
1,2b (syn) = 6.5 Hz, J1 ,p = 5.2 Hz, CH=N (syn)], 6.70 [0.64 X lH, dt, l2,, (anti) = 6.0 
Hz, J1 ,p = 5.0 Hz, CH=N (anti)], 4.05 (4H, dq, JCMCM = 7.1 Hz, 8.1 Hz, 
CH3CH2), 2.98 (0.64 X 1H, dd,J2a,2b = 6.0, J2ay = 21.9 Hz, H20, 2.70 (0.36 X 1H, dd, 
= 6.5 Hz, J2b,P = 21.8 Hz, H20, 1.24 (6H, t, j113m = 7.1 Hz, CH3 CH2); S (90 
MHz, CDCI 3) 141.7 [CH=N (syn), d, Jcp = 9.5 Hz], 140.2 [CH=N (anti), d, Jp = 7.8 
Hz], 62.3 (C2, d, Jp = 5.7 Hz), 27.8 [OCH2CH3 (syn), d, Jp = 141.0 Hz], 23.2 
[OCH2CH3 (anti), d, Jci = 139.9 Hz], 16.0 (OCH2CH3 , d, Jp = 5.5 Hz); mlz (FAB) 
196.07387 (M+H), C6H 15NO4P requires 196.07386; u m /cm (film) 3240.3, 
2984.1, 2908.4 (CH), 1647.9 (P=O), 1246.9, 1023.4, 971.3, 813.0, 807.0. 
3.2.3.4 (Diethoxyphosphoryl)acetohydroximoyl chloride (189) 
Chlorine gas was passed through a cooled solution (-20°C) of 
(diethoxyphosphoryl)acetaldehyde oxime (188) (7.00 g, 35.90 mmol) in chloroform 
(140 ml) until the solution had gone yellow/green (via an intermediate blue colour), 
when chlorination was judged to be complete. Nitrogen was then bubbled through 
the solution for 40 min to remove dissolved chlorine gas, the solution going very pale 
yellow. The solvent was evaporated in vacuo, and afforded a very pale blue oil (5.00 
g, 61%), mlz (FAB) 229 (M+H). 
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3.3 	Synthesis of Sugar Alkenes 
3.3.1 	1 ,2-Dideoxy-3,4-O-cyclohexylidene-D-g/ycero-but-1-enitol (195) 
This alkene was prepared in three steps from D-mannitol according to 
Scheme 38. 
3.3.1.1. 1,2: 5,6-Di-O-cyclohexylidene-D-mannitol (193)190 
A mixture of D-mannitol (30.00 g, 0.16 mol), cyclohexanone (60 ml), 
triethyl orthoformate (20 ml) and boron trifluoride etherate (2 ml) in dry DMSO (80 
ml) was stirred overnight at room temperature. The mixture was poured into 
ice/sodium hydrogen carbonate (200 ml) and extracted with ether (6 x 100 ml). The 
extract was washed with water (200 ml), brine (200 ml), dried (MgSO 4) and 
evaporated in vacuo to yield crude product containing excess cyclohexanone. The 
residual syrup was crystallised from hexane and further recrystallised from hexane-
ether (2 : 1) (3 x 40 ml) to yield (193) as a white powder (38.20 g, 70%); m.p. 98-
101°C (lit. 105-105.5°C,' 90 101-102°C'90); 8H  (60 MHz, CDC1 3) 4.50-3.67 (4H, m, 
H,, ''2, H5 , H6), 2.67-2.23 (2H, d, J3,OH = 6 Hz, 2 x OH), 3.03-2.67 (2H, br, H 3 , H4), 
2.23-1.30 (20H, m, CH 2); mlz (FAB) 343.21205 (M+H), C 18H31 06 requires 
343.2 1205. 
3.3.1.2 2,3-0-Cyclohexylideno-D-glyceraldehye (194)' ° 
To a solution of 1,2:5,6-di-O-cyclohexylidene-D-mannitol (193) (30.22 g, 
88.40 mmol) in ether (300 ml) was added a solution of sodium metaperiodate (22.72 
g, 88.40 mmol) and tetrabutylammonium bromide (603 mg, 1.88 mmol) in water 
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(270 ml), and the mixture stirred for 3 hr at room temperature. The organic layer was 
separated, and the aqueous layer extracted with ether (3 x 200 ml). The combined 
organic extracts were washed with water (180 ml), dried (MgSO 4) and evaporated in 
vacuo. The crude product was purified by distillation/sublimation to yield aldehyde 
(194) (21.94 g, 73%) as a colourless syrup, (b.p. 90-92°C, 2 mmHg), (lit. 190  102°C, 1 
mmHg); 5H  (200 MHz, CDC1 3) 9.65 (1H, d, J,,2 = 1.9 Hz, H 1 ), 4.32 (1H, ddd, J,,2 = 
1.9 Hz, J2,3a = 7.1 Hz, J2,3b = 5.0 Hz, H2), 4.10 (1H, dd, J2,3a = 7.1 Hz, J3a,3b = 8.7 Hz, 
H3 a), 4.02 (11-1, dd,J23b = 5.0 Hz,J3a,3b = 8.7 Hz, H3b), 1.61-1.57 (10H, m, CH2); mlz 
(FAB) 171.10097 (M+H), C 9H 1503 requires 171.10212. 
3.3.1.3 1,2-Dideoxy-3,4-0-cyclohexylidene-D-g/ycero-but-1-enitol (195) 
Potassium tert-butoxide (11.38 g, 100.00 mmol) in dry THF (80 ml) was 
added to methyltriphenyl-phosphonium iodide (25.76 g, 64.00 mmol) under nitrogen, 
and the solution stirred for 1.5 hr at room temperature. Freshly distilled aldehyde 
(194) (6.60 g, 38.80 mmol) in dry THF (50 ml) was added dropwise over 10 mm, and 
the solution stirred for 3 hr. Water (80 ml) was added and the mixture extracted with 
hexane (4 x 150 ml). The combined organic extracts were dried (MgSO 4), and the 
solvent removed in vacuo to afford a syrup which was purified by dry flash 
chromatography on silica using 30% ether/hexane as eluent, to afford the product as 
a colourless oil (5.80 g, 89%); oH (200 MHz, CDC1 3) see Table 77; m/z (FAB) 






Resonance 511/ppm Coupling JIHz 
la 5.33 la,lb 1.6 
lb 5.19 1a,2 17.2 
2 5.81 1b,2 10.2 
3 4.49 2,3 7.1 
4a 3.58 3,4a 7.6 
4b 4.08 3,4b 6.2 




3.3.2 	1,2-Dideoxy-3,5-0-elhylidene-D-erythro-pent-l-enitol (260) 
This alkene was prepared in three steps from D-glucose (Scheme 58). 
3.3.2.1 4,6-0-Ethylidene-D-glucose ( 26 1)219 
This was prepared utilising the method of Hockett et a1219 modified in the 
following fashion. 
D-Glucose (30.00 g, 0.17 mol) was treated with paraldehyde (22.5 ml, 0.17 
mol, 1.01 M eq) containing concentrated sulphuric acid (0.17 ml). The reaction was 
stirred vigorously until it became semi-solid (30 mm) and then set at room 
temperature for 3 days. The mixture was slurried in ethanol (100 ml) and the pH 
adjusted to 6.5-7.0 with ethanolic KOH (1 M). The solids were brought into solution 
by heating, and the pH kept at 6.5 by addition of alkali. Decolourising charcoal (1 g) 
was added, the solution filtered through a pad of celite and washed with hot ethanol. 
On standing the filtrate deposited crystalline material, which was recrystallised from 
ethanol. The filtrate was concentrated to dryness to remove excess paraldehyde and 
from the crystalline residue more material of the same m.p. obtained by 
recrystallisation from ethanol. 4,6-0-Ethylidene-D-glucose (261) was afforded as 
white crystals (16.13 g, 47%), m.p. 178-180°C (lit. 219 179-181°C); [Found : C, 46.5; 
H, 6.9. C 8H 1406 requires C, 46.6; H, 6.8]; 8H  (400 MHz, CD30D) see Table 78; 6 
(90 MHz, CD 3 0D) 98.9, 98.8 (C2), 96.8, 92.6 (C 9), 80.4, 79.8 (C4), 75.1, 72.6, 72.3, 
69.7 (C 7 , CO,  67.7, 67.2 (CO,  65.7, 61.5 (CO,  18.7 (CCH3); m/z (FAB) 205.07073 
(MtH), C8H 1306 requires 205.07 121. 
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OH (H9) HO. 	1- 
I H5 OH I 
H7 	H9 (OR) 
(261) 
Anomer Resonance 8H/PPM Coupling JIHz 
a 
CH3 1.21 CH3 CH 5.1 
2 4.70 6a,6e 10.1 
4 - 6a,5 10.1 
5 3.63 6e,5 4.8 
6a 3.42* 4,5 9.9 
6e 3.90 4,7 9.3 
7 3.53 7,70H 5.0 
8 3.25 7,8 9.3 
9 4.93 8,80H 6.8 
70H 4.99 8,9 3.7 
80H 4.72* 9,90H 4.6 
90H 6.46 
13 
CH3 1.21 CH3 CH 5.1 
2 4.70 6a,6e 10.1 
4 - 6a,5 9.9 
5 3.20* 6e,5 4.8 
6a 344* 4,5 9.7 
6e 3.97 4,7 nd 
7 - 7,70H nd 
8 2.96 7,8 8.7 
9 4.39 8,80H nd 
70H 5.11 8,9 7.7 
80H 5.11 9,90H 6.5 
90H 6.76 
Table 78 
* Alternative assignments 
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3.3.2.2 2,4-0-Ethylidene-D-erythrose ( 262)220 
4,6-0-Ethylidene-D-glucose (261) (12.00 g, 58.30 mmol) was dissolved in 
water (30 ml) and added dropwise over a period of 30 min to a well stirred solution 
of sodium periodate (25.17 g, 117.70 mmol) in water (233 ml). The temperature of 
the reaction was kept below 10°C with an ice bath and the pH maintained at 4, by 
dropwise addition of 8 N NaOH. The pH was then adjusted to 6.5 by addition of 8 N 
NaOH, causing rapid hydrolysis of the formyl group. The reaction mixture was 
concentrated at 40-45°C, and the resulting solids dried overnight at room temperature 
and 0.1 mmHg pressure, and then thoroughly extracted with hot ethyl acetate (600 
ml). The combined organic extracts were dried (Na 2SO4), and concentrated in vacuo 
to afford 2,4-0-ethylidene-D-glucose (262) (8.23 g, 97%), white crystalline glass, 
m.p. 108-110°C (lit. 220 110-111°C, 149-150°C); 5H  (250 MHz, CDC13) 9.70 (1H, s, 
CHO); mlz (FAB) 145.050081 (Mt-H), C 6H904 requires 145.05008. 
3.3.2.3 1 ,2-Dideoxy-3,5-O-ethylidene-D-erythro-pent-1-enitol (260) 
Potassium tert-butoxide (15.99 g, 142.50 mmol) in dry THF was added to 
methyltriphenyl-phosphonium bromide (31.32 g, 87.70 mmol) in dry THF, under 
argon, and the solution stirred for 1.5 hr at room temperature. 2,4-0-Ethylidene-D-
erythrose (262) (8.00 g, 54.8 mmol) dissolved in dry THF was added dropwise over 
10 mm, and the solution stirred overnight. Water (150 ml) was added and the mixture 
extracted with hexane (6 x 150 ml). The combined organic extracts were dried 
(MgSO4), and the solvent removed in vacuo to afford a syrup which was purified by 
MPLC (silica; hexane/ether gradient elution 10 : 0 -+ 6 : 4), and afforded alkene 
225 
(260) as a pale yellow oil (5.52 g, 70%); 1aID25  -22.7° (c = 1.29, CHC1 3); [Found: C, 
57.6; H, 8.2. C 7H 1203 requires C, 58.3; H, 8.3]; 6H  (360 MHz, CDC13) see Table 79; 
c (90 MHz, CDCI 3) 134.5 (C 2), 118.9 (C 1 ), 98.6 (CMe), 82.5 (C 3), 70.2 (C5), 64.8 








Resonance 511/ppm Coupling JIHz 
la 5.37 la,lb 1.3 
lb 5.27 la,2 17.3 
2 5.84 lb,2 10.4 
3 3.72 2,3 6.7 
4 3.41 3,4 8.7 
5a 3.36 4,5a 10.1 
5e 4.05 4,5e 4.6 
CH3CH 4.66 5a,5e 10.3 
CH3 CH 1.24 CH3CH 5.0 
40H 2.65 4,40H nd 
Table 79 
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3.3.3 	1 ,2-Dideoxy-3,5-O-benzylidene-L-threo-pent-1-enitol (286) 
This alkene was prepared in three steps from D-arabinitol according to 
Scheme 67. 
3.3.3.1 1 ,3-O-Benzylidene-L-arabinitol (287)223 
A rapid stream of dry hydrochloric acid gas was passed into a suspension of 
D-arabinitol (1.50 g, 9.90 mmol) in benzaldehyde (0.95 ml) at room temperature; the 
D-arabinitol dissolved completely in 10 mm. The reaction mixture was allowed to 
stand for 18 hr, during which period it became a magma of white crystals. The mass 
was broken up and hydrogen chloride removed as far as possible at room temperature 
and 0.1 mmHg. Final traces were removed by storage for 24 hr in an evacuated 
desiccator containing KOH and H2SO4.  The residue was dissolved in aqueous 
ammonia (20 ml) containing Na2 CO3 (0.5 g), and extracted with light petroleum (b.p. 
60-80°C) to remove benzaldehyde. Concentration of the aqueous solution yielded a 
white solid which was recrystallised from ethanol. 1 ,3-O-Benzylidene-L-arabinitol 
(287) was afforded as white needles (1.50 g, 63%), m.p. 142-143°C (lit. 
223  151-
152°C); [aID23  +7.7° (c = 0.89, CHC1 3); [Found : C, 59.7; H, 6.7. C 12H 1605 requires 
C, 60.0; H, 6.7]; 8H  (400 MHz, DMSO-d6) 5.52 (1H, s, PhCH), 4.69 (1H, d, 
CHOH,CHOH = 6.4 Hz, 2-OH), 4.68 (1H, d, J40H,4  6.3 Hz, 4-OH), 4.39 (1H, t, 
CH20H,CH20H= 5.7 Hz, CH20H), 4.03 (1H, dd, J4 ,5a = 1.7 Hz, 55b = 11.8 Hz, H50, 
3.71 (1 H, dd, J34 = 1.3 Hz, JCHOH = 8.6 Hz, H3), 3.64 (1H, ddd, J34 = 1.3 Hz, J4,5a = 
1.7 Hz, J4,5, = 1.5 Hz, H4), 3.99 (1H, dd, J4, 5e = 1.5 Hz, 5a,5e = 11.8 Hz, H5e), 3.68 
(1H, ddd, j12 = 2.8 Hz, J3,CHOH = 8.6 Hz, H2), 3.57-3.40 (2H, m, JCHOH,CMOH = 2.8 
227 
Hz, JCH20H,CH20H = 5.7 Hz, H 1 ); 6c  (90 MHz, CD30D) 127.8, 127.1, 125.5 (5 x 
PhCH), 100.6 (CPh), 78.1 (C 3), 71.9 (C 5), 69.0 (C4), 62.2 (C 1 ), 62.0 (C2); mlz (FAB) 
241.10760 (M+H), C 12H 1705 requires 241.10759. 
3.3.3.2 2,4-0-Benzylidene-L-threose (288) 224 
A solution of 1,3-0-benzylidene-L-arabinitol (287) (1.50 g, 6.30 mmol) and 
sodium periodate (2.14 g, 0.01 mol, 1.6 M eq) in water (100 ml) was stirred for 2 hr 
at room temperature, and the pH of the solution maintained at 4. The reaction 
mixture was then adjusted to pH 6.5 by the addition of saturated NaHCO 3 , and the 
solution [containing a small amount (0.1 g) of solid Na 2C03 1 concentrated at 40°C. 
The residue was dehydrated using ethanol (3 x 10 ml), more ethanol added and the 
suspension filtered. The filtrate was concentrated in vacuo to yield 2,4-0-
benzylidene-L-threose (288) as white crystals (0.91 g, 70%), m.p. 161-163°C (lit. 224 
165°C); oH  (250 MHz, CDCI 3) 9.65 (1H, s, CHO), 7.60-7.30 (5 x PhCH); mlz (FAB) 
209.08137 (M+H), C 11 H 1304 requires 209.08138. 
3.3.3.3 1 ,2-Dideoxy-3,5-O-benzylidene-L-threo-pent-1-enitol (286) 
Potassium tert-butoxide (0.98 g, 8.75 mmol) in dry THF was added to 
methyltriphenyl-phosphonium bromide (2.18 g, 5.38 mmol) in dry THF, under 
nitrogen and the solution stirred for 1.5 hr at room temperature. 2,4-0-Benzylidene-
L-threose (288) (0.70 g, 3.37 mmol) dissolved in dry THF was added dropwise over 
10 mm, and the solution stirred overnight. Water (30 ml) was added and the mixture 
extracted with hexane (3 x 50 ml). The combined organic extracts were dried 
228 
(MgSO4), and the solvent removed in vacuo to afford a syrup which was purified by 
dry flash chromatography (silica; hexane/ether gradient elution 10: 0 —+ 4 : 6), and 
afforded alkene (286) as a yellow oil (0.34 g, 49%); [aID26 3•30 (c = 0.23, CHC1 3 ); 
H (360 MHz, CDCI 3) see Table 80; ö (90 MHz, CDC1 3) 134.6 (C2), 128.8, 128.0, 
125.8 (5 x PhCH), 117.3 (C 1 ), 101.0 (CPh), 80.1 (C 3), 72.1 (C 5), 65.6 (C4); mlz 
(FAB) 207.1021 12 (M+H), C 12H1503 requires 207.10211. 
H5a 
H3 
Ph 	0 	H5e 





Resonance 11/ppm Coupling JIHz 
la 5.45 la,lb 1.6 
lb 5.33 1a,2 17.4 
2 5.98 1b,2 10.7 
3 4.46 2,3 5.2 
4 3.57 3,4 1.5 
5a 4.24 4,5a 1.9 
5e 4.07 4,5e 1.3 
PhCH 5.63 5a,5e 11.9 




3.3.4 	1,2-Dideoxy-3,4:5,6-di-0-isopropylidene-o-arabino-hex-1-enitol (293) 
This alkene was prepared in four steps utilising two different synthetic 
pathways. 
From D-arabinose, (Scheme 70) by the method of Zinner 225 in 29% overall yield. 
From D-mannitol, (Scheme 71) by the method of Wiggins 226  in 14% overall yield. 
3.3.4.1 D-Arabinose diethyldithioacetal (294) 
To a stirred solution of D-arabinose (10.03 g, 66.80 mmol) in concentrated 
hydrochloric acid (10 ml) was added ethanethiol (10 ml) dropwise over 20 mm. On 
cooling the solution to 0°C a precipitate formed. After 5 mm, water (40 ml) was 
added to form a slurry, which on filtering yielded an off-white precipitate, which was 
washed with cold water (2 x 25 ml). Recrystallisation from boiling water (50 ml) 
with hot filtration yielded D-arabinose diethyldithioacetal (294) as fine white needles 
(8.40 g, 49%), m.p. 124-126°C (lit. 225 126°C from isobutanol); mlz (FAB) 
256.08228 (M), C9H2004S2 requires 256.08030; u m /cm' (nujol) 3260 (OH). 
3.3.4.2 2,3 :4,5-Di-O-isopropylidene-D-arabinose diethyldithioacetal (295) 
D-Arabinose diethyldithioacetal (294) (4.02 g, 15.70 mmol) was added to 
dry acetone (40 ml) containing concentrated sulphuric acid (0.6 ml), and the mixture 
shaken overnight at room temperature. The reaction mixture was neutralised with 
anhydrous ammonia gas, filtered over a pad of celite and the filtrate stirred for 58 hr 
at room temperature with anhydrous copper sulphate (1.50 g). The filtrate was 
concentrated under reduced pressure and the resulting oil chromatographed on silica 
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with ethyl acetate-hexane (1: 9) as eluent to produce 2,3 :4,5-di-O-isopropylidene-D-
arabinose diethyldithioacetal (295) (3.97 g, 75%) as a yellow syrup. 
3.3.4.3 2,3: 4,5-Di-O-isopropylidene-aldehydo-D-arabinose (296) 
Mercuric(II)oxide (6.03 g, 27.00 mmol) and mercuric(II)chloride (6.03 g, 
22.20 mol) were added to a magnetically stirred solution of the bisacetonide (295) 
(4.04 g, 15.8 mmol) in acetone (37 ml) and water (3 ml) and then the mixture heated 
for 2 hr at 30°C, 1 hr at 50C, and 2 hr at reflux. After cooling, the reaction mixture 
was filtered over a pad of celite and the filtrate concentrated in vacuo to give a 
yellow oily residue. This was dissolved in chloroform (125 ml), shaken with 
saturated potassium iodide (2 x 125 ml), washed with water (90 ml), and dried 
(MgSO4). The solvent was evaporated in vacuo to afford the crude aldehyde as a 
yellow oil, which was purified by distillation/sublimation to yield aldehyde (296) 
(2.91 g, 80%) as a colourless oil, (b.p. 60-65°C, 0.08 mmHg); oH  (200 MHz, CDC1 3) 
9.72 (1H, d, j12 = 1.1 Hz, H 1 ), 4.38 (1H, dd, JI,2 = 1.1 Hz, J23 = 5.9 Hz, H2), 4.12 
(1H, dd, J4,5b = 6.7 Hz, J5,5b = 5.9 Hz, H50, 4.09 (1H, dd, "4,5a = 6.6 Hz, 5,,,5b  59 
Hz, H5a), 4.02 (1H, dd, J2,3 = 5.9 Hz, J34 = 3.7 Hz, H3), 3.94 (1H, ddd, J34 = 3.7 Hz, 
= 6.6 Hz, 4,5b = 6.7 Hz, H4), 1.44, 1.39, 1.34, 1.31 (12H, 4 x s, 4 x Cl-I3). 
3.3.4.4 1,2-Didcoxy-3,4:5,6-di-0-isopropylidene-D-arabino-hex-1-enitol (293) 
Potassium tert-butoxide (0.82 g, 7.28 mmol) in dry THF (6 ml) was 
added to methyltriphenyl-phosphonium iodide (1.96 g, 4.85 mmol) in dry THF (13 
ml) under nitrogen, and the solution stirred for 1.5 hr at room temperature. Freshly 
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distilled aldehyde (296) (0.52 g, 2.26 mmol) in dry THF (6 ml) was added dropwise 
over 10 min,and the solution stirred for 3 hr. Water (12 ml) was added and the 
mixture extracted with hexane (3 x 40 ml). The combined organic extracts were dried 
(MgSO4) and the solvent removed in vacuo to afford a syrup which was purified by 
dry flash chromatography on silica using 10% ether/hexane as eluent, to afford the 
product (293) as a yellow oil (0.29 g, 56%); [Found : C, 62.8; H, 9.0. C 12H2004 
requires C, 63.2; H, 8.8]; oH (360 MHz, CDCI 3) see Table 81; 0c  (90 MHz, CDC13) 
135.7 (C2), 117.1(C 1 ), 109.5, 109.2 [2 x C(Me) 21, 81.0 C 3), 80.3 (C 4), 76.5 (CO,  66.8 
(CO, 26.8, 26.5, 25.1 (4 x c113), mlz (FAB) 229 (M+H). 
H6. H 




Resonance OH/ppm Coupling J/Hz 
la 5.38 la.lb 1.5 
lb 5.18 1a,2 17.2 
2 5.88 1b,2 10.5 
3 4.33 lb,3 1.2 
4 3.67 2,3 6.1 
5 3.92 3,4 7.6 
6a 4.10 4,5 7.1 
6b 4.06 5,6a 4.6 




3.3.4.5 1,2:3,4: 5,6-Triisopropylidene-D-mannitol (297) 
A mixture of D-mannitol (10.00 g, 54.90 mmol), anhydrous acetone (125 
ml, 1.71 mol) and concentrated sulphuric acid (1 ml) was shaken for 18 hr at room 
temperature, neutralised with concentrated aqueous ammonia solution (4 ml), and 
sodium carbonate (6.25 g, 59.00 mmol), and filtered. The filtrate and acetone 
washings were combined, and concentrated at water pressure (12 mmHg), in the 
presence of a small amount of sodium carbonate, to ca 30 ml amd poured into ice-
water (300 ml). Recrystallisation of the white precipitate from aqueous acetone 
containing a trace of ammonia, yielded white needles of the required product (297) 
(10.01 g, 60%), m.p. 64-66°C (lit. 226 69-70°C); 8H  (200 MHz, CDC1 3) 4.22-3.90 (8H, 
m, 2 x H 1 , H2, H3, H4, H5 , 2 x 1-16), 1.39-1.32 (18H, m, 6 x CH 3); 6C (50 MHz, 
CDC13) 110.0, 109.4 (3 x C(Me)2), 80.5, 79.2, 76.2 (C 2, C3 , C4 , CO,  66.1 (C 1 , C6), 
27.3, 26.6, 25.3, 26.2, 25.1, 24.9 (6 x CR3); mlz (FAB) 303.18073 (M+H), 
C 15H2706 requires 303.18075. 
3.3.4.6 1,2 :3,4-Diisopropylidene-D-mannitol (298) 
1,2:3,4:5,6-Triisopropylidene-D-mannitol (297) (5.92 g, 19.60 mmol) was 
dissolved in 70% ethanol (118 ml) containing concentrated hydrochloric acid (0.4 
ml) and the solution warmed at 40-45°C for 60 mm. The acid was neutralised with 
barium carbonate, the filtrate solution evaporated to dryness, and the residue 
extracted with acetone. The acetone extract, on evaporation, gave a residue which 
was dissolved in a little ethanol and poured into water, when unchanged 1,2:3,4:5,6-
triisopropylidene-D-mannitiol (297) was precipitated (0.59 g, 10%) as white needles. 
L
, -, -, 
i.) 
Evaporation of the filtrate in vacuo followed by column chromatography yielded, in 
order of elution, further 1,2:3,4:5,6-triisopropylidene-D-mannitol (297) (0.53 g, 9%), 
the desired 1,2:3,4-diisopropylidene-D-mannitol (298) (1.77 g, 35%), and 3,4-mono-
isopropylidene-D-mannitol (298) (1.39 g, 32%). 1,2:3,4-Diisopropylidene-D-
mannitol (298), white needles, m.p. 33-35°C; 8H  (200 MHz, CDCI 3) 4.19-3.72 (811, 
m, 2 x H 1 , I12, H3 , H4, H5 , 2 x 116), 2.52 (211, b, 2 x OH), 1.43, 1.35 (12H, d, 4 x 
CH3); 8C (50MHz, CDC1 3) 110.0, 109.5 [2 x C(Me)21, 80.6 (C 3 , C4), 76.3 (CO, 72.1 
(C2), 67.8 (CO,  63.8 (C 1 ), 26.6, 26.2, 24.9 (4x Cl-I 3), mlz (FAB) 263.14840 (M+H), 
C 121-12306 requires 263.14946. 
3.3.4.7 2,3: 4,5-Di-O-isopropylidene-aldehydo-D-arabinose (296) 
Using this synthetic route the above compound (296) was prepared by 
oxidation of 1 ,2:3,4-diisopropylidene-D-mannitiol (298). In a well stirred and cooled 
flask was placed a solution of 1,2:3,4-diisopropylidene-D-mannitiol (298) (1.41 g, 
5.37 mmol) dissolved in water (4.5 ml). A solution of sodium periodate (1.29 g, 6.03 
mmol) in water (20 ml) was added, maintaining the mixture at 0-5°C. The reaction 
mixture was allowed to remain at this temperature for 1 hr, then saturated with 
sodium chloride, and extracted with chloroform (10 x 10 ml). After drying over 
NaSO4, removing the solvent at room temperature and distillation, (296) was 
afforded as a colourless oil (0.60 g, 49%) (b.p. 80°C, 0.01 mmHg); o (200 MHz, 
CDC13) see Section 3.3.1.3. 
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3.3.4.8 1,2-Dideoxy-3,4:5,6-di-0-isopropylidene-D-arabino-hex-1-enitol (293) 
This was prepared in the same way as previously described in Section 
3.3.4.4. 
3.3.5 Methyl 5,6-dideoxy-2,3-0-isopropylidene-a-D-lyxo-hex-5-eno-
furanoside (317) 227 
This alkene was prepared in four steps from D-mannose (Scheme 78). 
3.3.5.1 Methyl 2,3 :5,6-di-O-isopropylidene-ct-D-manno-furanoside (318) 
The title compound was prepared by a literature method. 227  A solution of D-
mannose (25.00 g, 0.14 mol), 2,2-dimethoxypropane (85 ml), acetone (82.5 ml), 
methanol (82.5 ml) and concentrated hydrochloric acid (2.5 ml) was refluxed for 2 
hr. The solution was cooled, water added (250 ml) and concentrated to - 250 ml at 
<30°C. The product was not isolated, but instead carried directly onto the next stage. 
3.3.5.2 Methyl 2,3-0-isopropylidene-a-D-manno-furanoside (319) 227 
To the stirred solution of (318) prepared in Section 3.3.5.1, methanol (250 
ml) and concentrated hydrochloric acid (6.25 ml) were added and the resulting 
solution stirred at 23°C for 200 mm. The solution was neutralised by addition of 
sodium hydrogen carbonate solution (1 M, 160 ml) and then concentrated to remove 
the methanol. The resulting aqueous solution was continuously extracted with 
chloroform for 3 hr in a liquid-liquid extractor, the extract dried (MgSO 4) and then 
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concentrated to a syrup. This syrup was not purified, but taken directly onto the next 
stage. 
3.3.5.3 Methyl 2,3-O-isopropylidene-5,6-di-O-methylsulphonyl-a-D-manno-
furanoside (320) 227  
Syrup (319) was dissolved in pyridine (125 ml) and methanesulphonyl 
chloride (37.5 ml) added while keeping the stirred solution below 35°C. The solution 
was stirred at 20°C for 2 hr and then excess methanesulphonyl chloride decomposed 
by slow addition of water keeping the temperature below 50°C. More water (300 ml) 
was added and the product filtered off, washed with water and dried. The crude 
product was recrystallised from ethanol to yield white needles (29.79 g, 55% from D-
mannose); m.p. 145-146°C (lit. 227 144.5-146.0°C); mlz (FAB) 391.07392 (M+H). 
C 12H230 10 S2 requires 391.07327. 
3.3.5.4 Methyl 5,6-Dideoxy-2,3-0-isopropylidene-a-D-/yxo-hex-5-eno-
furanoside (317) 
This alkene was prepared by reduction 
221 
 ofdimesylate (320). (320) (19.54 
g, 50.10 mmol), sodium iodide (38.50 g, 0.26 mol, dried over P205), ZnICu couple 
(prepared 228 from 17.60 g of zinc powder), DMF (229 ml) and dimethoxyethane (48 
ml) were stirred together at reflux for 70 mm. After cooling, the mixture was poured 
into water (500 ml) with rapid stirring. Toluene (300 ml) was added and the mixture 
filtered through celite. The filter pad was washed with toluene (2 x 300 ml) and the 
washes used to extract the aqueous layer. The combined organics were washed with 
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water (2 x 200 ml), dried (MgSO 4) and the solvent removed in vacuo to produce a 
syrup which was purified by dry flash chromatography (silica gel, hexane/ether 80: 
20) to yield alkene (317) as a colourless oil (9.54 g, 89 %); 6H  (360 MHz, CDCI3) see 
Table 82; 6c  (90 MHz, CDC1 3) 132.2 (C2), 118.9 (C 1 ), 107.0 (C6), 85.1 (C 3), 81.3, 
81.0 (C4, C5), 54.5 (OMe), 25.9, 24.8 (2 x Cl-I3). 




411" 	 5 
(317) 
Resonance 11/ppm Coupling JIHz 
la 5.37 la,lb 1.3 
lb 5.30 la,2 17.6 
2 5.95 1b,2 10.4 
3 4.35 2,3 7.4 
4 4.64 3,4 3.7 
5 4.54 4,5 5.9 
6 4.87 5,6 - 
OMe 3.31 
isopropyl.CH3 1.43, 1.27 
Table 82 
237 
3.3.6 	(6R,7R,145)-14-Ethenyl-1 ,8,13,16-tetraoxadispiro 15.0.5.41- 
hexadecane (226) 
This aikene was prepared in two steps from (6R,7R, 145)-i 4-(2-
hydroxyethyl)- 1,8,13,1 6-tetraoxadispiro[5 .0.5 .4]hexadecane (224). 
3.3.6.1 (6R,7R,14S)-14- [ 2-(4-Methylphenylsulphonyl)ethyll -1,8,13,1 6-tetra-
oxadispiro 15.0.5.41 hexadecane (225) 208  
To a stirred solution of (224) (300 mg, 1.10 mmol) in pyridine (0.8 ml) 
under argon was added at 0°C a solution of TsCl (315 mg, 1.65 mmol) in pyridine 
(0.19 ml). On completion of the addition, the reaction mixture was allowed to warm 
up to room temperature. After 3 hr the reaction was quenched by addition of water (6 
ml) and then extracted with CH 2C12 (3 x 50 ml). The organic extracts were washed 
with 10% HCl (3 x 10 ml) and water (3 x 10 ml), dried (MgSO4), filtered and 
concentrated in vacuo to give (225) after purification by column chromatography, as 
an off-white crystalline solid (375 mg, 80%), m.p. 97.8-100.0°C [lit. 208  104-105°C 
(Et20)]; oH (3 60 MHz, CDC1 3) 7.77 (2H, d, J= 8.3 Hz, o-tolyl), 7.32 (2H, d, J= 8.3 
Hz, m-tolyl), 4.32-4.25 (1H, m, H 18), 4.18-4.13 (1H, m, H 18), 4.06-3.99 (lH, m, H 14), 
3.65-3.43 (5H, m), 3.38 (1H, dd, J15 , = 11.2 Hz, J14,15, = 3.1 Hz, H15 e), 2.43 (3H, 
s, CH3), 1.77-1.37 (14H, m); Oc  (90 MHz, CDC13) 144.7, 133.0 (CPh), 129.7, 127.8 
(PhCH), 96.2, 95.2 (C 6, C7), 62.2 (C 14), 66.0, 62.4 (C 17 , C 18), 60.7, 30.4, 28.4, 28.2, 
24.8, 17.9, 17.8 (C2, C3 , C4, C5 , C9, C 103 C 11 , C 12, C 15), 21.5 [CH3 (Tos)]; mlz (FAB) 
426.17121 (M), C21 H3007 S requires 426.1708. 
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3.3.6.2 (6R,7R,14S)-14-Ethenyl-1 ,8,13,1 6-tetraoxadispiro [5.O.5.4]hexa-
decane (226) 
To (225) (375 mg, 0.88 mmol) at room temperature were added potassium 
tert-butoxide (1.19 g, 10.56 mmol) and DMSO (20 ml) and the solution stirred for 2 
hr. The resultant red-brown solution was added to saturated aqueous NaHCO 3 (35 
ml) and extracted with ether (35 ml). The ethereal extract was washed with water (2 
x 35 ml) and dried (MgSO4), filtered, concentrated in vacuo and the residue purified 
by dry flash chromatography on silica gel, eluting with ether! hexane (1: 1) to give 
(226) as a colourless oil (0.63 g, 71%); 6H  (360 MHz, CDC1 3) see Table 83; 5 C (90 
MHz, CDC13) 134.1 (C 17), 117.3, (C 18), 96.3, 95.0 (C 6, C7), 67.8 (C 14), 62.0, 61.0, 
60.6 (C2, C9, C 15), 29.6, 28.5, 28.3, 24.9, 24.86, 18.0, 17.8 (C 3 , C4, C5 , C 10, C 11 , C 12); 
mlz (FAB) 255.15759 (M+H), C 14H2304 requires 255.15963. 
3.3.7 trans-3,4-Didehydro-3,4-Dideoxy-1 ,2 :5,6-di-O-cyclohexylidene-D-threo-
hexitol (232) 
This alkene was prepared in three steps from D-mannitol according to 
Scheme 45. 
3.3.7.1 1,2: 5,6-Di-O-cyclohexylidene-D-mannitol ( 193) 190 
This was prepared according to the method previously outlined in Section 
3.3.2.1. 
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3.3.7.2 1,2: 5,6-Di-O-isopropylidene-D-mannitol-3,4-thionocarbonate (231) 
1,2:5,6-Di-O-cyclohexylidene-D-mannitol (193) (5.76 g, 16.90 mmol) was 
refluxed in toluene (80 ml) with 1,1'-thiocarbonyldiimidazole (3.00 g, 16.90 mmol) 
for 16 hr. After cooling the mixture, water (70 in]) was added, and the mixture 
extracted with dichioromethane (3 x 70 ml). The combined organic extracts were 
dried (MgSO4) and evaporated in vacuo to yield a yellow oil, which was purified by 
dry flash chromatography (silica; hexane/ether gradient elution 10 : 0 —+ 1: 4). (23 1) 
was afforded as white platelets (4.62 g, 71%), m.p. 130-131°C; [a]D2 +9 . 10 (c = 
2.04, CHC13); [Found: C, 59.3; H, 7.3. C 19H2806S requires C, 59.4; H, 7.31; oH (360 
MHz, CDC13) 4.68 (2H, dd, J23 = 6.4 Hz, H3), 4.25 (2H, ddd, Jla,2 = 3.8 Hz, JIb,2 = 
6.7 Hz, H2), 4.12 (1H, dd, JIb2 = 6.7 Hz, JI!b = 9.3 Hz, HIb), 3.94 (1H, dd, JIa,2 = 
3.8 Hz, Jlalb = 9.3 Hz, Hi a), 1.61-1.52 (20H, m, cyclohexyl. CH 2); O (50 MHz, 
CDC13 ) 190.5 (C=S), 111.3 (cyclohexyl. quat.), 82.8 (C 3), 73.2 (C2), 65.1 (C 1 ), 33.9, 
33.7, 24.8, 23.8, 23.4 (cyclohexyl. CH 2); m/z (FAB) 385.16845 (M+H), C 19H2906S 
requires 385.16847. 
3.3.7.3 trans-3,4-Didehydro-3,4-dideoxy-1 ,2 : 5,6-di-O-cyclohexylidene-D-threo-
hexitol (232) 
(231) (3.60 g, 9.38 mmol) was refluxed in triethyl phosphite (14.4 ml, 84.1 
mmol, 9 M eq), under nitrogen for 12 hr. After cooling, saturated sodium hydroxide 
solution (300 ml) was added, and the mixture extracted with ether (3 x 300 ml). The 
combined organic extracts were dried (MgSO 4) and evaporated in vacuo to afford a 
syrup which was purified by dry flash chromatography (silica, hexane/ether gradient 
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elution 10 : 0 -* 6 4), and yielded alkene (232) as a colourless oil (2.75 g, 95%); 
[aID25  +24.4° (c = 2.69, CHC1 3); 5H  (200 MHz, CDC1 3) see Table 84; 8 (50 MHz, 
CDC13) 131.0 (C 3), 109.9 (cyclohexyl. quat.), 75.6 (C2), 68.8 (C 1 ), 36.1, 35.3, 25.0, 
23.8, 23.7 (cyclohexyl. CH 2); mlz (FAB) 308.19876 (M), C 18H2804 requires 
308.19875. 
2 








Resonance 11/ppm Coupling J/Hz 
18a 5.19 18a,18b 1.5 
18b 5.34 17,18a 10.6 
17 5.76 17,18b 17.3 
14 4.42 14,17 6.0 
15a 3.70-3.62 14,15a 9.4 
15e 3.45 14,15e 3.2 
2a,2e,9a,9e 3.70-3.62 15a,15e 11.2 
3, 4,5, 10, 11, 12 1.87-1.45 
Table 83 
241 
z _P H.2 
(232) 
Resonance 8H/PPM Coupling JfI{z 
la 3.56 la,lb 8.1 
lb 4.05 1a,2 6.2 
2 4.50 lb,2 7.6 
3 5.76 2,3 3.9 
cyclohexyl. CH2 1.61-1.53 
Table 84 
3.4 	Nitrile Oxide Cycloaddition Reactions 
General Procedure 
A solution of triethylamine (1.1 M eq) in dry ether was added over 32-45 hr 
using a motorised syringe pump, to an ice-cooled stirred solution of alkene (1.5 M 
eq) and hydroximoyl chloride (1.0 M eq) in dry ether. The solution was left stirring 
for a further 8 hr. After filtration of the precipitated triethylamine hydrochloride, and 
removal in vacuo of the solvent, TLC of the crude reaction mixture showed evidence 
of either three or four spots. 10% of the crude mixture was retained for isomer ratio 
242 
determination by 'H-NMR and/or reverse phase HPLC. From the reaction mixture 
was isolated by chromatography on silica (gradient elution) : unreacted alkene, 
furazan N-oxide [identified by comparison (TLC) with authentic sample] and a pair 
of diastereomeric isoxazoline cycloadducts. In some cases these cycloadducts could 
not be separated by chromatography. 
3.4.1 	Cycloadditions of Nitrile Oxides to 1,2-Dideoxy-3,4-0-cyclohexylidene- 
o-g/ycero-but-1-enitol (195) 
3.4.1.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chloro-oximinoacetate (186) (433 mg, 2.86 mmol) to alkene 
(195) (720 mg, 4.29 mmol) was carried out utilising the general procedure outlined 
above. The syrup was purified by dry flash chromatography (silica; hexane/ether 
gradient elution 10 : 1 -). 1 : 1), and afforded in order of elution, unreacted alkene 
(104.5 mg, 22%), 3,4-diethoxycarbonylfurazan N-oxide (57.3 mg, 17%) and a pair of 
diastereomeric isoxazoline cycloadducts (198) and (199) in a ratio 77 23 (erythro 
threo) as determined by the ratio of the integral of the H 5 protons in the 'H-NMR 
(360 MHz, CDC1 3). The major isomer was identified as 5S-5-(1,2-0-
cyclohexylidene-D-glycero-diitol- l-yl)-3  -ethoxycarbonyl-2-isoxazoline (198), (421 
mg, 52%), white needles, m.p. 40.8-41.9°C; [a]D24  +58.1° (c = 0.31, CHC1 3); [Found 
C, 59.7; H, 7.7; N, 5.0. C 14H21N05 requires C, 59.4; H, 7.4; N, 5.0]; SM (360 MHz, 
CDC13) see Table 85; S  (90 MHz, CDC13) 160.3 (C3), 151.6 (C0), 110.5 
(cyclohexyl. quat.), 83.5 (CO,  75.1  (CO,  66.4  (CO,  62.0 (CH3 C1-120), 36.3 (C4), 36.0, 
34.4, 24.9, 23.8, 23.6 (cyclohexyl. CH2), 14.0 (CH3 CH20); mlz (FAB) 284.14980 
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(M+H), C 14H22N05 requires 284.14979. The minor isomer was identified as 5R-5-
(1,2 -O-cyclohexylidene-D-gl ycero-diitol- 1 -yl)-3-ethoxycarbonyl-2-isoxazoline ( 199), 
(132 mg, 16%), cream needles, m.p. 47-49°C; [aID24  -153.8° (c = 0.10, CHC1 3); 
[Found: C, 59.4; H, 7.7; N, 4.6. C 14H21N05 requires C, 59.4; H, 7.4; N,5.0]; oH  (360 
MHz, CDC13) see Table 85; 8c  (90 MHz, CDC1 3) 160.4 (C 3), 151.4 (C=O), 110.7 
(cyclohexyl. quat.), 82.5 (C 5), 75.6 (CO,  64.6 (C7), 62.0 (CH3 CH20), 35.6 (C4), 35.3, 
34.6, 24.9, 23.7, 23.6 (cyclohexyl. CH 2), 14.0 (CH3CH20); mlz (FAB) 284.14980 





Erythro isomer (198) 
Q 
H  6 H, 
Hlb' H5hh>j__ 













4a 3.26 3.24 4a,4b - 17.8 
4b 3.26 3.14 4a,5 8.9 11.4 
5 4.70 4.83 4b,5 8.9 8.5 
6 3.85 4.25 5,6 7.0 4.2 
7a 4.10 4.05 6,7a 6.3 6.8 
7b 4.06 3.84 6,7b 4.0 6.3 
CH3 CH2 4.33 4.33 7a,7b 7.7 8.7 
CH3 CH2 1.35 1.35 CH3CH2 7.1 7.1 
cyclohexyl. CH 2 1.61-1.50 1.61-1.50 
Table 85 
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3.4.1.2 Benzonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (2.16 g, 13.87 mmol) to 
alkene (195) (3.50 g, 20.80 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; 
hexane/ether gradient elution 10 : 1 -* 1 : 1), and afforded in order of elution, 
unreacted alkene (171 mg, 7%), 3 ,4-diphenylfurazan N-oxide (84 mg, 5%) and a pair 
of diastereomeric isoxazoline cycloadducts (196) and (197) in a ratio 79 : 21 (erythro 
threo) as determined by the ratio of the integral of the H 5 protons in the 'H-NMR 
(200 MHz, CDC13). The major isomer was identified as 5S-5-(1,2-0-
cyclohexylidene-D-glycero-diitol- 1 -yl)-3-phenyl-2-isoxazoline (196), (2.78 g, 70%), 
cream needles, m.p. 61-63°C, (lit. 191  73.5°C (after 5 recrystallisations)); [a]D24 
+23.4° (c = 0.14, CHCI3); [Found: C, 71.1; H, 7.6; N, 4.7. C 17H21 NO3 requires C, 
71.1, H, 7.3; N, 4.9]; 5H  (200 MHz, CDC1 3) see Table 86; 8c (50 MHz, CDC13) 156.5 
(C3), 129.2 (CPh), 130.1, 128.6, 126.6 (5 x PhCH), 110.2 (cyclohexyl. quat.), 81.3 
(CO' 75.5 (C6), 66.8 (C 7), 37.7 (C 4), 36.4, 34.5, 25.0, 23.9, 23.6 (cyclohexyl. CH 2); 
m/z (FAB) 288.15997 (M+H), C 17H22NO3 requires 288.15996. The minor isomer 
was identified as 5R-5-( 1 ,2-O-cyclohexylidene-D-glycero-diitol- l-yl)-3  -phenyl-2- 
isoxazoline (197), (0.72 g, 18.3%), white needles, m.p. 96-98°C; [aID24  -39.1° (c = 
0.23. CHC13); [Found : C, 70.7; H, 7.7; N, 4.7. C 17H21NO3 requires C, 71.1; H, 7.3; 
N, 4.9]; 6H  (200 MHz, CDC1 3) see Table 86; ö (50 MHz, CDC1 3) 156.3 (C3), 129.2 
(CPh), 130.0, 128.5, 126.6 (5 x PhCH), 110.4 (cyclohexyl. quat.), 80.3 (CO, 75.8 
(CO, 64.8 (C 7), 36.5 (C4), 35.7, 34.6, 25.0, 23.8, 23.6 (cyclohexyl. Cl-I 2); mlz (FAB) 
288.15997 (M+H), C 171122NO3 requires 288.15996. 
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Q 
H7b 	 H4. 
Ph 0
1, 


















4a 3.37 3.88 4a,4b 17.0 17.1 
4b 3.47 3.26 4a,5 7.3 10.7 
5 4.64 4.81 4b,5 9.3 8.3 
6 4.05 4.33 5,6 7.6 4.4 
7a 4.14 4.08 6,7a 5.7 6.7 
7b 3.95 3.88 6,7b 4.1 6.3 
Ph 7.64, 7.39 7.65, 7.38 7a,7b 7.7 8.6 
cyclohexyl. 1.68-1.52 1.68-1.52 
Table 86 
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3.4.1.3 (Diethoxyphosphoryl)acetonitrile Oxide 
Addition of (diethoxyphosphoryl)acetohydroximoyl chloride (189) (453 mg, 
1.99 mmol) to alkene (195) (500 mg, 2.98 mmol) was carried out utilising the 
general procedure outlined above. The syrup was purified by dry flash 
chromatography (silica; hexane/ether/ethyl acetate gradient elution 10 : 0 -* 1 1), 
and afforded in order of elution, unreacted alkene (100 mg, 30%), 3,4-di-
(diethoxyphosphorylmethyl)-furazan-N-oxide (15 mg, 15%) and a pair of 
diastereomeric cycloadducts, 5 S-5-( 1,2 -O-cyclohexylidene-D-gl ycero-diitol- l-yl)-3 - 
(diethoxyphosphorylmethyl)-2-isoxazoline (200) and 5R-5-( 1 ,2-O-cyclohexylidene-D-
glycero-diitol- l-yl)-3 -(diethoxyphosphorylmethyl)-2-isoxazoline (201), (287 mg, 
40%) in a ratio 79 : 21 (erythro : threo) as determined by the ratio of the integral of 
the H 5 protons in the 'H-NMR. The isomers were unable to be separated. 8H  (360 
MHz, CDC13) see Table 87; mlz (FAB) 362.17285 (M+H), C 16H29N06P requires 
362.17325. 
3.4.1.4 Acetonitrile Oxide 
A solution of nitroethane (89 mg, 1.19 mmol) in 1,1,1 -trichioroethane (44 
ml) was added at room temperature to a stirred solution of alkene (195) (200 mg, 
1.19 mmol), TDI (620 mg, 3.56 mmol) and triethylamine (60 mg, 0.59 mmol) in 
1,1,1 -trichloroethane (20 ml) via a motorised syringe pump over a period of 40 hr. 
The solution was cooled to 0°C, and then 1 ,2-diaminoethane (0.32 ml) in ether (5 ml) 
added over 30 min to the ice cooled solution which was then stirred for a further 30 
mm. The precipitated polymeric urea was filtered off through celite and the filter pad 
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washed with ether (5 ml) and chloroform (5 ml). The filtrate and washings were 
combined and reduced in vacuo. The residue was dissolved in ethyl acetate (10 ml) 
and filtered through a silica pad which was then washed with ethyl acetate (2 x 10 
ml). The combined filtrate and washings were reduced in vacuo to afford an oil. This 
was purified by dry flash chromatography (silica; hexane/ether gradient elution 10 : 0 
- 1: 9), and afforded in order of elution, unreacted alkene (50 mg, 22%) and a pair 
of diastereomeric isoxazoline cycloadducts (202) and (203) in a ratio 82 : 18 (erythro 
threo) as determined by the ratio of the integral of the H 5 protons in the 'H-NMR. 
The major isomer was identified as 5S-5-(1,2-O-cyclohexylidene-D-glycero-diitol-1-
yl)-3-methyl-2-isoxazoline (202), (87 mg, 33%), pale yellow oil; oH  (200 MHz, 
CDC13) see Table 88; O- (90 MHz, CDC1 3) 155.3 (C3), 110.0 (cyclohexyl. quat.), 
80.3 (CO'  75.6  (CO,  66.8 (C 7), 36.4 (C4), 34.5, 24.9, 23.8, 23.6 (cyclohexyl. CH 2), 
12.9 (CH3); mlz (FAB) 226.14432 (M+H), C 12H20NO3 requires 226.14431. The 
minor isomer was identified as 5R-5-(l,2-O-cyclohexylidene-D-glycero-diitol-l-yl)-
3-methyl-2-isoxazoline (203), pale yellow oil, (85 mg, 32%); 0H  (200 MHz, CDC13 ) 
see Table 88; 8 (90 MHz, CDC1 3 ) 155.3 (C3 ), 110.2 (cyclohexyl. quat.), 79.3 (CO, 
75.8 (CO,  64.7 (C 7), 35.7 (C4), 34.5, 24.9, 23.8, 23.6 (cyclohexyl. CH 2), 12.8 (CH3); 








Erythro isomer (200)  
Q 
H6  HO  

















4a 3.12 3.25 4a,4b - - 
4b 3.20 3.17 4a,5 6.5 11.1 
5 4.54 4.62 4b,5 10.6 8.0 
6 4.20-4.00 4.20-4.00 5,6 6.5 5.2 
7a 4.20-4.00 4.20-4.00 6,7a nd nd 
7b 4.20-4.00 4.20-4.00 6,7b nd nd 
CH2P(0) 3.04 3.04 7a,7b nd nd 
OCH2CH3 nd nd P 3.9 4.4 
OCH2CH3 1.57 1.57 P 4.4 4.3 










	 0 	CH 
Eryt/iro isomer (202) 
	













4a 2.91 2.94 4a,4b 17.3 17.2 
4b 3.01 2.81 4a,5 6.4 10.9 
5 4.41 4.59 4b,5 10.1 7.9 
6 3.95 4.20 5,6 7.8 4.6 
7a 4.05 4.00 6,7a 6.1 6.7 
7b 3.83 3.76 6,7b 4.8 6.2 
CH3 1.32-1.30 1.32-1.30 7a,7b 8.5 8.6 
cyclohexyl. Cl-I 2 1.60-1.50 1.60-1.50 
Table 88 
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3.4.2 	Cycloadditions of Nitrile Oxides to 1 ,2-Dideoxy-3,5-O-ethylidene-D- 
erythro-pent-1-enitol (260) 
3.4.2.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chioro-oximinoacetate (284) (3.25 g, 21.47 mmol) to 
alkene (260) (4.64 g, 32.20 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by MPLC (silica; hexane/ether gradient 
elution 10 : 0 -> 3.5 : 6.5 and hexane/ethyl acetate 10 : 0 -* 6.5 : 3.5) and afforded in 
order of elution, unreacted alkene (1.67 g, 54%), 3,4-diethoxycarbonylfurazan N-
oxide (247 mg, 10%) and a pair of diastereomeric isoxazoline cycloadducts (263) and 
(264) in a ratio 53 : 47 (erythro : rhreo) as determined by the ratio of the integral of 
the H5 protons in the 'H-NMR (360 MHz, CDC1 3). The major isomer was identified 
as 5 S-5-( 1 ,3-O-ethylidene-D-erytbro-triitol-1 -yl)-3-ethoxycarbonyl-2-isoxazoline 
(263), (2.30 g, 41%), white needles, m.p. 82.8-85.4°C; [aID25 +105.6° (c = 0.80, 
CHC13); [Found : C, 51.2; H, 6.2; N, 5.3. C 11 H 17N06 requires C, 51.0; H, 6.6; N, 
5.4]; 5H  (400 MHz, CDC1 3) see Table 89; ö (90 MHz, CDC1 3) 160.3 (C0), 151.9 
98.7 (CivIc), 83.8 (CO,  79.8  (CO,  70.1  (CO,  63.6  (CO,  62.1 (CH3 CH20), 35.1 
20.1 (CCH3), 13.9 (CH3 CH20); mlz (FAB) 260.11343 (M+H), C 11 H 18N06 
requires 260.11340. The minor isomer was identified as 5R-5-(1,3-O-ethylidene-D-
erythro-triitol-1-yT)-3-ethoxycarbonyl-2-isoxazoline ( 264), (1.99 g, 36%), white 
needles, m.p. 99-100°C; [aID25  -213.5° (c = 0.56, CHC13); [Found : C, 51.0; H, 6.7; 
N, 5.2. C 11 H 17N06 requires C, 51.0; H, 6.6; N, 5.4]; 5H  (400 MHz, CDCI 3) see Table 
89; 8C * (90 MHz, CDC13) 160.1 (C=O), 151.7 (C 3), 98.3 (CMe), 80.9 (C 5), 80.5 (CO, 





70.3 (CO,  61.3 (CH3 CFI20), 60.7 (CO,  34.0 (C4), 20.3 (CCH 3), 13.9 (CH3 CH20); 
mlz (FAB) 260.11343 (M+I-I), C 11 H 18N06 requires 260.11340. Unseparated 
cycloadducts (1.30 g, 23%) were also obtained. 
'8a 









0 - COEt 













4a 3.34 3.21 4a,4b 17.8 17.6 
4b 3.23 3.38 4a,5 7.7 11.7 
5 5.01 5.15 4b,5 11.4 8.8 
6 3.53 3.45 5,6 4.8 2.9 
7 3.63 3.98 6,7 9.3 9.3 
8a 3.36 3.38 7,8a 10.0 10.6 
8e 4.10 4.15 7,8e 5.3 5.4 
CH3 CH 4.65 4.66 8a,8e 10.9 10.7 
CH3 CH 1.27 1.38 CH3CH2 7.1 7.2 
CH3 CH2 4.32 4.35 CH3 CH 5.0 5.0 
CH3 CH2 1.34 1.32 7,70H 4.1 - 
70H 2.65 1.95 
Table 89 
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3.4.2.2 Benzonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (3.30 g, 21.20 mmol) to 
alkene (260) (4.58 g, 31.80 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; 
hexane/ether gradient elution 10 : 0 -* 0 : 10) and afforded in order of elution, 
unreacted alkene (1.79 g, 59%), 3,4-diphenylfurazan N-oxide (30 mg, 1%) and a pair 
of diastereomeric isoxazoline cycloadducts (265) and (266) in a ratio 52 : 48 (erythro 
threo) as determined by the ratio of the integral of the H 5 protons in the 1 H- NMR 
(360 MHz, CDC13). The combined yield of isoxazolines was 75%. The major isomer 
was identified as 5 S-5-( 1,3 -O-ethylidene-D-erythro-triitol- l-yo-3-phenyl-2- 
isoxazoline (265), (2.50 g, 45%), white needles, m.p. 164.8-166.2°C; 1aID25 +47.2° (c 
= 0. 17, CHC1 3); [Found: C, 63.8; H, 6.7; N, 5.1. C 14H 17N0 4 requires C, 63.9; H, 6.5; 
N, 5.3]; ö (360 MHz, CDC13) see Table 90; & (90 MHz, CDC1 3) 157.2 (C3), 130.4, 
128.7, 128.66, 126.8 (5 x PhCH), 98.8 (CMe), 82.4 (C 5), 77.3 (C6), 69.9 (C 8), 65.0 
(C 7), 38.1 (C4), 20.2 (CH3); m/z (FAB) 264.12358 (M+H), C 14H 18N04 requires 
264.12357. The minor isomer was identified as 5R-5-(1,3-O-ethylidene-D-erytbro-
triirol-1-yl)-3-phenyl-2-isoxazoline (266). Pure minor isomer was not isolated. (NMR 
data are obtained from spectra containing both isomers). 8H  (360 MHz, CDC13) see 
Table 90; & (90 MHz, CDC1 3 ) 157.2 (C3), 130.3, 129.1, 128.8, 126.7 (5 x PhCH), 
99.1 (CMe), 80.4 (CO,  78.8  (CO,  70.4 (C 8), 61.4 (CO,  35.6 (C4), 20.2 (CH3); m/z 
(FAB) 264.12306 (M+H), C 14H 18N04 requires 264.12358. 
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H8a 











Erythro isomer (265) 
	













4a 3.44 3.34 4a,4b 17.5 16.7 
4b 3.45 3.45 4a,5 7.1 11.5 
5 4.89 5.07 4b,5 11.5 8.6 
6 3.45 3.53 5,6 5.3 3.2 
7 3.77 3.94 6,7 8.7 9.9 
8a 3.38 3.46 7,8a 10.2 9.9 
8e 4.15 4.14 7,8e 5.5 5.4 
CH3 CH 4.66 4.66 8a,8e 11.0 10.8 
CH3 CH 1.30 1.27 CH3 CH 5.0 5.0 
Ph 7.68-7.37 7.67-7.36 7,70H nd nd 
7011 3.10 3.10 
Table 90 
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3.4.2.3 (Diethoxyphosphoryl)acetonitrile Oxide 
Addition of (diethoxyphosphoryl)acetohydroximoyl chloride (189) (4.22 g, 
18.53 mmol) to alkene (195) (4.00 g, 27.78 mmol) was carried out utilising the 
general procedure outlined above. The syrup was purified by MPLC (silica; 
hexane/ether/methanol gradient elution 10 : 0 -)- 0 : 10) and afforded in order of 
elution, unreacted alkene (1.40 g, 53%), 3,4-di-(diethoxyphosphorylmethyl)-furazan 
N-oxide (150 mg, 5%) and a pair of diastereomeric cycloadducts, 5S-5-(1,3-0-
ethylidene-D-erytbro-triitol- 1 -yl)-3 -(diethoryp ho sp ho rylmethy T-2-isoxazo1ine (267) 
and 5R-5-( 1,3 -O-ethylidene-D-erythro-triitol- 1 -yl)-3-(diethoxyphosphorylmethyl)-2-
isoxazoline (268), in a ratio 50: 50 (erythro : threo) as determined by the ratio of the 
integral of the H5 protons in the 1 H-NMR (360 MHz, CDC1 3). The combined yield of 
isomers was 38% and they were unable to be separated. 6H  (360 MHz, CDC13) see 






CH3 	0 	H8 	CH3 




O.., ,, CH2P(0)(OEt) 2 	0 , 	- CH2P(0)(OEt)2 
N 	 N 













4a 3.20-2.85 3.20-2.85 4a,4b nd nd 
4b 3.20-2.85 3.20-2.85 4a,5 6.2 11.4 
5 4.83 4.95 4b,5 11.4 8.2 
6 3.42 3.48 5,6 6.2 3.4 
7 3.86 3.73 6,7 9.6 9.4 
8a nd nd 7,8a 9.3 9.8 
8e 3.32 3.15 7,8e 4.2 4.2 
CH3CH 4.67 4.67 8a,8e 11.0 11.2 
CH3CH 1.37-1.25 1.37-1.25 CH3CH 5.0 5.0 
CH3CH20 4.19-4.10 4.19-4.10 CH2P 21.8 21.8 
CH3 CH20 1.37-1.25 1.37-1.25 
CH2P(0) 2.96 2.96 
Table 91 
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3.4.3 Cycloadditions of Nitrite Oxides to 1,2-Dideoxy-3,5-0-benzylidene-L-
threo-pent-1-enitol (286) 
3.4.3.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chioro-oximinoacetate (184) (74 mg, 0.49 mmol) to alkene 
(286) (150 mg, 0.73 mmol) was carried out utilising the general procedure outlined 
above. The syrup was purified by dry flash chromatography (silica; hexane/ether 
gradient elution 10 : 0 -+ 0 : 10) and afforded in order of elution, unreacted alkene 
(30 mg, 30%) and a pair of diastereomeric isoxazoline cycloadducts (291) and (292) 
in a ratio 83 : 17 (erythro : threo) as determined by the ratio of the integral of the H 6 
protons in the 'H-NMR (360 MHz, CDC1 3). [82: 18 ratio measured by reverse phase 
HPLC (55% H20/MeOH)]. The major isomer was identified as 5S-5-(1,3-0-
benzylidene-L-threo-triitol- 1-yl)-3 -ethoxycarbonyl-2-isoxazoline (191), (89 mg, 
57%), white needles; 8H  (360 MHz, CDC13) see Table 92; mlz (FAB) 322.12908 
(M+H), C 16H20N06 requires 322.12905. The minor isomer was identified as 5R-5-
(1,3 -O-benzylidene-L-threo-triitol- l -yl)-3  -ethoxycarbonyl-2-isoxazoline (292), (19 
mg, 12%), pale yellow oil; 8H  (360 MHz, CDC1 3) see Table 92; mlz (FAB) 
322.12908 (M+H), C 16H20N06 requires 322.12905. 
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H8a 	 H8a 
Ph 	0 
	
H8e 	 Ph 
0 
OH H4b 
- 	 "H 
& N" CO2Et 
Erythro isomer (291) 
OH HO 
I ~""IH- 4a  
O - 0O2Et 













4a 3.35 3.33 4a,4b 18.2 17.7 
4b 3.26 3.13 4a,5 7.3 11.4 
5 5.07 5.06 4b,5 10.9 8.9 
6 3.88 3.98 5,6 7.5 7.5 
7 3.78 3.63 6,7 1.3 1.2 
8a 4.24 4.23 7,8a 1.9 2.0 
8e 4.04 4.06 7,8e 1.3 1.4 
PhCH 5.57 5.59 8a,8e 12.1 12.1 
Ph 7.49-7.34 7.99-7.31 CH3 CH2 7.1 7.2 
CH3 CH2 4.33 4.34 




3.4.3.2 Benzonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (37 mg, 0.24 mmol) to alkene 
(286) (75 mg, 0.36 mmol) was carried out utilising the general procedure outlined 
above. The syrup was purified by dry flash chromatography (silica; hexane/ether 
gradient elution 10 : 0 -~ 0 : 10) and afforded in order of elution, unreacted alkene 
(13 mg, 26%) and a pair of diastereomeric isoxazoline cycloadducts (289) and (290) 
in a ratio 81 : 19 (erythro : threo) as determined by reverse phase HPLC (45% 
H20IMeOH). The major isomer was identified as 5S-5-(1,3-O-benzylidene-L-threo- 
triitol-1-yl)-3-phenyl-2-isoxazoline (289), (39 mg, 50%), white needles, m.p. 152.6-
153.9°C; [Found : C, 69.7; H, 5.6; N, 4.3. C 19H19N04 requires C, 70.2; H, 5.9; N, 
4.3]; 6H  (360 MHz, CDC13) see Table 93; 8C (90 MHz, CDC13) 156.9 (C3), 130.3-
125.8 (5 x PhCH), 101.4 (CMe), 79.2 (CO,  78.0 (C6), 72.3 (CO,  63.2 (C 7), 37.1 (C4); 
mlz (El) 325.13140 (M), C 191-1 19N04 requires 325.1314. The minor isomer was 
identified as 5R-5-( 1,3 -O-benzylidene-L-threo-triitol- 1 -y[)-3-phenyl-2-isoxazoline 
(290), (9 mg, 12%), pale yellow oil; 8H  (360 MHz, CDC13) see Table 93; Ec (90 
MHz, CDC13) 134.3 (C 3), 130.3-125.9 (5 x PhCH), 101.3 (CMe), 80.9 (CO,  80.5 
(C6), 72.5 (CO,  62.0 (C 7), 37.1 (C4); mlz (FAB) 326.13926 (M+H), C 19H20N04 
requires 326.13922. 
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Hga 	 H8a 
Ph 
	





) u lIH 
Erythro isomer (289) 
	













4a 3.46 3.49 4a,4b 17.1 16.7 
4b 3.45 3.26 4a,5 7.7 10.8 
5 5.06 5.03 4b,5 9.2 8.4 
6 3.86 4.03 5,6 8.4 7.4 
7 3.90 3.91 6,7 1.1 1.2 
8a 4.28 4.25 7,8a 1.9 2.0 
8e 4.07 4.08 7,8e 1.2 1.3 
PhCH 5.58 5.62 8a,8e 12.0 12.0 
Ph 7.71-7.36 7.70-7.36 7,70H 11.2 10.8 
70H 2.72 2.96 
Table 93 
3.4.4 Cycloadditions of Nitrile Oxides to 1,2-Dideoxy-4-0-acelal-3,5-0-
ethylidene-D-erythro-penl-l-enitol (271) 
3.4.4.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chloro-oximinoacetate (184) (163 mg, 1.07 mmol) to 
alkene (271) (300 mg, 1.61 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; 
hexane/ether gradient elution 10 : 0 -* 0 : 10) and afforded in order of elution, 
unreacted alkene (120 mg, 60%), 3,4-diethoxycarbonylfurazan N-oxide (17 mg, 
12%) and a pair of diastereomeric isoxazoline cycloadducts (274) and (275) in a ratio 
59 : 41 (erythro : threo) as determined by the ratio of the integral of the H 6 protons in 
the 'H-NMR (360 MHz, CDC1 3). The major isomer was identified as 5S-5-(2-0-
acetyl- 1,3 -O-ethylidene-D-erythro-triitol- 1 -yT)-3-ethoxycarbonyl-2-isoxazoline (274), 
(90 mg, 28%), white needles, as prepared by acetylation of 5S-5-(1,3-ethylidene-D-
erythro-triitol-1-yl)-3-ethoxycarbonyl-2-isoxazoline (263) (57 mg, 99%), m.p. 72-
7°C; [aID25 + 68.6° (c = 0.68, CHC1 3); [Found: C, 51.4; H, 6.5; N, 4.6. C 13H 19N07 
requires C, 51.8; H, 6.3; N, 4.7]; oH (360 MHz, CDC1 3) see Table 94; & (90 MHz, 
CDC13) 169.8 (CH3 C=O), 160.3 (C=O), 151.4 (C3), 98.9 (CMe), 82.5 (C5), 77.5 (CO, 
673 (C 8), 63.4 (CH3 CH20), 61.9 (C 7), 33.6 (C4), 20.6 (CH3 C=O), 20.1 (CCH3), 14.0 
(CH3 CH20); mlz (FAB) 302.12395 (M+H), C 13H20N07 requires 302.12396. The 
minor isomer was identified as 5R-5-(2-O-aceiyl-1,3-O-ethylidene-D-erythro-triitOl-
1-yl)-3-ethoxycarbonyl-2-isoxazoline (275), (58 mg, 18%), white needles, as 
prepared by acetylation of 5R-5-( 1,3 -ethylidene-D-erythro-triitol- l -yl) -3-
ethoxycarbonyl-2-isoxazoline (264) (57 mg, 98%), m.p. 68.5-70.5°C; [aID25 -224.0° 
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(c = 1. 19, CHC13); [Found: C, 51.8; H, 6.7; N, 4.5. C 13H 19N07 requires C, 51.8; H, 
6.3; N, 4.7]; 8H  (360 MHz, CDC13) see Table 94; & (90 MHz, CDC1 3) 169.3 
(CH3 C=O), 160.4 (C=O), 151.3 (C3), 99.4 (CMe), 80.1 (C 5), 78.1 (CO,  67.2  (CO, 
63.0 (CH3 CI-120), 61.9 (C7), 34.1 (C4), 20.6 (CH3C=O), 20.1 (CCH3), 13.9 
(CH3 CH20); mlz (FAB) 302.12395 (M+H), C 13H20N07 requires 302.12396. 
8a 
CH3 	0 	H8e 
 
HO  
- 	 I IH 
COEt 
Erythro isomer (274)  
k8a 




















4a 3.38 3.16 4a,4b 17.7 17.5 
4b 3.15 3.24 4a,5 8.3 11.4 
5 4.79 4.90 4b,5 11.7 8.6 
6 3.80 3.61 5,6 3.2 2.6 
7 4.69 4.96 6,7 9.9 9.8 
8a 3.44 3.32 7,8a 10.1 9.9 
8e 4.13 4.28 7,8e 5.4 5.3 
CH3 CH 4.69 4.66 8a,8e 10.8 10.7 
CH3CH 1.28 1.28 CH3 CH2 7.1 7.1 
CH3 CH2 4.31 4.30 CH3 CH 5.0 5.0 
CH3 CH2 1.33 1.32 
CH3 CO 2.02 2.02 
Table 94 
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3.4.4.2 Benzonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (178 mg, 1.15 mmol) to 
alkene (271) (319 mg, 1.72 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; 
hexane/ether gradient elution 10 : 0 -+ 0 : 10) and afforded in order of elution, 
unreacted alkene (93 mg, 44%), 3,4-diphenylfurazan N-oxide (5 mg, 4%) and a pair 
of diastereomeric isoxazoline cycloadducts (272) and (273) in a ratio 63 : 37 (erythro 
threo) as determined by the ratio of the integral of the H 6 protons in the 'H-NMR 
(360 MHz, CDC13). [65 : 35 ratio measured by reverse phase HPLC (60% 
H20/MeOH)]. The major isomer was identified as 5S-5-(2-0-acetyl-1,3-0-
ethylidene-D-erythro-triitol- l-yl)-3  -phenyl-2-isoxazoline (272), (157 mg, 45%), white 
needles, m.p. 92-92.6°C; {cx] 025 + 41.5° (c = 0.65, CHC13); [Found: C, 62.9; H, 6.4; 
N, 4.4. C 16H 19N05 requires C, 63.0; H, 6.2; N, 4.6]; 6H  (360 MHz, CDC13) see Table 
95 c  (90 MHz, CDC13) 169.8 (CH3 C=O), 156.3 (C3), 129.9, 129.2, 128.5, 126.6 (5 
x PhCH), 98.9 (CMe), 80.2 (CO,  77.9  (CO,  67.3 (C 8), 63.8 (C7), 35.1 (C4), 20.6 
(CH3C=O), 20.1 (CCH3); mlz (FAB) 306.13415 (M+H), C 16H20N05 requires 
306.13414. The minor isomer was identified as 5R-5-(2-O-acetyl- 1 ,3-O-ethylidene-
D-erythro-triitol-1-yl)-3-phenyl-2-isoxazoline ( 273), (93 mg, 27%), white needles, 
m.p. 130.1-130.9°C; [a]D25  -200.0° (c = 0.34, CHC1 3); [Found : C, 63.0; H, 6.4; N, 
4.3. CHN05 requires C, 63.0; H, 6.2; N, 4.6]; 6H  (360 MHz, CDC13) see Table 95 
c (90 MHz, CDC13) 169.3 (CH3 C=O), 156.3 (C 3), 129.9, 129.3, 128.5, 126.5 (5 x 
PhCH), 99.4 (CMe), 78.2 (CO,  78.2 (C6), 67.3 (CO,  63.3 (C7), 35.5 (C4), 20.6 
263 
(CH3 C=O), 20.1 (CCFI3); mlz (FAB) 306.13415 (M+H), C 16H20N05 requires 
306.13414. 
H8a 
CH3 	0 	H8 
OCOCH3 
H4b 
\ "H4.  
0 	Ph 
N 
Erythro isomer (272) 
H8a 




O , 	Ph 
N 











4a 3.51 3.32 4a,4b 16.6 16.4 
4b 3.32 3.41 4a,5 7.9 11.2 
5 4.77 4.88 4b,5 11.2 8.4 
6 3.84 3.71 5,6 3.2 2.9 
7 4.82 5.04 6,7 9.8 9.7 
8a 3.46 3.37 7,8a 10.2 10.0 
8e 4.16 4.31 7,8e 5.4 5.4 
CH3 CH 4.72 4.69 8a,8e 10.7 10.6 
CH3 CH 1.28 1.29 CH3 CH 5.0 5.0 
Ph 7.67-7.36 7.65-7.36 
CH3 CO 2.00 2.04 
Table 95 
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3.4.5 Cycloadditions of Nitrile Oxides to 1,2-Dideoxy-D-erythro-pent-1-
enitol (276) 
3.4.5.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chioro-oximinoacetate (184) (53 mg, 0.35 mmol) to alkene 
(276) (61 mg, 0.52 mmol) was carried out utilising the general procedure outlined 
above. The syrup was purified by dry flash chromatography (silica; ethyl 
acetate/ethanol gradient elution 10 : 0 -* 9 : 1) and afforded in order of elution, 
unreacted alkene (18 mg, 45%), 3,4-diethoxycarbonylfurazan N-oxide (3 mg, 7%) 
and a pair of diastereomeric isoxa.zoline cycloadducts 5 S-5-(D-erythro-triitol- l -yl) -3-
ethoxycarbonyl-2-isoxazoline ( 277) and 5R-5-(D-erythro-Iriitol- 1 -yl)-3-ethoxy-
carbonyl-2-isoxazoline (278) (24 mg, 30%) in a ratio 55 45 (erythro : threo) as 
determined by 'H-NMR [360 MHz, (CD 3)2C0]. These adducts are identical to those 
obtained by deprotection of 5 S-5-( 1,3 -O-ethylidene-D-erythro-triitol- l-yl)-3-
ethoxycarbonyl-2-isoxazoline (263) (Section 3.7.8) and 5R-5-( 1,3 -O-ethylidene-D-
erythro-triitol- l-yl)-3 -ethoxycarbonyl-2-isoxazoline ( 264) (Section 3.7.9). 
3.4.5.2 Benzonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (132 mg, 0.85 mmol) to 
alkene (276) (150 mg, 1.27 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; ethyl 
acetate/ethanol gradient elution 10 : 0 -3 9 : 1) and afforded in order of elution, 
unreacted alkene (50 mg, 50%), 3,4-diphenylfurazan N-oxide (10 mg, 10%) and a 
pair of diastereomeric isoxazoline cycloadducts 5 S-5-(D-erythro-triitol- l -yl)-3- 
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phenyl-2-isoxazoline (279) and 5R-5-(D-erythro-triitol- 1 -yl)-3-phenyl-2-isoxazoline 
(280) (50 mg, 25%) in a ratio 62 : 38 (erythro : threo) as determined 'H-NMR [360 
MHz, (CD3)2C0] The major adduct is identical to that obtained by deprotection of 
5R-5 -(1 ,3 -O-ethylidene-D-erythro-triitol- l-yT)-3 -phenyl-2-isoxazoline (265) (Section 
3.7.12). 
3.4.6 	Cycloadditions of Nitrile Oxides to 1,2-Dideoxy-3,4:5,6-di-0- 
isopropylidene-D-arabino-hex-1-enitol (293) 
3.4.6.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chioro-oximinoacetate (184) (209 mg, 1.38 mmol) to alkene 
(293) (472 mg, 2.07 mmol) was carried out utilising the general procedure outlined 
above. The syrup was purified by dry flash chromatography (silica; hexane/ether 
gradient elution 10 : 0 - 1 : 1), and afforded in order of elution, unreacted alkene 
(138 mg, 44%), 3,4-diethoxycarbonylfurazan N-oxide (38 mg, 24%) and a pair of 
diastereomeric isoxazoline cycloadducts 5R-5-( 1,2:3 ,4-di-O-isopropylidene-D-
arabino-tetritol- l-yl)-3 -ethoxycarbonyl-2-isoxazoline (301) and 5S-5-(1,2:3,4-di-0- 
isopropylidene-D-arabino-tetritol- l-yl)-3 -ethoxycarbonyl-2-isoxazoline (302) [418 
mg (combined yield), 88%] which could not be separated. The ratio of (301) to (302) 
was 62.5 : 37.5 (erythro : threo) as determined by 'H-NMR. NMR data have been 
obtained from the mixed isomer spectrum. 6H  (360 MHz, CDC1 3 ) see Table 96; 
(62 MHz, CDC1 3) 160.4 (C3 , threo), 160.2 (C3 , erythro), 152.0 (C=O, erythro), 151.5 
(C=O, threo), 110.1 [C(Me)2, erythro], 109.8 [C(Me) 2, threo], 83.5, 79.2, 78.9, 72.4 
(C 5 , C6, C7 , C8 , erythro), 83.0, 81.7, 80.7, 72.7 (C 5 , C6, C7, C 8 , threo), 63.7 (C9 , 
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erythro), 63.5 (C9, threo), 62.1 (CH3 CH20, erythro), 62.0 (CH3 CH20, threo), 35.9 
(C4 , fhreo), 35.1 (C4, erythro), 29.6, 26.9 [C(CH3)2, erythro], 27.2, 26.3 [C(CH3)2, 






• )______( III H4a 
H5 I 
O, ,, CO2Et 
N 


















4a 3.15 3.28 4a,4b 17.5 - 
4b 3.32 3.26 4a,5 11.7 8.6 
5 5.06 4.92 4b,5 8.4 11.0 
6 4.20 4.40-3.96 5,6 3.0 2.2 
7 4.40-3.96 4.40-3.96 6,7 7.4 nd 
8 4.40-3.96 4.40-3.96 7,8 nd nd 
9a 3.91 4.06 8,9a 4.9 4.7 
9b 4.12 4.14 8,9b 6.2 6.0 
CH3CH2 4.34 4.34 9a,9b 8.4 8.4 
CH3 CH2 1.42-1.32 1.42-1.32 CH3CH2 7.1 7.1 
isopropyl.CH3 1.37-1.35 1.37-1.35 
Table 96 
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3.4.6.2 Benzonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (595 mg, 3.83 mmol) to 
alkene (293) (1.31 g, 5.74 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; 
hexane/ether gradient elution 10 : 0 -+ 1 : 1), and afforded in order of elution, 
unreacted alkene (380 mg, 44%), 3,4-diphenylfurazan N-oxide (12 mg, 26%) and a 
pair of diastereomeric isoxazoline cycloadducts 5R-5-( 1,2:3 ,4-di-O-isopropylidene-
D-arabino-tetritol- 1 -yT)-3-phenyl-2-isoxazoline (299) and 5S-5-( l,2:3 ,4-di-0- 
isopropylidene-D-arabino-tetritol- 1-yT)-3 -phenyl-2-isoxazoline (300) [791 mg 
(combined yield), 60%] which could not be separated. The ratio of (299) to (300) 
was 67 : 33 (erythro : threo) as determined by 'H-NMR. A small sample of pure 
major isomer (5R) was obtained after repeated recrystallisation from ether, m.p. 
131.6-133.3°C; [Found: C, 65.4; H, 7.2; N, 4.1. C 19H25N05 requires C, 65.7; H, 7.2; 
N, 4.01. NMR and mass spectrometry data have been obtained from the mixed isomer 
spectrum. 8H  (360 MHz, CDC13) see Table 97; 6 (50 MHz, CDC1 3) 156.4 (C3 , 
erythro), 156.2 (C 3, threo), 110.1, 109.9, 109.6 [C(Me)2], 81.9 (C 5, threo), 80.7 (C5 , 
erythro), 80.5, 79.4, 78.9, 77.5, 77.4, 76.9, 76.6, 76.2 (C 6, C7, C8), 67.8 (C9, threo), 
67.2 (C9, erythro), 37.1 (C4, threo), 35.6 (C4, erythro), 29.6, 29.2, 29.0, 27.1, 26.7, 
26.3, 25.1 {C(CH 3)2]; m/z (FAB) 348.18107 (M+H), C 19H26N05 requires 
348. 19108. 
H9b9a 
I 7 O 
111 0 
—0 H8 	 H4b 
0 	Ph 




0, , 	Ph 
N 













4a 3.34 3.47 4a,4b 16.5 16.5 
4b 3.45 3.38 4a,5 11.2 7.9 
5 4.98 4.87 4b,5 7.8 10.8 
6 4.01 4.19 5,6 3.9 3.8 
7 4.16-4.04 4.16-4.04 6,7 8.2 7.1 
8 4.16-4.04 4.16-4.04 7,8 nd nd 
9a 4.16-3.78 4.16-3.78 8,9a nd nd 
nd 4.16-3.78 4.16-3.78 8,9b nd nd 
Ph 7.66, 7.39 7.66, 7.39 9a,9b nd nd 
isopropyl. CH3 1.46-1.28 1.46-1.28 
Table 97 
269 
3.4.6.3 (Diethoxyphosphoryl)acetonitrile Oxide 
Addition of (diethoxyphosphoryl)acetohydroximoyl chloride (189) (1.00 g, 
4.39 mmol) to alkene (293) (1.50 g, 6.58 mmol) was carried out utilising the general 
procedure outlined above. The syrup was purified by MPLC (silica; 
hexane/ether/ethyl acetate gradient elution 10 : 0 —* 0: 10), and afforded in order of 
elution, unreacted alkene (3 00 mg, 30%), 3 ,4-di-(diethoxyphosphorylmethyl)-furazafl 
N-oxide (106 mg, 15%) and a pair of diastereomeric isoxazoline cycloadducts (303) 
and (304) (554 mg, 30%) which could not be separated. The ratio of (303) to (304) 
was 63 : 37 (erythro : threo) as determined by 1 H-NMR. NMR data have been 
obtained from the mixed isomer spectrum. 5H  (360 MHz, CDC1 3) see Table 98; m/z 
(FAB) 422.19437 (M+H), C 18H33N08P requires 422.19436. 
H9bi9a 	 119J9a 
07 H 

















4a 3.03 2.88k 4a,4b 15.0 15.0 
4b 2.94k 2.99 4a,5 10.6 8.4 
5 4.85 4.75 4b,5 8.4 10.8 
CH2CH3 4.31-4.10 4.31-4.10 5,6 3.8 2.4 
CH2CH3 1.43-1.29 1.43-1.29 





3.4.7 Cycloadditions of Nitrile Oxides to Methyl 5,6-dideoxy-2,3-0-
isopropylidene-a-D-Iyxo-hex-5-enofuranoside (317) 
3.4.7.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chloro-oximinoacetate (184) (2.27 g, 15.00 mmol) to 
alkene (317) (4.50 g, 22.50 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; 
hexane/ether gradient elution 10 : 0 -* 4 : 6) and afforded in order of elution, 
unreacted alkene (0.60 g, 20%), 3,4-diethoxycarbonylfurazan N-oxide (0.47 g, 20%) 
and a pair of diastereomeric isoxazoline cycloadducts (323) and (324) in a ratio 81: 
19 (erythro : threo) as determined by 'H-NMR. The major isomer was identified as 
5R-5-(2,3-O-isopropylidene- 1 -O-methyl-a-D-lyxo-tetrofuranos-4-yl)-3-ethoxy- 
carbonyl-2-isoxazoline (323), (3.07 g, 65%), white needles, m.p. 72-73°C (from 
ethanol) and by TLC comparison to authentic sample; mlz (FAB) 316.14038 
(M+H), C 14H22N07 requires 316.13963. The minor isomer was identified as 5S-5-
(2,3-0-isopropylidene-l-0-methyl-a-D-lyxo-tetrofuranos-4-yl)-3-ethoxycarbony1-2- 
isoxazoline (324), (0.71 g, 15%), white needles, m.p. 85.1-86.0°C (from ethanol); 
mlz (FAB) 316.14130 (M+H), C 14H22N07 requires 316.13963. 
3.4.7.2 Benzonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (1.94 g, 12.50 mmol) to 
alkene (317) (3.75 g, 18.75 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; 
hexane/ether gradient elution 10 : 0 -), 4 : 6) and afforded in order of elution, 
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unreacted alkene (1.04 g, 26%), 3,4-diphenylfurazan N-oxide (208 mg, 14%) and a 
pair of diastereomeric isoxazoline cycloadducts (321) and (322) in a ratio 81: 19 
(erythro : threo) as determined by 'H-NIvIR. The major isomer was identified as 5R-
5-(2,3 -O-isopropylidene- 1 -O-methyl-a-D-lyxo-tetrofuranos-4-yl)-3-phenyl-2- 
isoxazoline (321), (2.67 g, 67%), white needles, m.p. 123-125°C (from methanol); 
m/z (FAB) 320.14830 (M+H), C 17H22N05 requires 320.14980. The minor isomer 
was identified as 5 S-5-(2,3 -O-isopropylidene-a-D-lyxo-tetrofuranos-4-yl)-3 -p he nyl-
2-isoxazoline (322), (0.64g, 16%), white needles, m.p. 130-131°C (from methanol); 
mlz (FAB) 320.14806 (M+H), C 17H22N05 requires 320.14980. 
3.4.7.3 (Diethoxyphosphoryl)acetonitrile Oxide 
Addition of (diethoxyphosphoryl)acetohydroximoyl chloride (189) (304 mg, 
1.33 mmol) to alkene (317) (400 mg, 2.00 mmol) was carried out utilising the 
general procedure outlined above. The syrup was purified by dry flash 
chromatography (silica; hexane/ether/ethyl acetate gradient elution 10 : 0 -> 3 : 7) 
and afforded in order of elution, unreacted alkene (67 mg, 25%), 3,4-di-
(diethoxyphosphorylmethyl)-furazan N-oxide (39 mg, 18%) and a pair of 
diastereomeric isoxazoline cycloadducts 5R-5 -(2,3 -O-isopropylidene- 1-0-methyl-a-
D-lyxo-tetrofuranos-4-yT)-3-(diethoxyphosphorylmethyT)-2-iSOXaZOlifle ( 325) and 5 S-
5-(2,3-O-isopropylidene- 1 -O-methyl-a-D-lyxo-tetrofuranos-4-yl)-3-(diethoxy- 
phosphorylmethyl)-2-isoxazoline (326) (67 mg, 30%) in a ratio 88 : 12 (erythro 
threo) as determined by 1 H-NMR. The isomers were unable to be separated. 6H  (360 
MHz, CDC13) see Table 99; 5 C  (90 MHz, CDC13) 147.6 (C3), 112.5 [C(Me)2}, 107.1 
(C9), 84.7 (CO,  79.3, 79.1 (C 7, C8), 78.0 (C5), 62.4 (CH3 CH20), 54.5 (OMe), 39.7 
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(C4), 26.9, 25.4 [CH2P(0), JCH2,P = 141.0 Hz], 25.7, 24.2 [C(CH3)21, 16.2 
(CH3CH20); mlz (FAB) 394.16308 (M+H), C 16H29N08P requires 394.16306. 
H (EtO)2(0)PCH2 



















4a 3.19 3.20 4a,4b - - 
4b 3.18 3.18 4a,5 8.5 10.5 
5 4.91 4.91 4b,5 9.6 8.8 
6 3.98 3.98 5,6 6.4 6.4 
7 4.74 4.74 6,7 3.7 3.7 
8 4.54 4.54 7,8 5.9 5.9 
9 4.87 4.87 8,9 - - 
OMe 3.29 3.32 CH2,P 21.7 21.7 
isopropyl.CH 1.44,1.34-1.29 CH2CH3 7.1 7.1 
CH2P(0) 2.95 2.95 
OCH2CH3 4.18-4.08 4.18-4.08 
OCH2CH3 1.34-1.29 1.34-1.29 
Table 99 
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3.4.8 	Cycloadditions of Nitrile Oxides to (6R,7R,14S)-14-Ethenyl-1 ,8,13,16- 
tetraoxadispiro[5.O.5.4[hexadecane (226) 
3.4.8.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chloro-oximinoacetate (184) (90 mg, 0.59 mmol) to alkene 
(226) (225 mg, 0.89 mmol) was carried out utilising the general procedure outlined 
above. The syrup was purified by dry flash chromatography (silica ; hexane/ether 
gradient elution 10 : 0 -* 6 : 4), and afforded in order of elution, unreacted alkene 
(79 mg, 53%), 3,4-diethoxycarbonylftirazan N-oxide (4 mg, 6%) and a pair of 
diastereomeric isoxazoline cycloadducts (227) and (228) in a ratio 72 : 28 (erythro: 
threo) as determined by the ratio of the integral of the H 5 protons in the 1 H-NMR 
(360 MHz, CDC13). [71 : 29 ratio measured by reverse phase HPLC (45% 
H20/MeOH)]. The major isomer was identified as 5S-3-ethoxycarbonyl-5-
(6R,7R, 1 4S- 1,8,13,1 6-tetraoxadispiro [5.0.5 .4]hexadecan- 1 4-yl)-4,5-dihydro-2- 
isoxazoline (227), (87 mg, 42%), white needles (from hexane/diethyl ether), m.p. 
110-111°C; [aID24  +14.9° (c = 0.33, CHC1 3); [Found : C, 58.7; H, 7.2; N, 3.3. 
C 18H27N07 requires C, 58.5; H, 7.3; N, 3.8]; 8H  (360 MHz, CDC1 3) see Table 100; ö 
(90 MHz, CDC13) 160.5 (C=O), 151.4 (C3), 96.3, 95.2 (C 8, C9), 82.4 (C5), 66.7 (CO, 
62.0, 60.9, 60.7, 59.7 (C 11 , C 13 , C 18, CH3CH20), 38.4 (C4), 28.2, 28.1, 24.7, 17.8, 
17.7 (C 14, C 15 , C 16, C 19, C20, C21 ), 13.9 (C113 CH20); mlz (FAB) 370.18657 (M+H), 
C 181128N07 requires 370.18656. The minor isomer was identified as 5R-3-
ethoxycarbonyl-5 -( 6R,7R, 1 4S- 1,8,13,1 6-tetraoxadispiro [5.0.5 .4]hexadecan- 1 4-yl)-
4,5-dihydro-2-isoxazoline (228), (41 mg, 17%), pale yellow oil; [aID24  -206.5° (c = 
0.68, CHC1 3); 
5H 
 (360 MHz, CDC13) see Table 100; E, (90 MHz, CDC1 3) 151.1 (C3), 
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96.5, 95.2 (C 8, C9), 82.1 (C5), 67.1 (CO,  61.9, 60.9, 60.6, 58.4 (C 11 , C 13 , C 18 , 
CH3CH20), 34.5 (C4), 28.5, 28.2, 24.9, 24.7, 17.9, 17.8 (C 149 C 159 C 169 C 199 C20, C20, 






Erythro isomer (227) 
0 
0 













4a 3.18 3.18 4a,4b 17.8 - 
4b 3.25 3.18 4a,5 10.9 10.2 
5 4.64 4.76 4b,5 8.1 10.2 
6 nd 4.01 5,6 7.0 4.8 
7e nd 3.45 6,7a nd 7.5 
CH3 CH2 4.29 4.32 6,7e nd 2.8 
CH3CH2 1.31 1.33 7a,7e nd 10.9 
CH3CH2 7.1 7.1 
Table 100 
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3.4.8.2 Benzonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (92 mg, 0.59 mmol) to alkene 
(226) (225 mg, 0.89 mmol) was carried out utilising the general procedure outlined 
above. The syrup was purified by dry flash chromatography (silica ; hexane/ether 
gradient elution 10 : 0 -* 0 : 10), and afforded in order of elution, unreacted alkene 
(81 mg, 54%), 3,4-diphenylfurazan N-oxide (6 mg, 8%) and a pair of diastereomeric 
isoxazoline cycloadducts (229) and (230) in a ratio 75 : 25 (erythro : threo) as 
determined by the ratio of the integral of the H 5 protons in the 'H-NMR (360 MHz, 
CDC13). The major isomer was identified as 5 S-3 -phenyl-5-(6R,7R, 1 4S- 1,8,13,16-
tetraoxadispiro[5 .0.5 .4]hexadecan- 1 4-yT)-4,5-dihydro-2-isoxazoline (229), (66 mg, 
30%), white needles (from hexane/ether), m.p. 189.2-190.3°C [a]D24  -3.5° (c = 0.56, 
CHCI3); [Found : C, 67.8; H, 7.4; N, 3.7. C 21 H28N05 requires C, 67.6; H, 7.2; N, 
3.8]; 8H  (360 MHz, CDC1 3) see Table 101; & (90 Hz, CDC1 3) 156.2 (C3), 96.3, 95.1 
(C8, C9), 80.2 (CO,  67.0  (CO,  60.9, 60.7, 60.3 (C 11 , C 13, C 18), 37.2 (C4), 28.24, 28.17, 
24.7, 17.88, 17.86 (C 14, C 15 , C 169 C 19, C20, C2 0; m/z (FAB) 374.19674 (M+H), 
C21 H28N05 requires 374.19673. The minor isomer was identified as 5R-3-phenyl-5-
(6R,7R, 1 4S- 1,8,13,1 6-tetraoxadispiro[5 .0.5 .4]hexadecan- 1 4-yl)-4,5-dihydro-2- 
isoxazoline (230), (33 mg, 10%), pale yellow oil, [a]D24  -175.7° (c = 0.33, CHC1 3); 
6H (360 MHz, CDC13) see Table 101; 8c (90 MHz, CDC13) 156.1 (C 3), 96.5, 95.3 
(C8, C9), 79.9 (C 5), 69.2 (CO,  60.9, 60.6, 58.6 (C 119 C 13 , C 18), 35.9 (C4), 28.6, 28.3, 
24.82, 24.77 9 18.0, 17.8 (C 14, C 15, C 16 , C 19, C20, C2 0; m/z (FAB) 374.19674 (M+H), 
C21 H28N05 requires 374.19673. 
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4a 	- H4bj\$j 
Ph -4 ,o 
N  


















4a 3.40 3.31 4a,4b - - 
4b 3.40 3.31 4a,5 8.8 9.8 
5 4.63 4.73 4b,5 8.8 9.8 
6 3.95 4.12 5,6 7.7 5.3 
7e 3.60 3.52 6,7a 9.3 8.2 
Ph 7.68-7.37 7.67-7.36 6,7e 4.0 2.9 
7a,7e 10.9 11.0 
Table 101 
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3.4.9 Cycloadditions of Nitrile Oxides to Trans-3,4-didehydro-3,4-dideoxy-
1,2 :5,6-di-O-cyclohe.xylidene-D-threo-hexitol (232) 
3.4.9.1 Ethoxycarbonylformonitrile Oxide 
Addition of ethyl chloro-oximinoacetate (184) (328 mg, 2.17 mmol) to 
alkene (232) (1.00 g, 3.25 mmol) was carried out utilising the general procedure 
outlined above. The syrup was purified by dry flash chromatography (silica; 
hexane/ether gradient elution 10 : 0 -* 0 : 10), and afforded in order of elution, 
unreacted alkene (500 mg, 75%) and 3,4-diethoxycarbonylflirazan N-oxide (20 mg, 
8%). There was no evidence by TLC or 'H-NMR of any cycloaddition reaction 
occurring. 
3.4.9.2 Beiizonitrile Oxide 
Addition of benzohydroximoyl chloride (185) (95 mg, 0.61 mmol) to alkene 
(232) (284 mg, 0.92 nimol) was carried out utilising the general procedure outlined 
above. The syrup was purified by dry flash chromatography (silica; hexane/ether 
gradient elution 10 : 0 -> 0 : 10), and afforded in order of elution, unreacted alkene 
(135 mg, 71%) and 3,4-diphenylfurazan N-oxide (7 mg, 10%). There was no 
evidence by TLC or 'H-NMR of any cycloaddition reaction occurring. 
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3.5 	Synthesis of Acetate Derivatives 
3.5.1 	1,2-Dideoxy-4-0-acetyl-3,5-0-ethylidene-D-erythro-pent-1-enito1 (271) 
Dry acetic anhydride (1.31 ml, 13.89 mmol, 5 M eq) was added to a stirred 
solution of 1,2-dideoxy-3,5-0-ethylidene-D-erythro-pent-1-enitol (260) (400 mg, 2.77 
mmol) in dry pyridine (24 ml). After stirring at room temperature for 16 hr, the 
mixture was concentrated in vacuo, and purified by preparatory TLC on silica using 
100% ether as solvent, to afford 1 ,2-dideoxy-4-O-acetyl-3 ,5-O-ethylidene-D-erythro-
pent-i -enitol (271) as a very pale yellow oil (319 mg, 62%); 6H  (360 MHz, CDC1 3) 
see Table 102; ö (90 MHz, CDC1 3) 169.5 (CH3CO), 134.0 (C 2), 118.7 (CO'  98.8 
(CCH3), 79.7 (C 3), 67.5 (C 5), 65.9 (C4), 20.6 (CH3CO), 20.3 (CCH3); m/z (FAB) 187 
(M+H). 
3.5.2 	5S-5-(2-O-Acetyl-1 ,3-O-ethylidene-D-erythro-triitol-1-yt)-3-ethoxy- 
carbonyl-2-isoxazoline (274) 
Using the same procedure as for (271), isoxazoline (263) (50 mg, 0.19 
mmol) afforded 5 S-5-(2-O-acetyl- 1,3-O-ethylidene-D-erythro-triitol- 1 -yl)-3-ethoxy-
carbonyl-2-isoxazoline (274) as white needles (57 mg, 99%), m.p. 72-74°C; 6H  (360 
MHz, CDC13) see Table 94; & (90 MHz, CDC1 3) see Section 3.4.5.1; m/z (FAB) 
302.12395 (M+H), C 13H20N07 requires 302.12396. This product (274) is identical 
to that obtained from the cycloaddition of ethoxycarbonylformonitrile oxide to 1,2-
dideoxy-4-0-acetyl-3 ,5-O-ethylidene-D-erythro-pent- 1 -enitol (271). (By comparison 
of m.p., TLC and FAB MS data). 
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H5a 
5e - CH3 	
HOCOCH3 
HI , 	\ H4 
Hib 
(271) 
Resonance H/ppm Coupling JIHz 
la 5.42 la,lb 1.0 
lb 5.22 1a,2 17.2 
2 5.79 lb,2 10.5 
3 3.94 2,3 6.7 
4 4.67 3,4 9.6 
5a 3.41 4,5a 10.2 
5e 4.16 4,5e 5.3 
CH3CH 4.71 5a,5e 10.6 
CH3 CH 1.33 CH3 CH 5.1 
CH3 CO 1.98 
Table 102 
3.5.3 	5R-5-(2-O-Acetyl-1 ,3-O-elhylidene-D-erythro-triitol-1-yI)-3-ethoxy- 
carbonyl-2-isoxazoline (275) 
Using the same procedure as for (271), isoxazoline (264) (50 mg, 0.19 
mmol) afforded 5R-5-(2-O-acetyl- 1,3 -O -ethylidene-D-erythro-triitol- l-yl)-3  -ethoxy-
carbonyl-2-isoxazoline (275) as white needles (57 mg, 98%), m.p. 68.5-70.5°C; 6H 
(360 MHz, CDC13) see Table 94; & (90 MI1-Iz, CDC1 3) see Section 3.4.5.1; mlz 
(FAB) 302.12395 (M+H), C 13H20N07 requires 302.12396. This product (275) is 
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identical to that obtained from the cycloaddition of ethoxycarbonylformomtrile oxide 
to 1 ,2-dideoxy-4-O-acetyl-3 ,5-O-ethylidene-D-erythro-pent- 1 -enitol (264). (By 
comparison of m.p., TLC and FAB MS data). 
3.5.4 	5S5-(2-O-Acety1-1,3-O-etJiy1idene-D-erythro-triitO1-l-.Y1)-3-pheflYl-2- 
isoxazoline (272) and 5R-5-(2-O-acety/-1 ,3-O-ethylidene-D-erythro-
triitol-l-yl)-3-phenyl-2-isoxazoline (273) 
Using the same procedure as for (271), mixed isomers (265) and (266) (400 
mg, 1.52 mmol) were acetylated and then separated by dry flash chromatography 
(silica; hexane/ether gradient elution 10 : 0 - 0 10). 55-5-(2-0-Acetyl-1,3-0-
ethylidene-D-erythro-triitol- 1-yT)-3 -phenyl-2-isoxazoline (272) was isolated as white 
needles (218 mg, 47%); mlz (FAB) 306.13414 (M+H), C 16H20N05 requires 
306.13415 and 5R-5-(2-O-aceiyl- 1,3-O-ethylidene-D-erythro-triitol- 1 -yT)-3-phenyl-2-
isoxazoline (273) (209 mg, 45%); mlz (FAB) 306.13415 (M+H), C 16H20N05 
requires 306.134 14. These products (272) and (273) are identical to those obtained 
by cycloaddition of benzonitrile oxide to 1 ,2-dideoxy-4-O-acetyl-3 ,5-O-ethylidene-D-
erythro-pent-1-enitol (271). (By comparison of TLC and FAB MS data). Table 95 
shows the data obtained (Section 3.4.5.2). 
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3.6 	Reduction of Ethyl Ester to Alcohol 
General Procedure 
The isoxazoline (1 M eq) was stirred in ethanol and THF added dropwise 
until it had completely dissolved. Sodium borohydride (6 M eq) was added in 
portions and the resulting mixture stirred at room temperature overnight. After 
pouring into water and extracting with chloroform, the organic phase was dried 
(MgSO4) and the solvent removed in vacuo to afford the products, which were 
purified by recrystallisation. 
3.6.1 	5S-5-(1 ,2-O-Cyclohexylidene-D-glycero-diitol-l-yt)-3-hydroxymethyl-2- 
isoxazoline (204) 
Obtained from (198) (423 mg, 1.49 mmol) using the general procedure 
above, (204) was isolated as white needles (338 mg, 94%), m.p. 80-82°C (from 1: 1 
ether : hexane); [U]D24  +59.5° (c = 0.10, CHC13); [Found C, 59.5; H, 8.2; N, 5.6. 
C 12H 19N04 requires C, 59.8; H, 7.9; N, 5.8]; 6H  (360 MHz, CDC13) see Table 103; 
(90 MHz, CDC13) 158.5 (C3), 110.2 (cyclohexyl. quat.), 81.0 (CO,  75.5 (CO, 66.7 
(C7), 58.0 (CH20H), 37.6 (C 4), 36.4, 34.4, 24.9, 23.9, 23.6 (cyclohexyl. CH2); mlz 
(FAB) 242.139221 (M+H), C 12H20N04 requires 242.13922. 
3.6.2 5R-5-(1 ,2-O-Cyclohexylidene-D-glycero-diitol-1-yl)-3-hydroxymethyl-2-
isoxazoline (205) 
Obtained from (199) (300 mg, 1.06 mmol) using the general procedure 
above, (205) was isolated as white needles (244 mg, 96%), m.p. 83.5-85.5°C (from 1 
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I ether : hexane); MD 
24 -68.3° (c = 0.50, CHC13); 8H  (360 MHz, CDC13) see Table 
103; 6 (90 MHz, CDC1 3) 158.2 (CO,  110.5 (cyclohexyl. quat.), 80.0 (C 5), 75.5 (CO, 
64.8 (C7), 58.0 (CJ-120H), 36.6 (C4), 35.7, 34.6, 25.0, 24.9, 23.8, 23.7 (cyclohexyl. 



















(204) (205) (204) (205) 
4a 3.06 3.10 4a,4b 17.5 17.5 
4b 3.14 2.97 4a,5 6.9 11.0 
5 4.53 4.67 4b,5 10.1 7.9 
6 4.02 4.23 5,6 7.1 4.4 
7a 4.08 4.04 6,7a 6.2 6.8 
7b 3.85 3.82 6,7b 4.5 6.3 
CH20H 4.40 4.40 7a,7b 8.4 8.6 
CH20H 2.40 nd 
cyclohexyl. CH2 1.62-1.50 1.64-1.50 
Table 103 
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3.6.3 	5S-5-(1 ,3-O-Ethylidene-D-erythro-triitol-1-yl)-3-hydroxymelhyl-2- 
isoxazoline (269) 
Obtained from (263) (300 mg, 1.16 mmol) using the general procedure 
above including continuous extraction (CHC1 3), (269) was isolated as a very pale 
yellow oil (193 mg, 77%), 1aID26  +115.9° (c = 1.01, MeOH); 6H  [360 MHz, 
(CD3)2CO] see Table 104; E [90 MHz, (CD3 )2C0] 158.9 (C3), 98.4 (CCH3), 81.1 
(C5), 80.0 (CO,  70.6 (C 8), 62.8 (C7), 57.1 (CH20H), 35.1 (C4), 20.1 (CCH3); mlz 
(FAB) 218.10285 (M+H), C9H 16N05 requires 218.10285. 
3.6.4 5R-5-(1,3-O-Ethylidene-D-erythro-triitol-1-yl)-3-hydroxymethyl-2-
isoxazoline (270) 
Obtained from (264) (200 mg, 0.77 mmol) using the general procedure 
above including continuous extraction (CHC1 3), (270) was isolated as white needles 
(141 mg, 84%), m.p. 147-148.5'C; [a] 24 -225.8° (c = 0.96, MeOH); [Found : C, 
50.3; H, 7.3; N, 6.1. C9H 15N05 requires C, 49.8; H, 6.9; N, 6.5]; oH [360 MHz, 
(CD3)2CO] see Table 104; & [90 MHz, (CD3 )2CO] 158.8 (C 3 ), 98.0 (CCH3), 81.7 
(C 5), 77.7 (CO,  70.8  (CO,  61.5 (C 7), 57.1 (CH20H), 35.6 (C4), 20.1 (CCH3); m/z 
(FAB) 218.10284 (M+H), C9H 16N05 requires 218.10285. 
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H8a 	 H8a 
OH 	 OH 
CH3 	 CH3 	0 	H8e 
H4b 	 HO 
H4a J 
O 	CH20H 	 O 	-CH20H 
N N 





(269) (270) (269) (270) 
4a 3.19 3.10 4a,4b 16.9 - 
4b 3.07 3.13 4a,5 8.3 10.7 
5 4.85 4.85 4b,5 11.2 9.3 
6 3.58 3.36 5,6 2.6 2.8 
7 3.48 3.76 6,7 9.4 9.4 
8a 3.35 3.33 7,8a 10.0 10.4 
8e 4.00 4.02 7,8e 5.1 5.3 
CH3CH 4.69 4.66 8a,8e 10.5 10.6 
CH3CH 1.20 1.20 CH3 CH 5.0 5.0 
CH20H 4.28 4.28 7,70H - 5.8 
CH20H 2.14 3.01 





Obtained from (323) (1.52 g, 4.83 mmol) using the general procedure above, 
(327) was isolated as a colourless oil (1.30 g, 99%); [aID24  -5.6° (c = 1.12, CHC13); 
H (360 MHz, CDC13) see Table 105; E (90 MHz, CDC1 3) 159.0 (C3), 112.6 
[C(Me)2], 107.1 (C9), 84.7 (CO,  79.3 (C7), 79.1 (CO,  78.0  (CO,  57.9 (CH20H), 54.6 




Obtained from (324) (350 mg, 1.11 mmol) using the general procedure 
above, (328) was isolated as white needles (298 mg, 98%), m.p. 95-97°C; [aI D24 
+77.9° (c = 0.83, CHC13); 5H  (360 MHz, CDC1 3) see Table 105; & (90 MHz, CDC1 3 ) 
158.6 (C3), 112.8 [C(Me)2], 107.4 (C9), 84.6 (CO,  79.9 (C 7), 79.5 (C 5 , C8), 57.8 
(CH20H), 54.7 (OMe), 37.6 (C4), 25.8, 24.6 (2 x Me); mlz (FAB) 274.12906 
(M+H), C 12H20N06 requires 274.12905. 
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HOCH 	H4b 2 


















(327) (328) (327) (328) 
4a 3.13 3.24 4a,4b - 17.5 
4b 3.12 2.85 4a,5 8.5 10.6 
5 4.90 4.80 4b,5 10.0 8.8 
6 4.01 3.98 5,6 6.0 8.5 
7 4.74 4.68 6,7 3.7 3.8 
8 4.54 4.54 7,8 5.9 5.9 
9 4.88 4.94 8,9 - - 
OMe 3.29 3.32 
CH20H 4.38 4.38 
CFI20H 2.69 nd 




methyl-2-isoxazoline (305) and 5S-5-(1,2:3,4-di-O-isopropylidene-D-
arabino-letritol-1-yl)-3-hydroxymethyl-2-isoxazoline (306) 
Obtained from mixed isomers (301) and (302) (137 mg, 0.40 mmol) using 
the general procedure above, (305) and (306) were isolated as a white solid (106 mg, 
88%). The isomers were unable to be separated. [Found : C, 55.4; H, 7.9; N, 4.5. 
C 14H23N06 requires C, 55.8; H, 7.6; N, 4.7]; m/z (FAB) 302.16036 (M+H), 
C 14H24N06 requires 302.16035. The major isomer was identified as 5R-5-(1,2:3,4-di-
O-isopropylidene-D-arabino-tetritol- 1 -yl)-3-hydroxymethyl-2-isoxazoline (305), 8H 
(360 MHz, CDC1 3) see Table 106; E, (90 MHz, CDC1 3) 158.3 (CO,  110.2, 109.2 
[C(Me)2], 80.2 (C5), 80.3, 78.7, 76.6 (C 6, C7, C8), 67.2 (C9), 58.0 (CH20H), 35.1 
(C4), 27.2, 26,6, 25.0 (4 x CH3). The minor isomer was identified as 5S-5-(1,2:3,4-di-
0-isopropylidene-D-arabino-tetritol- l-yT)-3 -hydroxymethyl-2-isoxazoline (306), 6H 
(360 MHz, CDC1 3) see Table 106; ö (90 MHz, CDC1 3) 158.1 (C3), 109.9, 109.7 
[C(Me)2], 82.0 (CO, 79.0, 77.3, 77.0 (C 6, C7 , C8), 67.8 (C9), 58.0 (CH20H), 37.2 







O H6 H HO H8 
H4a 
H" 

















(305) (306) (305) (306) 
4a 3.02 3.11 4a,4b 17.0 - 
4b 3.12 3.11 4a,5 11.1 8.8 
5 4.87 4.46 4b,5 7.8 10.0 
6 4.16 4.12 5,6 3.5 2.5 
7 nd nd 6,7 7.3 8.5 
8 nd nd 7,8 nd nd 
9a nd nd 8,9a nd nd 
9b nd nd 8,9b nd nd 
CH20H 4.39 4.39 9a,9b nd nd 
CH20H 2.30 2.30 
isopropyl. 1.42-1.32 1.42-1.32 
Table 106 
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3.7 	Deprotection of Isoxazolines 
General Procedure 
The isoxazoline in a mixture of water/glacial acetic acid (1 : 4) was stirred at 
80°C for 2-10 hr. The solution was concentrated in vacuo, and after repeated addition 
(4 x 10 ml) and removal of a 1 : 1 mixture of toluene and heptane, the residue was 
triturated with isopropanol to afford the product, which was purified by preparative 
TLC on silica gel (100 % ethyl acetate or 50150 ethyl acetate/diethyl ether). 
3.7.1 	5S-5-(1,2-O-Cyclohexylidene-D-glycero-diitol-1-yl)-3-ethoxycarbonyl-2- 
isoxazoline (198) 
Using the general procedure above, isoxazoline (198) (80 mg, 0.28 mmol) 
afforded 5 S-5-(D-glycero-diitol- 1 -yl)-3-ethoxycarbonyl-2-isoxazoline (250) as a 
yellow oil (44 mg, 77%); [aID26  +109.9° (c = 0.78, CH30H); 6H  [360 MHz, 
(CD3)2C0] see Table 107; & [90 MHz, (CD 3)2C0] 160.7 (C=O), 151.9 (C3), 84.2 
(CO, 71.8  (CO,  63.1 (C7), 61.4 (CH3 CH20), 33.8 (C4), 13.7 (CH3CH20); mlz (FAB) 
204.08720 (M+H), C 8H 14N05 requires 204.087 19. 
3.7.2 	5R-5-(1 ,2-O-Cyclohexylidene-D-glycero-diitol-1 -yl)-3-ethoxycarbonyl-2- 
isoxazoline (199) 
Using the general procedure above, isoxazoline (199) (80 mg, 0.28 mmol) 
afforded 5R-5-(D-glycero-diitol- 1 -yl)-3-ethoxycarbonyl-2-isoxazoline (253) as a 
yellow oil (46 mg, 80%); [a]D26  -124.9° (c = 0.56, CH30H); 6H  [360 MHz, 
(CD3)2C0] see Table 107 ; E [90 MHz, (CD 3 )2 CO] 160.8 (C0), 151.9 (C3), 83.8 
(CO, 73.1  (CO,  63.0 (C 7), 61.4 (CH3 CH20), 35.3 (C4), 13.7 (CH3CH20); mlz (FAB) 












(250)a  (250) ° (253) (250y' (250)D (253) 
4a 3.29 3.30 3.28 4a,4b 17.6 17.6 17.4 
4b 3.17 3.18 3.20 4a,5 8.5 8.2 11.3 
5 4.86 4.88 4.91 4b,5 11.4 11.3 9.0 
6 nd nd nd 5,6 4.5 nd 3.1 
7a nd nd nd 6,7a nd nd nd 
7b nd nd nd 6,7b nd nd nd 
CH3 CH2 4.28 4.28 4.38 7a,7b nd nd nd 
CH3CH2 1.30 1.30 1.30 CH3 CH2 7.1 7.1 7.1 
Table 107 
Product from cyclohexylidene-protected isomer (198) 




Using the general procedure above, isoxazoline (204) (300 mg, 1.24 mmol) 
afforded 5 S-5-(D-glycero-diitol- 1 -yl)-3-hydroxymethyl-2-isoxazoline (251) as a pale 
yellow oil (142 mg, 71%); [U]D24 97•30 (c = 0.72, CH30H); 8H  [360 MHz, 
(CD3)2C0] see Table 108; E, [90 MHz, (CD 3)2C0] 159.2 (C3), 80.8 (CO,  72.3  (CO, 
63.5 (C7), 57.1 (CH20H), 36.0 (C4); mlz (FAB) 162.07664 (M+H), C6H 12N04 
requires 162.07663. 
3.7.4 5R-5-(1 ,2-O-Cyclohexylidene-D-glycero-diitol-1 -yl)-3-hydroxymet/zyl-2-
isoxazoline (205) 
Using the general procedure above, isoxazoline (205) (150 mg, 0.62 mmol) 
afforded 5R-5-(D-glycero-diitol- 1 -yl)-3-hydroxymethyl-2-isoxazoline (249) as a 
colourless oil (75 mg, 75%); 8H  [360 MHz, (CD3)2C0] see Table 108; &- [90 MHz, 
(CD3)2C0] 159.2 (C3), 80.8 (CO,  73.2  (CO,  63.3  (CO,  57.1 (CH20H), 36.7 (C4); mlz 
(FAB) 162.07664 (M+H), C 6H 12N04 requires 162.07663. 
3.7.5 	5S-5-(1 ,2-O-Cyc1ohexy1idene-D-g1ycero-diito1-1-y1-3-pheny1-2- 
isoxazoline (196) 
Using the general procedure above, isoxazoline (196) (500 mg, 1.74 mmol) 
afforded 5 S-5-(D-glycero-diitol- l-yl)-3 -phenyl-2-isoxazoline (249) as white needles 
(253 mg, 70%), m.p. 104-106°C (from acetone : hexane 1: 4); [aID24 +83 . 1 0  (c = 
0. 10, CH30H); [Found: C, 63.5; H, 6.5; N, 6.6. C 11 H 13NO3 requires C, 63.8; H, 6.3; 
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N, 6.8]; 8H  [360 MHz, (CD3)2C0] see Table 109; & [90 MHz, (CD 3)2C0] 156.6 
(C3), 129.9, 128.9, 126.7 (5 x PhCH), 81.8 (C 5), 72.3 (C6), 63.5 (C7), 35.5 (C4); mlz 

















(251) (254) (251) (254) 
4a 3.14 3.17 4a,4b 17.3 17.2 
4b 3.04 3.05 4a,5 8.0 10.5 
5 4.53 4.61 4b,5 10.7 8.8 
6 3.64 nd 5,6 5.6 3.9 
7a 3.61 nd 6,7a 5.8 nd 
7b 3.52 nd 6,7b 4.2 nd 





Using the general procedure above, isoxazoline (197) (300 mg, 1.05 mmol) 
afforded 5R-5-(D-glycero-diitol- 1 -yl)-3-phenyl-2-isoxazoline (252) as white needles 
(160 mg, 74%), m.p. 128-130°C; 1aID25  -158.9° (c = 0.30, CH30H); 8 [360 MHz, 
(CD3)2C0] see Table 109; & [90 MHz, (CD 3)2C0] 156.6 (C3), 129.9, 128.8, 126.7 
(5 x PhCH), 81.6 (C 5), 73.3 (C6), 63.3 (C 7), 36.4 (C4); mlz (El) 207.08954 (M), 












(249) (252) (249) (252) 
4a 3.48 3.47 4a,4b 16.9 16.8 
4b 3.37 3.40 4a,5 8.1 10.7 
5 4.75 4.82 4b,5 10.8 8.9 
6 3.90 3.94-3.67 5,6 5.4 3.5 
7a 3.61 3.94-3.67 6,7a 6.0 nd 
7b 3.68 3.94-3.67 6,7b 4.5 nd 
Ph 7.72-7.43 7.72-7.41 7a,7b 11.1 nd 
60H, 70H 3.20-3.00 nd 
Table 109 
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3.7.7 	1,2-Dideoxy-3,5-0-ethylidene-D-erythro-pent-1-enitol (260) 
Using the general procedure above, alkene (260) (300 mg, 2.08 mmol) 
afforded 1,2-dideoxy-D-erythro-pent-l-enitol (276) as a colourless oil (101 mg, 41%), 
1aID24  -30.6° (c = 0.51, CH30H); 5H  [360 MHz, (CD3)2C0] see Table 110; & [90 
MHz, (CD3)2C0] 138.9 (C2), 114.6 (C 1 ), 74.8 (C3)*,  73.8  (C4)*,  63.5 (C 5); mlz 




HO 	 OH 




Resonance oH/ppm Coupling f/Hz 
la 5.27 la,lb 1.9 
lb 5.10 1a,2 17.2 
2 6.00 lb,2 10.6 
3 3.54 la,3 1.7 
4 4.10 lb,3 1.5 
5a nd 2,3 5.7 
5e 3.65 3,4 4.3 








Using the general procedure above, isoxazoline (263) (200 mg, 0.77 mmol) 
afforded 5 S-5-(D-erythro-triitol- l-y/)-3  -ethoxycarbonyl-2-isoxazoline (277) as a 
white solid (157 mg, 87%), m.p. 123.6-125.2°C; [a] 025 +145.9° (c = 0.70, CH3 0H); 
oH [360 MHz, (CD3)2C0] see Table 111; O [90 MHz, (CD 3)2C01 160.8 (C=O), 
151.9 (C3), 85.1 (CO,  72.4  (CO,  71.4 (C7), 63.8 (CO,  61.3 (CH3 CH20), 32.6 (C4), 
13.7 (CH3CH20); mlz (FAB) 234.09776 (M+H), C 9H 16N06 requires 234.09775. 
3.7.9 	5R-5-(1,3-O-Ethy1idene-D-erythro-triiIo1-1-y1-3-ethoxycarbony1-2- 
isoxazoline (264) 
Using the general procedure above, isoxa.zoline (264) (150 mg, 0.58 mmol) 
afforded 5R-5-(D-erythro-triitol- l-yl)-3 -ethoxycarbonyl-2-isoxazoline (278) as white 
needles (65 mg, 48%), m.p. 100.2-102.5°C; [aID25  -175.7° (c = 0.82, CH30H); 0H 
[360 MHz, (CD 3)2C0] see Table 111; Oc  [90 MHz, (CD3)2C0] 160.8 (C0), 152.0 
(C3), 83.3 (CO'  73.2  (CO,  71.5 (C 7), 64.1 (CO'  61.3 (CH3 CH20), 35.3 (C2), 13.7 
(CFI3 CH20); mlz (FAB) 234.09776 (M+I-I'), C 9H 16N06 requires 234.09775. 
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HO 	\H8e 	 HO 
HO 	 HO - 
5 	HO 













(277) (278) (277) (278) 
4a 3.30 3.29 4a,4b 17.4 17.5 
4b 3.14 3.20 4a,5 9.1 11.5 
5 5.10 5.14 4b,5 11.6 9.0 
6 3.92 3.73 5,6 2.6 2.4 
7 3.52 3.55 6,7 7.9 nd 
8a 3.65 3.67 7,8a 5.6 5.1 
8e 3.76 3.80 7,8e 3.9 3.6 
CH3CH2 4.27 4.27 8a,8e 11.1 10.4 
CH3 CH2 1.30 1.29 CH3CH2 7.1 7.1 





Using the general procedure above, isoxazoline (269) (63 mg, 0.75 mmol) 
afforded 5 S-5-(D-erytbro-triitol- 1-yl)-3  -hydroxymethyl-2-isoxazoline (281) as a pale 
yellow oil (89 mg, 62%); 6H  [360 MHz, (CD 3)2C0] see Table 112; & [90 MHz, 
(CD3)2C0] 158.1 (C3), 80.6 (C 5), 71.6 (CO,  70.8 (C7), 62.9 (CO,  56.1 (CH20H), 33.5 
(C4); m/z (FAB) 192.08760 (M±H), C 7H 14N05 requires 192.08720. 
3.7.11 5R-5-(1 ,3-O-Ethylidene-D-erythro-triitol-1-yl)-3-hydroxymethyl-2-
isoxazoline (270) 
Using the general procedure above, isoxazoline (270) (70 mg, 0.32 mmol) 
afforded 5R-5-(D-erythro-triitol- 1 -yT)-3-hydroxymethyl-2-isoxazoline (282) as a pale 
yellow oil (31 mg, 50%); oH [360 MHz, (CD 3)2C0] see Table 112; mlz (FAB) 
192.08720 (M+H), C 7H 14N05 requires 192.087 19. 
3.7.12 5S-5-(1 ,3-O-Ethylidene-D-erythrodriitol-1-yl)-3-phenyl-2- 
isoxazoline (265) 
Using the general procedure above, isoxazoline (265) (97 mg, 0.37 nimol) 
afforded 5 S-5-(D-erythro-triitol- l-yl)-3 -phenyl-2-isoxazoline (279) as white needles 
(72 mg, 82%), m.p. 115.5-119.5°C; [aID24  +99.6° (c = 0.55, CH30H); [Found C, 
61.1; H, 6.6; N, 5.4. C 121-1 15N04 requires C, 60.8; H, 6.3; N, 5.9]; 8H  [360 MHz, 
(CD3)2C0] see Table 113; 0c  [90 MHz, (CD3)2C0] 156.5 (C3), 129.8, 128.8, 126.7 
(5 x PhCH), 82.6 (C 5), 72.8 (CO,  71.9 (C7), 64.0 (CO,  34.1 (C2); mlz (El) 237.1001 























(281) (282) (281) (282) 
4a 3.16 3.11 4a,4b 17.1 - 
4b 3.00 3.10 4a,5 9.0 10.5 
5 4.79 4.83 4b,5 10.9 9.4 
6 3.81-3.50 3.89-3.44 5,6 3.6 3.0 
7 3.81-3.50 3.89-3.44 6,7 nd nd 
8a 3.81-3.50 3.89-3.44 7,8a nd nd 
8e 3.81-3.50 3.89-3.44 7,8e nd nd 
CH20H 4.29 4.28 8a,8e nd nd 
CH20H 3.91 nd 7,70H 4.7 nd 
7-OH 4.12 nd CH20H2OH 5.0 nd 
Table 112 
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3.7.13 5S-5-(2-O-AceIyl-1 ,3-O-ethylidene-D-erythro-triitol-1-yl)-3-phenyl 
2-isoxazoline (272) 
Using the general procedure above, isoxazoline (272) (150 mg, 0.49 mmol) 
afforded two products after preparative TLC. 5S-5-(D-erythro-triitol-1-yl)-3-phenyl-
2-isoxazoline (279) was isolated as white needles (14 mg, 12%), m.p. 115-119°C; oH 
[360 MHz, (CD 3)2C0] see Tables 113 and 114; Oc  [62 MHz, (CD 3)2C0] 156.5 (C3), 
129.8, 128.8, 126.7 (5 x PhCH), 82.6 (CO,  72.8  (CO,  71.9 (C7), 64.0 (CO,  34.0 (C4); 
m/z (FAB) 238.10794 (M+H), C 12H 16N04 requires 238.10792. This product (279) is 
identical to that obtained from deprotection of 5S-5-(1,3-O-ethylidene-D-erythro-
triitol- 1 -yl)-3-phenyl-2-isoxazoline (265). (See Section 3.7.12). The desired product 
5 S-5-(2-O-acelyl-D-erytbro-triitol- 1 -yT)-3-phenyl-2-isoxazoline (284) was also 
afforded as a white solid (32 mg, 24%); 0H  [360 MHz, (CD 3)2C0] see Tables 113 
and 114; mlz (FAB) 280.11850 (M+H). C 14H 18N05 requires 280.11849. 
3.7.14 5R-5-(2-O-Acetyl-1,3-O-ethylidene-D-erythro-triitol-1-yl)-3-phenyl-
2-isoxazoline (273) 
Using the general procedure above, isoxazoline (273) (100 mg, 0.33 mmol) 
afforded two products after preparative TLC. 5R-5-(D-erythro-triitol- l-yl)-3  -phenyl-
2-isoxazoline (280) was isolated as a pale yellow oil (8 mg, 10 %); 0H  [250 MHz, 
(CD3 )2C0] see Tables 113 and 114; & [62 MHz, (CD 3)2C0] 155.6 (C3), 130.3, 
129.5, 127.9, 127.7, 125.6 (5 x PhCH), 79.5 (CO,  72.5  (CO,  70.8 (C7), 63.2 (CO, 
35.5 (C4); m/z (FAB) 238.10814 (M+H), C 12 1-1 16N04 requires 238.10794. The 
desired product 5R-5-(2-0-acelyl-D-erythro-rriitol- l-yl)-3  -phenyl-2-isoxazoline (285) 
300 
was also afforded as a pale yellow oil (23 mg, 25%); 6H  [360 MHz, (CD3)2C0] see 
Tables 113 and 114; & [90 MHz, (CD 3)2C0] 156.7 (C3), 129.9, 128.9, 126.7 (5 x 
PhCH), 80.6 (CO,  73.0  (CO,  70.0  (CO,  66.7 (C8), 36.6 (C4), 20.2 (CH3CO); mlz 
(FAB) 280.11850 (M+H), C 14H18N05 requires 280.11849. 
k8a 
HO 	118e HO 	\ H e 
4b 	 HO 
OR HO 	 HO 	 OR 
H  
]F
O 	Ph 	 O. 	-Ph 
N N 
(279) R = H 	 (280) R= H 
(284) R= Ac (285) R = Ac 
R H COCH3 
Resonance 
511/ppm 11/ppm 
(279) (280) (284) (285) 
4a 3.51 3.47 3.51 3.51 
4b 3.34 3.44 3.36 3.43 
5 5.01 5.06 5.03 5.08 
6 3.98 3.58 3.91 3.58 
7 3.93 3.95 3.37 3.98 
8a 3.69 3.78-3.75 4.18 4.18 
8e 3.81 3.78-3.75 3.36 4.41 
Ph 7.74-7.37 7.74-7.42 7.73-7.41 7.72-7.41 
70H 4.27 - - 





HO -ç---.~s._-- OR 
H4b 
\H4a 




HO 	 OR > 
0 P 
(280) R = H 
(285) R =Ac 
R H COCH3 
Coupling 
f/Hz f/Hz 
(279) (280) (284) (285) 
4a,4b 16.7 16.3 16.7 16.8 
4a,5 8.9 10.7 8.7 11.1 
4b,5 11.1 9.1 11.0 8.9 
5,6 3.3 2.6 3.4 2.5 
6,7 7.0 7.7 4.7 8.9 
7,8a 5.8 5.4 6.5 6.3 
7,8e 3.7 3.7 3.0 2.6 




Using the general procedure above, isoxazoline (267)(268) (150 mg, 0.63 
mmol) afforded after preparative TLC (5 : 0.5 ethyl acetate/ethanol) 5S/R-5-(D-
erythro-triitol- l-yT)-3 -(dideoxyphosphorymethyT)-2-isoxazolines (283) as a colourless 
oil (50 mg, 36%), a mixture of both isomers, which crystallised from acetone to give 
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fine needles; 5H  [360 MHz, (CD3)2C0] 4.86 (1H, m, H5), 4.13 (2H, t, Jcmcm = 7.0 
Hz, CH3CH2), 3.79 (IF!, b, H8e), 3.67 (1H, b, H8a), 3.18-3.05 (2H, 2 X dd, H4 a  and 
H40, 2.99 [2H, d, Jip = 21.6 Hz, CH2P(0)], 1.30 (3H, t, JIJJJ = 7.0 Hz, 
CH3CH2); mlz (FAB) 312.12123 (M+H), C 11 H23N07P requires 312.12120. 
3.7.16 5R-5-(1,2:3,4-Di-O-Lcopropylidene-D-arabino-tetritol-1-yf)-3-hydroxy- 
methyl-2-isoxazoline (305) and 5S-5-(1 ,2 :3,4-di-O-isopropylidene-D-
arabino-tetritol-1-yl)-3-hydroxymethyl-2-isoxazoline (306) 
Using the general procedure above, isoxazolines (305) and (306) (50 mg, 
0.17 mmol) afforded a mixture of 5R-5-(D-arabino-tetritol-1-yT)-3-hydroxymethyl-2-
isoxazoline (307) and 5 S-5-(D-arabino-tetritol- l-yl)-3  -hydroxymethyl-2-isoxazoline 
(308) as a white solid recrystallised from isopropanol (36 mg, 98%); oH (360 MHz, 
D20) see Tables 115 and 116; & (90 MHz, D 20) 161.2 (C3 , erythro), 160.9 (C3 , 
threo), 81.8 (C5 , threo), 80.3 (C 5 , erythro), 70.9 (C6, threo), 70.7 (C6 , erythro), 69.9 
(C 7 , erythro, C7 , threo), 69.3 (C 8 , erythro, C8 , threo), 62.9 (C9 , erythro), 62.7 (C9 , 
threo), 56.50 (CI-120H, erythro), 56.47 (CH20H, threo), 36.9 (C4 , threo), 36.6 (C4 , 
erythro); m/z (El) 222.09774 (M+H), C 8H 16N06 requires 222.09775. 
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HOCH2 	n4b 	 HOCH2 
OH 	 N 	 OH 







(307)a (308)a (307)0 (308)c 
4a 3.21 3.24 3.25 3.28 
4b 3.21 2.96 3.25 3.00 
5 4.82 4.82 4.80 4.86 
6 3.91 3.86 3.95 3.90 
7 3.64 3.59 3.69 3.63 
8 3.73 3.76 3.78 3.80 
9a 3.65 3.65 3.69 3.69 
9b 3.84 3.83 3.88 3.87 
CH20H 4.39 4.48 4.43 4.42 
Table 115 
a Product from deprotection of (305)/(306) 
b Product from deprotection of (327) 
Product from deprotection of (328) 
304 
H 	 H HOCH2 	
,iliH4a 	
HOCH2 







(307)a (308)a (307)° (308)D 
4a,4b - 17.6 - 17.6 
4a,5 7.0 10.7 8.4 10.6 
4b,5 9.9 8.3 10.6 8.3 
5,6 6.8 6.9 6.7 7.1 
6,7 1.5 2.2 1.4 2.0 
7,8 8.8 8.4 8.7 8.3 
8,9a 6.2 6.2 6.2 6.0 
8,9b 2.8 2.8 2.7 2.8 
9a,9b 11.8 11.5 11.7 11.6 
Table 116 
U  Product from deprotection of (305)/(306) 
b Product from deprotection of (327) 
Product from deprotection of (328) 
305 
3.7.17 5R-5-(1,2:3,4-Di-O-isopropylidene-D-arabino-tetritol-1-yI)-3-hydroxy- 
methyl-2-isoxazoline (305) and 5S-5-(1,2 :3,4-di-O-isopropylidene-D-
arabino-tetritol-1 -yl)-3-hydroxymethyl-2-isoxazoline (306) 
Isoxazolines (305) and (306) (50 mg, 0.17 mmol) in a mixture of 
water/glacial acetic acid (2 : 3) were stirred at 40°C for 16 hr. Solvent was removed 
in vacuo, and after repeated addititon (4 x 10 ml) and removal of a 1 : 1 mixture of 
toluene and heptane, the residue was triturated with cold petroleum ether/ether (1: 1) 
to afford a mixture of 5R-5-(3,4-0-isopropylidene-D-arabino-tetritol-1-yl)-3-
hydroxymethyl-2-isoxazoline (309) and 5 S-5-(3,4-O-isopropylidene-D-arabino-
tetritol-1-yT)-3-hydroxymethyl-2-isoxazoline (310) as a white solid (25 mg, 66%) 
after recrystallisation from hot ethanol, which were unable to be separated, oH (360 
MHz, D20) see Table 117; 5c (90 MHz, D20) 160.8 (C3, erythro), 160.6 (C3, threo), 
110.7 [C(Me)2], 81.7, 80.7, 80.4, 80.3, 79.3, 79.0, 77.5, 76.5, 72.2, 70.8, 70.6, 69.8, 
69.2 (C 5, C6, C7 , CO,  63.0 (C9, threo), 62.9 (C9, erythro), 56.5 (C.H20H, threo), 56.4 
(CH20H, erythro), 36.7 (C4, threo), 35.2 (C4, erythro), 26.3, 26.0, 25.9, 25.8 (CH3); 
mlz (FAB) 262.12871 (M+H), C 11 H20N06 requires 262.12906. 
3.7.18 5S-3-Ethoxycarbonyl-5-(6R,7R,1 4S-1 ,8 ,13,16-tetraoxadispiro 15.0.5.41 - 
hexadecan-14-yl)-4,5-dihydroisoxazole (227) 
Isoxazoline (227) (30 mg, 81.30 mmol) in a mixture of TFA (1 ml) and 
water (0.1 ml) was stirred at room temperature for 1 hr. Solvent was removed in 
vacuo and after repeated addition (4 x 10 ml) and removal of a 1 : 1 mixture of 
toluene and heptane, the residue was purified by preparative TLC on silica gel using 
306 
100 % ether as eluent, to afford 5S-5-(D-glycero-.diitol-1-yl)-3-ethoxycarbonyl-2-
isoxazoline (250) as a yellow oil (15 mg, 9 1%); 8H  [3 60 MHz, (CD 3)2C0] see Table 
107; mlz (FAB) 204.08720 (M+H), C 811 13N0 5 requires 204.08719. This product is 
identical to that formed by deprotection of isoxazoline (198) (Section 3.7.1). 
9a 	 H4b 
H9b_____ !.___.( ii H4a 








(309) (310) (309) (310) 
4a 3.29 3.05 4a,4b 17.1 17.4 
4b 3.22 3.36 4a,5 10.9 8.3 
5 4.97 4.86 4b,5 7.4 11.0 
6 3.95 3.90 5,6 3.6 3.3 
7 3.69 3.63 6,7 6.9 6.7 
8 3.86 3.86 7,8 8.4 8.4 
9a 3.78 3.77 8,9a 2.6 2.6 
9b 3.69 3.63 8,9b 6.0 6.0 





3.8 	Acid Hydrolysis Followed by Reduction 
3.8.1 5R-5-(1-O-Methyl-a-D-lyxo-tetrofuranoside-4-yf)-3-hydroxymethyl-2-
isoxazoline (329) 
A solution of octofuranose derivative 5R-5-(2,3-0-isopropylidene-1-0-
methyl-a-D-lyxo-tez'rofuranoside-4-yI)-3-hydroxymethyl-2-isoxazoline (327) (100 
mg, 0.37 mmol) in TFAlwater (9: 1) (3 ml) was kept at room temperature for 20 mm 
and then evaporated under diminished pressure with occassional additions of water. 
The residue was purified by dry flash chromatography on silica using ethyl acetate as 
eluent, to afford the partially deprotected product 5R-5-(1-O-methyl-a-D-lyxo-
tetrofuranoside-4-yl)-3-hydroxymethyl-2-isoxazoline (329) as a colourless oil (60 mg, 
70%); 6H  (360 MHz, D20) see Tables 118 and 119; 6c  (90 MHz, D20) 159.2 (C 3 ), 
106.2 (CO,  77.6  (CO, 76.1 (CO, 73.6 (C7), 68.4 (CO,  54.3 (CH20H), 53.9 (OMe), 
34.7 (C4); m/z (FAB) 234.09776 (M+H), C9H 16N06 requires 234.09775. 
3.8.2 5R-5-(a-D-iyxo-tetrofuranoside-4-y1-3-hydroxymethy1-2 
isoxazoline (331) 
A solution of octofuranose derivative 5R-5-(2,3-0-isopropylidene-1-0-
methyl-a-D-lyxo-tetrofuranoside-4-yl)-3-hydroxymethyl-2-isoxazoline (327) (50 mg, 
0.18 mmol) in TFAlwater (9: 1) (2 ml) was kept at 40°C for 2 hr. Evaporation under 
vacuum with occassional additions of water afforded 5R-5-(a-D-lyxo-
retrofuranoside-4-yT)-3-hydroxymethyl-2-isoxazoline (331) as a colourless oil (24 mg, 
60%), a mixture of isomers (50 : 50) at the anomeric centre C 9 (360 MHz, D20) 
see Tables 118 and 119; 6c  (90 MHZ, D20) 163.9 (C3), 103.4, 98.0 (CO,  81.9, 81.0, 
308 
79.2, 73.3 (C 5 , C6, C7, C8), 59.0 (CH20H), 39.3 (C4); mlz (FAB) 220.082 13 (M+H), 
C8H14N06 requires 220.082 10. 
3.8.3 5R-5-(D-arabino-Ietrilol-1-yI)-3-/iydroxymethyl-2-isoxazoline (307) 




mg, 0.37 mmol) in TFAlwater (9 : 1) (3 ml) was kept at 50°C for 3 hr and then 
evaporated under diminished pressure with occassional additions of water. To a 
cooled (0°C) and stirred solution of the residue in water (6 ml) was gradually added 
sodium borohydride (0.1 g, 2.60 mmol), and the reaction mixture stirred for 3 hr at 
0°C, and then overnight at room temperature. Sodium ions were removed from the 
reaction mixture with Amberlite IR-200 (H) resin (3.5 g), and the resin filtered off 
and washed thoroughly with water. The filtrate and washings were combined and 
evaporated in vacuo, and methanol was added to, and evaporated from, the residue 
until no boric acid remained. The residue was triturated with methanol and yielded 
5R-5-(D-arabino-tetritol- 1 -yl)-3-hydroxymethyl-2-isoxazoline (307) as a white solid 
(60 mg, 74%), m.p. 139-142°C (from methanol); [a] 025 -76.2° (c = 0.55, CHC13); oH 
(360 MHz, D20) see Tables 115 and 116; & (62 MHz, D 20) 159.1 (C3), 78.3 (CO, 
68.6 (CO,  67.8  (CO,  67.2  (CO,  60.9  (CO,  54.4 (CH20H), 34.6 (C4); mlz (FAB) 
222.09984 (M+H), C 8H 16N06 requires 222.09776. 
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3.8.4 	5S-5-(D-arabino-tetritol-1-yl)-3-hydroxymethyl-2-isoxazoline (308) 
A solution of octofuranose derivative 5S-5-(2,3-0-isopropy1idene-1-0-
methyl-a-D-lyxo-tetrofuranoside-4-yl)-3-hydroxymethyl-2-isoxazoline (328) (100 
mg, 0.37 mmol) in TFAlwater (9: 1) (3 ml) was kept at 50°C for 3 hr. The reaction 
mixture was worked up in the same way as described in the preparation of 5R-5-(D-
arabino-tetritol- l-y/)-3  -hydroxymethyl-2-isoxazoline (307). 5 S-5-(D-arabino-tetritol-
1-yl)-3-hydroxymethyl-2-isoxazoline (308) was afforded as a white solid (65 mg, 
80%); [aID25  +100.1° (c = 1.02, CH 30H); oH (360 MHz, D20) see Tables 115 and 
116; 0c  (90 MHz, D20) 160.9 (C3), 81.7 (C5), 70.9 (CO,  70.6  (CO,  70.5  (CO,  62.7 




Using the same procedure as for 5R-5-(1-O-methyl-a-D-lyxo-
tetrofuranoside-4-yl)-3 -hydroxymethyl-2-isoxazoline (329) (Section 3.8.1), 
octofuranose derivative 5R-5-(2,3-0-isopropylidene- 1 -O-methyl-ct-D-lyxo-tetro-
furanoside-4-yl)-3-phenyl-2-isoxazoline (321) (100 mg, 0.31 mmol) afforded the 
partially deprotected product 5R-5-( 1 -O-methyl-a-D-lyxo-tetrofuranoside-4-yT)-3-
phenyl-2-isoxazoline (330) as a colourless oil (51 mg, 61%); 0H  (360 MHz, D20) see 
Tables 118 and 119; oc (62 MHz, D20) 157.5 (C3), 128.8, 126.8, 126.0, 124.7 (5 X 
PhCH), 106.2 (C 9), 77.8 (C 5), 76.7 (CO,  73.6 (C 7), 68.5 (CO, 53.9 (OMe), 34.7 (C 4); 















(329) (330) (331) 
4a 3.19 3.63 3.20, 3.33 
0 3.22 3.64 3.27, 3.22 
5 4.88 5.06 5.01, 4.93 
6 4.28 4.39 4.23 
7 4.34 4.44 4.40 
8 4.14 4.21 4.35, 4.14 
9 4.99 5.04 5.33 
OMe 4.44 3.49 - 
CH20H 4.38 - 4.43 




(329) (330) (331) 
4a,4b - - 17.6 
4a,5 8.6 8.4 8.4, 8.0 
4b,5 10.1 10.0 10.0, 10.2 
5,6 5.9 5.7 5.3,5.4 
6,7 3.8 4.0 3.7 
7,8 4.8 4.6 5.9, 6.3 






To an ice-chilled solution of the alcohol (204) (50 mg, 0.21 mmol) in 
dichioromethane (1 ml) was added successively triethylamine (42 mg, 0.42 mmol) 
and methanesuiphonyl chloride (47 mg, 0.41 mmol) under argon. After stirring for 4 
hr the mixture was concentrated in vacuo, dichloromethane (10 ml) was added and 
then washed with water (2 x 4 ml). The organic fraction was dried (MgSO 4), 
evaporated in vacuo and the crude product purified by preparative TLC on silica gel 
(50150 ethyl acetate/hexane) to afford 5 S-5 -(1 ,2-O-cyclohexylidene-D-glycero-diitol-
1-yT)-3-methanesulphonyloxymethyl-2-isoxazoline (258) (64 mg, 96%), very pale 
Yellow oil;  [aID26  +33.8° (c = 1.58, CHC13); oH (360 MHz, CDC13) 4.93 (2H, s, 
CH2OMs), 4.60 (1H, ddd, 4a,5 = 7.1 Hz, J4b,5 = 10.1 Hz, J56 = 3.8 Hz, H5), 4.07 (1H, 
dd, J6,7a = 6.3 Hz, J7a,7b = 7.8 Hz, H70, 4.03 (111, ddd, J5 ,6 = 3.8 Hz, 67a = 6.3 Hz, 
.4,71, = 4.0 Hz, H6), 3.80 (1H, dd, J6,7 1, = 4.0 Hz, J771, = 7.8 Hz, H70, 3.15 (lH, dd, 
= 10.1 Hz, J4a,4b = 17.5 Hz, H40, 3.08 (1H, dd, J4 a,5 7.1 Hz, 4,4b = 17.5 Hz, 
H40, 3.06 (3H, s, MeS0 2), 1.60-1.51 (10H, m, cyclohexyl.CH2); O (90 MHz, 
CDC13) 153.2 (C3), 110.4 (cyclohexyl. quat.), 81.9 (C 6), 75.3 (C 5), 66.4 (CO, 63.0 
(CH20Ms), 37.8 (Me MS ), 36.9 (C4), 36.3, 34.4, 31.4, 24.9, 23.8, 23.6 (cyclohexyl. 
CH2); m/z (FAB) 319.10780 (M+H), C 13H21N04S requires 319.10896. 
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3.9.2 	5R-5-(l,2:3,4-Di-O-isopropylidene-D-arabino-tetritol-1-yl)-3-methane- 
sulphonyloxymethyl-2-isoxazoline (315) and 5S-5-(1,2:3,4-di-0- 
isopropylidene-D-arabino-tetritol-1-yi)-3-methanesulphonylo.xymethyl-2- 
isoxazoline (316) 
Obtained from (305)/(306) (50 mg, 0.17 mmol) using the same procedure 
as for (258), (315)1(316) was isolated as a colourless oil (50 mg, 80%); oH (360 MHz, 
CDC13) 4.94 (CH2OMs), 4.93 {0.59H, ddd, 4 a,5 = 11.5 Hz, J4b,5 = 7.4 Hz, j56  3.3 
Hz, H5 , (erythro)}, 4.82 [0.41H, ddd, J4a s = 7.0 Hz, J4b,5 = 9.5 Hz, J5 ,6 = 2.2 Hz, H5 , 
(threo)], 4.17 [0.59H, dd, J56 = 3.3 Hz, J6 , 7 = 7.5 Hz, H6, (erythro)], 4.11 [0.59H, dd, 
J8,9b = 6.1 Hz, J9a,9b = 8.2 Hz, H9b (erythro)], 4.10 [0.41H, dd, J8,9b = 6.3 Hz, J9a,9b 
7.9 Hz, H9b(threo)], 4.13-3.87 [m, H7, H8 (erythro), H6, H7 , H8 (threo)], 4.06 [0.41H, 
dd, J8 ,9a = 4.5 Hz, 9a,9b = 8.2 Hz, H9 a  (threo)], 3.91 [0.59H, dd, J8,9a = 3.5 Hz, J9a,9b = 
7.9 Hz, H9a  (erythro)], 3.14 [0.59H, dd, J4b,5 = 7.4 Hz, J4a,4b = 17.0 Hz, H4b, 
(erythro)], 3.08 [1H, dd, J4a,5 = 11.5 Hz (erythro), J4a,4b  =17.0 Hz (erythro), J4b,5 = 
9.5 Hz (threo), J4a,4b = 17.0 Hz (threo)], 3.06 [0.41H, dd, J,5 = 7.0 Hz, 4,,,4b = 17.0 
Hz, H4a  (threo)], 1.40-1.30 (15H, m, isopropyl. CH 3 and S0 2CH3); E- (90 MHz, 
CDC13) 152.9 (C3 , erythro), 152.7 (C3 , threo), 110.3, 109.9 [C(Me) 2, erythro], 
109.74, 109.68 [C(Me) 2, threo], 81.9, 81.3, 80.1, 79.9, 78.6, 77.2, 76.9, 76.6 (C 5 , C6 , 
C7 , CO,  67.8 (C9, threo), 67.3 (C9, erythro), 63.4 (CH20Ms, threo), 63.2 (CH20Ms), 
erythro), 37.9 (MeM S, threo), 37.8 (Me MS , erythro), 36.9 (CO  threo), 34.6 (C4, 
erythro), 27.1, 27.0, 26.6, 26.3, 25.1, 25.0 [C(Me)2]; mlz (FAB) 380.13627 (M+H), 




Obtained from (327) (39 mg, 0.14 mmol) using the same procedure as for 
(258), (343) was isolated as a pale yellow oil (40 mg, 81%); 5H  (360 MHz, CDC1 3) 
4.97 (2H, S, CH20Ms), 4.97 (1H, ddd, J4a,5 = 8.3 Hz, J4b,5 = 10.8 Hz, J5 , 6 = 5.3 Hz, 
H5), 4.89 (1H, s, H9), 4.74 (1H, dd, J67 = 3.8 Hz, J78 = 5.9 Hz, H7), 4.55 (1H, d, j78 
= 5.9 Hz, H8), 4.07 (1H, dd, J56 = 5.3 Hz, J67 = 3.8 Hz, H6), 3.29 (3H, s, OMe), 3.22 
(1H, dd, J4a,5 = 8.3 Hz, 4a,4b = 17.7 Hz, H4a), 3.13 (1H, dd, J4b,5 = 10.8 Hz, J4a,4b 
17.7 Hz, H40, 3.06 (3H, s, MeSO 2), 1.44, 1.28 [6H, m, C(Me) 21; & (90 MHz, 
CDC13) 153.6 (C3), 112.7 [C(Me)21, 107.1 (C9), 84.7 (CO,  79.2, 79.14, 79.07 (C 5 , C7 , 
C0,63.3 (CH20Ms), 54.7 (OMe), 37.9 (Me MS), 36.7 (C4), 25.6, 24.2, [C(CH3)2]; mlz 




To an ice-chilled solution of the alcohol (204) (52 mg, 0.22 mmol) in 
dichloromethane (1 ml) was added successively triethylamine (44 mg, 0.43 mmol) 
and p-toluenesulphonyl chloride (82 mg, 0.43 mmol) under argon. After stirring for 
2.5 hr the mixture was concentrated in vacuo, dichloromethane (10 ml) was added 
and then washed with water (2 x 4 ml). The organic fraction was dried (MgSO 4), 
evaporated in vacuo and the crude product purified by preparative TLC on silica gel 
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(50150 ethyl acetate/hexane) to afford 5 S-5-( 1 ,2-O-cyclohexylidene-D-glycero-diitol-
1-yl)-3-p-toluenesulphonyloxymethyl-2-isoxazoline (259) (34 mg, 40%), pale yellow 
Oil; 5H (360 MHz, CDCI3) 7.90 (2H, d, om = 8.3 Hz, 2 x PhCH), 7.39 (2H, d, .,,n = 
8.3 Hz, 2 x PhCH), 4.58 (1H, ddd, J4 a,5 = 7.0 Hz, J4b,5 = 10.4 Hz, J56 = 7.0 Hz, H5), 
4.28 (211, S, CH2OTs), 4.08 (1H, dd, J6,7a  6.3 Hz, J7a,7b = 8.3 Hz, Hi a), 4.04 (1H, 
ddd, J5 ,6 = 6.3 Hz, J6,7a = 6.3 Hz, J6,7b = 4.3 HZ, H6), 3.84 (1H, dd, 67b = 4.3 Hz, 
7a,7b = 8.3 Hz, H70, 3.18 (1H, dd, J4b,5 = 10.4 Hz, J4a,4b = 17.5 Hz, H4b), 3.10 (1H, 
dd, J40,5 = 7.0 Hz, J4a,4b = 17.5 Hz, H4a), 2.47 (3H, s, MeT OS), 1.59-1.54 (1011, m, 
CH2). 
3.11 Reduction of Ester to Aldehyde 
3.11.1 5R-5-(2,3-O-Isopropylidene-1-O-methyl-a-D-Iyxo-tetrofuranoside-4-yt)- 
3-formyl-2-isoxazoline (344) 
DIBAL (1 M in hexanes, 24 ml, 24 mmol) was added slowly to a -78°C 
solution of ester (323) (200 mg, 0.63 mmol) in dry toluene (8 ml) (temperature 
maintained below -70°C throughout DIBAL addition). After stirring the mixture for a 
further 2 hr at -78°C, the reaction was quenched by slow addition of cold (-78°C) 
methanol at such a rate that the internal temperature did not exceed -65°C. The 
mixture was allowed to warm to room temperature, poured onto ice cold 1 M HC1 
(100 ml) and extracted with ethyl acetate (3 x 100 ml). The combined organics were 
washed with brine (2 x 60 ml), dried (MgSO 4) and evaporated in vacuo to an oil 
which was purified by preparative TLC on silica gel (100% ethyl acetate) yielding 
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aldehyde (344) as a colourless oil (135 mg, 68%); [a]D25 ..39•4o (c = 1.37, CHC1 3); oH 
(360 MHz, CDC1 3) see Table 120; 5c (90 MHz, CDCI3) 185.6 (CHO), 159.8 (C3), 
112.8 [C(Me)2], 107.1 (CO,  84.7, 82.1, 79.0, 78.9 (C 5, C6, C7, C8), 54.7 (OMe), 32.2 
(C4), 25.6, 24.1 (2 x Me); mlz (FAB) 272.11372 (M+H), C 121-1 18N06 requires 
272.11341. 
3.12 Oxidation of Alcohol to Aldehyde 
General Procedure 
Pyridinium chlorocbromate (316 mg, 1.47 mmol) was suspended in dry 
dichloromethane (13 ml) and a solution of the alcohol (150 mg, 0.55 mmol) in 
dichloromethane (6 ml) added. After stirring for 3 hr, TLC (100% ether) indicated all 
starting material had been consumed. The reaction mixture was diluted with dry ether 
(70 ml), and the supernatant liquid decanted off. The residual brown sludge was 
washed with ether (3 x 20 ml), and the combined organic extract filtered through a 
silica pad and then concentrated in vacuo. 
3.12.1 5R-5-(2,3-O-Isopropylidene-1-O-methyl-a-D-lyxo-tetrofuranoside-4-yO-
3-formyl-2-isoxazoline (344) 
Obtained from (327) (150 mg, 0.55 mmol) as a colourless oil (104 mg, 70%) 





Obtained from (328) (50 mg, 0.18 mmol) as a white solid (27 mg, 54%), 
m.p. 91.9-92.2°C; 10CID25  +5.9° (c = 0.89, CHC1 3); 8H  (360 MHz, CDC13) see Table 
120; 5c (90 MHz, CDCI 3) 185.3 (CH), 159.1 (C3), 113.0 [C(Me)2], 107.5 (C9), 
84.6, 83.8, 80.8, 79.4 (C 5, C6, C7, C8), 54.8 (OMe), 33.0 (C 4), 25.7, 24.5 (2 x Me); 













(344) (345) (344) (345) 
4a 3.26 3.30 4a,4b 17.9 17.8 
4b 3.12 2.90 4a,5 8.4 11.3 
5 5.10 5.02 4b,5 11.4 9.1 
6 4.12 4.00 5,6 4.9 8.4 
7 4.76 4.69 6,7 3.8 3.8 
8 4.56 4.55 7,8 5.9 5.9 
9 4.90 4.97 8,9 - - 
OMe 3.29 3.33 
CHO 9.90 9.91 
i 1.45
1 
 1.29 1.42, 1.26 
Table 120 
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3.13 Synthesis of Aldehyde Derivatives 
3.13.1 5R-5-(2,3-O-Isopropylidene-1-O-methyl-ct-D-Iyxo-letrofuranos-4-yl)-
elh-3-enyl-2-isoxazoline (346) 
Potassium tert-butoxide (0.23 g, 2.05 mmol) in dry THF was added to 
methyltriphenyl-phosphonium bromide (0.54 g, 1.34 mmol) in dry THF, under 
nitrogen and the solution stirred for 1.5 hr at room temperature. Aldehyde (344) (75 
mg, 0.28 mmol) dissolved in dry TI-IF was added dropwise over 10 mm, and the 
solution stirred overnight. Water (20 ml) was added and the mixture extracted with 
hexane (3 x 50 ml). The combined organic extracts were dried (MgSO 4), and 
evaporated in vacuo to an oil which was purified by preparative thin layer 
chromatography yielding alkene (346) as a colourless oil (60 mg, 80%); 8H  (360 
MHz, CDC13) see Tables 121 and 122; 8c (90 MHz, CDC13) 157.8 (C3), 126.8 (C2), 
122.0 (C 1 ), 112.6 [C(Me) 2], 107.1 (CO,  84.8  (CO,  79.4, 79.1 (C 7, CO, 78.2 (C 5), 54.6 




Potassium tert-butoxide (88 mg, 0.78 mmol) in dry ethylene glycol dimethyl 
ether (50 ml) was added to triethyl phosphonoacetate (117 mg, 0.52 mmol) in dry 
ethylene glycol dimethyl ether, under nitrogen and the solution stirred for 1.5 hr at 
room temperature. Aldehyde (344) (66 mg, 0.24 mmol) dissolved in dry ethylene 
glycol dimethyl ether was added dropwise over 10 mm, and the solution stirred 
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overnight. Water (50 ml) was added and the mixture extracted with hexane (3 x 75 
ml). The combined organic extracts were dried (MgSO 4), and evaporated in vacuo to 
an oil which was purified by preparative thin layer chromatography yielding alkene 
(347) as a colourless oil (62 mg, 75%); 5H  (360 MHz, CDC13) see Tables 121 and 
122; 6 (90 MHz, CDC1 3) 156.5 (C3), 133.0 (C 1 ), 125.6 (C2), 112.6 [C(Me)2], 84.7 
(CO, 60.9 (CH3 CH20), 54.7 (OCH), 34.8 (C4), 25.7, 24.2 [C(CH3 )2], 14.1 
(CH3CH20); mlz (FAB) 342.15480 (M+H), C 16F124N07 requires 342.15528. 
3.13.3 5R-5-(2,3-O-Isopropylidene-1-O-methyl-a-D-lyxo-tetrofuranos-4-yl)-3-
aldoximino-2-isoxazoline (348) 
To an aqueous solution of sodium hydroxide (2.3 g, 57.5 mmol) in water (10 
ml) was added hydroxylamine hydrochloride (2.4 g, 34.5 mol), followed by a 
solution of aldehyde (344) (50 mg, 0.18 mmol) in ether (10 ml) and the solution 
stirred overnight at room temperature. The organic layer was separated and the 
aqueous portion extracted with ethyl acetate (2 x 50 ml). The combined organic 
extract was washed with water (2 x 50 ml), brine (50 ml), dried (MgSO4) and 
concentrated in vacuo to yield the title compound, a colourless oil as a 2 : 3 
mixture of cis and trans isomers (348) (40 mg, 75%); 6H  (360 MHz, CDC1 3) 5.10-
5.00 (1H, b, OH), 4.88 (lH, s, 14 9), 4.83 [1H, ddd, .J,5 = 3.8 Hz (cis), 4a,5 = 2.8 Hz 
(trans), J4b,5 = 6.9 Hz (cis), J4b,5 = 8.4 Hz (trans), J5 , 6 = 8.5 Hz (cis), J5 , 6 = 8.1 Hz 
(trans), H 5 (cis + trans)], 4.58 [0.40H, d, J78 = 5.9 Hz, H8 (cis)], 4.55 [0.60H, d, J78 = 
5.9 Hz, H8 (trans)], 4.17 [1H, dd, J67 = 3.8 Hz (cis), J6 , 7 = 3.7 Hz (trails), J78 = 5.9 
Hz, H7 (cis + trans)], 3.88 [0.40H, dd, J56 = 8.5 Hz, J67 = 3.8 Hz, H6 (cis)], 3.79 
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[0.60H, dd, J5 , 6 = 8.1 Hz, J6 ,
7 
 = 3.7 Hz, H6 (trails)], 3.30 [0.60H, s, OMe(trans)], 3.29 
[0.40H, s, OMe (cis)], 2.78 [0.40H, dd, J4a,5 = 3.8 Hz, J4a,4b = 16.8 Hz, 114 a  (cis)], 
2.64 [0.40H, dd, J4b,5 = 6.9 Hz, J4a,4b = 16.8 Hz, H4b (cis)], 2.56 [0.60H, dd, *J4a,5 = 2.8 
liz, J4a,4b = 14.9 Hz, H4a  (trans)], 2.23 [0.60H, dd, J4b,5 = 8.4 Hz, J4a,4b = 14.9 Hz, H O  












la 5.56 / 
lb 5.48 6.07 
2 6.68 7.54 
4a 3.18 3.21 
4b 3.15 3.12 
5 4.94 5.02 
6 4.00 4.06 
7 4.77 4.76 
8 4.56 4.56 
9 4.89 4.89 
OMe 3.30 3.29 
isopropyl. CH3 1.46, 1.30 1.46, 1.30 
CH3 CH2 / 4.24 














la,lb 0.6 / 
la,2 10.8 / 
1b,2 17.7 / 
1,2 / 16.1 
4a,4b - 16.9 
4a,5 9.2 8.3 
4b,5 9.2 10.9 
5,6 6.5 5.7 
6,7 3.7 3.8 
7,8 5.9 5.9 
8,9 - - 
CH3CH2 / 7.1 
Table 122 
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3.14 Reductive Hydrolytic Cleavage of 2-Isoxazolines to J3-
Hydroxyketones 
3.14.1 Raney-Nickel Induced Hydrogenolysis of 2-Isoxazolines 
General Procedure 
The isoxazoline (1 M eq) and boric acid (6 M eq) were dissolved in a 
mixture of methanol and water (5 : 1) (8-12 ml per 100 mg of isoxazoline) and 
RaneyNickela (3 spatula tips per 100 mg of isoxa.zoline) added. The mixture was 
degassed and hydrogen filled several times, then left to stir vigorously under a 
hydrogen atmosphere. Upon reaction completion (monitored by TLC) the mixture 
was filtered through a celite pad and concentrated in vacuo (bath temperature 
<25°C). The excess boric acid was removed by repeated methanol addition and 
evaporation. The resulting oil was purified by preparative TLC on silica gel. 
3.14.1.1 Hydrogenolysis of 5S-5-(1 ,2-O-Cyclohexylidene-D-glycero-diitol-1-yl)-3-
phenyl-2-isoxazoline (196) 
According to the general procedure given above, isoxazoline (196) (63 mg, 
0.22 mmol) yielded after 4 hr, a mixture of crude products. Separation by preparative 
TLC (100% ether) afforded pure 4,5-0-cyclohexylidene-2-deoxy- 1 -phenyl-D-erythro-
5-pentose (244) as a very pale yellow oil (51 mg, 80%); [aID25  -22.6° (c = 1.01, 
CHC13); 6H  (360 MHz, CDC13) 7.99-7.44 (5H, 5 x PhCH), 4.12 (114, ddd, J5,6 = 4.9 
Hz, J6,7a = 7.1 Hz, J6,7b = 2.8 Hz, H 5), 4.03 (114, ddd, J4 a,5 = 2.5 Hz, J4b,5 = 8.7 Hz, J5 ,6 
= 4.9 Hz, H5), 4.02 (1H, dd, J6,7b = 2.8 Hz, J7a,7b = 14.1 Hz, H70, 3.47 (114, dd, J6,7a = 
a Best results were obtained when Raney-nickel was washed with water (stir, decant x 20) then 
stored under methanol in a freezer for 3-4 weeks prior to use 
322 
7.1 Hz, 77b = 14.1 Hz, H7 a), 3.42 (1H, dd, J4b,5 = 2.5 Hz, 40b = 17.8 Hz, H40, 3.12 
(1H, dd, J4a,5 = 8.7 Hz, J4,,4b = 17.8 Hz, H40, 1.59-1.56 (1 OH, m, cyclohexyl. CH2); 
c (90 MHz, CDC13) 200.0 (C3 ), 135.9 (CPh), 132.9, 128.0, 127.5 (5 x PhCH), 109.4 
(cyclohexyl. quat.), 76.7 (CO,  68.9  (CO,  66.0 (C7), 41.0 (C4), 35.7, 34.0, 24.4, 23.3, 
23.0 (cyclohexyl. CH 2); mlz (FAB) 290.15181 (M), C 17H2304 requires 290.15180, 
and an oil which gave a positive ninhydrin stain on TLC, believed to contain an 
inseparable mixture of y-aminoalcohols 3 -amino-4,5-O-cyclohexylidene-3 ,4-dideoxy-
D-erythro-pentose and 3 -amino-4,5-O-cyclohexylidene-3 ,4-dideoxy-D-threo-pentose 
(245) (6 mg, 10%); 5H  (360 MHz, CDC1 3) 128.8, 126.2 (5 x PhCH), 4.54-3.70 (8H, 
m, H3 , H4a, HO, H55 H6, H7a, H7b, 50H), 2.15-1.90 (2H, b, NH2); 6 (90 MHz, 
CDCI3) 129.2, 128.8, 128.4, 127.8, 126.7, 126.2 (5 x PhCH), 110.0 [C(Me) 2], 78.1 
and 77.5 (CO,  72.8 and 69.0 (CO,  65.3 and 65.0 (C7), 56.3 and 53.0 (C 3), 38.3 and 
38.0 (C4), 38.3, 38.0, 36.1, 34.2, 34.0, 25.0, 24.2, 23.9 (cyclohexyl. CH 2); mlz (FAB) 
292.19057 (M+H), C 17H26NO3 requires 292.19127. 
3.14.1.2 Hydrogenolysis of 5S-5-(1,2-0-Cyclohexylidene-D-glycero-diitol-1-yl)- 3-
hydroxymethyl-2-isoxazoline (204) 
According to the general procedure given above, isoxazoline (204) (80 mg, 
0.33 mmol) yielded, after 4 hr, a mixture of crude products. Separation by 
preparative TLC (100% ether) afforded pure 5,6-0-cyclohexylidene-3-deoxy-D-
erythro-2-hexulose (246) as a colourless oil (63 mg, 78%); 1aID25  -11.5° (c = 0.54, 
CHC13); 8H  (360 MHz, CDC1 3) 4.29 (2H, s, CH20H), 4.05 (1H, ddd, j56 = 5.7 Hz, 
6,7a = 7.8 Hz, J6,7b = 5.2 Hz, H6), 4.03 (1 H. ddd, J4a, 5 = 8.7 Hz, J4b,5 = 3.1 Hz, J56 = 
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5.7 Hz, H5), 3.95 (1H, dd, J6,7b = 5.2 Hz, 7,,,7b = 12.0 HZ, H70, 3.91 (1H, dd, J6,7a = 
7.8 Hz, J7a,7b = 12.0 Hz, H70, 3.10, 2.94 (2H, 2 X S, CH 20H, 5-OH), 2.74 (1H, dd, 
= 3.1 Hz, J4a,4b = 16.7 Hz, H40, 2.58 (1H, dd, 4a,5 = 8.7 Hz, .J4a,4b = 16.7 Hz, 
H40, 1.57-1.54 (1 OH, m, cyclohexyl. CH2); 8C (90 MHz, CDC1 3) 209.6 (C3), 110.1 
(cyclohexyl. quat.), 77.3 (C 5), 68.8 (CO,  68.7 (CH20H), 66.0 (CO,  41.7 (C4), 36.2, 
34.4, 24.9, 23.8, 23.6 (cyclohexyl. CH2); mlz (FAB) 246.14608 (M+H), C 12H2205 
requires 246.14672, and an oil which gave a positive ninhydrin stain on TLC, 
believed to contain an inseparable mixture of y-aminoalcohols, 3-amino-5,6-0-
cyclohexylidene-3,4-dideoxy-D-erythro-2-hexulose and 3-amino-5,6-0-cyclo-
hexylidene-3,4-dideoxy-D-threo-2-hexulose (247) (7 mg, 8%); mlz (FAB) 246.17185 
(M+H), C12H24NO4  requires 246.17053. 
3.14.1.3 Hydrogenolysis of 5R-5-(2,3-O-Isopropylidene-1-O-methyl-a-D-lyxo-
tetrofuranos-4-yl)-3-hydroxymethyl-2-isoxazoline (327) 
According to the general procedure given above, isoxazoline (327) (80 mg, 
0.29 mmol) yielded, after 3 hr, a mixture of crude products. Separation by 
preparative TLC (100% ether) afforded methyl 6-deoxy-2,3 -O-isopropylidene-a-D-
manno-octulose-(1,4) (334) as a colourless oil (41 mg, 5 1%); 1ct1024 37•50  (c = 1.45, 
CHC13); 8H  (3 60 MHz, CDC1 3) 4.85 (1H, s, H9), 4.78 (1H, dd, J67 = 3.8 Hz, p7,8 = 5.9 
Hz, H7), 4.54 (1H, d, J78 = 5.9 Hz, H8), 4.38 (1H, ddd, J,5 = 8.9 Hz, J4b,5 = 3.3 Hz, 
J5 ,6 = 8.3 Hz, H5), 4.29 (1H, s, CH20H), 3.77 (1H, dd, J5 , 6 = 8.3 Hz, J6, 7 = 3.8 Hz, 
H6), 3.27 (3H, s, OMe), 3.30-3.10 (1H, b, CH 2 0H), 2.80 (1H, dd, J4b,5 = 3.3 Hz, J4a,4b 
= 16.1 Hz, H40, 2.67 (1H, dd, .J ,5 = 8.9 Hz, 4,,,4b = 16.1 Hz, H4 a), 1.44 (3H, s, Me), 
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1.33 (3H, s, Me); 8 C (90 MHz, CDC13) 209.0 (C 3), 112.7 [C(Me)2], 106.9 (CO,  84.7 
(CO, 81.3 (C 7), 79.3 (CO,  68.9 (CH20H), 66.1 (CO,  54.5 (OMe), 42.7 (CO,  25.8, 
24.5 [C(Me)2]; mlz (FAB) 277.12774 (M+H), C 12H21 07 requires 277.12873, and an 
oil which gave a positive ninhydrin stain on TLC, believed to contain an inseparable 
mixture of 'y-amnioalcohols methyl 7-amino-6,7-dideoxy-2,3-O-isopropylidene-D-
gluco-a-D-manno-2-octulose-(l,4) (335) (7 mg, 9%); mlz (FAB) 278.15992 (M+H), 
C 12H24N06 requires 278.16036. 
3.14.1.4 Hydrogenolysis of 5R-5-(2,3-O-Isopropylidene- 1 -0 -methyl-a-D-lyxo-
tetrofuranos-4-yl)-3-phenyl-2-isoxazoline (321) 
According to the general procedure given above, isoxazoline (321) (120 mg, 
0.38 mmol) yielded, after 3 hr, a mixture of crude products. Separation by 
preparative TLC (100% ether) afforded pure methyl 6-deoxy-2,3 -O-isopropylidene-7-
phenyl-a-D-manno-7-heptulose-(1,4) (336) as a colourless oil (57 mg, 47%); [a]D25+ 
1.3° (c = 1.83, CHC13); 6H  (360 MHz, CDC13) 7.58-7.43 (5H, m, 5 x PhCH), 4.87 
(1H, s, H9), 4.85 (1H, dd, J6 , 7 = 3.7 Hz, J7 , 8 = 5.9 Hz, H7), 4.56 (1H, d, J7,8  5.9 Hz, 
H8), 4.56 (1H, ddd, 4a,5 = 8.6 Hz, J4b,5 = 2.9 Hz, J56 = 8.3 Hz, H 5), 3.91 (1H, dd, J56 
= 8.3 Hz, J67 = 3.7 Hz, H6), 3.50 (1H, d, J5,50H = 4.7 Hz, 5-OH), 3.27 (3H, s, OMe), 
3.43 (1H, dd, J4b,5 = 2.9 Hz, J4a,4b = 17.3 Hz, H40, 3.22 (1H, dd, J4a,5 = 8.6 Hz, J4a,4b 
= 17.3 Hz, H4a), 1.45 (3H, s, Me), 1.32 (3H, s, Me); 6c  (90 MHz, CDC1 3) 200.5 (C 3), 
136.7, 133.3, 128.5, 128.0 (5 x PhCH), 112.5 [C(Me)2], 107.0 (C9), 84.7 (CO,  81.1 
(C7), 79.5 (CO,  66.1  (CO,  54.4 (OMe), 42.0 (C 4), 25.9, 24.5 [C(Me)2]; mlz (FAB) 
323.14932 (M+H'), C 17H2306 requires 323.14946, and an oil which gave a positive 
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ninhydrin stain on TLC, believed to contain an inseparable mixture of y -
aminoalcohols methyl 7-amino-6,7-dideoxy-2,3 -O-isopropylidene-7-phenyl-D-gluco-
a-D-manno-heptulose-( 1,4) and methyl 7-amino-6,7-dideoxy-2,3 -O-isopropylidene-
7-phenyl-D-manno-a-D-manno-heptulose-(1,4) (337) (20 mg, 16%); mlz (FAB) 
324.18312 (M+H), C 17H26N05 requires 324.18110. 
3.14.1.5 Hydrogenolysis of 5R-5-(1 ,2 :3,4-di-O-isopropylidene-D-arabino-
tetritol-1-yl)-3-hydroxymethyl-2-isoxazoline (305) and 5S-5-(1,2:3,4-di-0- 
isopropylidene-D-arabino-tetritol-1-yi)-3-hydroxymethyl-2- 
isoxazoline (306) 
According to the general procedure given above, isoxazolines (305) and 
(306) (58 mg, 0.19 mmol) yielded, after 4 hr, a mixture of crude products. Separation 
by preparative TLC (100% ether) yielded a mixture of 3-deoxy-5,6:7,8-di-0- 
isopropylidene-D-gluco/manno-2-octuloses (311) and (312), which were unable to be 
separated, as a colourless oil (38 mg, 65%); 8H  (360 MHz, CDCI 3) 4.28 (2H, s, 
CH20H), 4.18 (1H, dd, J8 ,9j, = 5.7 Hz, %,9b = 8.3 Hz, H9 a), 4.13 (1H, dd, '8,9b = 59 
Hz, j9a,9b  8.3 Hz, H90, 4.04 [1H, ddd, J4a,5 = 11.5 Hz, J4b,5 = 8.9 Hz, J5 , 6 = 4.0 Hz, 
H5 (threo)], 3.96 [1H, ddd, j4a,5 = 8.3 Hz, J4b,5 = 11.1 Hz, J5 , 6 = 3.8 Hz, H5 (erythro)], 
3.89 (1H, dd, J6 , 7 = 2.6 Hz, J7,8 = 5.3 Hz, H7), 3.70 {1H, dd, J5 , 6 = 3.8 Hz (erythro), 
= 4.0 Hz (threo), J6 , 7 = 2.6 Hz, H6 (erythro) and H6 (threo)], 2.75 [2H, 2 x dd, 
= 11.1 Hz (erythro), J4b ,5 = 8.9 Hz (threo), 4,4b = 15.3 Hz (erythro), J4a,4b = 
15.1 Hz (threo), HO  (erythro) and HO  (threo)], 2.63 [2H, 2 x dd, .J,5 = 8.3 Hz 
(erythro), J,5 = 11.5 Hz (threo), J4,,4b = 15.3 Hz (erythro), J4a,4b = 15.1 Hz (threo), 
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H4a (erythro) and H4a  (threo)], 1.43-1.33 (12H, m, 4 x CH3); & (90 MHz, CDC13) 
209.0 [C3 (erythro) and. C3 (threo)], 110.2, 109.2 [C(Me) 2 (erythro)], 109.8, 109.7 
[C(Me)2 (threo)], 82.7, 81.0, 76.1, 69.1 [C 5, C6, C7, C8 (erythro)J, 82.4, 77.1, 77.0, 
66.8 [C5, C6, C7, C8 (threo)j, 69.1 [CH20H (erythro) and CH20H (threo)], 67.8 [C9 
(erythro) and C9 (threo)], 42.9 [C4 (threo)], 42.6 [C4 (erythro)], 27.0, 26.7, 26.5, 25.1 
[C(CH3)2 (threo)], 26.6, 26.58, 26.3, 24.9 [C(CH 3)2 (erythro)]; m/z (FAB) 305.15940 
(M+H), C 14H2507 requires 305.16003, and an oil which gave a positive ninhydrin 
stain on TLC, believed to contain an inseparable mixture of four y-aminoalcohols 4-
amino-3 ,4-dfdeoxy-5 ,6:7,8-di-O-isopropylidene-D-gluco/manno-2-octuloses (313)! 
(314) (8 mg, 14%); mlz (FAB) 306.19300 (M+H), C 14H28N06 requires 306.19166. 
3.14.2 Palladium-on-Charcoal Catalysed Hydrogenolysis 
3.14.2.1 Hydrogenolysis of 5S-5-(1 ,2-O-Cyclohexylidene-D-glycero-diitol-1-y1)-3-
phenyl-2-isoxazoline (196) 
Isoxa.zoline (196) (50 mg, 0.17 mmol) and boric acid (65 mg, 1.05 mmol) 
were dissolved in methanol and water (5 : 1) (9 ml). 10% Palladium-on-charcoal (17 
mg) was added and the mixture degassed using a water pump and hydrogen flushed 
five times, then left to stir vigorously under a hydrogen atmosphere for 18 hr. The 
mixture was filtered through celite and evaporated several times in vacuo (no 
heating). Methanol was added and evaporated several times to remove the excess 
boric acid as the volatile trimethylborate. TLC analysis indicated the presence of 
unreacted isoxa.zoline and two more polar components. The reaction was set up again 
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with the same quantities of reagents and left to stir vigorously for a further 20 hr. 
Work up as above afforded, after preparative TLC (100% ether), unreacted 
isoxazoline (196) (4 mg, 7%), 4,5-0—cyclohexylidene-2-deoxy- 1 -phenyl-D-erythro-
5-penrose (244) (32mg, 64%), very pale yellow oil, and y-amino alcohols, 3 -amino-
4,5—O--cyclohexylidene-2,3 -dideoxy- 1 -phenyl-D-erythro-5-pentose and 3-amino-4,5— 
0—cyclohexylidene-2,3-dideoxy- 1 -phenyl-D-threo-5-pentose (245) as an oil, (14 mg, 
28%). See Section 3.14.1.1 for 'H and ' 3C NMR and mlz (FAB) data. These products 
were identified by comparison of TLC data. 
3.14.2.2 Hydrogenolysis of 5S-5-(1 ,2-O-Cyclohexylidene-D-glycero-diitol-1-
yt)-3-kydroxymethyl-2-isoxazoline (204) 
Using the same procedure as in Section 3.14.2.1, isoxazoline (204) (156 mg, 
0.65 mmol) yielded, after 24 hr, a mixture of crude products. Separation by 
preparative TLC (100% ether) afforded 5 ,6—O—cyclohexylidene-3 -deoxy-D-erythro-
hexulose (246) (95 mg, 60 %), colourless oil, and y-aminoalcohols 4-amino-5,6-0-
cyclohexylidene-3,4-dideoxy-D-erythro-5-hexulose and 4-amino-5 ,6—O—cyclohexyl-
idene-3,4-dideoxy-D-threo-5-hexulose ( 247) as an oil (40 mg, 25%). See Section 
3.14.1.2 for 'H and 13 C NMR and mlz (FAB) data. These products were identified by 
comparison of TLC data. 
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3.15 Reductive Hydrolytic Cleavage of 2-Isoxazolines to 2—Uloses 
General Procedure 
Isoxazoline (1 M eq) and boric acid (6 M eq) were dissolved in a mixture of 
methanol and water (5: 1) (8-12 ml per 100 mg of isoxazoline) and RaneyNickela  (3 
spatula tips per 100 mg of isoxazoline) added. The mixture was degassed and 
hydrogen filled several times, then left to stir vigorously under a hydrogen 
atmosphere. Upon reaction completion (monitored by TLC) the mixture was filtered 
through a celite pad and concentrated in vacuo (bath temperature <25°C). The excess 
boric acid was removed by repeated methanol addition and evaporation. The 
resulting oil was not purified further. 
3.15.1 Hydrogenolysis of 5S-5-(D-Glycero-diitol-1-yl)-3-phenyl-2-isoxazoline 
(249) to 1-phenyl-2-deoxy-D-xylose (255) 
According to the general procedure given above, isoxazoline (249) (50 mg, 
0.24 mmol) yielded after 4 hr, 1 -phenyl-2-deoxy-D-xylose (255) as a pale yellow oil 
(19 mg, 37%); oH [360 MHz, (CD 3)2C0] see Table 123; & [90 MHz, (CD 3 )2C0] 
200.7 (C3), 137.1 (CPh), 133.2, 128.6, 128.3, 126.8, 126.4 (5 x CHPh), 74.4 (CO, 
68.7 (CO,  62.9 (C 7), 41.9 (C4); mlz (FAB) 212.10485 (M+2), C 11 H 1604 requires 
212. 10483. 
a  Best results were obtained when Raney-nickel was washed with water (stir, decant x 20) then 
stored under methanol in a freezer for 3-4 weeks prior to use 
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OH H4 	ffl4.  
H6 	
4 








A a. 3.17 4a,  4b 16.5 
4b 3.39 4a,5 8.7 
5 4.22 4b,5 3.1 
6 3.61 5,6 6.7 
7a 3.77 6,7a 5.5 
7b 3.68 6,7b 4.1 
7a,7b 10.6 
Table 123 
3.15.2 Hydrogenolysis of 5R-5-(D-arabino-tetritol-1-y1)-3-hydroymethy1-2-
isoxazoline (307) to 3-deoxy-D-manno-2-octulose (339) 
According to the general procedure given above, isoxazoline (307) (50 mg, 
0.23mmol) yielded after 2 hr, 3-deoxy-D-manno-2-octulose (339) as a pale yellow oil 
(22 mg, 43%); oH (360 MHz, D20) see Table 124; 0c  (90 MHz, D20) 80.4 (C3), 73.3, 
70.8, 70.0, 69.4 (C5 , C6, C7 , CO,  63.0 (C9), 36.7 (C4), 56.5 (CH20H); mlz (FAB) 












4a 1.78 4a,4b 13.0 
4e 1.83 4a,5 9.0 
5 4.09 4e,5 6.0 
6 3.87-3.80 5,6 3.0 
7 3.87-3.60 6,7 nd 
8 3.87-3.80 7,8 nd 
9a 4.02 8,9a 2.6 
9b 3.63 8,9b 5.5 
CH20H 3.87-3.60 9a,9b 11.8 
Table 124 
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Appendix 1: DHQ Synthase Inhibitors 
Compound 1 	Compound Inhibition K4Ma 1 	Km/Ki 
Number]____________________ __J (pH 7.5) 
29 HO 
OH 
Competitive 1.1 16.4 
H02C 	
__O 
inhibitor, but less 2.56572 5461 
OH than (34) 




even at 500M. 
OH Weak competitive  
inhibitor 65 ' 72 
40 HO Competitive 35 nd ~t~OH inhibitor, but less 
OP03H2 than (29) 




Competitive 129 3' 0.14 
inhibitor, but 
CO2 FI weaker than (40) 
42 HO 
OH 
Competitive 33 35 nd 
inhibitor, but less 
CO2H 
than (29) 
43 HO Competitive 1 93 nd ~:t~OH inhibitor, but 
OP03H2 much weaker than 
(42) 






45 HO HO Very weak 1200/2 nd 
OH competitive 
PO3 H 2 
inhibitor 
34 HO Competitive slow 0.0054 5000' 
OH binding inhibitor. 








Number (pH 7.5) 
46 HO Poor inhibitor nd 21 
OH 
HO2C 	 0P03 H2 
OH 
47 HO OH Competitive 1 2 
61 





Competitive 0. 12"2 nd 
HO2C OpOH inhibitor 0.1669 
OH 
48 Inactive - 
HO2C 	 P03H2 No inhibition 
OH even at mM conc. 
30 OH Slowly 
o•22bi' 
nd 
H02C poH reversible 
OH 





31 HO 	O Irreversible 0.15' nd 
inhibitor. (short 
H02C 	 P03 H2 Enzyme inhibition incub. 




Potent 0.0073 nd 





Competitive 25 25 '  
inhibitor, but less 
OH 	 P03H2 than (50) 
50 HO 
OH 
Competitive O.l6 0. 160 ' 
 




Compound Compound Inhibition KI/,LMa KmIKi 
Number  (pH 7.5) 
51 HO Modest inhibitor 100 ,11,  
HO2CV:_~7CO2H 
OH 
38 HO Neither substrate 
OH 
- 
~HO Opo,2 or inhibitor of 
62 enzyme 
52 ç_OPO3H2 	.N No significant - _' ---- O HOHO - 	 , N inhibition at sub 
NH 
7° mM conc.  
-OPO3 H2 No significant 
HO inhibition at sub 
HO_— 





-OH No significant N 





OH herbicidal or anti- 
bacterial activity70  
54 OH _-OH No significant 
N inhibition at sub 
HOI_[L.. mM conc. 
NH No significant 
herbicidal or anti- 
bacterial activity70  
55 OH OH No significant 
O inhibition at sub 
mM conc. 
HO No significant  Ml 
herbicidal or anti- 
N 	I bacterial activity 70 
'N 	
N 
56 OH -OH No significant 
N inhibition at sub 
HO-__1L... mM conc. 
NH No significant 
OH herbicidal or anti- 




Compound Inhibition K1/,.Ma Km/Ki 
 (pH 7.5) 
57 OH 	 N No significant - - 





herbicidal or anti- 
bacterial activity 70  
58 OH No significant - - 





/ 	*i herbicidal or anti- 
NI bacterial activity 70 
a Inhibition against enzyme purified from Escherichia coli 
Differences in K 1 values quoted may be due to purity of enzyme used and assay method used for 
kinetic measurements. 
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Appendix 2: CMP-KDO Inhibitors 
Compound Compound Inhibition Relative K1/itM 1050/9M 
Number Activity 
% 
96 HO./OH Potent 1001U2 
39113 10.5138 
competitive 
0 inhibitor, but 
HO inactive against 
Gram negative 
CO2 NH4 bacteria 
102,113 
97 HO 	OH  
HO  Inactive IUZI - - - 
HO 	 COfNH4 
112 HO/OH 
0 
Inactive 02 - - - 




	OH  Weak inhibitor <5 
OLUZ nd nd 
HO 
COCH2PO(OH)(0H3N0) 
114 Inactive" - - - 
HO 
CH2CO2NH4 
100 N Inactive"' - - - 
No antibacterial 
	







Inactive lUZ - - - 
HO 	 COjNH4 
CO2 NH4 
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Compound Compound Inhibition Relative K4tM IC5 4tM 
Activity 
Number % 




117 HO 	OH Good inhibitor 80902 = HO 
HO9  
CONHOH 
118 HO 	OH Inactive' 0' - - - HO 
HO 
CH2OH 






120 HO 	OH Inactive ' 1" - - - HO 
HO  
CONHBn 














123 HO 	OH  = Inactive "z - - HO
HO 
CO2Bn 
124 HO 	 OH Inactive "2 - - 
HO 
CH2PO(OHXONH4) 









HO 	 CO2H 
































131 HO 	OH Very weak nd nd 1860 HO 0 
inhibitor. 
No significant 
H 	 CO2H O  
antibacterial 
activity 
132 HO 	OH Very weak nd nd 1770 
HOCO\ 
inhibitor. 
HO No significant 
CO2H antibacterial 
activity 




134 HO HO 
	CH3 Competitive nd nd 4.7vo  
inhibitor, much 
HO stronger than 
CO2H compound (133). 
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Compound Compound Inhibition Relative K4tM 1C50/gm 
Number 
Activity 





136 HO 	OH Moderate nd nd nd HO 
inhibitor'30  
HO 	 OH f...._ 
CO2-NH4 
103 HO 	OH Very weak <15131 nd nd HO 
(at 











HO r_ CH3 inhibitor 
CO2H and 
KD0)  
137 HO 	OH Very weak <15'' nd nd HO 
(at 
inhibitor equimol. 














Compound Compound Inhibition Relative K14tM IC50/itM 
Number Activity 
% 




r_ CH2CO2H conc. of 
CO2 H inhibitor 
and 
____________  KD0) 
140 HO 	OH Very weak <15' s ' nd nd 
IsçclIio (at 
1-10 	 CH2CH2CO2H 
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Appendix 3 : t-Facia1 Selectivities for Nitrile Oxide Cycloadditions 
Alkene Nitrile Oxide erythro threo 
Six-carbon 
Analogues 
(195) Et02CCNO 77: 23 
PhCNO 79 : 21 
(EtO)2P(0)CH2CNO 81: 19 
MeCNO 82: 18 




(260) Et02CCNO 53 :47 
PhCNO 52 : 48 
(EtO)2P(0)CH2 CNO 50 :50 
(271) Et02CCNO 59 : 41 
PhCNO 63 : 37 
(276) Et02CCNO 55 : 45 
PhCNO 62 :38 
(286) Et02CCNO 83: 17 
PhCNO 81: 19 
Eight-carbon 
Analogues 
(293) Et02CCNO 62.5 : 37.5 
PhCNO 67:33 
(EtO)2P(0)CH2CNO 63 : 37 
(317) Et02CCNO 82: 18 
PhCNO 81:19 
(EtO)2P(0)CH2CNO 88 :12 
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